Conditions: Cytomegalovirus (CMV)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 352
Healthy volunteers: no

Brief summary:
The purpose of this study is to compare the efficacy of maribavir to investigator-assigned anti-Cytomegalovirus (CMV) therapy in CMV viremia clearance in transplant recipients who are refractory or resistant to prior anti-CMV treatment.

Detailed description:

Arms:
arm 1: Participants will receive 400 milligrams (mg) (2x200 mg tablets) maribavir twice daily orally (doses separated by a minimum of 8 hours) for 8 weeks. arm 2: Participants will receive anti-CMV agent best suited to treat the respective participant as per the investigator's prescribed dosing regimen for 8 weeks. Agents of choice include: ganciclovir, valganciclovir, foscarnet, or cidofovir.

Interventions: intervention 1: Maribavir intervention 2: Ganciclovir intervention 3: Valganciclovir intervention 4: Foscarnet intervention 5: Cidofovir
Intervention descriptions: intervention 1: Maribavir 400 milligrams (mg) (2x200 mg tablets) will be administered twice daily for 8 weeks. intervention 2: Ganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks. intervention 3: Valganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks. intervention 4: Foscarnet as per the investigator's prescribed dosing regimen will be administered for 8 weeks. intervention 5: Cidofovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.

Protocol document:
Prot_000.pdf: 
CLINICAL STUDY PROTOCOL 
 
 
NCT Number:   
NCT02931539 
 
Study Title:  
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to 
Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-
assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) 
Infections that are Refractory or Resistant to Treatment with Ganciclovir, 
Valganciclovir, Foscarnet, or Cidofovir 
 
 
Study Number:  
SHP620-303 
 
 
Protocol Version and Date:  
 
Amendment 6:  
07 Dec 2018 


PROTOCOL: SHP620-303
TITLE:
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study 
to Assess the Efficacy and Safety of Maribavir Treatment Compared to 
Investigator-assigned Treatment in Transplant Recipients with 
Cytomegalovirus (CMV) Infections that are Refractory or Resistant to 
Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir.
DRUG:
SHP620
IND:
IND 051001
EUDRACT NO.:
2015-004725-13
SPONSOR: 
Shire ViroPharma, Incorporated
300 Shire Way, Lexington, MA 02421 USA
PRINCIPAL/
COORDINATING
INVESTIGATOR:
Multicenter
PROTOCOL 
HISTORY:
Amendment 6: 07 December 2018
Amendment 6.1: 07 December 2018
Amendment 5.1: 20 August 2018 (Germany, Singapore, Switzerland)
Amendment 5: 11 July 2018
Amendment 4: 26 March 2018
Amendment 3.1: 10 October 2017 (Germany and Singapore)
Amendment 3: 01 March 2017
Amendment 2.1 : 18 May 2017 (Germany)
Amendment 2 (Version 3.0): 01 December 2016 
Amendment 1 (Version 2.0): 08 July 2016 
Original Protocol (Version 1.0): 25 April 2016
This document contains confidential and proprietary information of Shire and is disclosed pursuant to confidentiality 
and nondisclosure obligations. This information should be used solely for the purposes for which it was provided 
and should not be copied, shared with, or disclosed to any third party without the express written consent of Shire.
For non-commercial use only


PROTOCOL SIGNATURE PAGE 
Sponsor's (Shi•·e Vil·oPbarma, Incorporated) 
I Signature: 
, MD 
Investigator's Aclmowledgement 
Date: 
T have read this protocol for Shire ViroPharma, Incorporated Study SHP620-303. 
Title: A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the 
Efficacy and Safety ofMaribavir Treatment Compared to Investigator-assigned Treatment in 
Transplant Recipients with Cytomegalovirus (CMV) Infections that are Refractory or Resistant 
to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir. 
I have fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the study, 
without written authorization from the sponsor. lt is, however, permissible to provide the 
information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Confe1·ence on Harmonisation guidelines on Good Clinical 
Practice and with the applicable regulatory requirements. 
1 understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I undel'stand that the sponsor may decide to suspend or prematurely terminate the study at any 
time for whatever reason; such a decision will be communicated to me in writing. Conversely, 
should T decide to withdraw from execution of the study I will communicate my intention 
immediately in writing to the sponsor. 
Investigator Name and Address: 
(please hand print or type) 
Signature: --------------------------------
Date: 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 2 
 
07 Dec 2018
For non-commercial use only


Shire
Page 3
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
SUMMARY OF CHANGES FROM PREVIOUS VERSION
Amendment 6 to protocol SHP620-303 incorporates the following major changes:

Specified that any subject not tested for HIV within 3 months prior to screening must be 
tested during screening by a local laboratory and must have a negative HIV test result 
available before randomization.

Removed Hematopoetic Cell Transplant Comorbidity Index from assessments, and 
deleted corresponding appendix describing the tool. Specified Karnofsky Performance 
Status and Lansky scales as the only assessment tools for evaluation of comorbidity 
status.

Reduced minimum washout period prior to the first dose of study treatment for 
letermovir from 14 days to 3 days.

For subjects failing to attain viral clearance, added Visit 18/Week 20 (previously only 
Visit 16/Week 16) CMV DNA assessment result above the pre-defined cut off to 
necessitate CMV genotyping.  

Identified specific dated SmPCs as reference safety information for investigator-assigned 
treatments

Removed requirement of duplicate SAE and pregnancy reporting to PPD/CRO and 
Medical Monitors, removed corresponding erroneous contacts, updated name of Shire 
Global Drug Safety Department, and removed individual names of medical contacts at 
PPD.

Clarified that a product quality complaint from any site should be directed to a single 
central e-mail address.
Noteworthy changes to the protocol are captured in the table below. Other minor editorial 
revisions (including changes for consistency and clarity) are not described in this table.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 3 
 
07 Dec 2018
For non-commercial use only


Shire
Page 4
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
6
Amendment Date
07 Dec 2018
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
Modified SAE and pregnancy reporting procedure and limited contact 
information to only Shire Global Drug Safety; removed 
specific contact information and names of CRO 
medical monitors, and updated name of Shire Global 
Drug Safety Department.
Emergency Contact Information; 
Section 8.2.2; 
Section 8.2.4
Clarified that a product quality complaint from any site should be 
directed to a single central e-mail address.
Product Quality Complaints
Specified need for negative HIV test result within prior 3 months before 
randomization after exclusion criterion 8 to better 
ensure HIV negativity for all randomized subjects..
Synopsis, Section 3.1, Study 
Schedule Table 1, 
footnote i.; 
Section 4.2; 
Section 7.1.1, 
Section 7.2.3.5;
Section 7.2.5; 
Table 5
Reduced minimum washout period prior to the first dose of study 
treatment for letermovir from 14 days to 3 days to 
facilitate enrollment.
Synopsis, Section 4.2
Removed Hematopoetic Cell Transplant Comorbidity Index from Study 
Schedules, Procedures, and appendices as 
inappropriate assessment for the study. Specified 
Karnofsky Performance Status and Lansky scales as 
the only assessment tools for evaluation of comorbidity 
status.
Table 1, Table 2, Section 7.1.2, 
Section 7.1.3,
Section 7.2.2.7,
Appendix 5
Specified Summary of Product Characteristics versions to be used as 
reference safety information for investigator-prescribed 
medications to promote consistent reporting of 
treatment-related events
Section 8.2.1
For subjects failing to attain viral clearance, added Visit 18/Week 20 
(previously only Visit 16/Week 16) CMV DNA 
assessment result above the pre-defined cut off to 
necessitate CMV genotyping.  
Section 7.1.3
See Appendix 1 for protocol history.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 4 
 
07 Dec 2018
For non-commercial use only


Shire
Page 5
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
EMERGENCY CONTACT INFORMATION
In the event of a serious adverse event (SAE), the investigator must fax or e-mail the “Shire 
Clinical Study Adverse Event Form for Serious Adverse Events (SAEs) and Non-serious AEs as 
Required by Protocol” within 24 hours to the Shire Global Drug Safety Department. The fax 
number and e-mail address are provided on the form (sent under separate cover). 
Fax: 
 
e-mail: 
For protocol- or safety-related issues during normal business hours 8:00am - 5:00pm (local 
time per region), the investigator must contact the PPD medical monitor: 
Hotline numbers (24 hours a day/7 days a week):
North America: 
Europe, Middle East, Africa (EMEA)/Asia-Pacific (APAC): 
Fax numbers:
North America: 
 and 
EMEA/APAC: 
E-mail:
North America: RTP Safety Mailbox (SM) -
EMEA ASIA Safety Central Mailbox (SM) -
For protocol- or safety-related issues outside of normal business hours, the Investigator 
must contact:
Hotline numbers (24 hours a day /7 days a week): North America -
; EMEA 
/APAC -
  
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 5 
 
07 Dec 2018
For non-commercial use only


Shire
Page 6
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
PRODUCT QUALITY COMPLAINTS
Investigators are required to report investigational product quality complaints to Shire within 
24 hours. This includes any instances wherein the quality or performance of a Shire product 
(marketed or investigational) does not meet expectations (eg, inadequate or faulty closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the product (eg, wrong product such that the label and contents are different 
products). For instructions on reporting AEs related to product complaints, see Section 8.
Please report the Product Quality Complaint to: 
Telephone number (provided for reference if needed):
300 Shire Way, Lexington, MA 02421 USA
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 6 
 
07 Dec 2018
For non-commercial use only


Shire
Page 7
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
TABLE OF CONTENTS
PROTOCOL SIGNATURE PAGE .................................................................................................2
SUMMARY OF CHANGES FROM PREVIOUS VERSION........................................................3
EMERGENCY CONTACT INFORMATION................................................................................5
PRODUCT QUALITY COMPLAINTS..........................................................................................6
TABLE OF CONTENTS.................................................................................................................7
LIST OF TABLES.........................................................................................................................12
LIST OF FIGURES .......................................................................................................................12
LIST OF APPENDICES................................................................................................................12
ABBREVIATIONS .......................................................................................................................13
DEFINITIONS...............................................................................................................................15
STUDY SYNOPSIS ......................................................................................................................17
STUDY SCHEDULES..................................................................................................................34
1.
BACKGROUND INFORMATION.......................................................................................42
1.1
Indication and Current Treatment Options...............................................................42
1.2
Product Background and Clinical Information ........................................................43
1.2.1
Pharmacokinetics, metabolism, and drug-drug interactions..................................43
1.2.2
Efficacy..................................................................................................................45
1.2.3
Safety .....................................................................................................................47
2.
STUDY OBJECTIVES AND PURPOSE ..............................................................................49
2.1
Rationale for the Study.............................................................................................49
2.2
Rationale for the Study Design ................................................................................49
2.3
Rationale for Dose Selection....................................................................................51
2.4
Study Objectives ......................................................................................................52
2.4.1
Primary Objective..................................................................................................52
2.4.2
Key Secondary Objective ......................................................................................52
2.4.3
Secondary Objectives.............................................................................................52
2.4.4
Exploratory Objectives ..........................................................................................53
3.
STUDY DESIGN ...................................................................................................................54
3.1
Study Design and Flow Chart ..................................................................................54
3.2
Duration and Study Completion Definition .............................................................61
3.3
Sites and Regions .....................................................................................................61
4.
STUDY POPULATION.........................................................................................................62
4.1
Inclusion Criteria......................................................................................................62
4.2
Exclusion Criteria.....................................................................................................63
4.3
Restrictions...............................................................................................................65
4.4
Reproductive Potential .............................................................................................65
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 7 
 
07 Dec 2018
For non-commercial use only


Shire
Page 8
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
4.4.1
Female Contraception............................................................................................65
4.4.2
Male Contraception................................................................................................66
4.5
Discontinuation and/or Withdrawal of Subjects ......................................................66
4.5.1
Reasons for Discontinuation and/or Withdrawal...................................................68
4.5.2
Subjects ‘Lost to Follow-up’ Prior to Last Scheduled Visit..................................68
5.
PRIOR AND CONCOMITANT MEDICATIONS, THERAPIES, AND 
PROCEDURES..................................................................................................................69
5.1
Prior Medications, Therapies, and Procedures.........................................................69
5.2
Concomitant Medications, Treatments and Procedures...........................................70
5.2.1
Permitted Treatment during the Study Drug Treatment ........................................70
5.2.2
Prohibited Treatment .............................................................................................71
5.2.3
Treatments Taken During the Follow-up Phase ....................................................73
6.
IDENTITY OF STUDY TREATMENTS..............................................................................74
6.1
Blinding the Treatment Assignment ........................................................................74
6.2
Administration of Investigational Product(s)...........................................................74
6.2.1
Interactive Response Technology for Investigational Product Management ........74
6.2.2
Allocation of Subjects to Treatment ......................................................................74
6.2.3
Dosing....................................................................................................................75
6.3
Labeling, Packaging, Storage, and Handling ...........................................................77
6.3.1
Labeling .................................................................................................................77
6.3.2
Packaging...............................................................................................................78
6.3.3
Storage ...................................................................................................................78
6.4
Drug Accountability.................................................................................................79
6.5
Subject Compliance..................................................................................................80
7.
STUDY PROCEDURES........................................................................................................81
7.1
Study Schedule.........................................................................................................81
7.1.1
Screening Period....................................................................................................81
7.1.2
Study Drug Administration Period ........................................................................82
7.1.3
Follow-up Phase.....................................................................................................84
7.1.4
Maribavir Rescue Arm...........................................................................................85
7.1.5
Additional Care of Subjects after the Study ..........................................................85
7.2
Study Evaluations and Procedures ...........................................................................85
7.2.1
Demographic and Other Baseline Characteristics .................................................85
7.2.2
Efficacy..................................................................................................................86
7.2.2.1
CMV DNA Quantitation (CMV Infection)............................................86
7.2.2.2
CMV Genotyping and Phenotyping.......................................................86
7.2.2.3
Tissue Invasive CMV Disease and CMV Syndrome Assessments........86
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 8 
 
07 Dec 2018
For non-commercial use only


Shire
Page 9
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
7.2.2.5
Graft Status.............................................................................................88
7.2.2.6
Graft-versus-host-disease (GVHD) Assessments ..................................88
7.2.2.7
Comorbidity Status.................................................................................89
7.2.2.8
Subject Survival .....................................................................................89
7.2.3
Safety .....................................................................................................................89
7.2.3.1
Medical History......................................................................................89
7.2.3.2
Physical Examination (Including Weight) .............................................90
7.2.3.3
Vital Signs..............................................................................................90
7.2.3.4
Electrocardiogram ..................................................................................91
7.2.3.5
Clinical Laboratory Evaluations.............................................................91
7.2.3.6
Adverse Event Collection.......................................................................93
7.2.4
Others.....................................................................................................................93
7.2.4.1
Clinical Pharmacology Assessments......................................................93
7.2.5
Volume of Blood to be Drawn from Each Subject Per Visit.................................96
8.
ADVERSE AND SERIOUS ADVERSE EVENTS ASSESSMENT ....................................99
8.1
Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events.......................................................................................................................99
8.1.1
Severity Categorization..........................................................................................99
8.1.2
Relationship Categorization.................................................................................100
8.1.3
Outcome Categorization ......................................................................................100
8.1.4
Adverse Events of Special Interest ......................................................................101
8.1.5
Disease Under Study............................................................................................102
8.1.6
Clinical Laboratory and Other Safety Evaluations..............................................104
8.1.7
Pregnancy.............................................................................................................104
8.1.8
Abuse, Misuse, Overdose, and Medication Error................................................105
8.2
Serious Adverse Event Procedures ........................................................................105
8.2.1
Reference Safety Information..............................................................................105
8.2.2
Reporting Procedures...........................................................................................106
8.2.3
Serious Adverse Event Definition .......................................................................106
8.2.4
Serious Adverse Event Collection Time Frame...................................................107
8.2.5
Serious Adverse Event Onset and Resolution Dates ...........................................107
8.2.6
Fatal Outcome......................................................................................................107
8.2.7
Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting..............................................................................................................108
9.
DATA MANAGEMENT AND STATISTICAL METHODS.............................................109
9.1
Data Collection.......................................................................................................109
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 9 
 
07 Dec 2018
For non-commercial use only


Shire
Page 10
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
9.2
Clinical Data Management.....................................................................................109
9.3
Statistical Analysis Process....................................................................................109
9.4
Data Monitoring Committee ..................................................................................110
9.5
Endpoint Adjudication Committee.........................................................................110
9.6
Sample Size Calculation and Power Considerations..............................................110
9.7
Study Analysis Population .....................................................................................111
9.8
Efficacy Analyses...................................................................................................111
9.8.1
Primary Efficacy Endpoint ..................................................................................112
9.8.2
Key Secondary Efficacy Endpoint.......................................................................114
9.8.3
Multiplicity Adjustment.......................................................................................116
9.8.4
Subgroup Analyses ..............................................................................................117
9.8.5
Secondary Efficacy Endpoints.............................................................................117
9.8.6
Exploratory Efficacy Endpoints...........................................................................119
9.9
Safety Analyses......................................................................................................120
9.10
Other Analyses .......................................................................................................122
9.10.3 Pharmacokinetic Analyses...................................................................................122
10. SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES .........................................124
10.1
Sponsor’s Responsibilities .....................................................................................124
10.1.1 Good Clinical Practice Compliance.....................................................................124
10.1.2 Indemnity/Liability and Insurance.......................................................................124
10.1.3 Public Posting of Study Information....................................................................124
10.1.4 Submission of Summary of Clinical Study Report to Competent Authorities 
of Member States Concerned and Ethics Committees.........................................125
10.1.5 Study Suspension, Termination, and Completion................................................125
10.2
Investigator’s Responsibilities ...............................................................................125
10.2.1 Good Clinical Practice Compliance.....................................................................125
10.2.2 Protocol Adherence and Investigator Agreement................................................126
10.2.3 Documentation and Retention of Records ...........................................................126
10.2.3.1
Case Report Forms...............................................................................126
10.2.3.2
Recording, Access, and Retention of Source Data and Study 
Documents............................................................................................126
10.2.3.3
Audit/Inspection...................................................................................127
10.2.3.4
Financial Disclosure.............................................................................127
10.2.4 Compliance to all Local, State, and National Controlled-substance 
Biohazard and Infectious Disease Regulations and Legislation..........................127
10.3
Ethical Considerations............................................................................................128
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 10 
 
07 Dec 2018
For non-commercial use only


Shire
Page 11
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
10.3.1 Informed Consent.................................................................................................128
10.3.2 Institutional Review Board or Ethics Committee................................................128
10.4
Privacy and Confidentiality....................................................................................129
10.5
Study Results/Publication Policy ...........................................................................129
11. REFERENCES .....................................................................................................................131
12. APPENDICES ......................................................................................................................136
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 11 
 
07 Dec 2018
For non-commercial use only


Shire
Page 12
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
LIST OF TABLES
Table 1:
Schedule of Assessment 1: Screening Phase and Study Treatment 
Phase..............................................................................................................34
Table 2:
Schedule of Assessment 2: Follow-up Phase ................................................39
Table 3:
Prior Medications, Therapies, and Procedures..............................................69
Table 4:
Maribavir Dosing Regimen ...........................................................................76
Table 5:
Volume of Blood Drawn Per Study Visit......................................................97
Table 6:
Criteria for reporting CMV infection as an AE or as an SAE.....................103
Table 7:
Assessments of Virological Responders at Study Week 8..........................113
Table 8:
Assessments of Responders for Key Secondary Endpoint..........................116
LIST OF FIGURES
Figure 1:
Study Design Flow Chart ..............................................................................56
LIST OF APPENDICES
Appendix 1
Protocol History...........................................................................................137
Appendix 2
Child-Pugh Classification of Chronic Liver Disease ..................................167
Appendix 3
Definitions of Tissue Invasive CMV Disease AND CMV SYndrome.......168
Appendix 4
CMV Genetic Mutations Associated with Resistance to anti-CMV 
Drugs ...........................................................................................................171
Appendix 5
Karnofsky Performance Status Scale ..........................................................177
Appendix 6
Lansky Performance Status Scale ...............................................................179
Appendix 7
Scales and Assessments...............................................................................181
Appendix 8
Acute Graft-versus-host Disease: Clinical Staging and Grading ................182
Appendix 9
Recommendations for Chronic GVHD Diagnosis and Grading .................184
Appendix 10
Diagnostic Criteria for Chronic GVHD ......................................................189
Appendix 11
Modification of Diet in Renal Disease (MDRD) and Schwartz 
Formulae......................................................................................................195
Appendix 12
Bacterial and Fungal Infections Assessment...............................................196
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 12 
 
07 Dec 2018
For non-commercial use only


Shire
Page 13
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
ABBREVIATIONS
AAG
alpha-1-1acid-glycoprotein
AE
adverse event
AESI
adverse events of special interest
ALP
alkaline phosphatase
ALT
alanine aminotransferase
ANC
absolute neutrophil count
AST
aspartate aminotransferase
ATP
adenosine triphosphate
AUC
area under the plasma concentration versus time curve
-HCG
beta-human chorionic gonadotropin
BAL
bronchoalveolar lavage
BID
twice daily
Cmax
maximum observed plasma concentration 
Cmin
minimum observed plasma concentration
CMV
cytomegalovirus
CNS
central nervous system
CoD
Certificates of Destruction 
CRA
clinical research associate
CRF
case report form
CRO
contract research organization
CTCAE
Common Terminology Criteria for Adverse Events 
DMC
data monitoring committee
EAC
Endpoint Adjudication Committee
EC
ethics committee
ECG/EKG
electrocardiogram
EIND
emergency investigational new drug
EU
European Union
FDA
Food and Drug Administration
GCP
Good Clinical Practice
GI
gastrointestinal
GVHD
graft-versus-host disease
HBV
hepatitis B virus
HCV
hepatitis C virus
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 13 
 
07 Dec 2018
For non-commercial use only


Shire
Page 14
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
HIPAA
Health Insurance Portability and Accountability Act
HIV
human immunodeficiency virus
HLA
human leukocyte antigen
HSA
human serum albumin
HSCT
hematopoietic stem cell transplant
HSV
herpes simplex virus
IAT
investigator-assigned anti-CMV treatment
ICH
International Conference on Harmonisation
IRB
Institutional Review Board
IRT
interactive response technology
IVIg
intravenous immunoglobulin
KPS
Karnofsky Performance Status 
LLOQ
lower limit of quantification
OTC
over-the-counter
PCR
polymerase chain reaction
P-gp
P-glycoprotein
PK
pharmacokinetic(s)
PO
per os (oral)
qPCR
quantitative polymerase chain reaction
QTc
corrected QT interval
SAE
serious adverse event
SAP
statistical analysis plan
SOT
solid organ transplant
TEAE
treatment-emergent adverse event
TID
3 times daily
ULN
upper limit of normal
US
United States
VZV
varicella zoster virus
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 14 
 
07 Dec 2018
For non-commercial use only


Shire
Page 15
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
DEFINITIONS
Term
Definition
Confirmed viremia 
clearance
Defined as plasma cytomegalovirus (CMV) DNA concentration 
below the lower limit of quantification (<LLOQ; ie, <137 
IU/mL]), when assessed by COBAS® AmpliPrep/COBAS®
TaqMan® CMV Test at a central specialty laboratory, in 2 
consecutive post-baseline samples, separated by at least 5 days.
Recurrence of CMV 
viremia
Defined as plasma CMV DNA concentration ≥LLOQ when 
assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV 
Test in 2 consecutive plasma samples at least 5 days apart, after 
achieving confirmed viremia clearance.
Rebound of CMV viremia
Defined as increase in viral DNA load for >1 log10 above nadir 
without prior clearance of viremia. 
Recurrence of symptomatic 
CMV infection
Defined as the presence of signs or symptoms of the tissue 
invasive CMV disease or CMV syndrome (same or new 
symptomatology) confirmed as per Ljungman et al. 2017, after the 
period of resolution of symptomatic CMV infection in subjects 
symptomatic at baseline.
Refractory
Documented failure to achieve >1 log10 (common logarithm to 
base 10) decrease in CMV DNA level in whole blood or plasma 
after a 14 day or longer treatment period with IV ganciclovir/oral 
valganciclovir, IV foscarnet, or IV cidofovir. This definition 
applies to the current CMV infection and the most recently 
administered anti-CMV agent.
Resistant
Documented failure to achieve >1 log10 (common logarithm to 
base 10) decrease in CMV DNA level in whole blood or plasma 
after a 14 day or longer treatment period with IV ganciclovir/oral 
valganciclovir, IV foscarnet, or IV cidofovir. This definition 
applies to the current CMV infection and the most recently 
administered anti-CMV agent.
AND
Documentation of 1 or more CMV genetic mutations associated
with resistance to ganciclovir/valganciclovir, foscarnet, and/or 
cidofovir.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 15 
 
07 Dec 2018
For non-commercial use only


Shire
Page 16
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Term
Definition
Symptomatic subjects
Eligible enrolled subjects who have tissue-invasive CMV disease 
or CMV syndrome (SOT subjects only) at baseline, as determined 
by the investigator.
Asymptomatic subjects
Eligible enrolled subjects who do not have tissue-invasive CMV 
disease or CMV syndrome (SOT subjects only) at baseline, as 
determined by the investigator.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 16 
 
07 Dec 2018
For non-commercial use only


Shire
Page 17
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
STUDY SYNOPSIS
Protocol number: SHP620-303
Drug: Maribavir
Title of the study: A phase 3, multicenter, randomized, open-label, active-controlled study to assess the efficacy 
and safety of maribavir treatment compared to investigator-assigned treatment in transplant recipients with 
cytomegalovirus (CMV) infections that are refractory or resistant to treatment with ganciclovir, valganciclovir, 
foscarnet, or cidofovir.
Number of subjects (total and for each treatment arm): Approximately 413 subjects will be screened to 
randomize approximately 351 subjects in a 2:1 ratio (234 [maribavir treatment]: 117 
[investigator-assigned anti-CMV treatment (IAT)]) 
Investigator(s): A multicenter study to be conducted at approximately 140 sites worldwide. 
Site(s) and Region(s): Approximately 140 sites in North America, Europe, and Asia Pacific.
Study period (planned): 2016-2019
Clinical phase: 3
Primary Objective:
To compare the efficacy of maribavir to investigator-assigned anti-CMV therapy on CMV viremia clearance at the 
end of Study Week 8, in transplant recipients who are refractory or resistant to prior anti-CMV treatment.
Key Secondary Objective:
To compare the efficacy of the 2 study treatment arms on CMV viremia clearance and symptomatic CMV infection 
(tissue invasive disease and CMV syndrome) improvement or resolution at the end of Study Week 
8, and maintenance of this treatment effect through Study Week 16 (8 weeks of post-
treatment/follow-up phase).
Secondary Objectives:

To compare the efficacy of maribavir to investigator-assigned anti-CMV therapy on CMV viremia clearance 
after completion of 8 weeks of study treatment in transplant recipients who are refractory or resistant to prior 
anti-CMV treatment.

To compare the efficacy of the 2 study treatment arms on CMV viremia clearance and symptomatic CMV 
infection (tissue invasive disease and CMV syndrome) improvement or resolution after completion of 8 weeks 
of study treatment and maintenance of this treatment effect through Study Weeks 12 (4 weeks post-treatment 
period), 16 (8 weeks post-treatment/follow-up phase), and 20 (12 weeks post-treatment).

To assess the 2 study treatment arms for maintenance of CMV viremia clearance, and resolution or 
improvement of tissue invasive CMV disease, achieved at the end of Study Week 8, through weeks 12 (4 weeks 
of post treatment period), and 20 (12 weeks post treatment).

To evaluate the incidence of recurrence of CMV viremia in the 2 study treatment arms during the first 8 weeks 
of the study, during the 12 weeks of the follow-up study phase, and any time during the study.

To evaluate the incidence of recurrence of CMV viremia in the 2 study treatment arms when patients are on 
treatment and off treatment.

To assess the profile of mutations in the CMV genes conferring resistance to maribavir.

To evaluate the all-cause mortality.

To assess the safety and tolerability of maribavir.

To assess the efficacy, maintenance of the treatment effect, and the safety of maribavir administered as the 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 17 
 
07 Dec 2018
For non-commercial use only


Shire
Page 18
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
rescue treatment.

To characterize the pharmacokinetics of maribavir.
Exploratory Objectives:
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 18 
 
07 Dec 2018
For non-commercial use only


Shire
Page 19
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Rationale:
The population of hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients whose 
CMV infections are refractory to available antiviral treatment (ie, ganciclovir, valganciclovir, 
foscarnet, or cidofovir) is an area of high unmet medical need. Some patients refractory to anti-
CMV treatment are found to harbor virus with mutations conferring resistance to a particular drug.
Maribavir is a potent member of a new class of drugs, the benzimidazole ribosides, which bind to viral 
serine/threonine kinase (UL97) that plays a role in nuclear viral egress, viral replication, or 
regulation of host cell cycle. Favorable results from a Phase 2 study support the safety, 
tolerability, and anti-viral activity of maribavir as a potential option for the treatment of CMV 
infections that are refractory to treatment with ganciclovir, valganciclovir, foscarnet, or cidofovir,
including CMV infections with confirmed resistance to anti-CMV agents, in HSCT and SOT 
recipients. Consequently, Study SHP620-303 has been designed to further assess the efficacy of 
maribavir 400 mg twice daily (BID) treatment compared to investigator-assigned anti-CMV 
treatment in HSCT and SOT recipients with refractory CMV infections, including confirmed 
resistance to prior anti-CMV treatment.
The study will enroll pediatric subjects ≥12 to <18 years of age. Inclusion of adolescent patients in the study is 
based on the population PK modeling that showed that the same systemic exposures are reached in 
individuals ≥35 kg dosed with 400 mg BID of maribavir. Maribavir metabolism and excretion are 
not expected to differ in adolescents and adults, as the primary metabolism is through liver 
enzymes CYP3A4, CYP 2C19 and CYP 1A2 that reach adult levels in children of 1-2 years of age 
(Lu et al. 2014). It is not expected that the bioavailability and systemic exposure to maribavir in 
adolescent subjects of 12-18 years of age is different from adults at the same oral dose.
Study treatment
Investigational product, dose, and mode of administration:
Maribavir
The sponsor will provide maribavir 200 mg strength tablets, which will be administered orally (PO) at 400 mg twice 
daily (BID).
Investigator-assigned anti-CMV drugs:
Ganciclovir
Valganciclovir
Foscarnet
Cidofovir
Investigators will choose and administer/prescribe the anti-CMV agent best suited to treat the respective subject’s 
CMV infection based on their clinical judgment. The anti-CMV agents of choice include the 
following commercially available drugs: ganciclovir, valganciclovir, foscarnet, or cidofovir. In 
clinical practice, these agents are utilized for treatment of CMV infection/disease and endorsed by 
published guidelines (Kotton et al. 2013; Tomblyn et al., 2009), and by local institutional 
guidelines. The dose of these agents will be determined by the Investigator. 
Methodology:
This is a multicenter, randomized, open-label, active-controlled study to assess the efficacy and safety of maribavir 
treatment compared to investigator-assigned anti-CMV treatment in HSCT and SOT recipients with CMV infections 
that are refractory to treatment with ganciclovir, valganciclovir, foscarnet, or cidofovir, including CMV infections 
with confirmed resistance to 1or more anti-CMV agents. The study will assess the efficacy of maribavir by 
measuring the plasma CMV DNA clearance. To be eligible for the study, subjects must have a documented CMV 
infection in whole blood or plasma, with a screening value of ≥2730 IU/mL in whole blood or ≥910 IU/mL in 
plasma in 2 consecutive assessments, separated by at least 1 day, as determined by local or central specialty 
laboratory quantitative polymerase chain reaction (qPCR) or comparable quantitative CMV DNA results. Results 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 19 
 
07 Dec 2018
For non-commercial use only


Shire
Page 20
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
should be available before the subject is randomized to verify subject eligibility for the study. Both samples should 
be taken within 14 days prior to randomization with the second sample obtained within 5 days before randomization 
and will be used for the stratification level for the randomization. The same laboratory must be used for these 
assessments. The CMV infection must be refractory to 1 or more of the anti-CMV agents (ganciclovir, 
valganciclovir, foscarnet, or cidofovir) and the subjects must meet the remaining specified eligibility criteria.
“Refractory” will be defined as: 
Documented failure to achieve >1 log10 (common logarithm to base 10) decrease in CMV DNA level in whole 
blood or plasma after a 14 day or longer treatment period with IV ganciclovir/oral valganciclovir, IV foscarnet, or 
IV cidofovir. This definition applies to the current CMV infection and the most recently administered anti-CMV 
agent. 
“Resistant” will be defined as: 
Documented failure to achieve >1 log10 (common logarithm to base 10) decrease in CMV DNA level in whole 
blood or plasma after a 14 day or longer treatment period with IV ganciclovir/oral valganciclovir, IV foscarnet, or 
IV cidofovir . This definition applies to the current CMV infection and the most recently administered anti-CMV 
agent.
AND
Documentation of 1 or more CMV genetic mutations associated with resistance to ganciclovir/valganciclovir, 
foscarnet, and/or cidofovir.
Results from the same laboratory and the same sample type (whole blood or plasma) are to be used to determine the 
refractoriness. Note: Failure to respond to these agent(s) due to intolerance will not be considered ‘refractoriness’.
The documentation of the resistance during screening will be based on the local specialty laboratory genotyping 
assay results. Plasma samples obtained at baseline for CMV DNA genotyping will be used for the final 
determination of mutations in the UL97, UL27, and UL54 genes known to confer resistance to anti-CMV agent; this 
assessment will be based on the results from the central specialty laboratory and utilized for analysis. Subject 
enrollment will be monitored to achieve an approximate target of 60% of subjects who have a CMV infection with 
documented resistance to any of the anti-CMV agents (ganciclovir, valganciclovir, foscarnet, or cidofovir) according 
to the central specialty results from samples taken at baseline.
The subjects randomized to maribavir treatment arm will discontinue the therapy they were currently on at the time 
of enrollment. For subjects randomized to the investigator assigned treatment arm, the investigator will determine at 
the time of randomization/treatment initiation whether the subject will change the therapy they were currently on at 
the time of enrollment, or will remain on the same therapy (single or dual anti-CMV agent therapy) after 
randomization (per Inclusion Criterion 5). If the treatment was continued or started as 2 anti-CMV agents, 
withdrawal of 1 agent, while continuing the second one will be possible. Addition of or switch to another anti-CMV 
agent will be declared as a failure for the purpose of study analysis. After randomization changes to the investigator 
treatment of choice could include, change in dosing, dosing regimen, but will not include an addition of or switch to 
another anti-CMV agent. Note that changes between IV ganciclovir and oral valganciclovir are allowed. 
Combination therapy with cidofovir and foscarnet is prohibited.
All eligible subjects will be stratified by transplant type (HSCT or SOT) and screening whole blood or plasma CMV 
DNA concentration (high viral load with CMV DNA ≥273000 IU/mL in whole blood or ≥91000 IU/mL in 
plasma, intermediate viral load ≥27300 IU/mL and <273000 IU/mL in whole blood or ≥9100 IU/mL and <91000 
IU/mL in plasma, and low viral load <27300 IU/mL and ≥2730 IU/mL in whole blood or CMV DNA <9100 
IU/mL and ≥910 IU/mL in plasma as determined by the most recent local or central specialty laboratory qPCR 
results available at the time of randomization) as 2 stratification factors and then randomized in a 2:1 allocation ratio 
to receive maribavir 400 mg BID or investigator-assigned anti-CMV treatment for 8 weeks.
A cohort of subjects will have tissue-invasive CMV disease or CMV syndrome at baseline, as determined by the 
investigator (also referred as “symptomatic subjects”). Therefore, this study will also assess improvement or 
resolution of tissue-invasive CMV disease and CMV syndrome at the end of the 8-week study treatment phase and 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 20 
 
07 Dec 2018
For non-commercial use only


Shire
Page 21
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
during the follow-up phase for subjects with symptomatic infection present at baseline. “Asymptomatic subjects” 
will be defined as: Eligible enrolled subjects who do not have tissue-invasive CMV disease or CMV syndrome at 
baseline, as diagnosed by the investigator.
The investigator will perform the initial diagnosis of tissue invasive CMV disease or CMV syndrome (absence or 
presence) for the symptomatic subjects at baseline and new occurrence of tissue invasive CMV disease or CMV 
syndrome for the asymptomatic subjects at baseline through the study, and will continue with the assessment of the 
status (ie, no change, improvement, worsening, or resolution) at subsequent visits through the study. All 
investigator-assessed cases of tissue invasive CMV disease and CMV syndrome will be reviewed and adjudicated by 
an independent Endpoint Adjudication Committee (EAC) both for the confirmation of the diagnosis of baseline and 
new symptomatic CMV infection and for the outcome (ie, no change, improvement, worsening, or resolution).
An independent data monitoring committee (DMC) will be established to act in an expert, advisory capacity for 
periodic assessment of the data to monitor participant safety and to ensure the validity and scientific merit of the 
trial.
As shown in the study schematic in the Study Design Flow Chart (below), the study will have 3 phases: (1) Up to a 
2-week screening phase; (2) 8-week study treatment phase; and (3) 12-week follow-up phase. Subjects will be 
required to visit the site up to 19 times for up to a 22-week period. Subjects entering the maribavir rescue arm may 
participate in the study for a longer duration, depending on the time of the transition from the investigator-assigned 
study treatment to maribavir, with a maximal time of 29 weeks.
Screening Phase
Approximately 413 subjects will be screened during an approximately 2-week screening phase to establish 
eligibility for study participation. Historical laboratory results for tests specified in the Schedule of Assessment 1 
may be used during screening for the assessment of the eligibility, including local CMV DNA quantification test 
results. If local laboratory results are not available, the central laboratory assessments may be conducted. All clinical 
laboratory results required for eligibility verification must be available prior to randomization.
Study Treatment Phase
Approximately 351 eligible subjects with refractory or resistant CMV infection will be stratified and then 
randomized at Visit 2/Day 0 to receive either maribavir or investigator-assigned anti-CMV treatment (IAT) 
(collectively, study-assigned treatment) for 8 weeks.
The screening and Visit 2/Week 0/Day 0 visits can occur on the same day in the case when historical local 
laboratory results are available for determination of eligibility.
All Visit 2/Day 0 procedures and screening laboratory results needed to confirm eligibility must be completed and 
documented prior to randomization and study treatment administration. The whole blood/plasma samples for CMV 
DNA quantification, hematology, and chemistry testing must be taken for all patients at Visit 2/Week 0/Day 0. The 
test results of these assays will not be available prior to the start of treatment. Initiation of study treatment (ie, first 
dose) will only occur after completion of all required Visit 2/Day 0 procedures, confirmation of eligibility, and 
completion of randomization. This will be done under the supervision of investigator site personnel.
Subjects Randomized to Maribavir Treatment
Depending on the time of the first maribavir dose on Visit 2/Day 0, a second dose should be administered on 
Visit 2/Day 0 provided that doses can be separated by a minimum of 8 hours; otherwise, only 1 dose will be 
administered on Visit 2/Day 0. Maribavir will then be administered (preferably) every 12 hours (q12h). When q12h 
dosing is not feasible, the doses should be separated by a minimum of 8 hours. Since 200 mg strength maribavir 
tablets will be utilized, subjects will be required to take 2 tablets of maribavir q12h as shown below.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 21 
 
07 Dec 2018
For non-commercial use only


Shire
Page 22
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Maribavir Dosing Regimen
Regimen
AM
PM
400 mg BID
200 mg × 2 tablets
200 mg × 2 tablets
Subjects will take the maribavir 400 mg BID dose for the 8 weeks of the study treatment phase.
Subjects Randomized to Investigator-Assigned Anti-CMV Therapy
Investigator-assigned anti-CMV treatment strategies for the 8 weeks of the study treatment phase must only utilize 
up to 2 available anti-CMV agents from the following: ganciclovir, valganciclovir, foscarnet, or cidofovir (foscarnet 
and cidofovir in combination is prohibited).
After randomization, changes to the investigator treatment of choice could include, change in dosing, change in 
dosing regimen, but will not include a switch to or an addition of another anti-CMV agent (switching between 
valganciclovir and ganciclovir is allowed). The rationale for dose adjustment will be documented. Investigational 
anti-CMV agents are not permitted.
Subjects will follow the investigator’s prescribed anti-CMV treatment. Subjects will remain on their investigator-
assigned anti-CMV therapy for the 8 weeks of the study treatment phase. Subjects may stop treatment at the 
discretion of the investigator, for lack of confirmed viremia clearance and/or intolerance to the assigned treatment. 
Subjects may be assessed for rescue arm eligibility at the investigator’s discretion. Intolerance to assigned treatment 
without clear evidence of virologic and/or clinical failure will not qualify a patient for the rescue arm. Viremia 
clearance should be based on the results from the same laboratory used for randomization. Subjects may be assessed 
for entry into a rescue arm, starting at Visit 5/Week 3 (after a minimum 3 weeks of treatment), for treatment with 
maribavir 400 mg BID for 8 weeks. Subjects must meet 1 of the following criteria to be eligible to enter the 
maribavir rescue arm:
1.
Subject has increased whole blood or plasma CMV viremia levels of ≥1 log10 from baseline as measured 
by the local or central specialty laboratory qPCR assay (results from the same laboratory will be 
compared). Local specialty laboratory results must be documented.
2.
Subjects with tissue invasive CMV disease must meet both criteria after being on treatment for at least 
3 weeks:

Subject whole blood or plasma CMV DNA has decreased <1 log10 from baseline as measured by the 
local or specialty laboratory qPCR assay (results from the same laboratory will be compared). Local 
specialty laboratory results must be documented.

Symptomatic subject’s presenting tissue invasive CMV disease did not improve, or worsened as 
assessed by the investigator OR subject who was asymptomatic at baseline developed tissue invasive 
CMV disease.
3.
No CMV viremia clearance was achieved (results from the same laboratory will be assessed) necessitating 
continued anti-CMV treatment AND the subject has demonstrated intolerance to the investigator-assigned 
anti-CMV treatment as evidenced by 1 of the conditions:

Acute increase in serum creatinine, at least 50% increase from the baseline value, attributed to 
treatment (cidofovir, foscarnet) toxicity

Development of hemorrhagic cystitis when on treatment with cidofovir or foscarnet

Development of neutropenia (absolute neutrophil count [ANC <500/mm3 [0.5 x 109/L]) when on 
treatment with ganciclovir or valganciclovir
The transition into the rescue arm will be allowed after the study medical monitor has reviewed the investigator’s 
request and has approved the subject’s eligibility for the rescue arm. Blood sample taken for CMV DNA test at the 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 22 
 
07 Dec 2018
For non-commercial use only


Shire
Page 23
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
first visit of the maribavir rescue treatment period will be used as the ‘baseline’ assessment for the purpose of the 
analyses of the response to maribavir rescue treatment (including resistance analyses). Subjects who are unable to 
continue taking investigator-assigned anti-CMV treatment due to the lack of anti-viral activity and/or intolerance to 
the assigned treatment and who do not meet the eligibility criteria to enter the maribavir rescue arm will be treated 
as deemed appropriate by the investigator.
The investigator may also choose to interrupt therapy for a maximum of 7 consecutive days, or up to 2 study 
treatment interruptions for a total of up to 7 days. This will not result in permanent study treatment 
discontinuation. If study drug is interrupted for any reason and subsequently resumed, the end of 
the study drug administration period would remain fixed at a maximum of 8 weeks after the date 
of the start of treatment.
All subjects will undergo study-specific evaluations weekly during the study treatment phase. All subjects who 
complete the study treatment phase through Visit 10/Week 8 will enter the 12-week follow-up 
phase.
Subjects who prematurely discontinue study treatment in the investigator assigned treatment arm, and are not 
transferred to the maribavir rescue arm, will complete the end of treatment procedures described 
for Visit 10/Study Week 8 in the Schedule of Assessment 1. These subjects will continue on a 
modified schedule of assessments through the remaining weekly visits scheduled for the study 
treatment phase and the regular schedule of assessments through the 12-week follow-up phase. 
The end of treatment sample for immunosuppressant drug concentration level will be collected at 
the next visit scheduled 1 week after the treatment discontinuation. Subjects who discontinue 
maribavir treatment early will not be asked to complete the following procedures after the end of 
treatment visit for subsequent visits in the treatment phase: the use of the diary for study treatment 
compliance, dispense or use of any study treatment, and PK sample collection. After completing 
the 8-week duration specified for the study treatment phase, subjects will enter the 12-week 
follow-up phase. During the period after the study treatment discontinuation, and until the end of 
the study, subjects might be administered an anti-CMV treatment for lack of efficacy, recurrence 
of CMV viremia, or for worsening or new onset of CMV disease as deemed necessary by the 
investigator. Subjects who withdraw from the study during the follow-up phase will perform the 
end of study evaluations and procedures for Visit 18/Week 20 (Follow-up Week 12) as soon as 
possible.
Subjects who withdraw consent during the study treatment phase will be asked to undergo all end of treatment 
evaluations and procedures listed for Visit 10/Week 8. Subjects who withdraw from the study 
during the follow-up phase will undergo all end of study evaluations and procedures listed for 
Visit 18/Week 20 (Follow-up Week 12) as soon as possible and whenever possible, prior to 
initiation of any nonstudy anti-CMV treatment (as deemed by the investigator) for lack of 
efficacy, recurrence of CMV viremia, or for worsening or new onset of CMV disease; no further 
follow-up will be performed.
Subjects who are transferred to maribavir rescue arm will complete the end of treatment evaluations listed for 
Visit 10/Week 8 prior to being transferred. They will be treated with maribavir for 8 weeks and 
will follow the procedures in the manner similar to that followed by subjects in the maribavir 
treatment arm, as indicated in the Schedule of Assessment 1 (visits denoted with letter R). After 
the completion of 8 weeks of maribavir rescue treatment, subjects will enter the 12-week follow-
up phase and will follow the procedures indicated in the Schedule of Assessment 2.
Follow-up Phase
Study-specific evaluations including central specialty laboratory CMV testing and safety assessments will occur 
weekly for the first 4 weeks, then every 2 weeks for the final 8 weeks of the 12-week follow-up 
phase. Refer to Schedule of Assessment 2 for a complete list of the evaluations.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 23 
 
07 Dec 2018
For non-commercial use only


Shire
Page 24
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Study Design Flow Chart
*Visit 2A/A-R is only required for subjects taking tacrolimus, cyclosporine, everolimus, or sirolimus at Visit 
2/2R.
BID=twice daily; BL=baseline; R=rescue; Rand=randomized; wks=weeks
Note: Eligibility to enter maribavir rescue arm will be assessed starting at Visit 5/Week 3 up to Visit 9/Week 7
Notable Study Evaluations during Study Treatment Phase and Follow-up Phase
CMV DNA Quantitation 
Blood samples will be assessed at a central specialty laboratory for the quantitation of CMV DNA in plasma using 
the COBAS® AmpliPrep/COBAS® TaqMan® CMV Test. Central Specialty laboratory plasma 
CMV DNA results will be reported to the investigator site as available. Additional CMV DNA 
testing at local specialty laboratories may be performed at more frequent intervals or use 
additional assay methods at the discretion of the investigator.
Confirmed CMV viremia clearance will be defined as plasma CMV DNA concentration below the lower limit of 
quantification (<LLOQ; ie, <137 IU/mL]), when assessed by COBAS® AmpliPrep/COBAS®
TaqMan® CMV Test at a central specialty laboratory, in 2 consecutive post-baseline samples, 
separated by at least 5 days.
Recurrence or the recurrence of CMV viremia will be defined as plasma CMV DNA concentration ≥LLOQ when 
assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive plasma samples 
at least 5 days apart, after achieving confirmed viremia clearance. Every attempt should be made 
to collect the 2 consecutive plasma samples and monitor results to confirm recurrence.
CMV genotyping and phenotyping
Visit 2/Day 0 plasma samples will be used for CMV DNA genotyping to identify mutations in the viral UL97 and 
UL54 genes known to confer resistance to commercially available anti-CMV agents. In addition, viral UL27 gene 
will be tested. During the study, CMV genotyping will be conducted when the CMV DNA viral load is above a 
predefined cut off level (validated for this assay) in cases of failure to clear viremia during treatment, cases of 
recurrence of viremia on and off treatment and cases of viremia rebound if >1 log10 above nadir while on treatment 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 24 
 
07 Dec 2018
For non-commercial use only


Shire
Page 25
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
(rebound is defined as increase in viral DNA load for >1 log10 above nadir without prior clearance of viremia). The 
entire UL97, UL27, and UL54 CMV genes will be sequenced in every sample that meets the criteria for genotyping, 
including the baseline samples. Additionally, virus susceptibility testing will be performed on selected de novo 
CMV variant sequences of the relevant gene of maribavir treated subjects by recombinant resistance phenotyping. 
Details of the analysis will be specified in the resistance analysis plan.
Symptomatic CMV Infection Assessment
Tissue-invasive CMV disease will be defined as described by Ljungman et al. (2002 and 2017). The gold standard 
for diagnosing CMV tissue invasive disease is the identification of CMV inclusions in the infected cells of the 
tissues OR identification of CMV in biopsy tissue samples. However, in some cases both diagnostic methods are 
required when tissue samples have a high chance of being contaminated by body fluids that shed virus 
(bronchoalveolar lavage [BAL], urine or stool). In some subjects, when it is not possible to obtain a tissue biopsy, a 
culture of CMV from body fluids or CMV DNA quantitation (for selected cases) may be used to confirm diagnosis, 
with a lower level of confidence in diagnosis. CMV syndrome (in SOT subjects only) will also be defined as 
described by Ljungman et al. (2017), and requires at least 2 of 6 signs and symptoms to be present (see Appendix 3 
for full description of criteria).
All subjects will be monitored for the occurrence of CMV tissue invasive disease and CMV syndrome throughout 
the study. For symptomatic subjects who present with tissue invasive CMV disease and CMV 
syndrome at baseline, the investigator will document the initial diagnosis of CMV tissue invasive 
disease and CMV syndrome at Visit 2/Day 0 (ie, absence or presence at baseline) and all serial 
assessments of infection status (ie, no change, improvement, worsening, or resolution) at all 
subsequent visits in the study. Case charts documenting the symptomatic infection diagnosis 
(present at baseline or new symptomatic infection) and follow-up infection status at study visits 
will be provided for adjudication to an independent Endpoint Adjudication Committee. The roles, 
responsibilities, and rules governing operation of the independent Endpoint Adjudication 
Committee will be fully documented in an Endpoint Adjudication Committee charter.
The recurrence of symptomatic CMV infection will be defined as the presence of signs or symptoms of the tissue 
invasive CMV disease or CMV syndrome (same or new symptomatology) confirmed as per Ljungman et al. (2017) 
after the period of resolution of symptomatic CMV infection in subjects symptomatic at baseline.
In subjects asymptomatic at baseline, the occurrence of new CMV tissue invasive disease or CMV syndrome after 
start of study treatment will be initially assessed by the investigator followed by adjudication by 
the EAC.
Inclusion and exclusion criteria:
Inclusion Criteria:
1.
The subject must be able to provide written, personally signed, and dated informed consent to participate in the 
study before completing any study-related procedures. As applicable, a parent/both parents or legally authorized 
representative (LAR) must provide signature of informed consent and there must be documentation of assent by 
the subject before completing any study-related procedures.
2.
The subject must be a recipient of hematopoietic stem cell or solid organ transplant.
3.
The subject must have a documented CMV infection in whole blood or plasma, with a screening value of 
≥2730 IU/mL in whole blood or ≥910 IU/mL in plasma in 2 consecutive assessments, separated by at least 1 
day, as determined by local or central specialty laboratory quantitative polymerase chain reaction (qPCR) or 
comparable quantitative CMV DNA results. Both samples should be taken within 14 days prior to 
randomization with second sample obtained within 5 days prior to randomization. The same laboratory and 
same sample type (whole blood or plasma) must be used for these assessments.
4.
The subject must have a current CMV infection that is refractory to the most recently administered of the four 
anti-CMV treatment agent(s). Refractory is defined as documented failure to achieve >1 log10 (common 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 25 
 
07 Dec 2018
For non-commercial use only


Shire
Page 26
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
logarithm to base 10) decrease in CMV DNA level in whole blood or plasma after a 14 day or longer treatment 
period with IV ganciclovir/oral valganciclovir, IV foscarnet, or IV cidofovir. 

Subjects who have documentation of 1 or more CMV genetic mutations associated with resistance to 
ganciclovir/valganciclovir, foscarnet, and/or cidofovir must also meet the definition of refractory CMV 
infection.
5.
The investigator must be willing to treat the subject with at least 1 of the available anti-CMV drugs 
(ganciclovir, valganciclovir, foscarnet, or cidofovir). Note: Combination therapy with foscarnet and cidofovir is 
not permitted in the IAT arm due to the potential for serious nephrotoxicity.
6.
The subject must be ≥12 years of age at the time of consent.
7.
The subject must weigh ≥35 kg.
8.
The subject must have all of the following results as part of screening laboratory assessments (results from 
either the central laboratory or a local laboratory can be used for qualification):
a.
Absolute neutrophil count (ANC) ≥1000/mm3 [1.0 x 109/L]
b.
Platelet count ≥25000/mm3 [25 x 109/L]
c.
Hemoglobin ≥8g/dL
d.
Estimated glomerular filtration rate (eGFR) >30 mL/min/1.73m2 as assessed by Modification of Diet in 
Renal Disease (MDRD) formula for subjects ≥18 years of age or Schwartz formula for subjects 
<18 years of age (see Appendix 12 for the formulae).
9.
The subject must have a negative serum β-human chorionic gonadotropin (β-HCG) pregnancy test at screening, 
if a female of child bearing potential. Additional urine pregnancy tests may be done per institutional 
requirements; however they are not sufficient for eligibility determination. Sexually active females of child 
bearing potential must agree to comply with any applicable contraceptive requirements of the protocol. If male, 
must agree to use an acceptable method of birth control, as defined in the protocol, during the study treatment 
administration period and for 90 days afterward if treated with maribavir, ganciclovir, valganciclovir, or 
cidofovir and for 180 days afterward if treated with foscarnet.
10. The subject must be able to swallow tablets, or receive tablets crushed and/or dispersed in water via a 
nasogastric or orogastric tube.
11. The subject must be willing and have an understanding and ability to fully comply with study procedures and 
restrictions defined in the protocol.
12. The subject must be willing to provide necessary samples (eg, biopsy) for the diagnosis of tissue invasive CMV 
disease at baseline as determined by the investigator.
13. The subject must have a life expectancy of ≥8 weeks.
Exclusion Criteria:
Subjects must not:
1.
Have a current CMV infection that is considered refractory or resistant due to inadequate adherence to prior 
anti-CMV treatment, to the best knowledge of the investigator.
2.
Require ganciclovir, valganciclovir, foscarnet, or cidofovir administration for conditions other than CMV when 
study treatment is initiated (example: herpes simplex virus (HSV) coinfection requiring use of any of these 
agents after the randomization) or would need a coadministration with maribavir for CMV infection. NOTE: A 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 26 
 
07 Dec 2018
For non-commercial use only


Shire
Page 27
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
subject who is not continuing with the same anti-viral drug(s) (ganciclovir, valganciclovir, or foscarnet) for the 
study treatment (if randomized to the investigator assigned anti-CMV treatment arm), must discontinue their 
use before the first dose of study drug. If subject is currently being treated with cidofovir and is assigned 
another anti-CMV therapy by the investigator, the subject must discontinue its use at least 14 days prior to 
randomization at Visit 2/Day 0 and the first dose of study treatment.
3.
Be receiving leflunomide, letermovir, or artesunate when study treatment is initiated. NOTE: subjects receiving 
leflunomide must discontinue the use at least 14 days prior to randomization at Visit 2/Day 0 and the first dose 
of study treatment. Subjects receiving letermovir must discontinue at least 3 days prior to the first dose of study 
treatment. Subjects receiving artesunate must discontinue the use prior to the first dose of study treatment.
4.
Have severe vomiting, diarrhea, or other severe gastrointestinal illness within 24 hours prior to the first dose of 
study treatment that would preclude administration of oral/enteral medication.
5.
Have known hypersensitivity to the active substance or to an excipient for a study treatment.
6.
Have tissue invasive CMV disease with central nervous system involvement, including the retina (eg CMV 
retinitis).
7.
Have serum aspartate aminotransferase (AST) >5 times upper limit of normal (ULN) at screening, or serum 
alanine aminotransferase (ALT) >5 times ULN at screening, or total bilirubin ≥3.0 x ULN at screening (except 
for documented Gilbert’s syndrome), by local or central lab. Note: Subjects with biopsy confirmed CMV 
hepatitis will not be excluded from study participation despite AST or ALT >5 times ULN at screening.
8.
Have known positive results for human immunodeficiency virus (HIV). Subjects must have a confirmed 
negative HIV test result within 3 months of study entry or, if unavailable, be  tested by a local laboratory during 
the screening period.
9.
Require mechanical ventilation or vasopressors for hemodynamic support at the time of enrollment.
10. Be female and pregnant or breast feeding.
11. Have previously received maribavir.
12. Have received any investigational agent with known anti-CMV activity within 30 days before initiation of study 
treatment or CMV vaccine at any time. 
13. Have received any unapproved agent or device within 30 days before initiation of study treatment.
14. Have active malignancy with the exception of nonmelanoma skin cancer. Subjects who have had a HSCT and 
who experience relapse or progression of the malignancy, as per investigator’s opinion are not to be enrolled.
15. Be undergoing treatment for acute or chronic hepatitis C.
16. Have any clinically significant medical or surgical condition that in the investigator’s opinion could interfere 
with the interpretation of study results, contraindicate the administration of the assigned study treatment, or 
compromise the safety or well-being of the subject.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 27 
 
07 Dec 2018
For non-commercial use only


Shire
Page 28
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Maximum duration of subject involvement in the study:

Planned duration of screening phase: Up to 2 weeks

Planned duration of study treatment phase: 8 weeks

Planned duration of follow-up phase: 12 weeks

Planned duration of maribavir rescue arm including follow-up (as applicable): Up to 29 weeks 
Endpoints and statistical analysis:
Subject Population Sets:

The enrolled set will consist of all subjects who have signed an informed consent and have begun some study 
procedures.

The randomized set will consist of all subjects in the enrolled set who have been randomized to the study. 
Subjects will be analyzed in the treatment group to which they are randomized.

The safety set will consist of all subjects who have taken any dose of study treatment. Subjects will be analyzed 
according to the treatment actually received.

The per-protocol (PP) set will consist of all subjects in the randomized set who do not have predefined major 
protocol deviations that may affect the primary efficacy assessment.

The pharmacokinetic set will consist of all subjects in the safety set who had plasma samples drawn and tested 
for maribavir concentrations.
-
The adolescent pharmacokinetic set will consist of all subjects ≥12 to <18 years of age in the safety set 
who had plasma samples drawn and tested for maribavir concentrations.
The randomized set and the PP set will be used for efficacy analyses, with the randomized set as the primary 
analysis set and the PP set as the supportive one. 
Sample Size Justification:
In Study SHP620-202, the proportion of subjects with undetectable plasma CMV DNA was 70%, 63%, and 68% for 
the 400 mg, 800 mg, and 1200 mg BID dose groups, respectively, within 6 weeks. The proportion of subjects with 
undetectable plasma CMV DNA was 70%, 65%, and 75% for the 400 mg, 800 mg, and 1200 mg BID dose groups, 
respectively, within 12 weeks. Therefore, it is assumed that at least 60% of maribavir treated subjects will have 
achieved undetectable plasma CMV DNA at Visit 9/Week 7 and Visit 10/Week 8 when calculating the sample size.
A proportion of approximately 40% is considered as a reasonable estimate of the proportion of subjects with 
confirmed undetectable plasma CMV DNA at Visit 9/Week 7 and Visit 10/Week 8 in the investigator assigned 
treatment group when calculating the sample size. It is believed that the treatment difference of 20% higher in 
maribavir group compared to control group is larger than a clinically meaningful difference.
For the proposed trial, to demonstrate statistical superiority in the reduction of CMV DNA, it is assumed that the 
proportion of subjects with confirmed unquantifiable plasma CMV DNA at Visit 9/Week 7 and Visit 10/Week 8 in 
the maribavir and control groups is 60% and 40%, respectively, a total of 315 subjects is required in the ratio of 2:1 
(210 subjects in maribavir group and 105 subjects in the control group) to provide 90% power in hypothesis testing 
at an alpha level of 0.05 (2-sided test). The sample size is estimated based on a 2-group continuity corrected 
Chi-square test of equal proportions by using nQuery Advisor 7.0. Considering 10% drop-outs, 351 subjects 
(234 subjects in maribavir group and 117 subjects in the control group) will be enrolled and randomized.
Primary Efficacy Endpoint:
The primary efficacy endpoint (a binary response) for the study is confirmed clearance of plasma CMV DNA (CMV 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 28 
 
07 Dec 2018
For non-commercial use only


Shire
Page 29
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
viremia clearance) at the end of Study Week 8.
For clearance of CMV viremia to be declared at the end of Study Week 8 during the treatment period, the subject 
must have received exclusively study-assigned treatments.
Confirmed CMV viremia clearance at the end of Study Week 8 (Visit10) is defined as plasma CMV DNA 
concentrations <LLOQ (ie, <137 IU/mL), when assessed by COBAS® AmpliPrep/COBAS®
TaqMan® CMV Test at a central specialty laboratory, in 2 consecutive postbaseline samples 
separated by at least 5 days, regardless of whether either study-assigned treatment was 
discontinued before the end of the stipulated 8 weeks of therapy (see examples table below).
Assessments of Virological Responders at Study Week 8
Scenari
CMV DNA Weeks on Study
Response
Rationale
Week 6
Week 7
Week 8
Week 9*
1
+ / -
-
-
+/-/NA
Yes
2 consecutive “-” at Week 7 and 
Week 8
2
+ / -
-
+
+/-/NA
No
Not 2 consecutive “-” at Week 7 
and Week 8
3
+ / -
+
-
+/-/NA
No
Not 2 consecutive “-” at Week 7 
and Week 8
4
+ / -
-
NA
-
Yes
2 consecutive “-” as shown by 
available data and 
both “-” at week 
7 and week 9 for 
missing week 8, 
otherwise 
nonresponder
5
-
NA
-
+/-/NA
Yes
2 consecutive “-” as shown by 
available data and 
both “-” at week 
6 and week 8 for 
missing Week 7, 
otherwise 
nonresponder
6
-
NA
NA
-
Yes
2 consecutive “-” as shown by 
available data at 
week 6 and week 
9 and both “-”, 
otherwise 
nonresponder
NA = not available for evaluation of study drug effect; reason could be starting alternative anti-CMV treatment, 
withdrawal from study, etc.
*Week 9 data to be used only if Week 8 data is unavailable or missing.
Note: Scenarios in the table above are provided as examples and may not be all-inclusive of all possibilities.
Only CMV DNA data evaluable for assessment of effect of study drug will be included (ie, prior to the start 
of alternative anti-CMV treatment if any).
“-” = CMV DNA concentration <LLOQ (<137 IU/mL)
“+” = CMV DNA concentration ≥LLOQ (ie, quantifiable)
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 29 
 
07 Dec 2018
For non-commercial use only


Shire
Page 30
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Confirmed clearance of plasma CMV DNA (CMV viremia clearance) =2 consecutive post baseline 
assessments of CMV DNA target <LLOQ, separated by at least 5 days.
Statistical Methodology for Primary Efficacy Endpoint:
The difference in proportion of subjects with confirmed CMV viremia clearance, at the end of Study Week 8, 
between treatment groups (maribavir and investigator’s choice of anti-CMV treatment) will be obtained using 
Cochran-Mantel-Haenszel (CMH) weighted average across all strata, and assessed using CMH test with transplant 
type and baseline plasma CMV DNA concentration as 2 stratification factors. The baseline plasma CMV DNA 
levels will be the last central laboratory assessment before the first dose of study treatment. If the p-value from the 
CMH test is ≤0.05 and the proportion of response from maribavir is higher, it will be concluded that maribavir is 
more efficacious compared to the control group.
Subjects in the investigator-assigned treatment arm who are unable to continue taking investigator-assigned 
anti-CMV treatment due to the lack of anti-viral activity and/or intolerance to the assigned treatment (as evaluated 
starting at Visit 5/Week 3) may be evaluated for entry into a maribavir rescue arm. Subjects who take rescue 
medication will be considered as failures for primary efficacy analyses. The data collected post- maribavir rescue 
initiation, will be included in separate secondary analyses for efficacy and exploratory analysis for PK. Summary of 
all safety analyses will be provided separately for the maribavir rescue arm. The same is applicable for patients who 
might be discontinued from maribavir treatment due to intolerance. Subjects who discontinue due to intolerance and 
without viremia clearance at Study Week 8 will be considered failures in both treatment arms.
Key Secondary Endpoint:
The key secondary endpoint of this study is:

Achievement of CMV viremia clearance and resolution or improvement of symptomatic CMV infection 
(tissue invasive CMV disease or CMV syndrome (in SOT subjects only) for subjects symptomatic at
baseline or achievement of clearance of viremia and no symptoms of tissue invasive CMV disease or CMV 
syndrome for subjects asymptomatic at baseline at the end of Study Week 8, followed by maintenance of 
this treatment effect for an additional 8 weeks off-treatment (ie, Follow-up Week 16).
For treatment effect of clearance of CMV viremia and CMV infection symptom control (resolution or improvement 
of tissue invasive disease or CMV syndrome for symptomatic subjects at baseline, or no new symptoms for subjects 
asymptomatic at baseline) to be declared at the end of Study Week 8, and maintenance of such effect through Week 
16, the subject must have received exclusively a study-assigned treatment.
The investigator will perform the initial diagnosis of tissue-invasive CMV disease or CMV syndrome (absence or 
presence) for the symptomatic subjects at baseline and new occurrence of tissue invasive CMV 
disease or CMV syndrome for the asymptomatic subjects at baseline through the study, and will 
continue with the assessment of the infection status (ie, no change, improvement, worsening, or 
resolution) at subsequent visits through the study. All investigator-assessed cases of tissue 
invasive CMV disease and CMV syndrome will be reviewed and adjudicated by an independent 
EAC both for the confirmation of the diagnosis of baseline and new symptomatic CMV infection 
and for the outcome (ie, no change, improvement, worsening, or resolution).
Endpoint Adjudication Committee adjudicated tissue invasive CMV disease and CMV syndrome will be used for 
the efficacy analyses.
Statistical Methodology for Key Secondary Endpoint:
The key secondary endpoint will be analyzed using the same approach as the primary endpoint.
Multiplicity adjustment: 
The hypothesis testing of the primary and key secondary endpoint will be adjusted for multiple comparisons using a 
fixed sequence testing procedure to control the family-wise Type 1 error rate at α=5% level. The testing will be done 
in the order of primary efficacy endpoint, and the key secondary endpoint. First, the primary endpoint analysis 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 30 
 
07 Dec 2018
For non-commercial use only


Shire
Page 31
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
(CMV viremia clearance at Week 8) will be assessed at α=0.05. If and only after this is statistically significant, the 
key secondary endpoint of response based on maintaining CMV viremia clearance and resolution or 
improvement/no new development in symptoms at the end weeks of study through Follow-up Week 16 will be 
assessed at α=0.05. If this is statistically significant, it will be concluded that effect of maribavir is more sustainable 
compared to the control group at Follow-up Week 16 (ie, 8 weeks off treatment).
Subgroup Analyses:
Analyses for the primary and key secondary endpoints will be conducted for the following subgroups (inclusive, but 
not limited to):

Subjects symptomatic at baseline

SOT/HSCT recipients 

CMV DNA concentration levels (high, medium, low)

Resistant (yes/no)

Adolescents ≥12 to <18 years of age (exploratory analysis: may be conducted if sample size is adequate)
The secondary efficacy endpoints of this study are as follows:

The achievement of the confirmed CMV viremia clearance after 8 weeks of receiving study-assigned treatment.

The achievement of the confirmed CMV viremia clearance and CMV infection symptom control after receiving 
8 weeks of study-assigned treatment, followed by maintenance of this treatment effect through study weeks 12 
(4 weeks post-treatment period), 16 (8 weeks post treatment/follow-up phase), and 20 (12 weeks post 
treatment).

The maintenance of the CMV viremia clearance, and CMV infection symptom control, at the end of Study 
Week 8, through Weeks 12, and 20, regardless of whether either study-assigned treatment was discontinued 
before the end of the stipulated 8 weeks of therapy.

The recurrence of CMV viremia during the first 8 weeks of the study, in the follow-up period of 12 weeks, and 
at any time during the 20 weeks of the study, regardless of whether either study-assigned treatment was 
discontinued before the end of the stipulated 8 weeks of therapy. 

The recurrence of CMV viremia during study-assigned treatment and in the follow-up after the subject is 
discontinued from study-assigned treatment.

The maribavir CMV resistance profile.

All causes mortality by the end of the study (Visit 18/Week 20 [Follow-up Week 12]).
The secondary efficacy endpoints assessed for the maribavir rescue treatment arm are as follows: 

The clearance of plasma CMV DNA at the end of 8 weeks after starting maribavir rescue treatment.

Achievement of viremia clearance at the end of 8 weeks after starting maribavir rescue treatment and resolution 
or improvement of tissue invasive CMV disease or CMV syndrome for subjects who are symptomatic at the 
start of maribavir treatment or subjects who are asymptomatic at the start of maribavir treatment remain 
symptom free, followed by maintenance of the treatment effect for an additional 8 weeks when off maribavir 
rescue treatment (as evidenced by sustained clearance of viremia and improvement or resolution of tissue 
invasive CMV disease or CMV syndrome and no new tissue invasive CMV disease or CMV syndrome 
development between end of treatment and up to Week 16).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 31 
 
07 Dec 2018
For non-commercial use only


Shire
Page 32
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
The exploratory efficacy endpoints are as follows:
Pharmacokinetic endpoints for maribavir treatment and maribavir rescue treatment are as follows:
Secondary endpoint:
For all subjects who received maribavir treatment:

Maribavir Cmin (predose maribavir concentration).
For adolescent subjects who provided intensive PK samples at Visit 3/Week 1:

AUC(0-tau): area under the concentration time curve over the 12-hour dosing interval at steady state

Cmax: maximum concentration

Tmax: time when maximum concentration is observed

CL/F: apparent oral clearance

Vz/F: apparent volume of distribution
Exploratory endpoints:
Safety endpoints and analysis:
The safety analyses will include evaluation and procedures to meet the secondary objective of assessing the safety 
and tolerability of maribavir.
Safety evaluation will be made during the periods as illustrated in the Study Design Flow Chart, ie, screening phase, 
treatment phase, and follow-up phase.
Two observation periods are defined for the purpose of analyses:

The on-treatment observation period starts at the time of study treatment initiation through 7 days after the last 
dose of study treatment or through 21 days if cidofovir is used. For subjects who transfer from the study 
treatment to either maribavir rescue or to a nonstudy CMV treatment, the on treatment observation period starts 
at the time of the study treatment initiation through 7 days after the last dose of study treatment (or through 21 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 32 
 
07 Dec 2018
For non-commercial use only


Shire
Page 33
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
days if cidofovir is used), or until the maribavir rescue treatment initiation or until the nonstudy CMV treatment 
initiation, whichever is earlier. This will serve as the primary analysis of safety.

The overall-study observation period minus the period on rescue arm starts at the time of study treatment start 
through the end of the study. For subjects who receive maribavir rescue therapy, the overall-study observation 
period minus the period on rescue arm starts at the time of study treatment start  through the time before 
receiving maribavir rescue therapy.
Similar observation periods are defined for the safety analysis of the maribavir rescue arm. The events that occur 
from the time of ICF signature to first dose will be collected but will not be evaluated in the safety analyses. They 
will be listed as pretreatment adverse events. 
An AE (classified by preferred term) that has a start date on or after the first dose of study treatment or that has a 
start date before the date of first dose of study treatment, but increases in severity after the first dose of study 
treatment will be considered a treatment-emergent AE (TEAE). 
Safety endpoints will be summarized descriptively for the on treatment period, and overall-study period, as 
appropriate. Baseline assessments will be the last assessment before the first dose of study treatment. The safety set 
will be used to analyze the safety data. Summary of all safety analyses will be provided separately for the maribavir 
rescue arm.
The safety endpoints include the following:

TEAEs and treatment-emergent serious adverse events (SAEs), overall study AEs and overall study SAEs 

Clinical laboratory evaluations
Safety assessment will also include vital sign measurements, physical examination, and ECG.
The number of events, incidence, and percentage of TEAEs and overall-study AEs will be displayed for each 
treatment group by system organ class (SOC) and by Preferred Terms using the Medical Dictionary for Regulatory 
Activities (MedDRA®). Summaries in terms of severity and relationship to study medication will also be provided. 
Treatment-emergent SAEs will be summarized separately in a similar fashion. Summaries of AEs causing 
discontinuation of study medication, withdrawals, AEs leading to death, SAEs, and adverse events of special interest 
(AESI) will be provided. 
Adverse events of special interest, eg, tissue invasive CMV disease, dysgeusia, events of nausea, vomiting, and 
diarrhea, neutropenia, increased immunosuppressant drug concentration levels, graft rejection, opportunistic 
infections, and GVHD will be analyzed according to primary System Organ Classes (SOCs) and Preferred Terms 
(PTs). Additional grading of events of special interest will be applicable. Summary tables with SOCs and PTs will 
be generated presenting the number and percentage of subjects by AE, severity, seriousness, and relationship to 
study medication. 
Usage of concomitant medications will be summarized descriptively for each of the treatment groups and the 
maribavir rescue treatment group for the on treatment period and overall-study period. Treatment of hemopoietic 
growth factors, blood and blood transfusion products will be summarized separately.
Change from baseline in vital signs and clinical laboratory tests will be summarized for each treatment group with 
descriptive statistics at each assessment visit. Summary and shift tables will be produced for selected laboratory 
parameters based on National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE v4.0)
Abnormal physical examination findings will be listed.
Summary of electrocardiogram (ECG) findings will be provided by treatment groups. 
An independent data monitoring committee (DMC) will be established to assess the data for safety and to ensure the 
validity and scientific merit of the trial. Detailed plans for the DMC’s purpose and responsibilities will be described 
in the DMC charter and the statistical analysis plan.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 33 
 
07 Dec 2018
For non-commercial use only


Shire
Page 34
SHP620-303 Protocol Amendment 6
Maribavir 
07
STUDY SCHEDULES
Table 1:
Schedule of Assessment 1: Screening Phase and Study Treatment Phase
Phase
Screening 
Phase
Study Treatment Phaseu
Study Visit / Rescue Arm Visit
1/NA
2/2R
2A/ 
2ARw
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
9/9R
10/10R   (End 
of Treatment)
Study Weeka/Rescue Arm Week
-2 to 0
0/0R
0.5/ 
0.5R
1/1R
2/2R
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
Study Day /Rescue Arm Day
-14 to 0
0c/0R
4/4R
7/7R
14/14R
21/21R
28/28R
35/35R
42/42R
49/49R
56/56R
Informed consentb
X
Inclusion/exclusion criteriac
X
X
Randomization
X
Physical examination 
(including weight)d
X
X
X
Height
X
Weight
X
X
X
Vital signs
X
X
X
X
X
X
Medical history
X
Xe
Prior medications, therapies, 
and procedures
X
Xv
12-lead ECGf
X
X
Hematology/Chemistryg
X
X
X
X
X
X
X
Urinalysisg
X
X
X
X
X
Pregnancy testg, h
X
X
X
X
HIV statusi
X
HBV and HCV testsj
Xj,v
CMV DNA testk
X
X
X
X
X
X
X
X
X
X
Symptomatic CMV infection 
assessmentl
X
X
X
X
X
X
X
X
X
X
X
Immunosuppressant drug 
concentration levels
Xn
Xn
Xn
X
PK sampleso
Xo
Xo
X
Rescue Arm Eligibilityp
Xp
X
X
X
X
Interactive Response 
X
X
X
X
X
X
X
X
X
X
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 34 
 
07 Dec 2018
For non-commercial use only


Shire
Page 35
SHP620-303 Protocol Amendment 6
Maribavir 
07
Table 1:
Schedule of Assessment 1: Screening Phase and Study Treatment Phase
Phase
Screening 
Phase
Study Treatment Phaseu
Study Visit / Rescue Arm Visit
1/NA
2/2R
2A/ 
2ARw
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
9/9R
10/10R   (End 
of Treatment)
Study Weeka/Rescue Arm Week
-2 to 0
0/0R
0.5/ 
0.5R
1/1R
2/2R
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
Study Day /Rescue Arm Day
-14 to 0
0c/0R
4/4R
7/7R
14/14R
21/21R
28/28R
35/35R
42/42R
49/49R
56/56R
Technologyq
Study treatment dispensedr
X
X
X
X
X
X
X
X
Study diarys
X
X
X
X
X
X
X
X
X
X
Invasive bacterial, viral and 
fungal infection/transplant 
relevant infections assessment
X
X
X
X
X
X
X
X
X
Transplant status
X
X
X
X
X
X
X
X
X
GVHD assessment (for HSCT 
subjects only)
X
X
X
X
X
X
X
X
X
Liver function assessment by 
Child-Pugh classification
Xv
Comorbidity status evaluation
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant medications, 
therapies, and procedurest
X
X
X
X
X
X
X
X
X
X
AE/SAE monitoring
X
X
X
X
X
X
X
X
X
X
AE=adverse event; CMV=cytomegalovirus; ECG=electrocardiogram; 
;GVHD=graft-versus-host disease HBV= hepatitis B 
virus; HCV= hepatitis C virus; HIV=human immunodeficiency virus; HSCT= hematopoietic stem cell transplant; hx=history; IRT=interactive response technology 
PK=pharmacokinetic; R= rescue; SAE=serious adverse event;
Note: Subjects in the investigator-assigned anti-CMV treatment arm who discontinue study treatment phase to enter the maribavir rescue arm will follow the study procedures in
the Schedule of Assessment 1 for the study treatment phase, beginning with Study Week 0 (visits denoted as “R”), and will exit after 8 weeks of maribavir 400 mg BID treatment 
to enter the follow-up phase. For subjects entering the maribavir rescue arm on the day of their end-of-treatment visit, duplicate procedures do not need to be repeated.
a
Permissible assessment windows: Study Visit 2A/2AR (Day 4) ± 1 day; Study Visit 3/3R (Day 7) +2 days; Study Weeks 2-4 ± 2 days; Study Weeks 5-8 ± 3 days.
b
Informed consent must be obtained before any study-specific procedures are performed. All screening procedures will be completed within 14 days prior to initiation of 
study treatment, with the exception of: 1) screening clinical laboratory tests (hematology, chemistry, pregnancy), which must be performed within 7 days prior to initiation of study 
treatment; either central or local laboratory results for hematology/chemistry/pregnancy testing can be used for qualification, and 2) documentation of CMV infection in whole 
blood or plasma, with a screening value of ≥2730 IU/mL in whole blood or ≥910 IU/mL in plasma 2 assessments, separated by at least 1 day, as determined by local or central 
specialty laboratory quantitative polymerase chain reaction (qPCR) or comparable quantitative CMV DNA results. Results should be available before the subject is randomized to 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 35 
 
07 Dec 2018
For non-commercial use only


Shire
Page 36
SHP620-303 Protocol Amendment 6
Maribavir 
07
Table 1:
Schedule of Assessment 1: Screening Phase and Study Treatment Phase
Phase
Screening 
Phase
Study Treatment Phaseu
Study Visit / Rescue Arm Visit
1/NA
2/2R
2A/ 
2ARw
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
9/9R
10/10R   (End 
of Treatment)
Study Weeka/Rescue Arm Week
-2 to 0
0/0R
0.5/ 
0.5R
1/1R
2/2R
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
Study Day /Rescue Arm Day
-14 to 0
0c/0R
4/4R
7/7R
14/14R
21/21R
28/28R
35/35R
42/42R
49/49R
56/56R
verify subject eligibility for the study. Both samples should be taken within 14 days of randomization with second sample obtained within 5 days before randomization. Same 
laboratory should be used for these assessments. 
c
Screening and Visit 2/Day 0 visits can occur on the same day in the case when historical laboratory values are available for determination of the eligibility. All Visit 
2/Day 0 procedures and screening laboratory results needed to confirm eligibility must be completed and documented prior to randomization and initiation of study treatment 
administration. The test results for the samples taken at Visit 2, from central laboratory or central specialty laboratory, will not be available to be used for the screening. Initiation 
of study treatment (ie, first dose) will only occur after completion of all required Visit 2/Day 0 procedures, confirmation of eligibility, and completion of randomization. This will 
be done under the supervision of investigator site personnel. For subjects randomized to receive maribavir or investigator-assigned therapy, therapy must be initiated within 24 
hours of randomization.
d
Symptom-oriented physical examinations other than protocol-specified examinations will be performed when clinically indicated. 
e
Updated medical history on Visit 2/Day 0 (Section 5.1).
f
Electrocardiograms other than protocol-specified ECGs will be performed when clinically indicated.
g
Clinical laboratory test will be performed at a central laboratory for all specified time points during the study including baseline. Central or local laboratory results for 
hematology/chemistry/serum pregnancy testing can be used for eligibility and their results must be available prior to randomization. Local laboratory -human chorionic 
gonadotropin test results can be used for the assessment of pregnancy on Day 0/Week 0. Local laboratory will be used for Visit 2A/2AR (Day 4) potassium and magnesium levels, 
and Day 4 after starting tacrolimus, cyclosporine, everolimus, or sirolimus if the subject is not taking at V2/2R.
h
Female subjects of child-bearing potential will have serum pregnancy testing performed at a central or local laboratory. Urine test results are not sufficient for eligibility 
determination.   
i
HIV status will be used for the evaluation of this criterion. Subjects must have a confirmed negative result within 3 months of study entry or have testing done locally 
during the screening period. The test result must be available prior to randomization..
j
Hepatitis B and HCV historical results available within 3 months prior to study treatment initiation will be accepted. If historical values are not available then the test will 
be repeated at Visit 2/Day 0. The results of test do not have to be available prior to start of dosing.
k
Blood samples taken at all study visits (processed to obtain plasma), for all CMV DNA tests (quantitation, genotyping), will be tested in the central specialty laboratory. 
Only during screening period, local specialty laboratory results for CMV DNA quantitation could be used for eligibility assessment; in this case CMV DNA results from central 
laboratory are not required. At all other visits, CMV DNA test will be conducted at a central specialty laboratory. The screening results, regardless whether from the local or 
central specialty laboratory, will be utilized for stratification for randomization. 
l
Subjects with tissue invasive CMV disease or CMV syndrome (SOT subjects only) present at Visit 2/Day 0 (baseline) will have serial assessments at all subsequent visits 
for infection status (no change, improvement, worsening, or resolution of disease/syndrome and associated symptoms) until resolution. All subjects will be assessed at each visit 
for new tissue invasive disease or CMV syndrome, and any new tissue invasive disease or CMV syndrome will have serial assessments at all subsequent visits for infection status 
(no change, improvement, worsening, or resolution of disease/syndrome and associated symptoms) until resolution. 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 36 
 
07 Dec 2018
For non-commercial use only


Shire
Page 37
SHP620-303 Protocol Amendment 6
Maribavir 
07
Table 1:
Schedule of Assessment 1: Screening Phase and Study Treatment Phase
Phase
Screening 
Phase
Study Treatment Phaseu
Study Visit / Rescue Arm Visit
1/NA
2/2R
2A/ 
2ARw
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
9/9R
10/10R   (End 
of Treatment)
Study Weeka/Rescue Arm Week
-2 to 0
0/0R
0.5/ 
0.5R
1/1R
2/2R
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
Study Day /Rescue Arm Day
-14 to 0
0c/0R
4/4R
7/7R
14/14R
21/21R
28/28R
35/35R
42/42R
49/49R
56/56R
n
If the subject is receiving immunosuppressant drugs (cyclosporine, tacrolimus, sirolimus, or everolimus), as mentioned in Section 7.2.3.5, on Study Day 0, then a blood 
sample to measure immunosuppressant drug concentration level will be obtained on Visit 2/2R (Day 0) prior to study treatment, Visit 2A/2AR [Day 4 (±1 day)], Visit 3/3R [Day 7 
(+2 day)], and on Visit 10/10R (Week 8) If the subject is not receiving immunosuppressant drugs at Day 0, but starts any time after Day 0 while still receiving study treatment, 
then a blood sample to measure immunosuppressant drug concentration will be obtained 4 days after the first dose of immunosuppressant drug and at the next scheduled study 
visit. Additional monitoring of immunosuppressant drug levels may be performed at the discretion of the investigator. Tests will be performed at a local laboratory. For more 
details refer to Section 7.2.3.5.
o
Pharmacokinetic samples should be obtained and analyzed for only those subjects who are randomized to maribavir treatment arm. For subjects ≥18 years of age 
randomized to maribavir, a pre-morning dose PK sample should be obtained at all 3 PK visits and a 2-4 hour post-morning dose sample will be collected only at Visit 3/Week 1 
and Visit 10/Week 8. There will be no post dose PK sample collected for Visit 6/Week 4. Pharmacokinetic sample collection for adolescent subjects ≥12 to <18 years of age, 
randomized to maribavir, will be as follows: intensive PK sampling at Visit 3/Week 1 (pre-morning dose and 1, 2, 3, 4, 6, 8 [all ±5 min], and 12 hours [±15 min] post morning 
dose); at Visit 6/Week 4 (one premorning dose PK sample); at Visit 10/Week 8 (one premorning dose and one between 2-4 hour post morning dose PK samples). Additional PK 
samples will be collected from any subjects with biopsy proven graft-versus-host disease (GVHD) of gastrointestinal (GI) with diarrhea (>300 ml/day) or biopsy proven GVHD of 
GI with nausea and vomiting or documented acute GVHD of liver (Stage II), total bilirubin >3 mg/dL or biopsy-proven) with diarrhea (>500 ml/day) or biopsy proven acute 
GVHD of the skin with diarrhea (>500 mL/day) per Boeckh et al., 1998. Refer to Section 7.2.4.1 for more details.
p
The eligibility of subjects who must discontinue the investigator assigned anti-CMV treatment for lack of anti-viral activity and/or intolerance, will be assessed at Visit 
5/Week 3 up to Visit 9/Week 7 for entry into an rescue arm of treatment with maribavir 400 mg BID for up to 8 weeks.
q
Except at screening, baseline, and end of treatment, IRT will be used for maribavir dispensing. Subjects who are eligible for the rescue arm will be assigned maribavir by 
the IRT system. The IRT system will be used for stratification and randomization of eligible subjects at baseline. The IRT will be used to manage maribavir.
r
All dispensed investigational product will be documented on the CRFs and/or other investigational product record. Investigator assigned anti-CMV medication 
(ganciclovir, valganciclovir, foscarnet, or cidofovir) will also be documented on the CRFs and/or other study treatment accountability records, and may include additional 
information as required per applicable regulations. The disposition of unused supply of dispensed investigational product and investigator assigned anti-CMV medication that has 
been prescribed to the subject will be documented in the accountability log. 
s
The study diary will be dispensed at baseline and will be collected at the last follow-up visit.
 
. Note that the diary will only be utilized for study treatments that are given orally. The IV administration will be tracked 
in the source documents and CRF. 
t
Includes recording of medications and transfusions (packed red blood cells, platelets, fresh frozen plasma). Changes in immunosuppression regimens will also be 
recorded.
u
Subjects who prematurely discontinue study treatment will complete the end of treatment procedures described for Visit 10/Study Week 8; these subjects will continue a 
modified schedule of assessments through the remaining weekly visits scheduled for the study treatment phase and the regular schedule of assessments through the 12-week 
follow-up phase or if meeting criteria to enter maribavir rescue arm will start 8-week maribavir 400 mg BID treatment. The end of treatment (Visit 10/Study Week 8) sample for 
immunosuppressant drug concentration level will be collected at the next visit scheduled 1 week after the treatment discontinuation. For subjects entering the Rescue Arm, 
 the Visit 2R/Week 0R does not need to be 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 37 
 
07 Dec 2018
For non-commercial use only


Shire
Page 38
SHP620-303 Protocol Amendment 6
Maribavir 
07
Table 1:
Schedule of Assessment 1: Screening Phase and Study Treatment Phase
Phase
Screening 
Phase
Study Treatment Phaseu
Study Visit / Rescue Arm Visit
1/NA
2/2R
2A/ 
2ARw
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
9/9R
10/10R   (End 
of Treatment)
Study Weeka/Rescue Arm Week
-2 to 0
0/0R
0.5/ 
0.5R
1/1R
2/2R
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
Study Day /Rescue Arm Day
-14 to 0
0c/0R
4/4R
7/7R
14/14R
21/21R
28/28R
35/35R
42/42R
49/49R
56/56R
collected. Subjects who discontinue study treatment early will not be asked to complete the following procedures after the end of treatment visit for subsequent visits in the 
treatment phase: the use of the diary for study treatment compliance, dispense or use of any study treatment, and PK sample collection. After completing the 8-week study 
treatment phase, subjects will enter the 12-week follow-up phase. 
v
Not required at V2R.
w
V2A/A-R is only required for subjects taking tacrolimus, cyclosporine, everolimus, or sirolimus at Visit 2/2R.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 38 
 
07 Dec 2018
For non-commercial use only


Shire
Page 39
SHP620-303 Protocol Amendment 6
Maribavir 
07
Table 2:
Schedule of Assessment 2: Follow-up Phase
Phase
Follow-up Phasek,l
Visit
11/11R
12/12R
13/13R
14/14R
15/15R
16/16R
17/17R
18/18R (End of 
Study)
Study Week (Follow-up 
Week)a
9(1) /9R(1R)
10(2)/10R
(2R)
11(3)/11R(3R) 12(4)/12R
(4R)
14(6)/15R
(6R)
16(8)/16R
(8R)
18(10)/18R (10R)
20(12)/20R(12R)
Study Day (Follow-up 
Day)
63(7)/63R
(7R)
70(14)/70R
(14R)
77(21)/77R
(21R)
84(28)/84R
(28R)
98(42)/98R(42R)
112(56)/112R(56R) 126(70)/126R(70R) 140(84)/140R
(84R)
Physical examination 
(including weight)
X
Vital signs
X
12-Lead ECGb
X
Hematology/Chemistryc
X
X
X
X
Urinalysisc
X
Immunosuppressant drug 
concentration leveld
X
Invasive bacterial, viral 
and fungal Infection(s) 
assessment 
X
X
X
X
X
X
X
X
CMV DNA teste
X
X
X
X
X
X
X
X
Symptomatic CMV 
infection assessmentf
X
X
X
X
X
X
X
X
Transplant status
X
X
X
X
X
X
X
X
GVHD assessment (for 
HSCT subjects only)
X
X
X
X
X
X
X
X
Comorbidity status 
evaluation 
X
X
X
Study diaryg
X
X
X
X
X
X
X
X
X
 
X
X
X
X
X
X
X
X
 
X
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 39 
 
07 Dec 2018
For non-commercial use only


Shire
Page 40
SHP620-303 Protocol Amendment 6
Maribavir 
07
Table 2:
Schedule of Assessment 2: Follow-up Phase
Phase
Follow-up Phasek,l
Visit
11/11R
12/12R
13/13R
14/14R
15/15R
16/16R
17/17R
18/18R (End of 
Study)
Study Week (Follow-up 
Week)a
9(1) /9R(1R)
10(2)/10R
(2R)
11(3)/11R(3R) 12(4)/12R
(4R)
14(6)/15R
(6R)
16(8)/16R
(8R)
18(10)/18R (10R)
20(12)/20R(12R)
Study Day (Follow-up 
Day)
63(7)/63R
(7R)
70(14)/70R
(14R)
77(21)/77R
(21R)
84(28)/84R
(28R)
98(42)/98R(42R)
112(56)/112R(56R) 126(70)/126R(70R) 140(84)/140R
(84R)
 
AE monitoringi
X
X
X
X
X
X
X
X
SAE monitoringi
X
X
X
X
X
X
X
X
Concomitant medications, 
therapies, and proceduresj
X
X
X
X
X
X
X
X
Note: Subjects in the investigator-assigned anti-CMV treatment arm who discontinue the study treatment phase to enter the maribavir rescue arm will exit after 8 weeks of 
maribavir 400 mg BID treatment to enter the follow-up phase (visits denoted as “R”).
AE=adverse event; CMV=cytomegalovirus; ECG=electrocardiogram; GVHD=graft-versus-host disease; HBV= hepatitis B virus; HCV= hepatitis C virus; HIV=human 
immunodeficiency virus; HSCT=hematopoietic stem cell transplant; IRT=interactive response system; R= rescue; SAE=serious adverse event; SF-36= Short Form-36
a Permissible assessment windows: Study Weeks 9-12 (Follow-up Weeks 1-4) ± 2 days; Study Weeks 14-20 (Follow-up Weeks 6-12) ± 3 days.
b Electrocardiograms other than protocol-specified ECGs will be performed when clinically indicated.
c Clinical laboratory testing performed at a central laboratory for all specified time points during the follow-up phase.
d Refer to Section 7.2.3.5 for more details.
e Blood samples taken at all study visits (processed to obtain plasma), for all CMV DNA tests (quantitation, genotyping) during the follow-up phase will be tested in the central 
specialty laboratory. 
f Subjects with tissue invasive CMV disease or CMV syndrome (SOT subjects only) present at Visit 2/Day 0 (baseline) will have serial assessments at all subsequent visits for 
infection status (no change, improvement, worsening, or resolution of disease/syndrome and associated symptoms) until resolution. All subjects will be assessed at each visit for 
new tissue invasive disease or CMV syndrome, and any new tissue invasive disease or CMV syndrome will have serial assessments at all subsequent visits for infection status (no 
change, improvement, worsening, or resolution of disease/syndrome and associated symptoms) until resolution. 
g The study diary will be used for tracking completion of the 
during the follow-up phase. The study diary will be collected at the last follow-up visit.
i Adverse events and SAEs will be monitored and recorded through Visit 18/Week 20/Follow-up Week 12 (end of study) according to Section 7.2.3.6.
j All medications, therapies, and procedures used to treat AEs will be recorded through Visit 18/Week 20 (Follow-up Week 12 (end of study). 
k Subjects who withdraw from the study during the follow-up phase will perform the Visit 18/Week 20 (Follow-up Week 12) end of study procedures.
l If the subject is unable to or unwilling to travel to the site for the follow-up visits, these visits may be performed remotely (ie, at the subject’s home) by a qualified sponsor or site 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 40 
 
07 Dec 2018
For non-commercial use only


Shire
Page 41
SHP620-303 Protocol Amendment 6
Maribavir 
07
Table 2:
Schedule of Assessment 2: Follow-up Phase
Phase
Follow-up Phasek,l
Visit
11/11R
12/12R
13/13R
14/14R
15/15R
16/16R
17/17R
18/18R (End of 
Study)
Study Week (Follow-up 
Week)a
9(1) /9R(1R)
10(2)/10R
(2R)
11(3)/11R(3R) 12(4)/12R
(4R)
14(6)/15R
(6R)
16(8)/16R
(8R)
18(10)/18R (10R)
20(12)/20R(12R)
Study Day (Follow-up 
Day)
63(7)/63R
(7R)
70(14)/70R
(14R)
77(21)/77R
(21R)
84(28)/84R
(28R)
98(42)/98R(42R)
112(56)/112R(56R) 126(70)/126R(70R) 140(84)/140R
(84R)
designee, and only if permitted according to local regulations. Blood sample for DNA quantitation and clinical laboratory assessments will be collected. Adverse events and SAE 
collection may be completed by telephone follow-up call on the day of the scheduled visit.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 41 
 
07 Dec 2018
For non-commercial use only


Shire
Page 42
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
1.
BACKGROUND INFORMATION
1.1
Indication and Current Treatment Options 
Cytomegalovirus (CMV) is a beta herpesvirus that commonly infects humans; serologic 
evidence of prior infection can be found in 40-100% of various adult populations (de la Hoz et 
al., 2002). However, serious disease occurs almost exclusively in individuals with compromised 
immune systems. Cytomegalovirus remains a significant problem for patients undergoing 
various types of transplants that are associated with the use of potent immunosuppressive 
chemotherapy, including hematopoietic stem cell transplants (HSCT) and solid organ transplants 
(SOT) (de la Hoz et al., 2002; Razonable and Emery, 2004).
In addition to the direct effects that manifest as CMV organ disease or symptomatic infection, 
CMV also is known to have several potential indirect effects. These indirect effects include an 
increased incidence of opportunistic infections, an association between CMV and 
graft-versus-host disease (GVHD) predominately in HSCT patients, and associations between 
CMV and graft rejection or other allograft pathology in SOT patients, and reduced patient 
survival (Rubin, 1989; Hodson et al., 2005; Ljungman et al., 2006). Such organ-specific 
associations with CMV include bronchiolitis obliterans in lung recipients, vanishing bile duct 
syndrome in liver recipients, accelerated transplant vasculopathy in heart recipients and 
transplant glomerulopathy, transplant renal artery stenosis or increased risk of transplant 
rejection (Razonable and Emery, 2004; Legendre and Pascual, 2008; Richardson et al., 1981; 
Pouria et al., 1998; Farrugia and Schwab, 1992). These effects are believed to be mediated by the 
virus’s ability to modulate the immune system, either directly or secondary to the host antiviral 
response through regulation of cytokine, chemokine, and/or growth factor production. 
Cytomegalovirus prevention strategies (prophylaxis or preemptive therapy) for various high-risk 
transplant subjects exist, however, CMV infection or disease can still occur within the early 
(initial ~3 months) or later post-transplantation time periods (Boeckh et al., 2003; Legendre and 
Pascual, 2008). Cytomegalovirus viremia is considered one of the most important predictors of 
development of CMV disease (Emery et al., 2000; Humar et al., 1999). In kidney transplant 
recipients, the highest incidence of symptomatic CMV infection (syndrome) or disease occurs in 
CMV-seronegative recipients who receive a kidney from a CMV-seropositive donor (D+/R-) 
(Paya et al., 1989; Kanj et al., 1996; Singh et al., 2004; Winston et al., 1995). 
Although the currently available systemic anti-CMV agents, intravenous (IV) or oral ganciclovir, 
oral valganciclovir (a prodrug of ganciclovir with improved bioavailability), IV foscarnet, and IV 
cidofovir are generally effective, their use is limited by their respective toxicities; bone marrow 
suppression caused by ganciclovir/valganciclovir and renal impairment caused by foscarnet or 
cidofovir (Boeckh et al., 2003; Ljungman et al., 2001; Reusser et al., 2002; Salzberger et al., 
1997). These toxicities are of particular concern in transplant patients, in whom the bone marrow 
has been ablated or significantly suppressed (HSCT patients), who receive ongoing 
immunosuppressants to prevent organ rejection (SOT patients) or GVHD (in HSCT patients), or 
who may require the use of other therapies that are potentially toxic to the kidneys or other 
organs (SOT and HSCT patients). 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 42 
 
07 Dec 2018
For non-commercial use only


Shire
Page 43
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Development of anti-viral resistance to currently available anti-CMV agents is also an ongoing 
clinical problem in solid organ and stem cell transplantation leading to graft loss and even 
mortality for some transplant patients. As described by Limaye et al., 2000, ganciclovir 
resistance developed in 7% D+/R- kidney, liver, and pancreas recipients who were prophylaxed 
with 3 months of oral ganciclovir. Ganciclovir-resistant disease accounted for 20% of CMV 
disease, occurred late (a median of 10 months after transplantation), was associated with higher 
intensity of immunosuppression, and was considered a clinically serious concern (Avery, 2007). 
There are no approved therapies for the treatment of CMV infection or CMV disease in 
transplant recipients, and no approved treatment for CMV infection or disease that is resistant or 
refractory to currently available therapies in any population. Maribavir is currently under 
development for the treatment of CMV infection or disease, including those resistant or 
refractory to ganciclovir, valganciclovir, foscarnet, or cidofovir, in transplant recipients.
1.2
Product Background and Clinical Information
Maribavir is a potent and selective, orally bioavailable antiviral drug with a novel mechanism of 
action against CMV (Chulay et al., 1999) and a favorable nonclinical and clinical safety profile. 
It is a potent member of a new class of drugs, the benzimidazole ribosides (Williams et al., 
2003). In side-by-side in vitro assays it is 3- to 20-fold more potent than ganciclovir and 
cidofovir, and at least 100-fold more potent than foscarnet (Biron et al., 2002; Drew et al., 2006). 
Unlike currently available anti-CMV agents that inhibit CMV deoxyribonucleic acid (DNA) 
polymerase, maribavir inhibits the CMV UL97 serine/threonine kinase by competitively 
inhibiting the binding of adenosine triphosphate (ATP) to the kinase ATP-binding site (Biron et 
al., 2002; Williams et al., 2003; Krosky et al., 2003; Wolf et al., 2001; Kern et al., 2004); the 
dominant phenotypic inhibitory effect of maribavir is on viral DNA assembly and egress of viral 
capsids from the nucleus of infected cells (Biron et al., 2002). Except for ganciclovir, maribavir 
does not antagonize the effects of other anti-viral (anti-CMV) agents. Since ganciclovir is 
dependent on its initial phosphorylation by the viral UL97 kinase, maribavir may antagonize its 
clinical efficacy. Maribavir is active in vitro against strains of CMV that are resistant to 
ganciclovir, foscarnet, or cidofovir.
1.2.1
Pharmacokinetics, metabolism, and drug-drug interactions
Results from the Phase 1 studies demonstrated that following oral administration, maribavir was 
rapidly and well absorbed with mean peak plasma concentrations generally achieved between 1 
and 3 hours post dose. After administration of single and multiple doses (both twice daily [BID] 
and 3 times daily [TID] regimens) over 28 days, total maribavir plasma concentrations increased 
with increasing dose proportionally up to 900 mg. At dose levels ≥900 mg BID, there was no 
apparent increase in maximum observed plasma concentration (Cmax) levels, and above this level, 
the increase in area under the plasma concentration versus time curve (AUC) may be less than 
dose proportional. Maribavir demonstrates time-independent pharmacokinetics (PK). 
Pharmacokinetic data obtained in Phase 2 studies were similar to the data observed in healthy 
volunteers.
Administration of maribavir in conjunction with food resulted in a 28% decrease in Cmax without 
a significant effect on AUC when compared to administration under fasting conditions. 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 43 
 
07 Dec 2018
For non-commercial use only


Shire
Page 44
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Bioavailability of a 100 mg tablet was unaffected by crushing the tablet or changes in gastric pH. 
Maribavir was bound to plasma proteins, namely human serum albumin (HSA), lipoproteins, and 
alpha-1-1acid-glycoprotein (AAG). The fraction of unbound maribavir was estimated at 
approximately 1.5% in healthy subjects and 0.96% in transplant patients. The apparent plasma 
elimination half-life for unchanged maribavir was approximately 5-7 hours. Maribavir is 
metabolized primarily in the liver through CYP3A4 pathway with the formation of the primary 
metabolite, VP44469. Renal clearance is a minor route of elimination of maribavir.
A mass balance study in healthy male and female subjects following administration of a single 
400 mg oral dose of [14C] maribavir resulted in fecal recovery of radiolabel that averaged about 
14% and recovery of radiolabel in the urine that averaged about 61%. In plasma, the 
predominant drug-related species was unchanged maribavir, representing approximately 65% of 
total radioactivity and VP 44469 represented approximately 9% of urine and feces. The apparent 
plasma elimination half-lives for total radioactivity and unchanged maribavir were 
approximately 66 and 7 hours, respectively.
In vitro studies indicated that CYP 3A4 (a hepatic metabolizing enzyme) is the primary enzyme 
involved in the formation of VP 44469 from maribavir; CYP 2C19 and CYP 1A2 may also be 
involved in VP 44469 formation. Based on an in vitro study, UGT1A1, UGT1A3, UGT2B7, and 
possibly UGT1A9 were involved in the glucuronidation of maribavir however intrinsic clearance 
was too low to be quantified. These data suggests the contribution of glucuronidation to the 
overall clearance of maribavir is considered to be low and the potential for maribavir as the 
victim of drug interactions when coadministered with UGT inhibitors/inducers is expected to be 
low. In vitro studies also demonstrated that maribavir is not an inhibitor of CYP3A4, CYP2A6, 
CYP2B6, CYP2C8, CYP2D6, or CYP2E1. It is potentially a weak inhibitor of CYP 1A2, 2C9, 
and 2C19. VP 44469 is not an inhibitor of CYP enzymes. Maribavir is a substrate as well as an 
inhibitor of P-glycoprotein with an IC50 of 33.7 µM (P-gp: a transporter protein). Maribavir is a 
weak inhibitor for UGT1A1, UGT1A3, UGT1A9, and UGT2B7 enzymes with IC50 values at 
32.2µM, 184µM, 123µM, and 153 µM, respectively. Maribavir has no inhibitory effect on 
UGT1A4 and UGT1A6 at up to 500 µM.
Clinical studies conducted to evaluate the potential of drug-drug interactions demonstrated the 
following:

Concomitant administration of maribavir (400 mg BID) with tacrolimus, a substrate of 
CYP 3A4 and P-gp, resulted in increased tacrolimus Cmax and AUC by 38% and 51%, 
respectively.

Maribavir did not have a clinically significant effect on the activity of CYP 1A2, CYP 
3A, CYP 2C9, or CYP 2D6; however, it inhibited CYP2C19 activity (based on plasma 
omeprazole/5-OH omeprazole ratio). A follow-up clinical study indicated maribavir had 
no effect on the PK of voriconazole (a CYP2C19 substrate). Maribavir did not affect 
digoxin (a sensitive P-gp probe) AUC, however, it increased Cmax by 24.8%.

Concurrent administration of rifampin, an inducer of CYP 3A4 and P-gp, and maribavir 
significantly reduced plasma concentrations of maribavir, resulting in a 61% reduction in 
AUC, reduced half-life, and significantly increased clearance, most likely due to 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 44 
 
07 Dec 2018
For non-commercial use only


Shire
Page 45
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
induction of hepatic and intestinal CYP 3A4, and possible enhancement of P-gp 
transport.

Concomitant administration of antacid had no effect on maribavir exposure.

Concomitant administration of ketoconazole increased maribavir AUC and Cmax by 46% 
and 10%, respectively.
The effect of renal impairment on maribavir pharmacokinetic was evaluated in a single dose 
(400 mg) study with 12 subjects with normal renal function (creatinine clearance 
>80 mL/minute), 10 subjects with mild/moderate renal impairment (creatinine clearance 
30-80 mL/minute), and 9 subjects with severe renal impairment (creatinine clearance 
<30 mL/minute). Mean pharmacokinetic parameter estimates based on total or unbound plasma 
drug concentrations for subjects with normal renal function, mild/moderate renal impairment, 
and severe renal impairment were similar. Based on the results from this study, renal impairment 
does not affect the PK of maribavir; dose adjustment for subjects with mild to severe renal 
impairment is not needed. There is no experience with the use of maribavir in subjects receiving 
peritoneal dialysis or hemodialysis. Due to the high plasma protein binding of maribavir, dialysis 
is unlikely to reduce plasma concentrations of maribavir significantly.
The effect of hepatic impairment on the pharmacokinetic of maribavir was evaluated in a single-
dose study (200 mg) with 10 subjects with normal hepatic function and 10 subjects with 
moderate hepatic impairment based on a Child-Pugh Class B classification. Moderate hepatic 
impairment results in a modest increase in total plasma maribavir Cmax and AUC values (and 
modestly reduced clearance values) when compared to subjects with normal hepatic function. 
However, Cmax and AUC values based on unbound plasma concentrations of maribavir were 
comparable among these groups.
In Study 1263-200 (a Phase 2 study of maribavir for CMV prophylaxis), based on total drug 
concentrations in plasma, steady-state AUC values in HSCT recipients were 19-66% higher than 
AUC values in healthy subjects. This difference can be explained based on the differences in 
plasma protein binding in healthy subjects and transplant patients. In Study 1263-202 (SHP620-
202), a Phase 2 study of maribavir for CMV treatment, the PK parameters (AUC and Cmax) at 
400 mg BID dose were comparable to that in the healthy subjects.
1.2.2
Efficacy
Once the safety and tolerability of maribavir was established across a wide range of doses (up to 
2400 mg/day for 28 days) in 15 Phase 1 studies, the clinical development plan focused on 
maribavir as an anti-CMV agent for the prevention of CMV disease in transplant patients. 
Results from the Phase 3 trials for CMV prevention, where maribavir was administered at 
100 mg BID for up to 12 weeks in HSCT recipients and up to 14 weeks in liver transplant 
recipients, failed to reduce the incidence of endpoint adjudication committee confirmed CMV 
disease within 6 months following HSCT when compared with placebo (Study 1263-300), and 
failed to show noninferiority to ganciclovir with respect to the incidence of endpoint adjudication 
committee confirmed CMV disease within 6 months following liver transplantation (Study 
1263-301).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 45 
 
07 Dec 2018
For non-commercial use only


Shire
Page 46
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Maribavir was used for treatment of CMV infections in 6 transplant recipients (5 SOT, 1 HSCT) 
under individual emergency investigational new drug (EIND) applications in the United States 
(US) (Avery et al., 2010). All patients had previously been treated with multiple other anti-CMV 
drugs, and 4 out of 6 had known genotypic CMV resistance to 1 or more of those CMV drugs. 
For all 6 patients, oral maribavir treatment was initiated at a dose of 400 mg BID. In 2 patients, 
the dose was increased to 800 mg BID. The duration of treatment was individualized for each 
patient based on response. Maribavir appeared to be safe and well-tolerated, as it was 
administered for prolonged periods of time (4 out of 6 patients were dosed >6 months). Three 
patients reported 7 serious adverse events (SAEs), all of which were considered to be unrelated 
to maribavir.
Within 6 weeks of starting maribavir treatment, all subjects had a >1 log decrease in blood CMV 
DNA, and 4 of the 6 patients had no detectable CMV. Cytomegalovirus viremia persisted in 
2 patients despite dosing >6 months; 1 of these patients had unusually low exposure to maribavir 
based on trough blood levels. The other patient in whom CMV viremia persisted had a very high 
baseline CMV DNA level. The genotypic analysis for this patient revealed the presence of UL97 
maribavir-resistance mutations T409M and H411Y (Strasfeld et al., 2010). 
Subsequently, in Europe, more than 200 patients received maribavir through a named patient 
program (NPP), and in France, through the authorized therapeutic-use procedure. Data from only 
a small subset of the French NPP were reported. These data were consistent with the US EIND 
experience. Additional details regarding these patients are available in the maribavir 
investigator’s brochure.
The data obtained from the small number of patients in EIND and NPP, suggested that maribavir 
was associated with a reduction in CMV DNA in the blood in the majority of subjects, and could 
be a useful component for the treatment of CMV infections that are resistant or refractory to 
currently available anti-CMV therapies. As a result, two Phase 2 studies were conducted to 
assess the safety, tolerability, and anti-CMV activity of maribavir for treatment of CMV 
infections: Study SHP620-202 in transplant recipients with CMV infections or disease that are 
resistant or refractory to treatment with anti-CMV agents conducted in the US and Study 
1263-203 (SHP620-203) in transplant recipients with wild-type CMV infections who do not have 
CMV organ disease (asymptomatic) conducted in Europe. In both these studies subjects received 
1 of 3 dose strengths: 400, 800, or 1200 mg BID, and both studies demonstrated favorable 
anti-CMV activity for besides showing that was well-tolerated with no safety concerns at all 
doses evaluated.
The primary efficacy endpoint for Study SHP620-202 was confirmed undetectable plasma CMV 
DNA within the 6 weeks after starting study drug treatment, defined as 2 consecutive 
postbaseline, on treatment undetectable result (<200 copies/mL) separated by at least 5 days. 
Overall, 67% of subjects achieved confirmed undetectable plasma CMV DNA within 6 weeks. 
Among maribavir groups, there was no strong evidence of dose strength differentiation in the 
proportion of subjects achieving the endpoint. Among subjects with ≥1 investigator-reported 
CMV genetic mutation associated with resistance to ganciclovir/valganciclovir or foscarnet at 
baseline, 43/71 (61%) achieved confirmed undetectable plasma CMV DNA within 6 weeks after 
starting treatment with maribavir.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 46 
 
07 Dec 2018
For non-commercial use only


Shire
Page 47
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Secondary efficacy endpoints for Study SHP620-202 included CMV recurrence, defined as 
achievement of undetectable plasma CMV DNA in at least 2 consecutive samples separated by at 
least 5 days at any time after Day 1, followed by detectable plasma CMV DNA in at least 2 
consecutive samples separated by at least 5 days. Overall, 30/86 (35%) maribavir subjects had a 
CMV recurrence at any time during the study (Note: Percentage is based on the number of 
subjects achieving undetectable CMV DNA). Twenty-four of the 30 subjects had a CMV 
recurrence while on study drug. Thirteen of these 24 subjects developed UL97 mutations 
previously described to confer resistance to maribavir that were not present prior to study drug 
dosing. The remaining 6 maribavir subjects had a CMV recurrence after the end of treatment 
with study drug. 
The primary efficacy endpoint for Study SHP620-203 was confirmed undetectable plasma CMV 
DNA within 3 and 6 weeks after starting study drug treatment, defined as 2 consecutive 
postbaseline, on treatment undetectable results (<200 copies/mL) separated by at least 5 days. 
The proportion of subjects with undetectable plasma CMV DNA within 3 and 6 weeks after 
starting study drug treatment was numerically higher in the maribavir group than the 
valganciclovir group. Among the 3 maribavir dose strength groups, there was no difference in 
the proportion of subjects achieving the endpoint. In the subgroup of subjects whose transplant 
type was HSCT, a numerically higher percentage of subjects in the overall maribavir group 
(75%) than the valganciclovir group (48%) achieved confirmed undetectable plasma CMV DNA 
within 6 weeks. Although the percentage of subjects with high baseline plasma CMV DNA (≥
10000 copies/mL) was similar between the overall maribavir and valganciclovir groups (34% vs. 
33%), a numerically higher percentage of maribavir subjects (77%) achieved confirmed 
undetectable plasma CMV DNA within 6 weeks compared with valganciclovir (65%). 
Secondary efficacy endpoints for Study SHP620-203 included CMV recurrence; this was 
assessed within 6 weeks after starting study drug treatment and within the study participation 
period. Overall, 22/98 (22%) maribavir subjects and 5/28 (18%) valganciclovir subjects 
experienced a CMV recurrence within the study participation period (Note: Percentages are 
based on the number of subjects achieving undetectable CMV DNA). Four of the 22 maribavir 
subjects recurred while on study drug (2 subjects each in the 400 mg BID and 800 mg BID 
groups). All 4 of these subjects developed UL97 mutations previously described to confer 
resistance to maribavir that were not present prior to study drug dosing. The remaining 18 
maribavir subjects and all 5 valganciclovir subjects experienced a CMV recurrence after the end 
of study drug treatment.
Phase 3 registration trials are underway based on the results from these Phase 2 studies for CMV 
treatment.
1.2.3
Safety
Maribavir has been administered across a broad range of oral doses from 50-2400 mg/day. 
Clinical safety experience has been obtained from 15 Phase 1 studies in adult healthy volunteers, 
special populations (subjects with renal and hepatic impairment, and stable renal transplant 
recipients), and HIV-infected subjects. A definitive QT study demonstrated no clinically 
significant repolarization effect of maribavir administered orally at single doses of 100 mg and 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 47 
 
07 Dec 2018
For non-commercial use only


Shire
Page 48
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
1200 mg in healthy subjects. In addition, no other significant electrocardiographic effects of 
maribavir were found.
Maribavir had a favorable safety and tolerability profile in both the Phase 2 and Phase 3 trials for 
CMV prophylaxis. Adverse events (AEs) were most commonly associated with gastrointestinal 
(GI) disorders (eg, diarrhea, dysgeusia, nausea, and vomiting). These events were generally of 
mild or moderate intensity. There were no signals of clinically significant effects of maribavir on 
vital signs, ECG parameters, or laboratory findings in the studies conducted for CMV 
prophylaxis.
In both Phase 2 studies for treatment of CMV infection (Studies SHP620-202 and SHP620-203), 
subjects received maribavir at 1 of 3 dose strengths: 400, 800, or 1200 mg BID, and both studies 
demonstrated that maribavir was well-tolerated with no safety concerns at all doses evaluated. In 
Study SHP620-202, treatment-emergent AEs (TEAEs) that occurred were events already 
observed in previous studies (ie, dysgeusia, GI events, elevated immunosuppressant drug levels, 
and rash) and there were no additional safety concerns raised from this study. In Study 
SHP620-203, TEAEs that occurred at a higher frequency in maribavir subjects compared with 
valganciclovir were events already observed in previous studies with maribavir (ie, dysgeusia, GI 
events, and elevated immunosuppressant drug levels). Analyses of clinical laboratory, vital signs, 
and ECG data did not identify any clinically meaningful differences across the maribavir 
treatment groups.
Based on the Phase 2 CMV treatment and Phase 3 CMV prophylaxis studies, the adverse drug 
reactions (ADRs) associated with maribavir use are: abdominal pain, abdominal pain upper, 
decreased appetite, diarrhea, dizziness, dysgeusia, fatigue, headache, immunosuppressant drug 
level increased, nausea, and vomiting.
To date, maribavir has shown an overall favorable safety profile in placebo-controlled studies, 
open-label studies, and in studies that compared maribavir with other CMV therapies 
(ganciclovir, valganciclovir) for prophylaxis and for CMV treatment in HSCT and SOT patients. 
Treatment effect on viral load reduction (confirmed undetectable plasma CMV DNA: 67% of 
subjects within 6 weeks in Study SHP620-202; 60.5% of subjects in 3 weeks and 77.3% of 
subjects in 6 weeks in Study SHP620-203) seen in Phase 2 treatment studies coupled with 
acceptable safety and tolerability establish the positive benefit-risk profile and warrant further 
investigation of maribavir in the treatment of refractory CMV infections in transplant recipients.
Refer to the latest version of the maribavir investigator’s brochure for the most detailed and most 
current information regarding the drug metabolism, pharmacokinetics, efficacy and safety of 
maribavir.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 48 
 
07 Dec 2018
For non-commercial use only


Shire
Page 49
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
2.
STUDY OBJECTIVES AND PURPOSE
2.1
Rationale for the Study
The population of transplant recipients whose CMV infections are resistant or refractory to 
treatment with ganciclovir, valganciclovir, foscarnet, or cidofovir, including the pediatric 
population, is a significant unmet medical need. There are limited treatment options for these 
patients and no anti-viral drugs specifically approved for this purpose. Strategies to treat resistant 
or refractory CMV infections include minimizing immunosuppression when possible; increasing 
the dose of, combining, or switching among the available anti-viral drugs (ie, 
ganciclovir/valganciclovir, foscarnet, cidofovir); and the use of adjunctive treatments as 
intravenous immunoglobulin (IVIg), cytomegalovirus immune globulin (CMV Ig), adoptive 
infusions of CMV-specific T-cells, altering the immune suppressive regimen to mTOR inhibitors 
(sirolimus and everolimus), use of medications such as leflunomide, and artesunate (Kotton et 
al., 2013; Nishihori et al., 2015). No robust data are available on the effectiveness of these 
strategies reinforcing the need for an effective anti-CMV agent.
Results from the Phase 2 study SHP620-202 support the safety, tolerability, and anti-viral 
activity of maribavir for the treatment of resistant or refractory CMV infections in transplant 
recipients. Study SHP620-202 was a multicenter, randomized, dose-ranging, parallel-group study 
of maribavir for the treatment of CMV infections that were resistant or refractory to treatment 
with ganciclovir, valganciclovir, or foscarnet in HSCT and SOT recipients. Study subjects were 
randomized in a 1:1:1 allocation ratio to receive oral maribavir at 1 of 3 dose strengths (400 mg 
BID, 800 mg BID, or 1200 mg BID) for up to 24 weeks. While there was no strong evidence of 
differentiation among the 3 maribavir dose strengths, all maribavir doses were similarly effective 
at clearing CMV viremia based on the proportion of subjects with confirmed undetectable 
plasma CMV DNA within 6 weeks after starting study drug treatment. Maribavir was also 
generally well-tolerated across the dose range studied; commonly reported adverse events, such 
as dysgeusia and gastrointestinal events (eg, nausea, vomiting, diarrhea), were consistent with 
the known maribavir safety profile.
This Phase 3 study is designed to further assess and demonstrate the efficacy and safety of 
maribavir, dosed at 400 mg BID, compared to investigator-assigned anti-CMV treatment (IAT) 
of choice for the treatment of CMV infections that are resistant or refractory to treatment with 
ganciclovir, valganciclovir, foscarnet, or cidofovir in HSCT and SOT recipients.
2.2
Rationale for the Study Design
This study will assess the efficacy and safety of maribavir for the treatment of refractory CMV 
infections, including those with documented resistance to treatment with ganciclovir, 
valganciclovir, foscarnet, or cidofovir, on the basis of clearance of CMV viremia. Improvement 
or resolution of tissue invasive CMV disease and CMV syndrome will also be assessed as 
applicable. Based on published literature, ganciclovir-resistant disease accounted for 20% of 
CMV disease, occurred late (a median of 10 months after transplantation), was associated with 
higher intensity of immunosuppression, and is a clinically serious concern (Avery, 2007). As 
there are limited treatment alternatives and no anti-CMV agents specifically approved to treat 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 49 
 
07 Dec 2018
For non-commercial use only


Shire
Page 50
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
resistant or refractory CMV infections, treatment with maribavir may address the unmet medical 
need for this population. 
Investigator assigned anti-CMV treatment with 1 or 2 of the 4 anti-CMV drugs (ganciclovir, 
valganciclovir, foscarnet, or cidofovir) with additional strategies when deemed necessary by 
investigator (eg, change in the dose of the anti-CMV drug, reduction of immunosuppressant, 
addition of IVIG or CMV Ig) is the active control group for this study. The subject on single or 
dual therapy with anti–CMV agents at the time of enrollment, may either change therapy at the 
time of randomization/treatment initiation or remain on the same therapy as the investigator 
assigned anti-CMV treatment, if randomized to this study arm. If the treatment was continued or 
started as 2 anti-CMV agents, withdrawal of 1 agent, while continuing the second one will be 
possible.
While there are no approved therapies for the treatment of CMV infections, and those that are 
resistant or refractory to currently available anti-CMV agents, published CMV treatment 
guidelines include recommendations for the treatment of such infections (Kotton et al., 2013).
In HSCT recipients, when CMV replication is detected above the predefined threshold during the 
monitoring of CMV infection, the pre-emptive treatment is generally given for a minimum of 2 
weeks with further extension until CMV becomes undetectable. There is a difference in practice 
regarding the minimum duration of therapy. Valganciclovir (previously ganciclovir) is often used 
for pre-emptive therapy, although foscarnet can be used as well (Busca et al., 2007; Reusser et 
al., 2002). However, foscarnet is associated with nephrotoxicity, and requires intravenous 
hydration and frequent electrolyte monitoring (Reusser et al., 2002); cidofovir is used much less 
due to substantial side effects including nephrotoxicity and myelosuppression (Tomblyn et al., 
2009). Ganciclovir or valganciclovir use is associated with bone marrow toxicities that 
specifically in the HSCT recipients are a considerable clinical issue. Although these agents are 
used widely they are not approved for the CMV treatment indication. Furthermore, the use of a 
comparator arm in the context of a pivotal Phase 3 trial will provide for a more rigorous 
interpretation of virologic response to maribavir.
Study subjects will be randomized to receive either maribavir or investigator-assigned anti-CMV 
treatment for 8 weeks during the study treatment phase. In the SHP620-202 study (HSCT and 
SOT recipients with resistant or refractory CMV infections), the majority of maribavir subjects 
achieved confirmed undetectable plasma CMV DNA levels by Week 6 of study drug treatment, 
while CMV recurrence occurred at rates not unexpected for a population with such an 
overwhelmingly severe illness and concurrent lack of host immune responsiveness. A fixed 
duration, 8-week treatment regimen, in this Phase 3 study will account for a longer duration of 
treatment need in patients of certain transplant types (ie, lung transplant) consistent with clinical 
practice as well as secondary prophylaxis of recurrence after achieving undetectable plasma 
CMV DNA levels; furthermore, in the context of a clinical trial, the 8-week treatment duration 
will allow to standardize the duration for measuring the primary efficacy endpoint.
While the currently available anti-CMV agents ganciclovir, valganciclovir, foscarnet, and 
cidofovir may be considered in clinical practice to treat refractory or resistant CMV infections, 
their use is limited by their respective toxicities, most notably bone marrow suppression caused 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 50 
 
07 Dec 2018
For non-commercial use only


Shire
Page 51
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
by ganciclovir/valganciclovir and nephrotoxicity caused by foscarnet or cidofovir. Such 
toxicities can also worsen existing bone marrow suppression associated with transplant related 
maintenance with immunosuppressive therapy. Recognizing such safety limitations as well 
situations where no treatment effect is observed, subjects randomized to investigator-assigned 
anti-CMV treatment will be afforded the opportunity to enter into a maribavir rescue arm (for 
8 weeks of treatment) based on objective criteria relative to a lack of anti-CMV activity (impact 
on viremia) after a certain duration of therapy, with or without intolerance to their assigned 
treatment.
The clearance of CMV viremia (plasma CMV DNA clearance) is considered a surrogate marker 
that may correlate to direct clinical benefit for the treatment of CMV infection or disease. While 
no registration trials for the treatment of established CMV infection in transplant patients have 
been conducted the VICTOR study (Asberg et al., 2007) of IV ganciclovir versus oral 
valganciclovir for the treatment of CMV disease in SOT recipients demonstrated that clearance 
of CMV viremia was highly correlated with resolution of CMV disease. This correlation was 
further evidenced with the subsequent analysis of VICTOR study plasma samples using the 
COBAS® AmpliPrep/COBAS® TaqMan® CMV Test, a test calibrated to the World Health 
Organization International Standard for Human CMV for Nucleic Acid Amplification 
Techniques. These recent findings, together with the maribavir Phase 2 study results, support a 
primary efficacy endpoint weighted on the CMV viremia clearance to demonstrate the efficacy 
of maribavir for the treatment of resistant or refractory CMV infections. Clinicians consider 
CMV viremia clearance when evaluating the success of therapy hence the CMV plasma/blood 
monitoring protocols are employed in patients with high risk of CMV infection or reactivation of 
latent CMV infection, and information of the viral load guide the decision for the pre-emptive 
treatment in the absence of the symptomatic disease.
Primary endpoint based on CMV viremia clearance will be assessed at the end of Study Week 8 
as on treatment clearance is the most relevant assessment to determine anti-viral treatment effect. 
Assessment of treatment effect durability will be measured as key secondary and secondary 
endpoints. Although important from the clinical stand point, recurrence of CMV DNA after 
treatment is more influenced by other factors such as host immune status, other comorbidities, 
immunosuppressive treatments for prevention of transplant rejection than by the effectiveness of 
the anti-CMV drug treatment. In addition, CMV viremia clearance and clinical benefit of 
maribavir on tissue invasive CMV disease or CMV syndrome improvement or resolution after 
8 weeks of treatment and maintenance of this treatment effect through the study will be 
evaluated in subjects with tissue invasive CMV disease. As there are currently no approved 
therapies for the treatment of CMV infections in the pediatric transplant recipient population, this 
study will initiate the assessment of maribavir use in the pediatric population by enrolling 
adolescent subjects ≥12 to <18 years of age.
2.3
Rationale for Dose Selection
Results from the Phase 2 studies SHP620-202 (HSCT and SOT recipients with resistant or 
refractory CMV infections) and SHP620-203 (HSCT and SOT recipients with asymptomatic 
CMV infection) demonstrated comparable efficacy across the 400 mg BID, 800 mg BID, and 
1200 mg BID maribavir dose groups in the clearance of CMV viremia within up to 6 weeks after 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 51 
 
07 Dec 2018
For non-commercial use only


Shire
Page 52
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
starting study drug treatment. In study SHP620-202, however, a numerically higher CMV 
viremia clearance rate and lower CMV recurrence rate were observed for the 400 mg BID group 
compared to the 800 mg and 1200 mg BID groups. In both Phase 2 studies, the most common 
treatment-emergent adverse events (TEAEs) included dysgeusia, events of nausea, vomiting, and 
diarrhea, and elevated immunosuppressant drug concentration levels. There was a 
dose-dependence for dysgeusia and elevated immunosuppressant drug concentration levels. 
These findings (comparable efficacy and better safety profile with the 400 mg dose) support the 
further evaluation of 400 mg BID maribavir for the treatment of CMV.
Investigators will determine the anti-CMV therapy best suited to treat the respective subject’s 
CMV infection. Anti-CMV therapeutic strategies for this Phase 3 study will be limited to 
commercially available anti-viral (anti-CMV) agents, including ganciclovir, valganciclovir, 
foscarnet, and cidofovir that are utilized for treatment of patients in clinical practice. Subjects 
will be then randomly assigned (2:1) to either maribavir or investigator choice of treatment.
Currently available maribavir pharmacokinetics, PK modeling and extrapolation of systemic 
exposure from adults, and safety and tolerability data in adults support the administration of the 
400 mg BID dose in adolescents who weigh ≥35 kg and are able to swallow tablets. The 
expression of CYP3A4 and CYP 2C19, which are primary enzymes for maribavir metabolism in 
the liver, occurs during the first weeks of life (Lu and Rosenbaum, 2014). The expression of 
CYP1A2, which is also involved with maribavir metabolism, the last enzyme to develop, is 
present by 13 months of life. By 1 to 2 years of age, all the isoenzyme activities are similar to 
those of adults. Therefore, the bioavailability and systemic exposure of maribavir in adolescent 
subjects is not expected to be different from adults at the same oral dose.
2.4
Study Objectives
2.4.1
Primary Objective
The primary objective of this study is to compare the efficacy of maribavir to 
investigator-assigned anti-CMV therapy in CMV viremia clearance at the end of Study Week 8, 
in transplant recipients who are refractory or resistant to prior anti-CMV treatment. 
2.4.2
Key Secondary Objective
The key secondary objective of this study is to compare the efficacy of the 2 study treatment 
arms on CMV viremia clearance and tissue-invasive CMV disease and CMV syndrome 
improvement or resolution at the end of Study Week 8, and maintenance of this treatment effect 
through Study Week 16 (8 weeks of post-treatment/follow-up phase).
2.4.3
Secondary Objectives 
The secondary objectives of this study are:

To compare the efficacy of maribavir to investigator-assigned anti-CMV therapy on CMV 
viremia clearance after completion of 8 weeks of study treatment in transplant recipients who 
are refractory or resistant to prior anti-CMV treatment.

To compare the efficacy of the 2 study treatment arms on CMV viremia clearance and 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 52 
 
07 Dec 2018
For non-commercial use only


Shire
Page 53
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
tissue-invasive CMV disease and CMV syndrome improvement or resolution after 
completion of 8 weeks of study treatment and maintenance of this treatment effect through 
Study Weeks 12, (4 weeks post-treatment period), 16 (8 weeks post-treatment/follow-up 
phase), and 20 (12 weeks post-treatment). 

To assess the 2 study treatment arms for maintenance of CMV viremia clearance, and 
resolution or improvement of tissue invasive CMV disease and CMV syndrome, achieved at 
the end of Study Week 8, through weeks 12 (4 weeks of post treatment period), and 20 (12 
weeks post treatment).

To evaluate the incidence of recurrence of CMV viremia in the 2 study treatment arms during 
the first 8 weeks of the study, during the 12 weeks of the follow-up study phase, and at any 
time during the study.

To evaluate the incidence of recurrence of CMV viremia in the 2 study treatment arms, when 
subjects are on treatment and off treatment.

To assess the profile of mutations in the CMV genes conferring resistance to maribavir.

To evaluate the all-cause mortality.

To assess the safety and tolerability of maribavir.

To assess the efficacy, maintenance of the treatment effect, and the safety of maribavir 
administered as the rescue treatment.

To characterize the pharmacokinetics of maribavir.
2.4.4
Exploratory Objectives
The exploratory objectives of this study are:
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 53 
 
07 Dec 2018
For non-commercial use only


Shire
Page 54
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
3.
STUDY DESIGN
3.1
Study Design and Flow Chart
This is a multicenter, randomized, open-label, active-controlled study to assess the efficacy and 
safety of maribavir treatment compared to investigator-assigned anti-CMV treatment in HSCT 
and SOT recipients with CMV infections that are refractory to treatment with ganciclovir, 
valganciclovir, foscarnet, or cidofovir, including CMV infections with confirmed resistance to 1 
or more anti-CMV agents. The study will assess the efficacy of maribavir by measuring the 
plasma CMV DNA clearance. To be eligible for the study, subjects must have a documented 
CMV infection in whole blood or plasma, with a screening value of ≥2730 IU/mL in whole 
blood or ≥910 IU/mL in plasma in 2 consecutive assessments, separated by at least 1 day, as 
determined by local or central specialty laboratory quantitative polymerase chain reaction 
(qPCR) or comparable quantitative CMV DNA test. Results should be available before the 
subject is randomized to verify subject eligibility for the study. Both samples should be taken 
within 14 days prior to randomization with the second sample obtained within 5 days before 
randomization and will be used for the stratification level in the randomization. Results from the 
same laboratory and same sample type (whole blood or plasma) must be used for these 
assessments. The current CMV infection must be refractory to 1 or more of the available 
anti-CMV agents (ganciclovir, valganciclovir, foscarnet, or cidofovir) and the subject must meet 
the remaining specified eligibility criteria. 
“Refractory” will be defined as:

Documented failure to achieve >1 log10 (common logarithm to base 10) decrease in CMV 
DNA level in whole blood or plasma after a 14 day or longer treatment period with IV 
ganciclovir/oral valganciclovir, IV foscarnet, or IV cidofovir. This definition applies to the 
current CMV infection and the most recently administered anti-CMV agent. 
“Resistant” will be defined as:

Documented failure to achieve >1 log10 (common logarithm to base 10) decrease in CMV 
DNA level in whole blood or plasma after a 14 day or longer treatment period with IV 
ganciclovir/oral valganciclovir, IV foscarnet, or IV cidofovir. This definition applies to the 
current CMV infection and the most recently administered anti-CMV agent.
AND

Documentation of 1 or more CMV genetic mutations associated with resistance to 
ganciclovir/valganciclovir, foscarnet, and/or cidofovir. 
Results from the same laboratory and the same sample type (whole blood or plasma) are to be 
used to determine the refractoriness. Note: Failure to respond to these agent(s) due to intolerance 
will not be considered ‘refractoriness’.
The documentation of the resistance during screening will be based on the local specialty 
laboratory genotyping assay results. Plasma samples obtained at baseline for CMV DNA 
genotyping will be used for the final determination of mutations in the UL97, UL27, and UL54 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 54 
 
07 Dec 2018
For non-commercial use only


Shire
Page 55
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
genes known to confer resistance to anti-CMV agents; these assessments will be based on the 
results from the central specialty laboratory and utilized for analysis. Subject enrollment will be 
monitored to achieve an approximate target of 60% of subjects who have a CMV infection with 
documented resistance to any of the anti-CMV agents (ganciclovir, valganciclovir, foscarnet, or 
cidofovir) according to the central specialty results from samples taken at baseline.
The subjects randomized to maribavir treatment arm will discontinue the therapy they were 
currently on at the time of enrollment. For subjects randomized to the investigator assigned 
treatment arm, the investigator will determine at the time of randomization/treatment initiation 
whether the subject will change the therapy they were currently on at the time of enrollment, or 
will remain on the same therapy (single or dual anti-CMV agent therapy) after randomization 
(per Inclusion Criterion 5). If the treatment was continued or started as 2 anti-CMV agents, 
withdrawal of 1 agent, while continuing the second one will be possible. Addition of or switch to 
another anti-CMV agent will be declared as a failure for the purpose of study analysis. After 
randomization changes to the investigator treatment of choice could include, change in dosing, 
dosing regimen, but will not include an addition of or switch to another anti-CMV agent. Note 
that changes between IV ganciclovir and oral valganciclovir are allowed. Combination therapy 
with cidofovir and foscarnet is prohibited.
All eligible subjects will be stratified by transplant type (HSCT or SOT) and screening whole 
blood or plasma CMV DNA concentration (high viral load with CMV DNA ≥273000 IU/mL in 
whole blood or ≥91000 IU/mL in plasma, intermediate viral load ≥27300 and <273000 IU/mL 
in whole blood or ≥9100 and <91000 IU/mL in plasma, and low viral load <27300 and ≥2730 
IU/mL in whole blood or CMV DNA <9100 and ≥910 IU/mL in plasma as determined by the 
most recent local or central specialty laboratory qPCR results available at the time of 
randomization) as 2 stratification factors and then randomized in a 2:1 allocation ratio to receive 
maribavir 400 mg BID or investigator-assigned anti-CMV treatment for 8 weeks.
A cohort of subjects will have tissue-invasive CMV disease or CMV syndrome at baseline, as 
initially determined by the investigator (also referred as “symptomatic subjects”). Therefore, this 
study will also assess improvement or resolution of tissue-invasive CMV disease and CMV 
syndrome at the end of the 8-week study treatment phase and during the follow-up phase for 
subjects with symptomatic CMV infection present at baseline. “Asymptomatic subjects” will be 
defined as: Eligible enrolled subjects who do not have tissue-invasive CMV disease or CMV 
syndrome at baseline, as diagnosed by the investigator.
The investigator will perform the initial diagnosis of tissue invasive CMV disease or CMV 
syndrome (absence or presence) for the symptomatic subjects at baseline and new occurrence of 
tissue invasive CMV disease or CMV syndrome for the asymptomatic subjects at baseline 
through the study, and will continue with the assessment of the status (ie, no change, 
improvement, worsening, or resolution) at subsequent visits through the study. All investigator-
assessed cases of tissue invasive CMV disease and CMV syndrome will be reviewed and 
adjudicated by an independent Endpoint Adjudication Committee (EAC) both for the 
confirmation of the diagnosis of baseline and new symptomatic CMV infection and for the 
outcome (ie, no change, improvement, worsening, or resolution).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 55 
 
07 Dec 2018
For non-commercial use only


Shire
Page 56
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
An independent data monitoring committee (DMC) will be established to act in an expert, 
advisory capacity for periodic assessment of the data to monitor participant safety and to ensure 
the validity and scientific merit of the trial.
As shown in the study schematic in Figure 1, the study will have 3 phases: (1) Up to a 2-week 
screening phase; (2) 8-week study treatment phase; and (3) 12-week follow-up phase. Subjects 
will be required to visit the site up to 19 times for up to a 22-week period. Subjects entering the 
maribavir rescue arm may participate in the study for a longer duration, depending on the time of 
the transition from the investigator-assigned study treatment to maribavir, with a maximal time 
of 29 weeks.
Figure 1:
Study Design Flow Chart
*Visit 2A/A-R is only required for subjects taking tacrolimus, cyclosporine, everolimus, or sirolimus at Visit 2/2R.
BID=twice daily; BL=baseline; R=rescue; Rand=randomized; wks=weeks
Note: Eligibility to enter maribavir rescue arm will be assessed starting at Visit 5/week 3 up to Visit 9/Week 7
Screening Phase
As presented in Schedule of Assessment 1, Table 1, 413 subjects will be screened for 
approximately 2 weeks to establish eligibility for study participation. All screening procedures 
will be completed within 14 days prior to initiation of study treatment, with the exception of the 
following:
1. Screening clinical laboratory tests (hematology, chemistry, and pregnancy) must be 
performed within 7 days prior to initiation of study treatment.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 56 
 
07 Dec 2018
For non-commercial use only


Shire
Page 57
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
2. Subjects must have a documented CMV infection in whole blood or plasma with a screening 
value of ≥2730 IU/mL in whole blood or ≥910 IU/mL in plasma or in 2 consecutive 
assessments, separated by at least 1 day, as determined by local or central specialty 
laboratory quantitative polymerase chain reaction (PCR) or comparable quantitative CMV 
DNA results. The first sample must be available within 14 days prior to study enrollment (ie, 
start of study treatment) at Visit 2/Day 0. The second sample must be available within 5 days 
prior to the study enrollment. CMV DNA quantification may be performed by the local or 
central specialty laboratory. Already available results from the local laboratory (historical 
results) will be acceptable for screening, if taken within the time frames indicated and if from 
the same laboratory and same sample type (whole blood or plasma).
3. Historical results for human immunodeficiency virus (HIV) tests performed within 3 months 
prior to the study treatment initiation will be acceptable for screening. If no HIV test result 
within 3 months is available, the subject must have testing done locally during the screening 
period and have negative results available prior to randomization. 
4. The investigator must identify the remaining treatment options available for the subject and 
must be willing to treat the subject with at least 1 of the available anti-CMV drugs.
All clinical laboratory results required for eligibility verification (screening) must be available 
prior to randomization.
Study Treatment Phase
Approximately 351 eligible subjects with refractory or resistant CMV infection will be stratified 
and then randomized in a 2:1 ratio at Visit 2/Day 0 to receive either maribavir or 
investigator-assigned anti-CMV treatment (collectively, the study treatment; 234 subjects 
[maribavir]: 117 subjects [investigator-assigned anti-CMV treatment]) for 8 weeks.
The screening and Visit 2/Week 0/Day 0 visits can occur on the same day if the historical 
laboratory results including CMV DNA quantification results, needed for evaluation of eligibility 
are available or results can be obtained the same day. All Visit 2/Day 0 procedures and screening 
laboratory results needed to confirm eligibility, including blood collection for CMV DNA 
quantification, hematology and chemistry analysis in the central laboratory, must be completed 
and documented prior to randomization and study treatment administration. Central laboratory 
results of CMV DNA quantification and genotyping, hematology and chemistry from samples 
taken at Visit 2/Day 0 will not be available for use for screening the patients. Initiation of study 
treatment (ie, first dose) will only occur after completion of all required Visit 2/Day 0 
procedures, confirmation of eligibility, and completion of randomization. This will be done 
under the supervision of investigator site personnel.
All subjects will perform study-specific evaluations weekly during the 8-week study treatment 
phase. Refer to Schedule of Assessment 1 (Table 1) for a complete list of the evaluations 
performed in the study treatment phase. 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 57 
 
07 Dec 2018
For non-commercial use only


Shire
Page 58
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Subjects Randomized to Maribavir Treatment
Depending on the time of the first maribavir dose on Visit 2/Week 0/Day 0, a second dose should 
be administered on Visit 2/Day 0 provided that doses can be separated by a minimum of 8 hours; 
otherwise, only 1 dose should be administered on Visit 2/Day 0. Maribavir will then be 
administered (preferably) every 12 hours (q12h). When q12h dosing is not feasible, the doses 
should be separated by a minimum of 8 hours. Since 200 mg strength maribavir tablets will be 
utilized, subjects will be required to take 2 tablets of maribavir q12h as shown in Table 4. 
Subjects will take the maribavir 400 mg BID dose for the 8 weeks of the study treatment phase.
Subjects Randomized to Investigator-Assigned Anti-CMV Therapy
Investigator-assigned anti-CMV treatment strategies for the 8 weeks of the study treatment phase 
must only utilize up to 2 available anti-CMV agents from the following: ganciclovir, 
valganciclovir, foscarnet, or cidofovir. Combination therapy of cidofovir and foscarnet is 
prohibited due to the risk of nephrotoxicity.
If investigator’s decision is to change the pre-study anti-CMV agent(s), the investigator can 
select up to 2 new anti-CMV drugs (ganciclovir, valganciclovir, foscarnet, cidofovir) as the study 
treatment.
Investigator may also decide to keep the subject on the same anti-CMV drug(s), which was/were 
used for treatment of subject prior to randomization/ treatment initiation.
If the treatment was continued or started as 2 anti-CMV agents, withdrawal of one agent, while 
continuing the second one will be possible. After randomization changes to the investigator 
treatment of choice could include, change in dosing, change in dosing regimen, but will not 
include an addition of or switch to another anti-CMV agent (other than changing between IV 
ganciclovir and oral valganciclovir).
Dose adjustment is allowed as deemed appropriate by the investigator. The rationale for dose 
adjustment will be documented; change to another anti-CMV agent during the study treatment 
period is not allowed. Investigational anti-CMV agents are not permitted. Additional treatment 
strategies can complement the use of a single anti-CMV agent, for example, reducing or 
modifying the immunosuppressant drug use or use of IVIg or CMV Ig.
Subjects will follow the investigator’s prescribed anti-CMV treatment. Subjects will remain on 
their investigator-assigned anti-CMV therapy for the 8 weeks of the study treatment phase. 
Subjects may stop treatment at the discretion of the investigator, for lack of confirmed viremia 
clearance and/or intolerance to the assigned treatment. Subjects may be assessed for rescue arm 
eligibility at the investigator’s discretion. Intolerance to assigned treatment without clear 
evidence of virologic and/or clinical failure will not qualify a patient for the rescue arm. Viremia 
clearance should be based on the results from the same laboratory used for randomization. 
Subjects may be assessed for entry into a rescue arm, starting at Visit 5/Week 3 (after a 
minimum 3 weeks of treatment), for treatment with maribavir 400 mg BID for 8 weeks. Subjects 
must meet 1 of the following criteria to be eligible to enter the maribavir rescue arm:
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 58 
 
07 Dec 2018
For non-commercial use only


Shire
Page 59
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
1.
Subject has increased whole blood or plasma CMV viremia levels of ≥1 log10 from 
baseline as measured by the local or central specialty laboratory qPCR assay (results 
from the same laboratory will be compared). Local specialty laboratory results must be 
documented.
2.
Subjects with tissue invasive CMV disease must meet both criteria after being on
treatment for at least 3 weeks:

Subject whole blood or plasma CMV DNA has decreased <1 log10 from baseline as 
measured by the local or specialty laboratory qPCR assay (results from the same 
laboratory will be compared). Local specialty laboratory results must be documented.

Symptomatic subject’s presenting tissue invasive CMV disease did not improve, or 
worsened as assessed by the investigator OR subject who was asymptomatic at 
baseline developed tissue invasive CMV disease.
3.
No CMV viremia clearance was achieved (results from the same laboratory will be 
assessed) necessitating continued anti-CMV treatment AND the subject has demonstrated 
intolerance to the investigator-assigned anti-CMV treatment as evidenced by 1 of the 
conditions:

Acute increase in serum creatinine, at least 50% increase from the baseline value, 
attributed to treatment (cidofovir, foscarnet) toxicity.

Development of hemorrhagic cystitis when on treatment with cidofovir or foscarnet.

Development of neutropenia (absolute neutrophil count ANC <500/mm3 [0.5 x 
109/L]) when on treatment with ganciclovir or valganciclovir.
Assessments based on local laboratory results must be documented.
The transition into the rescue arm will be allowed after the study medical monitor has reviewed 
the investigator’s request and has approved the subject’s eligibility for the rescue arm. Blood 
sample taken for CMV DNA test at the first visit of the maribavir rescue treatment period will be 
used as the ‘baseline’ assessment for the purpose of the analyses of the response to maribavir 
rescue treatment (including resistance analyses). Subjects who are unable to continue taking 
investigator-assigned anti-CMV treatment due to the lack of anti-viral activity and/or intolerance 
to the assigned treatment and do not meet the eligibility criteria to enter the maribavir rescue arm 
will be treated as deemed appropriate by the investigator.
The investigator may also choose to interrupt therapy for a maximum of 7 consecutive days, or 
up to 2 study treatment interruptions for a total of up to 7 days. This will not result in permanent 
study treatment discontinuation. If study drug is interrupted for any reason and subsequently 
resumed, the end of the study drug administration period would remain fixed at a maximum of 
8 weeks after the date of the start of treatment.
All subjects will undergo study-specific evaluations weekly during the study treatment phase. 
Refer to Schedule of Assessment 1 (Table 1) for a complete list of the evaluations performed in 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 59 
 
07 Dec 2018
For non-commercial use only


Shire
Page 60
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
the study treatment phase. All subjects who complete the study treatment phase through Visit 
10/Week 8 will enter the 12-week follow-up phase. 
Subjects who prematurely discontinue study treatment and if in the investigator assigned 
anti-CMV treatment arm and not transferred to the maribavir rescue arm, will complete the end 
of treatment procedures described for Visit 10/Study Week 8 in the Schedule of Assessment 1; 
these subjects will continue a modified schedule of assessments through the remaining weekly 
visits scheduled for the study treatment phase and the regular schedule of assessments through 
the 12-week follow-up phase. The modified schedule of assessments through the remaining visits 
of study treatment phase will not include the use of the diary for study treatment compliance, 
dispense or use of any study treatment, and PK sample collection. The end of treatment sample 
for immunosuppressant drug concentration level will be collected at the next visit scheduled 1 
week after the treatment discontinuation. After completing the 8-week duration specified for the 
study treatment phase, subjects will enter the 12-week follow-up phase. 
Subjects who withdraw consent during the study treatment phase will be asked to undergo all 
end of treatment evaluations and procedures listed for Visit 10/Week 8; no further follow-up will 
be performed. 
Further details regarding discontinuation of subjects are provided in Section 4.5.1. 
Subjects who are transferred to maribavir rescue arm will be treated with maribavir for 8 weeks 
and will follow the procedures similar to subjects in the maribavir treatment arm, as indicated in 
the Schedule of Assessment 1 (Table 1; visits denoted with letter R). After the completion of 
8 weeks of maribavir rescue treatment, subjects will enter the 12-week follow-up phase and will 
follow the procedures indicated in the Schedule of Assessment 2 (Table 2).
Follow-up Phase
Study-specific evaluations including central specialty laboratory CMV test and safety 
assessments will occur weekly for the first 4 weeks, then every 2 weeks for the final 8 weeks of 
the 12-week follow-up phase. Refer to Schedule of Assessment 2 (Table 2) for a complete list of 
evaluations. Subjects who withdraw from the study during the follow-up phase will undergo the 
end of study evaluations and procedures for Visit 18/Week 20 (Follow-up Week 12) as soon as 
possible, and whenever possible, prior to initiation of any nonstudy anti-CMV treatment (as 
deemed by the investigator); no further follow-up will be performed.
If the subject is unable to travel to the site for the follow-up visits, these visits may be on 
exceptional basis performed remotely (ie, at subjects’ home) by a qualified sponsor or site 
designee, and only if permitted according to local regulations. Clinical laboratory assessments
will be collected and all other follow-up assessments will be completed. Adverse events and 
SAE collection may be completed by telephone follow-up call on the day of the scheduled visit. 
It is recommended that the end of study visit be completed at the site if the subject is able to 
travel.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 60 
 
07 Dec 2018
For non-commercial use only


Shire
Page 61
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
3.2
Duration and Study Completion Definition
The subject’s maximum duration of participation is expected to be approximately 22 weeks 
(screening: up to 2 weeks; open-label phase: 8 weeks; follow-up phase: 12 weeks). Follow-up 
visits will occur weekly for the first 4 weeks (Weeks 9-12), followed by visits every 2 weeks for 
the last 8 weeks (Weeks 12-20) of this 12-week follow-up phase.
For subjects in the maribavir rescue arm the maximal duration of study will be 29 weeks, 
depending on the time of the transfer into the rescue arm. 
The study will be completed in approximately 25 months. The study completion date is defined 
as the date the final subject, across all sites, completes their final protocol-defined assessment. 
This includes the follow-up visit or contact, whichever is later. The study completion date is used 
to ascertain timing for study results posting and reporting.
3.3
Sites and Regions
This is a multicenter study. Approximately 140 sites in North America, Europe, and Asia Pacific 
will participate.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 61 
 
07 Dec 2018
For non-commercial use only


Shire
Page 62
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
4.
STUDY POPULATION
Approximately 351 subjects, including adolescents ≥12 to <18 years of age, who are transplant 
recipients (HSCT or SOT) with a current CMV infection that is refractory or resistant to 
treatment with commercially available anti-CMV agents (ie, ganciclovir, valganciclovir, 
foscarnet, or cidofovir) will be enrolled. Each subject must participate in the informed consent 
process and provide written informed consent/assent before any procedures specified in the 
protocol are performed.
4.1
Inclusion Criteria 
The subject will not be considered eligible for the study without meeting all of the criteria below.
1. The subject must be able to provide written, personally signed, and dated informed consent to 
participate in the study before completing any study-related procedures. As applicable, a 
parent/both parents or legally authorized representative (LAR) must provide signature of 
informed consent and there must be documentation of assent by the subject before 
completing any study-related procedures.
2. The subject must be a recipient of hematopoietic stem cell or solid organ transplant.
3. The subject must have a documented CMV infection in whole blood or plasma, with a 
screening value of ≥2730 IU/mL in whole blood or ≥910 IU/mL in plasma in 2 consecutive 
assessments, separated by at least 1 day, as determined by local or central specialty 
laboratory quantitative polymerase chain reaction (qPCR) or comparable quantitative CMV 
DNA results. Both samples should be taken within 14 days prior to randomization with 
second sample obtained within 5 days prior to randomization. The same laboratory and same 
sample type (whole blood or plasma) must be used for these assessments.
4. The subject must have a current CMV infection that is refractory to the most recently 
administered of the four anti-CMV treatment agents. Refractory is defined as documented 
failure to achieve >1 log10 (common logarithm to base 10) decrease in CMV DNA level in 
whole blood or plasma after a 14 day or longer treatment period with IV ganciclovir/oral 
valganciclovir, IV foscarnet, or IV cidofovir. 

Subjects with documentation of 1 or more CMV genetic mutations associated with 
resistance to ganciclovir/valganciclovir, foscarnet, and/or cidofovir must also meet the 
definition of refractory CMV infection.
5. The investigator must be willing to treat the subject with at least 1 of the available anti-CMV 
drugs (ganciclovir, valganciclovir, foscarnet, or cidofovir). Note: Combination therapy with 
foscarnet and cidofovir is not permitted in the IAT arm due to the potential for serious 
nephrotoxicity. 
6. The subject must be ≥12 years of age at the time of consent.
7. The subject must weigh ≥35 kg.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 62 
 
07 Dec 2018
For non-commercial use only


Shire
Page 63
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
8. The subject must have all of the following results as part of screening laboratory assessments 
(results from either the central laboratory or a local laboratory can be used for qualification):
a.
Absolute neutrophil count (ANC) ≥1000/mm3 [1.0 x 109/L]
b. Platelet count ≥25000/mm3 [25 x 109/L]
c.
Hemoglobin ≥8g/dL
d. Estimated glomerular filtration rate (eGFR) >30 mL/min/1.73m2 as assessed by 
Modification of Diet in Renal Disease (MDRD) formula for subjects ≥18 years of 
age or Schwartz formula for subjects <18 years of age (see Appendix 11 for the 
formulae)
9. The subject must have a negative serum β-human chorionic gonadotropin (β-HCG) 
pregnancy test at screening, if a female of child bearing potential. Additional urine pregnancy 
tests may be done per institutional requirements. Sexually active females of child bearing 
potential must agree to comply with any applicable contraceptive requirements of the 
protocol. If male, must agree to use an acceptable method of birth control, as defined in the 
protocol, during the study treatment administration period and for 90 days afterward if 
treated with maribavir, ganciclovir, valganciclovir, or cidofovir and for 180 days afterward if 
treated with foscarnet.
10. The subject must be able to swallow tablets, or receive tablets crushed and/or dispersed in 
water via a nasogastric or orogastric tube.
11. The subject must be willing and have an understanding and ability to fully comply with study 
procedures and restrictions defined in the protocol.
12. The subject must be willing to provide necessary samples (eg, biopsy) for the diagnosis of 
tissue invasive CMV disease at baseline as determined by the investigator.
13. The subject must have a life expectancy of ≥8 weeks.
4.2
Exclusion Criteria
Subjects are excluded from the study if any of the following exclusion criteria are met. 
Subjects must not:
1. Have a current CMV infection that is considered refractory or resistant due to inadequate 
adherence to prior anti-CMV treatment, to the best knowledge of the investigator
2. Require ganciclovir, valganciclovir, foscarnet, or cidofovir administration for conditions 
other than CMV when study treatment is initiated (example: herpes simplex virus (HSV) 
coinfection requiring use of any of these agents after the randomization) or would need a 
coadministration with maribavir for CMV infection. NOTE: A subject who is not continuing 
with the same anti-viral drug(s) (ganciclovir, valganciclovir, or foscarnet) for the study 
treatment (if randomized to the investigator assigned anti-CMV treatment arm), must 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 63 
 
07 Dec 2018
For non-commercial use only


Shire
Page 64
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
discontinue their use before the first dose of study drug. If subject is currently being treated 
with cidofovir and is assigned another anti-CMV therapy by the investigator, the subject 
must discontinue its use at least 14 days prior to randomization at Visit 2/Day 0 and the first 
dose of study treatment.
3. Be receiving leflunomide, letermovir, or artesunate when study treatment is initiated. NOTE: 
Subjects receiving leflunomide must discontinue the use at least 14 days prior to 
randomization at Visit 2/Day 0 and the first dose of study treatment. Subjects receiving 
letermovir must discontinue use at least 3 days prior to the first dose of study treatment. 
Subjects receiving artesunate must discontinue the use prior to the first dose of study 
treatment.
4. Have severe vomiting, diarrhea, or other severe gastrointestinal illness within 24 hours prior 
to the first dose of study treatment that would preclude administration of oral/enteral 
medication.
5. Have known hypersensitivity to the active substance or to an excipient for a study treatment.
6. Have tissue invasive CMV disease with central nervous system involvement, including the 
retina (eg CMV retinitis).
7. Have serum aspartate aminotransferase (AST) >5 times upper limit of normal (ULN) at 
screening, or serum alanine aminotransferase (ALT) >5 times ULN at screening, or total 
bilirubin ≥3.0 x ULN at screening (except for documented Gilbert’s syndrome), by local or 
central lab. Note: Subjects with biopsy confirmed CMV hepatitis will not be excluded from 
study participation despite AST or ALT >5 times ULN at screening.
8. Have known positive results for human immunodeficiency virus (HIV). Subjects must have a 
confirmed negative HIV test result within 3 months of study entry or, if unavailable, be 
tested by a local laboratory during the screening period.
9. Require mechanical ventilation or vasopressors for hemodynamic support at the time of 
enrollment.
10. Be female and pregnant or breast feeding.
11. Have previously received maribavir.
12. Have received any investigational agent with known anti-CMV activity within 30 days 
before initiation of study treatment or investigational CMV vaccine at any time.
13. Have received any unapproved agent or device within 30 days before initiation of study 
treatment.
14. Have active malignancy with the exception of nonmelanoma skin cancer. Subjects who have 
had a HSCT and who experience relapse or progression of the malignancy, as per 
investigator’s opinion are not to be enrolled.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 64 
 
07 Dec 2018
For non-commercial use only


Shire
Page 65
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
15. Be undergoing treatment for acute or chronic hepatitis C.
16. Have any clinically significant medical or surgical condition that in the investigator’s opinion 
could interfere with the interpretation of study results, contraindicate the administration of 
the assigned study treatment, or compromise the safety or well-being of the subject.
4.3
Restrictions 
There will be no special restrictions for subjects participating in this study. Subjects are to 
maintain their normal diets, medications (except those listed in Section 5.2.2), and activities of 
daily life as determined by the investigator.
4.4
Reproductive Potential
4.4.1
Female Contraception
There is no clinical experience with maribavir in pregnant subjects. The investigator assigned 
treatments (ganciclovir, valganciclovir, or cidofovir) have no clinical experience in pregnant 
subjects and based on the reproductive toxicity observed in animal studies should be considered 
a potential teratogen and carcinogen in humans (Valcyte Prescribing Information). The 
reproductive toxicity studies with foscarnet (Foscavir) in animals were conducted using 
exposures that are inadequate to define the potential of teratogenicity at levels to which women 
will be exposed (Foscavir Prescribing Information). All female subjects of child-bearing potential 
will be tested and should have negative serum -human chorionic gonadotropin pregnancy test 
results prior to randomization. They must agree to abstain from sexual activity that could result 
in pregnancy or agree to use an acceptable method of contraception. Females of child-bearing 
potential must be advised to use acceptable contraceptives throughout the study period and for 
90 days after the last dose of study treatment. If hormonal contraceptives are used they should be 
administered according to the package insert and in conjunction with another acceptable method 
of contraception. Females of child-bearing potential who are not currently sexually active must 
agree to use acceptable contraception, as defined below, if they become sexually active during 
the period of the study and 90 days following the last dose of study treatment. Sexually active 
females of child-bearing potential should be using an acceptable form of highly effective method 
of contraception, as defined below. 
Methods of contraception that can achieve a failure rate of less than 1% per year when used 
consistently and correctly are considered highly effective birth control methods for females of 
child-bearing potential are presented below: 

Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation (oral, intravaginal, transdermal) or progestogen-only hormonal 
contraception associated with inhibition of ovulation (oral, injectable, implantable [low 
user dependency]) stabilized for at least 30 days prior to the screening visit (Visit 1), plus 
condoms. Note: Since hormonal contraception may be susceptible to interaction with the 
study treatment(s) in the study, which may reduce the efficacy of the contraception 
method, this method must be supplemented with a barrier method (preferably male 
condom). 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 65 
 
07 Dec 2018
For non-commercial use only


Shire
Page 66
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018

Intrauterine devices (IUD, all types) or intrauterine hormone releasing systems (IUS) plus 
condoms. Note: contraception methods that in the context of the clinical trial facilitation
group (CTFG) guidance are considered to have lower user dependency.

Bilateral tubal occlusion.

Vasectomized male partner is a highly effective birth control method provided that partner 
is the sole sexual partner of the female trial participant who is of child bearing potential 
and that the vasectomized partner has received medical assessment of the surgical success.

Sexual abstinence defined as refraining from heterosexual intercourse during the entire 
period of risk associated with the study treatments. Note: the reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the clinical trial and the 
preferred and usual lifestyle of the subject.
Female subjects 12 years of age and older, who are amenorrheic for reasons other than 
menopause (12 consecutive months of spontaneous amenorrhea in patients with previous normal 
menstruation), including subjects who did not yet have the menarche, would be allowed to 
participate provided they agree to abstinence or an acceptable form of contraception, as defined 
above.
Female subjects who are postmenopausal (12 consecutive months of spontaneous amenorrhea) or 
surgically sterile (having undergone 1 of the following surgical acts: hysterectomy, bilateral 
tubal ligation, bilateral oophorectomy or bilateral salpingectomy) and are at least 6 weeks 
poststerilization do not need a pregnancy test performed prior to randomization and do not have 
to agree to the use of acceptable methods of contraception.
4.4.2
Male Contraception
Male subjects will be required to use a condom in conjunction with a highly effective method of 
birth control for their female partners of child-bearing age (described in Section 4.4.1). Both 
male participants and their female partners must use this form of birth control from the time prior 
to first dosing until 90 days after the last dose of study treatment (ie, maribavir, ganciclovir, 
valganciclovir, or cidofovir) or 180 days after the last dose, if treated with foscarnet. For male 
subjects, sexual intercourse with pregnant partners should also be avoided during the course of 
the study unless condoms are used from the time prior to the first dose until 90 days after the last 
dose of study treatment (ie, maribavir, ganciclovir, valganciclovir, or cidofovir) or 180 days after 
the last dose, if treated with foscarnet. Male subjects must not donate sperm until 90 days after 
the last dose of study treatment (ie, maribavir, ganciclovir, valganciclovir, or cidofovir) or 
180 days after the last dose, if treated with foscarnet.
4.5
Discontinuation and/or Withdrawal of Subjects
A subject may withdraw (eg, withdraw consent) from the study at any time for any reason 
without prejudice to their future medical care by the physician or at the institution. The 
investigator or the sponsor may withdraw the subject at any time (eg, in the interest of the 
subject’s safety). The investigator is encouraged to discuss withdrawal of a subject from study 
treatment with the sponsor’s medical monitor when possible. Subjects who withdraw consent 
during the study treatment phase will be asked to undergo all end of treatment evaluations and 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 66 
 
07 Dec 2018
For non-commercial use only


Shire
Page 67
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
procedures listed for Visit 10/Week 8, if they agree; subjects who withdraw from the study 
during the follow-up phase will undergo all end of study evaluations and procedures listed for 
Visit 18/Week 20 (Follow-up Week 12) as soon as possible and whenever possible, if they agree, 
prior to initiation of any nonstudy anti-CMV treatment (as deemed by the investigator); no 
further follow-up will be performed. 
Subjects who prematurely discontinue study treatment and if in the investigator-assigned 
treatment and not transferred to the maribavir rescue arm, will complete the end of treatment 
procedures described for Visit 10/Study Week 8 in the Schedule of Assessment 1 (Table 1); 
these subjects will continue a modified schedule of assessments through the remaining weekly 
visits scheduled for the study treatment phase and the regular schedule of assessments through 
the 12-week follow-up phase. The modified schedule will exclude the use of the diary for study 
treatment compliance, dispense or use of any study treatment, and PK sample collection. The end 
of treatment sample for immunosuppressant drug concentration level will be collected at the next 
visit scheduled 1 week after the treatment discontinuation. During the period after the study 
treatment discontinuation and until the end of the study, subjects might be administered an 
anti-CMV treatment for lack of efficacy, recurrence of CMV viremia, or for worsening or new 
onset of CMV disease as deemed necessary by the investigator. 
Subjects in the investigator-assigned anti-CMV treatment who cannot continue the treatment 
they have been randomized to and meet the criteria (see Section 3.1) to be transferred to 
maribavir rescue arm will complete the end of treatment evaluations listed for Visit 10/Week 8 
prior to being transferred. Overlapping study procedures for Visit 2R/Week 0R do not need to be 
repeated when the end-of-treatment visit is performed on the same day as rescue arm entry. They 
will be treated with maribavir for 8 weeks and will follow the procedures in the manner similar 
to that followed by subjects in the maribavir treatment arm, as indicated in the Schedule of 
Assessment 1 (Table 1) (visits denoted with letter R). After the completion of 8 weeks of 
maribavir rescue treatment, subjects will enter the 12-week follow-up phase and will follow the 
procedures indicated in the Schedule of Assessment 2 (Table 2).
Subjects who withdraw consent during the study treatment phase will be asked to undergo all 
end of treatment evaluations and procedures listed for Visit 10/Week 8 as soon as possible, if 
they agree, prior to initiation of any nonstudy anti-CMV treatment for lack of efficacy, 
recurrence of CMV viremia, or for worsening or new onset of CMV disease (as deemed by the 
investigator). Subjects who withdraw consent during the follow-up phase will be asked to 
undergo all end of study evaluations and procedures listed for Visit 18/Week 20 as soon as 
possible, if they agree, prior to initiation of any nonstudy anti-CMV treatment (as deemed by the 
investigator). No further follow-up will be performed.
The reason for treatment discontinuation, study termination, date of stopping study treatment 
(maribavir or investigator-assigned anti-CMV treatment), and the total amount of study treatment 
taken will be recorded in the electronic diary, case report form (CRF), and source documents as 
appropriate.
Subjects who discontinue will not be replaced.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 67 
 
07 Dec 2018
For non-commercial use only


Shire
Page 68
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
4.5.1
Reasons for Discontinuation and/or Withdrawal
The reason for study treatment discontinuation (maribavir or investigator-assigned anti-CMV 
treatment) and/or withdrawal from the study must be determined by the investigator and 
recorded in the subject’s medical record and in the CRF. If a subject discontinues treatment or is 
withdrawn from the study for more than 1 reason, each reason should be documented in the 
source document and the most clinically relevant reason should be entered in the CRF.
Reasons for discontinuation include but are not limited to:

Withdrawal of consent (by subject or by a parent or both parents/legal guardian for pediatric 
subjects)

Adverse event (must specify on the CRF)

CMV central nervous system (CNS) infection
-
Maribavir does not cross the blood-brain barrier. If a subject in the study develops CMV 
CNS infection (eg, meningo-encephalitis), then the subject will discontinue study 
treatment in order to be treated for this condition.

Protocol deviation (eg, lack of compliance, use of experimental drug) 

Pregnancy

Sponsor decision (must specify on the CRF)

Death

Lost to follow-up

Lack of efficacy
Other (must specify on the CRF)
The end of study treatment and the end of study date for each subject (ie, the date of completion 
of the study or premature withdrawal from the study) will be recorded in the CRF.
4.5.2
Subjects ‘Lost to Follow-up’ Prior to Last Scheduled Visit
A minimum of 3 documented attempts must be made to contact any subject lost to follow-up at 
any time point prior to the last scheduled contact (office visit or telephone contact). At least 1 of 
these documented attempts must include a written communication sent to the subject’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they 
return to the site for final safety evaluations and return any unused investigational product.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 68 
 
07 Dec 2018
For non-commercial use only


Shire
Page 69
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
5.
PRIOR AND CONCOMITANT MEDICATIONS, THERAPIES, AND 
PROCEDURES
5.1
Prior Medications, Therapies, and Procedures
Prior treatment information must be recorded on the appropriate CRF page, and will include the 
following presented in Table 3.
Table 3:
Prior Medications, Therapies, and Procedures
Time Period
(Prior to Visit 2/Day 0)
Category
Prior Medications, Therapies, and Procedures
Medications/procedures 
administered/performed 
for transplant related 
reason from their start 
or date of transplant 
(whichever is first) to 
the first dose of study 
treatment on 
Visit 2/Day 0
Induction 
Therapy for 
Transplant*
Including but not limited to: 

Pre-transplant irradiation

Chemotherapy agents

Lymphocyte depleting and nondepleting therapies, 
including monoclonal, polyclonal, and 
anti-thymocyte globulin preparations
Anti-CMV 
Prophylaxis 
and Treatment*
Including, but not limited to:

Ganciclovir

Valganciclovir

Foscarnet

Cidofovir

CMV immune globulin (CCMV-GIV, Cytogam®)

Leflunomide

IVIG

Artesunate

CMV specific T-cell transfer (considered investigational)

Letermovir
All medications within 
3 months prior to the 
first dose of study 
treatment on Visit 
2/Week 0/Day 0
Transplant 
maintenance, 
rejection 
treatment, and 
other 
adjuvant/related 
therapy
Including, but not limited to:

Systemic steroids

Cyclosporine, tacrolimus, sirolimus, everolimus, 
mycophenolate

GVHD prophylaxis and treatment

Antirejection medications including T-cell depleting 
therapies

Photopheresis
Hematopoietic 
Growth 
Factors
Blood or Blood 
Product 
Transfusions
Other
Anti-Infective 
Agents

Prophylaxis and/or treatment of viral, bacterial and 
fungal infections
Within 30 days or 5 
half-lives (whichever is 
longer)
All Other 

All other prescription medications

All other over-the-counter medications (OTC)

All herbal supplements**
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 69 
 
07 Dec 2018
For non-commercial use only


Shire
Page 70
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Table 3:
Prior Medications, Therapies, and Procedures
Time Period
(Prior to Visit 2/Day 0)
Category
Prior Medications, Therapies, and Procedures
Any therapeutic or 
diagnostic intervention 
performed within 30 
days prior to the first 
dose of study treatment 
on Visit 2/Week 0/Day 
0
Including, but not limited to:

Biopsies (along with the results obtained)

Dialysis

X-rays, CT scans, MRI, ultrasound imaging (along with 
significant findings)
CMV=cytomegalovirus; GVHD=graft-versus-host-disease; HSV=herpes simplex virus; IVIg=intravenous immunoglobulin; 
VZV=varicella zoster virus; OTC=over-the-counter medications
*Subjects for whom transplant was performed >3 months from the time of screening limited (no dose data) information for 
induction therapy will be collected. Similarly for anti-CMV treatment data older than >3 month prior to screening will be 
recorded in more limited manner (dose prescribed, major interruptions, overall treatment duration).
**If half-life is unknown, report use within 30 days prior to study. 
5.2
Concomitant Medications, Treatments and Procedures 
Concomitant treatment refers to all treatment (including medications) taken between the dates of 
the first dose of study treatment and the end of the follow-up phase, inclusive. A concomitant 
procedure is any therapeutic and diagnostic intervention (eg, surgery/biopsy) or diagnostic 
assessment (bacterial cultures, imaging such as X-ray, CT scans) performed between the dates of 
the first dose of the study treatment and the end of the follow-up phase, inclusive.
5.2.1
Permitted Treatment during the Study Drug Treatment
All concomitant treatment information must be recorded on the appropriate CRF page. 
Additional treatment strategies may complement the use of the study specified anti-CMV agents, 
eg, reducing or modifying the immunosuppressant drug use, or use of hemopoietic growth 
factors as needed for neutropenia.
Of note, changes in the net state of immunosuppression can influence response to treatment of 
CMV infection, so the reason for the change in immunosuppression with the date of change must 
be provided on the CRF. Note that the sample for the assessment of immunosuppressant agent 
concentration is included in the schedule of assessments as maribavir was found to impact the 
metabolism of some immunosuppressive agents. Any changes in immunosuppression regimens 
due to the concomitant administration with maribavir or other reasons must be recorded in the 
CRF.
Maribavir is specifically intended to treat human CMV infections. Maribavir is not active in vitro 
against most non CMV herpesvirus infections, including herpes simplex virus (HSV type 1 and 
type 2) and VZV. At baseline, investigators will assess subjects to determine whether 
prophylaxis for these viruses is appropriate according to institutional guidelines or standard 
practices. If considered appropriate, permitted medications to use for this purpose include 
systemic acyclovir, valacyclovir, or famciclovir. Choice of medication, dose, and duration of 
such therapy is at the discretion of the investigator based on a given subject’s clinical condition 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 70 
 
07 Dec 2018
For non-commercial use only


Shire
Page 71
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
(eg, net state of immunosuppression, risk factors, and other medications). These medications 
(acyclovir, valacyclovir, or famciclovir) also can be used to treat any HSV or VZV infection that 
may occur during the study. Antifungal and antibacterial prophylactic medications will be 
allowed. Although potent inhibitors of CYP 3A4 (such as ketoconazole) could increase blood 
levels of maribavir, they are likely to be associated with minimal increased risk given the safety 
profile of maribavir demonstrated at up to 1200mg BID in Phase 2 studies. 
The following concomitant medications should be taken with caution: 
Maribavir has the potential to inhibit CYP2C19 and P-gp and therefore, may increase the 
concentration of drugs that are substrates of CYP2C19 and P-gp. For drugs with narrow 
therapeutic window, the increase in drug concentration may lead to toxicity. A drug interaction 
study showed that maribavir (400 mg BID) increased blood concentrations of tacrolimus (a 
substrate of CYP3A and P-gp) with Cmax and AUC increased by 38% and 51%, respectively. 
Therefore monitoring tacrolimus (and other narrow therapeutic index immunosuppressants) 
blood concentration and tacrolimus-associated adverse events, and the appropriate dose 
adjustment of tacrolimus is recommended when maribavir and tacrolimus are used 
concomitantly. Conversely, after a period of coadministration, discontinuation of maribavir
could lead to reduced blood levels of tacrolimus and potentially reduced therapeutic effect. 
Similarly, for drugs that are substrates of CYP2C19 or P-gp and have narrow therapeutic 
window, careful monitoring is recommended both after initiation of maribavir (when substrate 
levels may increase) and after discontinuation of maribavir (when substrate levels may decrease).
Although maribavir does not affect the activity of CYP3A enzyme nor other CYP enzymes other 
than CYP2C19 (including CYP1A2, CYP2B6, CYP 2C9, CYP2C8, CYP2D6, and CYP2E1), 
additional caution is needed when a patient receives other concomitant medications that affect 
cytochrome P450. For patients who receive concomitant medications that are inhibitors/inducers 
of CYP3A while on maribavir treatment, additional monitoring of immunosuppressant blood 
concentrations and immunosuppressant-associated adverse events may be needed within a few 
days after the start of concomitant medications or maribavir.
5.2.2
Prohibited Treatment 
Concomitant use of the following medications/treatments is prohibited for all subjects during the 
study: 

Any unapproved agent or device.

Any investigational anti-CMV agent, including receipt of CMV vaccine at any time prior 
to study.

Infusion of T-cells specific for CMV or regulatory T-cells (Tregs) for the control of 
transplant tolerance, which is an experimental treatment.
Maribavir 
Concomitant use of any of the following medications is prohibited while the subject is receiving 
maribavir:
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 71 
 
07 Dec 2018
For non-commercial use only


Shire
Page 72
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018

Strong CYP 3A inducers: avasimibe, carbamazepine, phenytoin, rifampin, rifabutin, 
St. John’s wort (Hypericum perforatum)

Herbal medications known to have potential toxicities or drug interactions, eg, 
Ginkgo biloba or Piper methysticum (kava)

Any of the following systemic anti-CMV therapies (except unintentional 
administration for no longer than 1 day):
-
Ganciclovir
-
Valganciclovir
-
Foscarnet
-
Cidofovir
-
Leflunomide
-
Artesunate
-
Letermovir
Except for ganciclovir/valganciclovir, maribavir does not antagonize the effects of other 
anti-viral (anti-CMV) agents. Maribavir inhibits the CMV UL97 serine/threonine kinase by 
competitively inhibiting the binding of adenosine triphosphate (ATP) to the kinase ATP-binding 
site. Since ganciclovir/valganciclovir is dependent on its initial phosphorylation by the viral 
UL97 kinase, maribavir may antagonize its clinical efficacy. Therefore, concomitant treatment 
with maribavir and ganciclovir/valganciclovir is not allowed.
Potent inducers of CYP 3A4 and/or P-gp (such as rifampin, rifabutin, or phenobarbital) could 
reduce blood levels of maribavir, potentially reducing its antiviral activity. Use of alternate 
agents with less enzyme induction potential should be considered during administration of 
maribavir.
In vivo drug interaction studies with Valcyte have not been performed. Since valganciclovir is 
extensively and rapidly metabolized to ganciclovir; drug interactions associated with ganciclovir 
will be expected for valganciclovir (Valcyte SmPC).
Maribavir does not cross the blood-brain barrier. If a subject in the maribavir treatment arm 
develops CMV central nervous system (CNS) infection (eg, meningo-encephalitis) then the 
subject will discontinue maribavir treatment in order to be treated for this condition. Subjects 
who develop new CMV retinitis while in the maribavir treatment arm may continue on therapy if 
the investigator does not intend to add another systemic or intraocular anti-CMV agent to treat 
the retinitis.
Administration of any of the prohibited treatments (except coadministration of foscarnet or 
cidofovir for indications other than CMV infection) will require discontinuation of maribavir 
(including the subjects in the maribavir rescue arm).
Investigator-assigned anti-CMV treatment strategies for the 8 weeks of the study treatment phase 
must only utilize available 1 or 2 anti-CMV agent from the following: ganciclovir, 
valganciclovir, foscarnet, or cidofovir. Dual agent therapy is allowed only if 1) the subject is on 
dual therapy prior to enrollment and this is continued as IAT during the treatment period or 2) if 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 72 
 
07 Dec 2018
For non-commercial use only


Shire
Page 73
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
dual therapy is initiated at the time of randomization. Addition of a second agent after 
randomization is not allowed. If on dual therapy, withdrawal of one of the two agents during the 
treatment phase is allowed. Dose adjustment for safety or efficacy will be allowed as deemed 
appropriate by the investigator. The rationale for dose adjustment will be documented; change to 
another anti-CMV agent during the study treatment period is not allowed (except for change 
from valganciclovir to ganciclovir, or vice versa).
Investigational anti-CMV agents are not permitted. Additional treatment strategies can 
complement the use of a single anti-CMV agent, for example, reducing or modifying the use of 
immunosuppressant drug or use of IVIg or CMV Ig. 
Concomitant use of any of the following medications is prohibited while the subject is receiving 
investigator-assigned anti-CMV treatment (except unintentional administration for no longer 
than one day):

Leflunomide

Artesunate

Letermovir
Investigator should refer to the Prescribing Information for ganciclovir, valganciclovir, foscarnet, 
and cidofovir for details on contraindication and precaution to ensure the appropriate use and 
monitoring of these drugs and concurrent medications. Addition of any of these treatments to the 
single investigator-assigned anti-CMV treatment strategy is not allowed during study treatment.
5.2.3
Treatments Taken During the Follow-up Phase
All permitted (Section 5.2.1) and prohibited medications (Section 5.2.2) specified for the study 
treatment phase are applicable to the follow-up phase; however, in case of no viremia clearance, 
presence of tissue invasive CMV disease, a CMV recurrence, appropriate medications required 
for CMV treatment may be administered in the follow-up phase as deemed necessary by the 
investigator. The secondary prophylaxis for subjects with viral clearance is not recommended in 
the follow-up phase. All medications will be recorded on the CRF.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 73 
 
07 Dec 2018
For non-commercial use only


Shire
Page 74
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
6.
IDENTITY OF STUDY TREATMENTS
The investigational product is maribavir (SHP620), which will be provided by the sponsor in 
200 mg strength tablet form. Additional information is provided in the current maribavir 
investigator's brochure.
Investigator-assigned anti-CMV treatment will not be considered an investigational product in 
the context of this study. Study investigators will choose and prescribe an anti-CMV drug of 
their choice from the available products utilized for treatment of CMV infection/disease in 
clinical practice, as endorsed in published guidance documents, institutional guidelines, and 
other published literature (Kotton et al., 2013; Tomblyn et al., 2009). The investigator-assigned 
anti-CMV treatment arm may utilize 1 or 2 (only if the subject’s current dual therapy at 
enrollment is continued after randomization or started at randomization) of the following 4 
anti-CMV agents: (change from ganciclovir to valganciclovir or vice versa will be allowed):

Ganciclovir

Valganciclovir

Foscarnet

Cidofovir
Combination therapy of cidofovir with foscarnet is prohibited.
Dose and dose regimen of the investigator-assigned anti-CMV treatment will be at the discretion 
of the investigator following clinical practice. Adjustment of the dose (increase or decrease) 
could be done for either efficacy or safety, as deemed appropriate by the investigator. Reason for 
dose adjustment will be recorded.
6.1
Blinding the Treatment Assignment
This is an open-label study. The investigator(s) and the subjects will be unblinded to the 
treatment assignment.
6.2
Administration of Investigational Product(s)
6.2.1
Interactive Response Technology for Investigational Product Management
An IRT (interactive response technology) will be employed in this study to manage the tracking 
and confirmation of shipment, supply, inventory, ordering, expiration, randomization, 
site-assignments of the investigational product, and accountability. The IRT provider will 
provide a user manual and training to each site, with detailed instruction on the use of the IRT.
6.2.2
Allocation of Subjects to Treatment 
This is a randomized, open-label, active-controlled study. Subject numbers are assigned to all 
subjects as they consent to take part in the study. Within each site (numbered uniquely within a 
protocol), the subject number is assigned to subjects according to the sequence of presentation 
for study participation.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 74 
 
07 Dec 2018
For non-commercial use only


Shire
Page 75
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
All eligible subjects will first be stratified based on 2 factors:
1. By transplant type (HSCT or SOT)
2. By the most recent screening whole blood or plasma CMV DNA concentration 
categorized in to 3 CMV DNA concentration level groups based on local or central 
specialty laboratory qPCR results:

High viral load with CMV DNA ≥273,000 IU/mL in whole blood or ≥
91,000 IU/mL in plasma, or

Intermediate viral load with CMV DNA ≥27,300 and <273,000 IU/mL in whole 
blood or ≥9,100 and <91,000 IU/mL in plasma, or

Low viral load with CMV DNA <27,300 and ≥2,730 IU/mL in whole blood or 
<9100 and ≥910 IU/mL in plasma
Following stratification, subjects will be randomized in a 2:1 allocation ratio to receive 
open-label maribavir 400 mg BID or investigator-assigned anti-CMV treatment for 8 weeks. The 
actual treatment given to individual subjects is determined by a randomization schedule 
automatically assigned by the interactive response technology (IRT). The randomization number 
represents a unique number corresponding to study treatment allocated to the subject, once 
eligibility has been determined. Once a randomization number/unique identifier has been 
assigned, that number must not be used again if, for example, a subject is withdrawn from the 
study. If a randomization number/unique identifier is allocated incorrectly, the clinical research 
associate (CRA)/study monitor must be notified as soon as the error is discovered.
Investigational product packaging identification numbers, separate from randomization 
numbers/unique identifiers, may also be assigned to subjects for specific treatment assignment as 
dictated by the study. In these cases, the same investigational product packing identification 
number may not be assigned to more than 1 subject.
6.2.3
Dosing
Initiation of study treatment, ie, the first dose administration, will occur at Visit 2/Week 0 on 
Day 0 after completion of all required assessments for that visit. The first dose should be 
administered under supervision of investigator site personnel, and be initiated as soon as possible 
after randomization. In cases where IV anti-CMV agents cannot be ordered, prepared, and 
administered immediately after randomization, the first dose of drug must be given within 24 
hours of randomization.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 75 
 
07 Dec 2018
For non-commercial use only


Shire
Page 76
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Subjects Randomized to Maribavir Treatment
Depending on the time of the first maribavir dose on Visit 2/Day 0, a second dose should be 
administered on Visit 2/Day 0 provided that doses can be separated by a minimum of 8 hours; 
otherwise, only 1 dose should be administered on Visit 2/Day 0. Maribavir will then be 
administered (preferably) every 12 hours (q12h). When q12h dosing is not feasible, the doses 
should be separated by a minimum of 8 hours. Since 200 mg strength maribavir tablets will be 
utilized, subjects will be required to take 2 tablets of maribavir q12h as shown in Table 4.
Maribavir may be administered with or without food. Maribavir tablets may be administered 
crushed and/or dispersed in water via orogastric or nasogastric tube for a short period of time 
during the study treatment phase to avoid interruption or discontinuation of treatment. Consult 
the maribavir pharmacy manual for additional information. 
Table 4:
Maribavir Dosing Regimen
Regimen
AM
PM
400 mg BID
200 mg ×2 tablets
200 mg × 2 tablets
Duration of Dosing: Subjects will take the maribavir 400 mg BID dose for the 8 weeks of the 
study treatment phase. 
The investigator may also choose to interrupt therapy for a maximum of 7 consecutive days, or 
up to 2 study treatment interruptions for a total of up to 7 days. This will not result in permanent 
study treatment discontinuation. If study drug is interrupted for any reason and subsequently 
resumed, the end of the study drug administration period would remain fixed at a maximum of 
8 weeks after the date of the start of treatment. Subjects can be on the investigational studies of 
approved products, such as different prophylactic regimens for GVHD or other anti-infective 
agents. However, the use of investigational treatment is prohibited.
Subjects Randomized to Investigator-Assigned anti-CMV Treatment
Investigator-assigned anti-CMV treatment strategies for the 8 weeks of the study treatment phase 
must only utilize 1 or 2 of the available anti-CMV agent from the following: ganciclovir, 
valganciclovir, foscarnet, or cidofovir. The subject receiving 1 or 2 anti–CMV agents at the time 
of enrollment, may either change therapy at the time of randomization/treatment initiation or 
remain on the same therapy as the investigator assigned anti-CMV agent, if randomized to this 
study treatment arm. After randomization, changes to the investigator treatment of choice could 
include, change in dosing, change in dosing regimen, but will not include an addition of or 
switch to another anti-CMV agent (switching between valganciclovir and ganciclovir is 
allowed). If the treatment was continued or was started (post-randomization) as 2 anti-CMV 
agents, withdrawal of one agent while continuing with the second one will be possible. 
Combination therapy of cidofovir with foscarnet is prohibited.
Dose adjustment is allowed as deemed appropriate by the investigator. The rationale for dose 
adjustment will be documented; change of treatment to another anti-CMV agent or addition of 
another anti-CMV agent during the study treatment will be declared as treatment failure. 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 76 
 
07 Dec 2018
For non-commercial use only


Shire
Page 77
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Subjects will follow the investigator’s prescribed dosing regimen for their investigator’s choice 
of anti-CMV treatment. 
Investigational anti-CMV agents are not permitted. Subjects will remain on their assigned 
treatment for the 8 weeks of the study treatment phase. Subjects may be assessed, based on the 
eligibility criteria specified in Section 3.1, for entry into a rescue arm for treatment with 
maribavir 400 mg BID for up to 8 weeks. 
The investigator may also choose to interrupt therapy for a maximum of 7 consecutive days, or 
up to 2 study treatment interruptions for a total of up to 7 days. This will not result in permanent 
study treatment discontinuation. If study drug is interrupted for any reason and subsequently
resumed, the end of the study drug administration period would remain fixed at a maximum of 
8 weeks after the date of the start of treatment.
Subjects who would require the treatment with 1 of the 4 available anti-CMV drugs in the 
dosages comparable or higher than used in the study for longer than 1 day, for indications other 
than CMV treatment (eg, foscarnet for other viral infections), would continue with assigned 
study treatment for 8 weeks per protocol. Concomitant treatment of ganciclovir/valganciclovir 
with maribavir is not allowed (see Section 5.2.2). 
Additional treatment strategies can complement the use of maribavir treatment and the study 
specified anti-CMV agents, for example, reducing or modifying the immunosuppressant drug use 
if possible or use of IVIg or CMV Ig.
6.3
Labeling, Packaging, Storage, and Handling
6.3.1
Labeling
Labels containing study information and pack identification are applied to the maribavir 
container. Study drug kits and individual bottles will be affixed with a label containing 
minimally the protocol number, study drug kit number, dosage form, storage conditions, the 
statements 'For clinical trial use only', and/or 'CAUTION: New Drug - Limited by Federal (US) 
Law to Investigational Use', and other information that may be required by the local laws.
Maribavir will be supplied as blue, film-coated, oval shaped convex tablets intended for oral 
administration. The tablet cores are composed of common compendial ingredients 
(Microcrystalline Cellulose, NF; Sodium Starch Glycolate, NF; and Magnesium Stearate, NF). 
The core tablet contains 200 mg maribavir and is coated with a blue standard Opadry II 
pharmaceutical coating.
Investigator-assigned anti-CMV treatment (ganciclovir, valganciclovir, foscarnet or cidofovir) 
will be prescribed by the investigator and either administered at the hospital or other facility used 
to administer IV products as per local site standard practice, or will be prescribed by the 
investigator and typically purchased by the study subject at the commercial pharmacy. This study 
protocol does not modify the treatment that the subject normally would have received regardless 
of his/her participation in the study. For feasibility reasons and because there is no modification 
to the treatment plan that the investigator would otherwise follow, if the patient was not enrolled 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 77 
 
07 Dec 2018
For non-commercial use only


Shire
Page 78
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
in the study, labeling of the investigator treatment of choice is not planned, unless required by 
country-specific regulations. The investigator assigned anti-CMV treatment will be chosen and 
prescribed by the investigator and typically purchased by the study subject at the commercial or 
hospital pharmacy, or will be administered at the hospital (in case of drugs that require IV 
administration, per local guidelines).
6.3.2
Packaging
The investigational product, maribavir, is packaged in 40-count white 60cc square HDPE bottles 
with child-resistant cap and foil induction seal.
Changes to sponsor-supplied packaging prior to dosing may not occur without full agreement in 
advance by the sponsor.
6.3.3
Storage
The investigator has overall responsibility for ensuring that investigational product is stored in a 
secure, limited-access location. Maribavir tablets will be stored at room temperature (15-30°C or 
59-86°F). Limited responsibility may be delegated to the pharmacy or member of the study team, 
but this delegation must be documented. Investigational products are distributed by the pharmacy 
or nominated member of the study team. The pharmacist/nominated team member will enter the 
unique subject identifier on the investigational product bottle/carton labels as they are 
distributed.
Investigational product must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage location to ensure that the investigational 
product is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study and that 
records are maintained; the temperature should be monitored continuously by using either an 
in-house system, a mechanical recording device such as a calibrated chart recorder, or by manual 
means, such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
would require manual resetting upon each recording. The sponsor must be notified immediately 
upon discovery of any excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary. Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use by the sponsor.
The sponsor should be notified immediately if there are any changes to the storage area of the 
investigational product that could affect the integrity of the product(s), eg, fumigation of a 
storage room.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 78 
 
07 Dec 2018
For non-commercial use only


Shire
Page 79
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
6.4
Drug Accountability
Investigators will be provided with sufficient amounts of the investigational product (maribavir) 
to carry out this protocol for the agreed number of subjects. The investigator or designee will 
acknowledge receipt of the investigational product, documenting shipment content and 
condition. Accurate records of all investigational product dispensed, used, returned, and/or 
destroyed must be maintained as detailed further in this section. An interactive response 
technology (IRT) will be used to manage subject randomization and the investigational product.
The investigator has overall responsibility for administering/dispensing investigational 
product. Where permissible, tasks may be delegated to a qualified designee (eg, a pharmacist) 
who is adequately trained in the protocol and who works under the direct supervision of the 
investigator. This delegation must be documented in the applicable study delegation of authority 
form.
The investigator or his/her designee (as documented by the investigator in the applicable study 
delegation of authority form) will dispense the investigational product (maribavir) only to 
subjects included in this study following the procedures set out in the study protocol. Each 
subject will be given (if assigned to maribavir) or prescribed (if assigned to the 
investigator-assigned anti-CMV treatment) only the study treatment carrying his/her treatment 
assignment. The principal investigator must maintain accurate records of investigational products 
received, including dates of receipt, expiry, dispensing, and lot numbers. All dispensed or 
prescribed medication will be documented on the CRFs and/or other investigational product 
record. The investigator is responsible for assuring the retrieval of all investigational product 
supplies from subjects. Investigator-assigned anti-CMV medication (ganciclovir, valganciclovir, 
foscarnet, or cidofovir) will also be documented on the CRFs and/or other study treatment 
accountability records, and may include additional information as required per applicable 
regulations. Compliance will be collected in the subject's e-diary. The disposition of the unused 
supply of the dispensed investigational product and the prescribed investigator-assigned 
anti-CMV medication will be documented in the accountability log.
No investigational product stock or returned inventory from a Shire-sponsored study may be 
removed from the site where originally shipped without prior knowledge and consent by the 
sponsor. If such transfer is authorized by the sponsor, all applicable local, state, and national 
laws must be adhered to for the transfer.
The sponsor or its representatives must be permitted access to review the supplies storage and 
distribution procedures and records.
With the written agreement of the sponsor, at the end of the study, or as instructed by the 
sponsor, all unused investigational product stock, subject-returned investigational product, and 
empty/used investigational product packaging will be returned to a sponsor specified 
designation. Should local, state or national laws prohibit the return of unused stock, subject 
returned investigational product, or empty/used investigational product packaging to the sponsor 
designated locations, it may be destroyed at the site or local facility once the sponsor has 
reviewed and approved the site's SOP. In this case, Certificates of Destruction (CoD) identifying 
what was destroyed, when and how, must be obtained with copies provided to the sponsor. 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 79 
 
07 Dec 2018
For non-commercial use only


Shire
Page 80
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Destruction of investigational products must be in accordance with local, state, and national 
laws.
Based on entries in the site drug accountability forms, it must be possible to reconcile 
investigational products delivered with those used and returned. All investigational products 
must be accounted for and all discrepancies investigated and documented to the sponsor’s 
satisfaction.
6.5
Subject Compliance
For drug administration at the site, hospital staff or study personnel will administer all doses of 
study drug. Missed/incorrect doses will be recorded in the subject’s electronic diary (e-diary) and 
CRF, as appropriate.
Investigator assigned anti-CMV treatments will be chosen and prescribed by the investigator, 
and will be either administered at the hospital or other facilities used to administer IV products, 
as per local site standard practice, or will be prescribed by the investigator and typically 
purchased by the study subject at the commercial or hospital pharmacy. For drug administration 
as outpatients, a study diary for tracking adherence to study drug dosing and an adequate supply 
of study drug will be dispensed for home use. Subjects must be instructed to bring their unused 
study drug, empty/used study treatment packaging, and the study diary to every visit. Drug 
accountability must be assessed at the container/packaging level for unused study drug that is 
contained within the original tamper-evident sealed container (eg, bottles, trays, vials) or at the 
individual count level for opened containers/packaging. Unused investigational product will not 
be redispensed. The pharmacist/nominated person will record details on the drug accountability 
form. Instructions will be provided in the pharmacy manual.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 80 
 
07 Dec 2018
For non-commercial use only


Shire
Page 81
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
7.
STUDY PROCEDURES
7.1
Study Schedule
See Table 1 for study procedures for the study treatment phase and Table 2 for study procedures 
for the follow-up phase. 
7.1.1
Screening Period 
Screening Visit (Visit 1/ Day -14 to Day 0/Week -2 to Week 0) 
As specified in Table 1, the screening procedures will include:

Informed consent

Inclusion/Exclusion criteria (see Sections 4.1 and 4.2)

Height and body weight (Section 7.2.3.2)

Vital signs (Section 7.2.3.3)

Medical history, including transplant history and CMV history

Prior medication, including any prior anti-CMV medication used to treat the current CMV 
infection, therapies, and procedures (Section 5.1)

HIV status: Historical results for human immunodeficiency virus (HIV) tests performed 
within 3 months prior to the study treatment initiation will be acceptable for screening. If no 
HIV test result within 3 months is available, the subject must have testing done locally during 
the screening period and have the results available prior to randomization (Exclusion 
Criterion 8)

Hematology/Chemistry (Section 7.2.3.5)

Serum pregnancy test for all females of child bearing potential (Inclusion Criterion 9; see 
Section 7.2.3.5). Additional urine pregnancy tests may be done per institutional requirements. 
Urine pregnancy test results are not sufficient for eligibility determination.

Interactive response technology (IRT [IV/WRS]; Section 6.2.1)

CMV DNA test (quantitation): Documentation of CMV infection in whole blood or plasma 
(with a screening value of ≥910 IU/mL, in 2 consecutive samples separated by at least 1 day 
as determined by local or central specialty laboratory qPCR or comparable quantitative CMV 
DNA results with the first sample available within 14 days prior to randomization at 
Visit 2/Week 0/Day 0. The second sample must be taken within 5 days prior to 
randomization. Results from the same laboratory are to be used to assess subject eligibility 
criteria. The laboratory used for DNA quantification could be either local specialty 
laboratory or central specialty laboratory.
Available local specialty laboratory genotyping results from the plasma samples obtained within 
the screening period will be collected.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 81 
 
07 Dec 2018
For non-commercial use only


Shire
Page 82
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Informed consent must be obtained before any study specific procedures are performed. All 
screening procedures will be completed within 14 days prior to randomization, with the 
exception of following:

At screening, either central or local laboratory results for CMV DNA quantification 
hematology/chemistry/pregnancy testing can be used for qualification.
A screen failure is a subject who has given informed consent and failed to meet the inclusion 
and/or met at least 1 of the exclusion criteria and has not been randomized or administered study 
treatment. Screen failures due to low platelet count, hemoglobin, and low neutrophil counts or 
liver and renal parameters can be rescreened once within the 14 day screening period at the 
investigator’s discretion when other inclusion criteria are fulfilled. Other screen failures may be 
rescreened in the future (with new informed consent and screening period) if their clinical course 
results in a change that deems them eligible for the trial.
The screening visit (Visit 1) and Visit 2/Week 0/Day 0 visits can occur on the same day.
7.1.2
Study Drug Administration Period
Visit 2/Week 0 (Baseline; Day 0) to Visit 10/Week 8 (End of Treatment)
Permissible assessment windows during the 8-week study treatment phase are: Study Visit 2A 
(Day 4) ± 1 day; Study Visit 3 (Day 7) +2 days; Study Weeks 2 to 4 ± 2 days; Study Weeks 5 to 
8 ± 3 days.
As specified in Table 1 the following assessments will be performed during the study treatment 
phase:

Randomization on Visit 2/Week 0 (Day 0; baseline)

Physical examination (including weight) at Visit 2/Week 0, Visit 6/Week 4, and 
Visit 10/Week 8 (Section 7.2.3.2)

Review of medical history and prior medication at Visit 2/Week 0 (Section 5.1)

Weight at Visit 4/Week 2 and Visit 8/Week 6 (Section 7.2.3.2)

Vital signs at Visit 2/Week 0, Visit 4/Week 2, Visit 6/Week 4, Visit 8/Week 6, and 
Visit 10/Week 8 (Section 7.2.3.3)

12-lead electrocardiogram (ECG) at Visit 2/Week 0, Visit 10/Week 8 (Section 7.2.3.4)

Hematology/Chemistry at Visit 2/Week 0, Visit 4/Week 2, Visit 6/Week 4, Visit 8/Week 6, 
and Visit 10/Week 8; Potassium and magnesium at Visit 2A (Section 7.2.3.5)

Urinalysis at Visit 2/Week 0, Visit 4/Week 2, Visit 6/Week 4, Visit 8/Week 6, and 
Visit 10/Week 8 (Section 7.2.3.5)

Pregnancy test at Visit 2/Week 0, Visit 6/Week 4, Visit 10/Week 8 (Section 7.2.3.5)

HBV and HCV test at Visit 2/Week 0

CMV DNA test: Cytomegalovirus quantification in the plasma samples taken at each visit of 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 82 
 
07 Dec 2018
For non-commercial use only


Shire
Page 83
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
study treatment phase will be conducted at central specialty laboratory. Cytomegalovirus 
genotyping to assess for mutations in the UL97, UL27, and UL54 genes will be conducted 
only on the following samples: at baseline; from subjects with failure to attain CMV viremia 
clearance AND viral load above the predefined cut off (presented in the CMV resistance 
plan) taken at Study Weeks 4 and 8; and collected during recurrence or rebound of viremia at 
any time during the study treatment. 

Tissue invasive CMV disease and CMV syndrome assessment (see Appendix 3) at all visits 
through the study treatment phase.

 

Immunosuppressant drug concentration levels measured at Visit 2/Week 0, Visit 2A/Day 4, 
Visit 3/Week 1, and Visit 10/Week 8 (see Section 7.2.3.5). If maribavir is discontinued early 
during the treatment phase, Immunosuppressant drug concentration should also be measured 
one week after discontinuation.

Pharmacokinetic sample collection for adult subjects ≥18 years of age, randomized to 
maribavir will be as follows: at Visit 3/Day 7/Week 1 (premorning maribavir dose and 
between 2-4 hour postmorning maribavir dose); at Visit 6/Week 4 (only one premorning 
maribavir dose); and at Visit 10/Week 8 (one premorning dose and one between 2-4 hour 
postmorning maribavir dose). Pharmacokinetic sample collection for adolescent subjects ≥
12 to <18 years of age, randomized to maribavir, will be as follows: intensive PK sampling at 
Visit 3/Week 1 (pre-morning dose and 1, 2, 3, 4, 6, 8 [all ±5 min], and 12 hours [±15 min] 
post morning dose); at Visit 6/Week 4 (one premorning dose PK sample); at Visit 10/Week 8 
(one premorning dose and one between 2-4 hour post morning dose PK samples).

Maribavir rescue arm eligibility assessed at Visit 5/Week 3 up to Visit 9/Week 7 
(Section 7.1.2).

IRT at all visits through the study treatment phase, except Visit 10/Week 8. 

Study drug dispensed at every visit except Visit 10/Week 8; study drug administration 
through 8 weeks of study treatment phase (Study Week 0 through Study Week 7).

Study diary dispensed at baseline and collected at the last follow-up visit; will be used for 
tracking compliance throughout the study treatment phase and for tracking completion of 
 
. Note: The diary will only be utilized for study 
treatments that are given orally. The IV administration will be tracked in the source 
documents and CRF.

Invasive bacterial, viral and fungal infections/transplant relevant infection assessed at 
baseline, Visit 2/Week 0, and at all visits throughout the study treatment phase.

Transplant status at baseline, Visit 2/Week 0, and at all visits throughout the study treatment 
phase.

Hepatic function grading according to the Child-Pugh classification (see Appendix 2 and
Section 7.2.3.1) at Visit 2/Week 0.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 83 
 
07 Dec 2018
For non-commercial use only


Shire
Page 84
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018

GVHD assessment (for HSCT subjects only) at all visits through the study treatment phase.

Comorbidity status evaluation: Karnofsky Performance Status (KPS) scale for subjects ≥
16 years of age and Lansky performance status scale for subjects ≥12 to <16 years of age; at 
baseline, Visit 2/Week 0, Visit 6/Week 4, and Visit 10/Week 8.
 

Concomitant medications, therapies, and procedures through the study treatment phase.

AE/SAE monitoring throughout the study treatment phase.
7.1.3
Follow-up Phase 
Visit 11/Week 9/Follow-up Week 1 to Visit 18/Week 20/Follow-up Week 12 (End of Study)
The follow-up period for this protocol is 84 days or 12 weeks (post-treatment Visits 11-18). The 
permissible assessment windows for the visits are: Study Weeks 9-12 (Follow-up Weeks 1-4) ± 2 
days; Study Weeks 14-20 (Follow-up Weeks 6-12) ± 3 days. 
As specified in Table 2 study evaluations include:

Physical examination (including weight) at Visit18/Week 20

Vital signs at Visit18/Week 20

12-Lead ECG at Visit 18/Week 20

Hematology/Chemistry at Visit 12/Week 10, Visit 14/Week 12, Visit 16/Week 16, 
Visit 18/Week 20

Urinalysis at Visit 18/Week 20

Immunosuppressant drug concentration level at Visit 11/Week 9, if treatment continued until 
Week 8 (drug concentration level to be measured 1 week after the end of the study treatment)

Invasive bacterial, viral and fungal infection assessment at all visits during the follow-up 
phase; Visit 11/Week 9, Visit 12/Week 10, Visit 13/Week 11, Visit 14/Week 12, 
Visit 15/Week 14, Visit 16/Week 16, Visit 17/Week 18, and Visit 18/Week 20

CMV DNA test: Cytomegalovirus DNA quantification in the plasma samples taken at each 
visit of study follow-up phase (Visit 11/Week 9, Visit 12/Week 10, Visit 13/Week 11, Visit 
14/Week 12, Visit 15/Week 14, Visit 16/Week 16, Visit 17/Week 18, and Visit 18/Week 20) 
will be conducted at central specialty laboratory. Cytomegalovirus genotyping will be 
conducted only on the samples: from subjects who fail to attain CMV viremia clearance 
AND have viral load above the predefined cut off (presented in the CMV resistance plan), 
taken at Visit 16/Week 16 and Visit 18/Week 20; from cases of recurrence of viremia at any 
visit in the follow-up phase.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 84 
 
07 Dec 2018
For non-commercial use only


Shire
Page 85
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018

Tissue invasive CMV disease and CMV syndrome assessment (see Appendix 3) at all visits 
through the study follow up phase

Transplant status at all visits throughout the follow-up phase

GVHD assessment (for HSCT subjects only) at all visits through the follow-up phase

Comorbidity status evaluation: KPS scale for subjects ≥16 years of age and Lansky 
performance status scale for ≥12 to <16 years of age; at Visit 14/Week 12, 
Visit 16/Week 16, and Visit 18/Week 20


AE/SAE monitoring through the follow-up phase according to Section 7.2.3.6

Concomitant medications and procedures collected throughout the follow-up phase
All SAEs not resolved at the time of end of study visit (Visit 18/Week 12 or Follow-up Week 12) 
will be followed to closure or stabilization (see Section 8.1). If a subject is withdrawn from the 
study, all Follow-up Week 12/end of study procedures must be performed as soon as possible 
after discontinuation. 
7.1.4
Maribavir Rescue Arm
All procedures presented in Table 1 (Schedule of Assessment 1), beginning at Visit 2/Week 0, 
will be performed for the subjects who discontinue the investigator-assigned anti-CMV 
treatment, meet the eligibility criteria to enter the rescue arm where maribavir 400 mg BID will 
be administered for a duration of 8 weeks, and complete the end-of-treatment evaluations listed 
for Visit 10/Week 8 prior to being transferred to the maribavir rescue arm. Subjects will enter the 
12-week follow-up phase after completing 8 weeks of maribavir treatment in the rescue arm.
7.1.5
Additional Care of Subjects after the Study
No after care is planned for this study.
7.2
Study Evaluations and Procedures
All study evaluations and procedures are specified in Schedule of Assessment 1, Table 1, and 
Schedule of Assessment 2, Table 2.
7.2.1
Demographic and Other Baseline Characteristics
Age and/or year of birth, sex, race, and ethnicity will be recorded for all subjects.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 85 
 
07 Dec 2018
For non-commercial use only


Shire
Page 86
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
7.2.2
Efficacy
7.2.2.1
CMV DNA Quantitation (CMV Infection)
Blood samples collected will be assessed at a central specialty laboratory for the quantification of 
CMV DNA in plasma using the COBAS® AmpliPrep/COBAS® TaqMan® CMV Test. Central 
specialty laboratory plasma CMV DNA results will be reported to the investigator site as 
available. Additional CMV DNA tests at local specialty laboratories may be performed and 
collected at more frequent intervals or use additional assay methods at the discretion of the 
investigator utilizing local specialty laboratory. These results will also be collected when 
available.
Confirmed CMV viremia clearance will be defined as plasma CMV DNA concentration below 
the lower limit of quantification (<LLOQ; ie, <137 IU/mL) when assessed by COBAS®
AmpliPrep/COBAS® TaqMan® CMV Test at a central specialty laboratory, in 2 consecutive 
postbaseline samples, separated by at least 5 days.
Recurrence or the recurrence of CMV viremia will be defined as plasma CMV DNA 
concentration ≥LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test 
in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia 
clearance. Every attempt should be made by study investigators to collect the 2 consecutive 
plasma samples and monitor results to confirm recurrence prior to initiating alternative available 
therapy.
7.2.2.2
CMV Genotyping and Phenotyping
Plasma samples collected at Visit 2/Week 0 for protocol-specified CMV DNA testing at the 
central specialty laboratory will be genotyped for the final determination of mutations in the viral 
UL97 and UL54 genes known to confer resistance to commercially available anti-CMV agents. 
In addition, viral UL27 gene will be tested. During the study, CMV genotyping will be 
conducted at prespecified time points when the CMV DNA viral load is above a predefined cut 
off level (validated for this type of analysis) in cases of failure to clear CMV viremia, in cases of 
recurrence of viremia on and off treatment, and in cases of viremia rebound if >1 log10 above 
nadir while on treatment (Rebound is defined as increase in viral DNA load for >1 log10 above 
nadir without prior clearance of viremia) at any time during the study. The entire UL97, UL27, 
and UL54 CMV genes will be sequenced in every sample that meets the criteria for genotyping, 
including the baseline samples. Additionally, virus susceptibility testing will be performed on 
selected de novo CMV sequence variants of maribavir treated subjects by recombinant resistance 
phenotyping. Details of the analysis will be specified in the resistance analysis plan. The list of 
CMV mutations conferring resistance to ganciclovir, valganciclovir, foscarnet, or cidofovir is 
presented in Appendix 4.
7.2.2.3
Tissue Invasive CMV Disease and CMV Syndrome Assessments 
Tissue-invasive CMV disease will be defined as described by Ljungman et al., 2002 and 
Ljungman et al., 2017 (see Appendix 3). The gold standard for diagnosing CMV tissue invasive 
disease is the identification of CMV inclusions in the infected cells of the tissues OR 
identification of CMV in biopsy tissue samples. However, in some cases both diagnostic 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 86 
 
07 Dec 2018
For non-commercial use only


Shire
Page 87
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
methods are required, for example when tissue samples have a high chance of being 
contaminated by body fluids that shed virus (bronchoalveolar lavage [BAL], urine or stool). In 
some subjects, when it is not possible to obtain a tissue biopsy, a culture of body fluids or DNA 
quantification (for selected cases) may be used to confirm diagnosis, with a lower level of 
confidence. In cases of CMV retinitis, the retinal images taken by the ophthalmologist may be 
used as the evidence supporting the diagnosis. CMV syndrome (in SOT subjects only) will also 
be defined as described by Ljungman et al., 2017, and requires at least 2 of 6 signs and 
symptoms to be present (see Appendix 3 for full description of criteria).
All subjects will be monitored for the occurrence of tissue invasive CMV disease and CMV 
syndrome throughout the study. For symptomatic subjects who present with tissue invasive CMV 
disease or CMV syndrome at baseline, the investigator will document the initial diagnosis of 
CMV disease at Visit 2/Day 0 (ie, absence or presence at baseline) and all serial assessments of 
infection status (ie, no change, improvement, worsening, or resolution) at all subsequent visits in 
the study. In subjects asymptomatic at baseline, the occurrence of new tissue invasive CMV 
disease or CMV syndrome after start of study treatment will be initially assessed by the 
investigator at the study visit when the diagnosis is made, and serial assessments of infection 
status (ie, no change, improvement, worsening, or resolution) at all subsequent visits in the 
study. Case charts documenting the infection diagnosis (baseline or new symptomatic infection) 
and follow-up status at study visits will be provided for adjudication to an independent Endpoint 
Adjudication Committee. The definitions and requirements for the diagnosis of different CMV 
diseases and CMV syndrome will be the basis for the data collection charts that are required to 
support the diagnosis of the each tissue invasive CMV disease type or CMV syndrome. Sites are 
encouraged to take tissue biopsies to support the diagnosis of the disease as per Ljungman et al., 
2002 and Ljungman et al., 2017. The roles, responsibilities, and rules governing operation of the 
independent Endpoint Adjudication Committee will be fully documented in an Endpoint 
Adjudication Committee charter.
During the medical monitoring, additional cases not identified by the investigator with 
symptomatology similar to tissue invasive disease (eg, GVHD with GI symptoms, transplanted 
organ rejection) may be identified as requiring adjudication by the EAC for confirmation or 
exclusion of the tissue invasive CMV disease.
The recurrence of the symptomatic CMV infection will be defined as the presence of signs or 
symptoms of the tissue invasive CMV disease or CMV syndrome (same or new 
symptomatology) confirmed as per Ljungman et al., 2002 and Ljungman et al., 2017 after the 
period of resolution of symptomatic CMV infection in subjects symptomatic at baseline.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 87 
 
07 Dec 2018
For non-commercial use only


Shire
Page 88
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
CMV antigen (pp65) producing lymphokines, interferon gamma (IFN, tumor necrosis factor 
alpha (TNFor interleukin-2 (IL-2) will be assessed using flow cytometry.
7.2.2.5
Graft Status 
History of the current transplant and its status at screening and baseline will be collected for all 
transplant types, including dates of transplant, graft complications, and use of antirejection 
therapies for prophylaxis or treatment of graft rejection.
Assessment of the transplant throughout the study will include the status of the graft function, the 
presence of the episode(s) of acute rejection, or development of other relevant complications (eg, 
new onset diabetes). The outcome of graft failure is a clinical determination that the graft 
irreversibly and irrevocably ceases functioning (eg, in case of renal transplant, with the subject 
returning to permanent dialysis if dialysis-dependent prior to transplant or return to insulin 
dependency in the case of pancreas transplant) as determined by the investigator.
Detailed information will be collected in separate CRF forms for SOT (by organ) or HSCT, as 
specified in the study manual.
7.2.2.6
Graft-versus-host-disease (GVHD) Assessments
GVHD is a well-recognized complication of transplantation, much more frequently in HSCT 
transplants. GVHD occurs when the donor cells (the “graft”) recognize the patient being 
transplanted (the “host”) as being foreign, ie, when donor T lymphocytes respond to mismatched 
protein antigens expressed in host T-cells. It presents in an acute and chronic form.
The most influential protein mismatches are human leukocyte antigens (HLAs) and the incidence 
of acute GVHD is directly related to the degree of mismatch between HLA proteins expressed by 
the HCT donor and recipient (Loiseau et al., 2007). Even in patients that receive HLA-matched 
(HLA-A/B/C/DRB1) grafts, however, GVHD arises in approximately 40% of patients due to 
differences in minor histocompatibility antigens, and requires systemic therapy. Acute GVHD 
that typically occurs in first 100 days after transplant includes: erythema, maculopapular rash, 
nausea, vomiting, anorexia, profuse diarrhea, ileus or cholestatic liver disease.
Chronic GVHD typically occurs later (>100 days after transplant) and is manifested on skin, 
appendages, mouth, eyes, lungs, genitalia, esophagus and connective tissues. Chronic GVHD 
diagnosis is supported by histologic evidence of GVHD from any affected site. The diagnosis 
might be difficult as negative histological findings do not exclude the existence of chronic 
GVHD, and similarity to other conditions that often occur in HSCT patients (such as 
mycophenolate mofetil (MMF) toxicity or the presence of GI tissue invasive CMV disease.
Investigators are expected to consider recommendations for diagnosis provided in guidance in 
Appendix 9 and Appendix 10 (Jagasia et al., 2015; Shulman et al., 2015). Detailed information 
on GVHD and its grading, at baseline and during the study will be collected in separate CRF 
forms.
Assessment of absence or presence of acute GVHD will be done at baseline, and if present, 
grading will be performed according to published guidelines provided in Appendix 8 (Harris et 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 88 
 
07 Dec 2018
For non-commercial use only


Shire
Page 89
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
al., 2016); acute or chronic GVHD present at baseline will also be followed throughout the study 
treatment phase, at every study visit, utilizing the same diagnosis until resolution (during the 
duration of the study) as indicated in Table 1 and Table 2. New onset of acute or chronic GVHD 
will be reported as the event of special interest.
7.2.2.7
Comorbidity Status
Transplant patients often have multiple other comorbidities, resulting from their 
immunosuppressed status (co-infections, graft versus host disease, transplant malfunctioning due 
to rejection), toxicities from therapies for maintenance of the transplant or reactivation of the 
baseline disease for which they had been transplanted (malignancy for example), and other 
concomitant diseases resulting in very diverse population that might be enrolled into the study. 
The comorbidity assessment will be conducted to allow for the comparison of the population 
enrolled into 2 treatment arms and to account for the subjects’ health status when assessing 
overall and individual subject response.
Comorbidity assessment as evaluated by the Karnofsky Performance Sstatus or Lansky 
performance status scale will be performed at time points indicated in Table 1 and Table 2. 
Given the possible difference in confounding comorbidities in the HSCT and SOT recipients, 
assessment of comorbidity at baseline and over time in the study will be performed. The 
difference between treatment arms in terms of baseline comorbidities might be controlled for in 
the analyses if determined to be substantial.
Comorbidity assessment for both HSCT and SOT recipients will utilize KPS scale for subjects 
≥16 years of age (Peus et al., 2013; Schag et al., 1984) and Lansky performance status scale for 
≥12 to <16 years of age (Lansky et al., 1987).
Karnofsky Performance Status is a valuable tool for measurement of and comparison between 
the functional statuses of individual patients. It is increasingly utilized as the prognostic factor in 
renal transplant patients (prior to transplantation).
Refer to Appendix 5 and Appendix 6, respectively, for the KPS and Lansky performance status 
scale forms.
7.2.2.8
Subject Survival 
Subject survival (yes/no) will be determined at all visits during the study. The date and cause of 
death will be recorded in the CRF, and will be reported as a serious adverse event according to 
Section 8.2.
7.2.3
Safety 
7.2.3.1
Medical History
A medical history will be taken during the screening period and updated on 
Visit 2/Day 0/Week 0 as specified in Table 1. All medical history findings that have been 
present/active within the 2 years prior to enrollment at Visit 2/Day 0 will be recorded regardless 
of clinical relevance or presence at study start. Medical history finding that have not been 
present/active within the 2 years prior to enrollment will be recorded if deemed clinically 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 89 
 
07 Dec 2018
For non-commercial use only


Shire
Page 90
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
relevant by the investigator to the conduct of the study. Medical history related to the transplant 
(including the disease/diseases leading to transplant) and CMV infection will be recorded 
without a time limit. The medical history should include any history of allergic reactions to 
drugs. Refer to Section 5.1 for prior medication history.
Specific information regarding the subject’s transplant history that will be collected, including 
but not limited to, are: the number of past transplants prior to the current transplant; the type of 
transplant and details for each, such as cell source and type for HSCT or organ for SOT; the 
human leukocyte antigen (HLA) matching level; the date and the history of the current transplant 
including complications; transplant related infections; induction and maintenance therapy 
received for transplant; history of relevant viral serology; history of anti-viral prophylaxis; and 
status of the transplant at baseline.
Specific information regarding the subject’s CMV infection will be collected in separate CRFs. 
The collected information will include, but will not be limited to: CMV serology of donor and 
recipient; CMV infection episodes with viral loads and/or treatment; CMV resistance 
information (sequencing data); prophylactic treatment, if utilized. More details will be specified 
in the study manual.
Subjects will be classified into 1 of the following categories with respect to hepatic function, 
based on baseline clinical and laboratory assessments (see Appendix 2). This information will 
primarily be utilized in the interpretation of the PK data for which the samples will be collected 
at the specified visits in the study:

No chronic liver disease

Chronic liver disease - Child-Pugh Class A

Chronic liver disease - Child-Pugh Class B

Chronic liver disease - Child-Pugh Class C
7.2.3.2
Physical Examination (Including Weight)
Abnormalities identified at the screening visit (Visit 1) will be documented in the subject’s 
source documents and on the medical history CRF. Changes after the screening visit (Visit 1) 
will be captured as AEs on the AE CRF page, as deemed clinically relevant by the investigator.
The investigator or designee will perform physical examinations at time points specified in 
Table 1 and Table 2. Physical examinations will be performed in accordance with standard 
practices at the investigational site. Body weight and height will be measured at time points 
specified in the schedule of assessments.
7.2.3.3
Vital Signs
Vital signs (body temperature, arterial blood pressure, and pulse) will be collected in a standard 
manner at the time points specified in Table 1 and Table 2. Any clinically significant deviations 
from baseline (Visit 2/Day 0/Week 0) vital signs which are deemed clinically significant in the 
opinion of the investigator are to be recorded as an AE.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 90 
 
07 Dec 2018
For non-commercial use only


Shire
Page 91
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
7.2.3.4
Electrocardiogram 
A 12-lead ECG will be performed at Visit 2/Day 0, Visit 10/Week 8 (end of treatment visit), 
Visit 18/Week 20 (end of study visit), and at any additional time during the study, if clinically 
indicated. Each ECG will include heart rate, RR Duration, PR duration, QT duration, QRS 
duration. The corrected QT interval (QTc) will be calculated using the Fridericia’s formula. The 
investigator will be responsible for providing the interpretation for all ECGs in terms of clinical 
significance to the subject.
7.2.3.5
Clinical Laboratory Evaluations
Laboratory Assessments
Clinical laboratory tests (hematology, chemistry, urinalysis, HBV, HCV, pregnancy) will be 
performed by a central laboratory at the time points specified in Table 1 and Table 2. During 
screening, clinical laboratory tests will be performed by the central laboratory, however local 
laboratory results if available might be utilized for the assessment of the eligibility. If no result of 
HIV testing within 3 months prior to screening is available, an HIV test will be performed at a 
local laboratory during the screening period for eligibility assessment. If local laboratory results 
are used for the assessment of the eligibility, the reference ranges must be provided. This also 
applies to CMV DNA quantitation results. At baseline (Visit 2/Week 0) blood samples will be 
taken for CMV DNA quantitation and genotyping, hematology and chemistry and tested in the 
central specialty laboratory. All clinical laboratory assays will be performed according to the 
central laboratory’s standard procedures. Reference ranges will be supplied by the central 
laboratory and will be used to assess the clinical laboratory data for clinical significance and out-
of-range pathological changes. The investigator should assess out-of-range clinical laboratory 
values for clinical significance, indicating if the value(s) is/are not clinically significant or 
clinically significant. Clinically significant finding should be reported as an AE unless signs of 
already reported conditions exist. Abnormal clinical laboratory values that are unexpected or not 
explained by the subject’s clinical condition may, at the discretion of the investigator or sponsor, 
be repeated as soon as possible until confirmed, explained, or resolved.
The following clinical laboratory assessments will be performed: 
Chemistry
Serum sodium, potassium, chloride, bicarbonate/carbon dioxide, glucose, blood urea nitrogen, 
creatinine, calcium, phosphorus, magnesium, uric acid, total protein, albumin, creatine 
phosphokinase, total bilirubin, direct bilirubin, ALT, AST, gamma-glutamyltransferase 
(GGT), alkaline phosphatase (ALP), cholesterol (total and HDL/LDL ratio), triglycerides, and 
immunoglobulins. The samples for chemistry are preferred to be taken under fasting 
conditions, although this is not mandatory. The information whether samples were taken 
under fasting conditions will be collected.
Potassium and magnesium levels will be performed at a local laboratory at Visit 2A/2AR 
(Day 4 ±1 day) if on tacrolimus, cyclosporine, everolimus or sirolimus at Visit 2/2R, and at 
four days ±1 day after initiation of tacrolimus, cyclosporine, everolimus, or sirolimus (if the 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 91 
 
07 Dec 2018
For non-commercial use only


Shire
Page 92
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
subject is not taking the agent at baseline).
Hematology
White blood cell (WBC) and differential counts (with absolute neutrophil count [ANC]), 
hemoglobin, hematocrit, red blood cell (RBC) count, reticulocytes, and platelet count.
International normalized ratio (INR) and prothrombin time at baseline only.
Urinalysis
pH, specific gravity, protein, glucose, ketones, hemoglobin, leukocyte esterase, 
protein/creatinine ratio and microscopic evaluation (RBC, WBC, crystals, casts, bacteria).
Virology

Hepatitis (hepatitis B Surface Antigen and/or viral DNA, hepatitis C antibody and/or viral 
RNA). Historical results within 3 months of randomization are acceptable. If historical 
results are unavailable, blood will be drawn at Visit 2/Week 0 for hepatitis B surface 
antigen and hepatitis C antibody testing at the central lab. Central lab results do not need 
to be available prior to randomization.

Human immunodeficiency virus (HIV) test. Historical results within 3 months prior to the 
study treatment initiation will be acceptable for screening. If no result of HIV testing 
within the prior 3 months is available, the subject must have testing done locally during 
the screening period, and must have the results available prior to randomization.
Local Laboratory Test to Monitor Immunosuppressant Drug Concentration Levels
For subjects who are receiving tacrolimus, cyclosporine, sirolimus, or everolimus, testing of the 
blood concentration levels of these drugs will be performed at each site’s local laboratory, using 
each site’s standard assay and standard therapeutic drug monitoring practice (eg, time of sample 
collection relative to dosing). The testing will be performed at the time points outlined below, 
provided the subject is still receiving tacrolimus, cyclosporine, or everolimus on these study 
days.
If the subject is receiving tacrolimus, cyclosporine, sirolimus or everolimus on Study Visit 
2/Day 0/Week 0, obtain a tacrolimus, cyclosporine, sirolimus or everolimus blood level:

On Visit 2/Day 0/Week 0 prior to initiation of study treatment

At the Visit 2A/Day 4 (± 1 day) study visit

At the Visit 3/Day 7 (+2 day)/Week 1 study visit

At Visit 10/Week 8 (± 2 day) or on end of treatment visit (if earlier than Week 8)

At the Week 1 post-treatment follow-up visit (ie, 1 week [± 2 days] after discontinuation 
of study treatment)
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 92 
 
07 Dec 2018
For non-commercial use only


Shire
Page 93
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
If the subject is not receiving tacrolimus, cyclosporine, sirolimus or everolimus on Study Day 0, 
but starts any of these drugs after Day 0 while still receiving study treatment, obtain a tacrolimus, 
cyclosporine, sirolimus or everolimus blood level:

Four days (± 1 day) after the first dose of tacrolimus, cyclosporine, sirolimus, or 
everolimus

At the next scheduled study visit after first starting the tacrolimus, cyclosporine, 
sirolimus or everolimus, while still receiving study treatment

At Visit 10/Week 8 (± 2 day) or on end of treatment visit (if earlier than Week 8)

At the Week 1 post-treatment follow-up visit (ie, 1 week [± 2 days] after 
discontinuation of study treatment
For the subjects transferred to the maribavir rescue arm, obtain a tacrolimus, cyclosporine, 
sirolimus or everolimus blood level prior to initiation of maribavir, at Visit 2AR/Day 4R (± 1 
day) at Visit 3R/Week 1R, at Visit 10R/Week 8R or at the end of rescue treatment, and at 
Week 1 post-treatment follow-up visit after the end of the rescue treatment.
Pregnancy Test
A serum β-HCG pregnancy test will be performed on all females of child-bearing potential at the 
screening visit (Visit 1), baseline (Visit 2/Week 0), Visit 6/Week 4, and at the end of study 
treatment visit (Visit 10/Week 8), or if pregnancy is suspected, or on withdrawal of the subject 
from the study. A pregnancy test performed within 7 days prior to randomization will not be 
repeated at baseline (if central laboratory is utilized). Local or central laboratory analysis 
performed on samples taken between Day -7 and Day -14 will be repeated on Day 0 before 
randomization. Local laboratory test results can be used for the assessment of pregnancy on 
Day 0/Week 0.
7.2.3.6
Adverse Event Collection
At each study visit, subjects will be questioned in a general way to ascertain if AEs have 
occurred since the previous visit (eg, “Have you had any health problems since your last visit?”). 
All AEs will be recorded from the time informed consent is signed through 30 days after the last 
dose of investigational product. Following the 30-day capture period for all AEs, only those AEs 
deemed related to investigational product or other protocol-mandated procedures and all SAEs 
(regardless of causality assessment) will be collected through the end of the study (Visit 
18/Week 20 [Follow-up Week 12]). Refer to Section 8 for detailed AE reporting requirements.
7.2.4
Others 
7.2.4.1
Clinical Pharmacology Assessments 
For subjects ≥18 years of age, randomized to maribavir, 1 or 2 PK samples will be collected on 
each of the study days specified in Table 1. The premorning dose PK sample will be obtained at 
all 3 PK visits. The postmorning dose PK samples at Visit 3/Week 1 and at Visit 10/Week 8 will 
be obtained any time between 2-4 hours after the morning dose. Any episode of vomiting 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 93 
 
07 Dec 2018
For non-commercial use only


Shire
Page 94
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
occurring within 2 to 4 hours after the morning dose and before the postmorning dose PK sample 
collection must be documented. Subjects will record the date and time of the previous maribavir 
dose taken before a PK visit in their electronic diary. The instructions will be provided in the 
study manual.
Subjects ≥18 years Sparse PK Schedule
Week 1, Day 7 (±1d) 
Week 4, Day 28 (±2d)
Week 8, Day 56 (±2d)
Study Treatment Period
Pre-morning dose
2-4 hours post morning dose
One pre-morning dose 
Pre-morning dose 
2-4 hours post morning dose
For subjects ≥12 to <18 years of age, an intensive PK sampling will be performed at 
Visit 3/Week 1. Subjects will be asked to complete the 12 hour post morning dose PK sample 
prior to taking their evening dose of maribavir. Sparse PK sampling similar to adults (≥18 
years) will be performed at Week 4 and Week 8.
Subjects ≥12 to < 18, Including Intensive PK (Week 1) Schedule
Week 1, Day 7 (±1d) (Intensive PK)
Week 4, Day 28 (±2d)
Week 8, Day 56 (±2d)
Study Treatment Period
Premorning dose, 1, 2, 3, 4, 6, 8 (all ±5 
min), and 12 hours (±15 min) post 
morning dose
One premorning dose 
Premorning dose and
2-4 hours post morning 
dose
The following will be recorded in the CRF:

Date and time of the last dose of maribavir before the predose PK sample was taken

Date and time that the predose PK sample was taken

Date and time of the last dose of maribavir before the postdose PK sample was taken

Date and time that the 2-4 hour postdose PK sample was taken

Date and time of vomiting within 2-4 hours after the morning dose and before the 
postmorning dose PK sample collection
If a subject has maribavir dose interrupted for 2 consecutive days prior to the morning maribavir 
dose on a PK visit, no PK sample will be collected. If a subject has completed the premorning 
dose PK sample collection, but has missed the morning dose of maribavir on the day of the PK 
visit, then no postdose PK sample will be collected.
Unscheduled PK sample collection
For purposes of special PK sampling, gastrointestinal (GI) GVHD is defined as any of the 
following (Boeckh et al., 1998):

Biopsy-proven GVHD of the GI tract plus diarrhea (>300 mL/day)

Biopsy proven GVHD of the GI tract and nausea
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 94 
 
07 Dec 2018
For non-commercial use only


Shire
Page 95
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018

Documented acute GVHD of the liver (stage II, total bilirubin >3 mg/dL or 
biopsy-proven) plus diarrhea (>500 mL/day) with no other explanation or

Biopsy-proven acute GVHD of the skin plus diarrhea (>500 mL/day) with no 
other explanation
If a subject on maribavir treatment is diagnosed with GI GVHD during the study treatment phase 
and therapy with study drug remained permissible, study drug will be continued and blood 
samples for the determination of maribavir plasma concentrations will be collected. This 
unscheduled PK sampling will occur at the next visit after the first occurrence of a GI GVHD 
diagnosis, and will follow the schedule of sampling and recording of information as described in 
Table 1 (Schedule of Assessment 1).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 95 
 
07 Dec 2018
For non-commercial use only


Shire
Page 96
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
7.2.5
Volume of Blood to be Drawn from Each Subject Per Visit
The volume of blood drawn from each subject per visit is shown in Table 5. 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 96 
 
07 Dec 2018
For non-commercial use only


Shire
Page 97
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Table 5:
Volume of Blood Drawn Per Study Visit
Study Visit / Rescue Arm Visit
Blood Volume per Visit (mL)
Visit 1/NA Rescue Arm Visit (Screening)
33a
Visit 2/2R
48
Visit 2A/2A-R
11
Visit 3/3R
26
Visit 4/4R
23
Visit 5/5R
15
Visit 6/6R
29
Visit 7/7R
35
Visit 8/8R
23
Visit 9/9R
15
Visit 10/10R (End of Treatment)
60
Visit 11/11R
20
Visit 12/12R
23
Visit 13/13R
15
Visit 14/14R
23
Visit 15/15R
15
Visit 16/16R
23
Visit 17/17R
15
Visit 18/18R (End of Study)
43
Additional PK
PK Blood Volume per Visit (mL)
See Section 7.2.4.1
4
a Includes an additional 4 mL sample for local HIV testing to be drawn from subjects lacking result of an HIV test within 3 
months prior to Screening.
Note: Refer to Schedule of Assessments 1 (Table 1) and 2 (Table 2)
PK=pharmacokinetics
During this study, it is expected that approximately 491 mL of blood will be drawn from each 
subject, regardless of sex. In addition, subjects between the ages of 12 and 18 years will have up 
to 24 mL of blood drawn for intensive PK visits.
Note: The amount of blood to be drawn for each assessment at any visit is an estimate. The 
amount of blood to be drawn may vary according to the instructions provided by the 
manufacturer or laboratory for an individual assessment. When more than 1 blood assessment is 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 97 
 
07 Dec 2018
For non-commercial use only


Shire
Page 98
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
to be done at the time point/period, if they require the same type of tube, the assessments may be 
combined.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 98 
 
07 Dec 2018
For non-commercial use only


Shire
Page 99
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
8.
ADVERSE AND SERIOUS ADVERSE EVENTS ASSESSMENT
8.1
Definition of Adverse Events, Period of Observation, Recording of Adverse Events
An AE is any untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and that does not necessarily have a causal relationship with this 
treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
(investigational/investigator assigned anti-CMV treatment) product, whether or not related to the 
medicinal (investigational/investigator assigned anti-CMV treatment) product (International 
Conference on Harmonisation [ICH] Guidance E2A 1995). 
All AEs will be recorded from the time the informed consent is signed through 30 days after the 
last dose of investigational product. This includes events occurring during the screening phase of 
the study, regardless of whether or not study treatment is administered. Following the 30-day 
capture period for all AEs, only those AEs deemed related to investigational product or other 
protocol-mandated procedures and all SAEs (regardless of causality assessment) will be 
collected until the defined follow-up period stated in Section 7.1.3. Where possible, a diagnosis 
rather than a list of symptoms should be recorded. If a diagnosis has not been made, then each 
symptom should be listed individually. All AEs should be captured on the appropriate AE pages 
in the CRF and in source documents. In addition to untoward AEs, unexpected benefits outside 
the investigational product indication should also be captured on the AE CRF.
All SAEs must be followed to closure (the subject’s health has returned to his/her baseline status 
or all variables have returned to normal), regardless of whether the subject is still participating in 
the study. Closure indicates that an outcome is reached, stabilization achieved (the investigator 
does not expect any further improvement or worsening of the event), or the event is otherwise 
explained. When appropriate, medical tests and examinations are performed so that resolution of 
event(s) can be documented.
8.1.1
Severity Categorization
The severity of AEs must be recorded during the course of the event including the start and stop 
dates. The highest level of severity will be recorded for an event. Worsening of pretreatment 
events, after initiation of study treatment, must be recorded as new AEs (for example, if a subject 
experiences mild intermittent dyspepsia prior to dosing of investigational product, but the 
dyspepsia becomes severe and more frequent after first dose of investigational product has been 
administered, a new AE of severe dyspepsia [with the appropriate date of onset] is recorded on 
the appropriate CRF).
The medical assessment of severity is determined by using the following definitions:
Mild:
A type of AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual 
activities of daily living.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 99 
 
07 Dec 2018
For non-commercial use only


Shire
Page 100
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Moderate:
A type of AE that is usually alleviated with specific therapeutic intervention. The 
event interferes with usual activities of daily living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe:
A type of AE that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.
Besides the above mentioned standard categories of severity grading for tissue invasive CMV 
disease and a few selected events of special interest (see Section 8.1.4), the severity (intensity) of 
AEs will also be assessed according to the National Cancer Institute Common Terminology 
Criteria for Adverse Events (CTCAE) Version 4.03. 
8.1.2
Relationship Categorization
A physician/investigator must make the assessment of relationship to study treatment for each 
AE. The investigator should decide whether, in his or her medical judgment, there is a reasonable 
possibility that the event may have been caused by the study treatment. If there is no valid reason 
for suggesting a relationship, then the AE should be classified as “not related”. Otherwise, if 
there is any valid reason, even if undetermined or untested, for suspecting a possible cause-and-
effect relationship between the study treatment and the occurrence of the AE, then the AE should 
be considered “related”. The causality assessment must be documented in the source document.
The following additional guidance may be helpful:
Term
Relationship Definition
Related
The temporal relationship between the event and the administration of the study 
treatment is compelling and/or follows a known or suspected 
response pattern to that product, and the event cannot be 
explained by the subject’s medical condition, other therapies, or 
accident.
Not Related
The event can be readily explained by other factors such as the subject’s 
underlying medical condition, concomitant therapy, or accident 
and no plausible temporal or biologic relationship exists between 
the study treatment and the event.
8.1.3
Outcome Categorization
The outcome of AEs must be recorded during the course of the study on the CRF. Outcomes are 
as follows:

Fatal

Not Recovered/Not Resolved

Recovered/Resolved

Recovered/Resolved with Sequelae 

Recovering/Resolving

Unknown
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 100 
 
07 Dec 2018
For non-commercial use only


Shire
Page 101
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
8.1.4
Adverse Events of Special Interest 
In addition, the following adverse events of special interest will be closely monitored and 
reported throughout the study regardless of seriousness or of relationship to study treatment. 
Medical assessment of severity will be determined using standard grading category (mild, 
moderate, and severe), and by using other specific severity grading for each AESI as mentioned 
below:
Adverse Events of Special Interest (severity grading based on CTCAE Version 4.03)
1. Tissue invasive CMV disease and CMV syndrome. It is expected that certain number of 
subjects will also have tissue invasive CMV disease or CMV syndrome at baseline and its 
clinical course will be monitored throughout the study; the effect of the study treatment 
on this event will be assessed. At each visit the investigator will provide the evaluation of 
the tissue invasive CMV disease or CMV syndrome until resolution, which will be 
collected on the CRF. The investigator will have the final discretion in determining 
whether or not the CMV DNA test results and other clinical data represent a new tissue 
invasive CMV disease or CMV syndrome for a given subject. When these events are 
entered into the CRF, they should be recorded using the terminology shown in Appendix 
3 (eg, 'CMV pneumonitis', 'CMV colitis', etc.). For details on how the disease under study 
will be reported see Section 8.1.5.
2. Taste disturbance (dysgeusia): If a subject reports an AE of taste disturbance, the 
investigator will record the subject’s description of the taste disturbance (when available) 
as part of the event verbatim in the CRF.
4. Events of nausea, vomiting, and diarrhea will be recorded. Additional information for 
each case of diarrhea will be collected, including the information whether condition such 
as GVHD, GI-CMV or enteric infection confirmed by culture/PCR or other method is 
present.
5. Neutropenia.
Adverse Events of Special Interest (grading based on standard severity categorization to 
mild, moderate, and severe) 
1. Immunosuppressant drug concentration level increased: Immunosuppressant drug levels 
will be monitored as specified Section 7.2.3.5. High to toxic levels will be recorded as 
AEs.
2. Graft rejection (acute, chronic, or failure): Transplant status will be captured at every 
visit as shown in the Schedule of Assessments (Table 1 and Table 2), and graft rejections 
will be captured.
3. Invasive fungal (aspergillus, candida, Pneumocystis jiroveci, etc.) or bacterial infections 
(Staphylococcus aureus, Streptococcus pneumonia, enterococcus, pseudomonas, etc.). 
Baseline conditions will be captured as part of medical history, while new events will be 
captured as AEs. The additional information such as diagnostic method used for the 
pathogen and the source of the sample used for the diagnosis will be collected. 
Additionally the presence of viral infections frequently occurring in transplant population 
will also be collected.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 101 
 
07 Dec 2018
For non-commercial use only


Shire
Page 102
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
4. Graft-versus-host-disease (HSCT subjects): GVHD will be diagnosed based on the 
investigator’s judgment (see Section 7.2.2.6). Severity of Acute GVHD (Grading I-IV) 
will be assessed using grading scale provided in Appendix 8 as in published guidelines 
(Harris et al., 2016) and for chronic GVHD using severity grading into mild, moderate 
and severe according to the scoring provided in Appendix 9, as in the published 
guidelines (Jagasia et al., 2015). Harris et al (2016) provides the confidence levels of the 
diagnosis (see Confidence Level Criteria Table in Appendix 9). For the purpose of this 
study the disease considered ‘confirmed’ or ‘probable’ should be reported as GVHD. 
Acute or chronic GVHD present at baseline will also be followed utilizing the same 
diagnosis and severity assessments at every study visit until resolution (during the 
duration of the study). The baseline presence of the acute or chronic GVHD will be 
reported on the Transplant History page.
8.1.5
Disease Under Study
Subjects will be enrolled in study after fulfilling the criteria for CMV viremia (≥910 IU/mL) 
and their viral load will be monitored throughout the study. Viremia clearance, persistence, or 
recurrence will be reported as the part of efficacy assessment based on central laboratory result.
It is expected that certain number of subjects will also have tissue invasive CMV disease or
CMV syndrome (SOT subjects only) at baseline and its clinical course will be monitored 
throughout the study and will be reported as part of the secondary efficacy assessment.
Since new tissue invasive CMV disease or CMV syndrome constitutes a medically important 
event, independent of hospitalization or prolongation of hospitalization required for this event, it 
will qualify to be reported as an SAE.
In the event of worsening of tissue invasive CMV disease or CMV syndrome present at baseline, 
an SAE reporting will be determined based on that event fulfilling the seriousness criteria 
(definition in Section 8.2.3).
The investigator has the final discretion in determining whether or not CMV test results and 
other clinical data represent a new CMV event for a given subject.
If a CMV event crosses into different categories over time, the category of greatest severity 
should be recorded.
If a subject is initially diagnosed with an asymptomatic CMV infection, but this event evolves 
into CMV organ disease (eg, colitis), the event would be recorded as CMV colitis and reported 
as SAE.
The terminology used for reporting should be:

Asymptomatic CMV infection

CMV syndrome (applicable only in SOT subjects)

Tissue invasive CMV disease, specify organ for example CMV pneumonitis, CMV 
colitis
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 102 
 
07 Dec 2018
For non-commercial use only


Shire
Page 103
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Table 6 presents the criteria for reporting CMV infection as an AE or as an SAE during its 
clinical course during the study.
Table 6:
Criteria for reporting CMV infection as an AE or as an SAE
Course during the study 
(based on the 
investigator’s 
assessment)
Reportable as AE
Reportable as SAE
Tissue invasive CMV 
disease at baseline 
No change
No
No
Improving
No
No
Worsening, but does not 
meet criteria for SAE as 
determined by the 
investigator
Yes 
No
Worsening and meeting 
criteria for SAE (see 
definition in Section 8.2.3) 
No
Yes 
New onset of tissue 
invasive CMV disease 
No
Yes 
Improving 
No
No
Worsening 
No
Yes but same event with 
upgraded severity
CMV syndrome at 
baseline 
Improving 
No
No
Worsening but does not 
meet criteria for SAE
Yes 
No
Worsening and meeting 
criteria for SAE (see 
definition Section 8.2.3)
No
Yes
Worsening to 
tissue-invasive CMV 
disease 
No
Yes 
Asymptomatic CMV 
infection at baseline 
Improving 
No
No 
Worsening CMV viremia 
(or CMV viremia 
recurrence or rebound 
after clearance) 
Determined by the 
investigator based on the 
assessment of clinical 
significance; either local 
or central laboratory 
results to be used at 
investigator’s discretion.
Yes, if fulfilling 
seriousness criteria.
If the only reason for 
hospital admission or 
prolongation of 
hospitalization is the need 
for IV treatment in the 
hospital setting, then this 
will not qualify as an SAE 
Worsening to tissue 
invasive CMV disease 
No 
Yes 
Worsening to CMV 
syndrome 
No 
Yes
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 103 
 
07 Dec 2018
For non-commercial use only


Shire
Page 104
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Table 6:
Criteria for reporting CMV infection as an AE or as an SAE
Course during the study 
(based on the 
investigator’s 
assessment)
Reportable as AE
Reportable as SAE
CMV=cytomegalovirus; AE=adverse event; SAE=serious adverse event
8.1.6
Clinical Laboratory and Other Safety Evaluations
A change in the value of a clinical laboratory, vital sign, or ECG assessment can represent an AE 
if the change is clinically relevant or if, during study, a shift of a parameter is observed from a 
normal value to an abnormal value, or a further worsening of an already abnormal value. When 
evaluating such changes, the extent of deviation from the reference range, the duration until 
return to the reference range, either while continuing treatment or after the end of treatment with 
the investigational product, and the range of variation of the respective parameter within its 
reference range, must be taken into consideration.
If, at the end of the study treatment phase or at the end of the follow-up phase, there are 
abnormal clinical laboratory, vital sign, or ECG values which were not present at baseline, 
further investigations should be performed until the values return to within the reference range or 
until a plausible explanation (eg, concomitant disease) is found for the abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory, vital sign, or ECG parameter is clinically 
significant and therefore represents an AE.
8.1.7
Pregnancy
All pregnancies are to be reported from the time informed consent is signed until the defined 
follow-up period stated in Section 7.1.3.
Any report of pregnancy for any female study participant or the partner of a male study 
participant must be reported within 24 hours to the Shire Global Drug Safety Department using 
the Shire investigational and marketed products pregnancy report form. The pregnant female 
study participant must be withdrawn from the study.
Every effort should be made to gather information regarding the pregnancy outcome and 
condition of the infant. It is the responsibility of the investigator to obtain this information within
30 calendar days after the initial notification and approximately 30 calendar days and 1 year 
postpartum. An ethics committee (EC) and Institutional Review Board (IRB) approved informed 
consent form must be signed by a pregnant partner of a study participant prior to obtaining 
pregnancy outcome information from the nonstudy participant.
Pregnancy complications such as spontaneous abortion/miscarriage or congenital abnormality 
are considered SAEs and must be reported using the Shire clinical study serious adverse event 
and nonserious AEs required by the protocol form. Note: An elective abortion is not considered 
an SAE.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 104 
 
07 Dec 2018
For non-commercial use only


Shire
Page 105
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
In addition to the above, if the investigator determines that the pregnancy meets serious criteria, 
it must be reported as an SAE using the Shire clinical study serious adverse event and nonserious 
AEs required by the protocol form as well as the Shire investigational and marketed products 
pregnancy report form. The test date of the first positive serum/urine -HCG test or ultrasound 
result will determine the pregnancy onset date.
8.1.8
Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication error (as defined below) must be reported to the sponsor 
according to the SAE reporting procedure whether or not they result in an AE/SAE as described 
in Section 8.2. Note: The 24-hour reporting requirement for SAEs does not apply to reports of 
abuse, misuse, overdose, or medication errors unless these result in an SAE.
The categories below are not mutually exclusive; the event can meet more than 1 category.

Abuse–Persistent or sporadic intentional intake of study treatment when used for a 
nonmedical purpose (eg, to alter one’s state of consciousness or get high) in a manner that 
may be detrimental to the individual and/or society.

Misuse–Intentional use of study treatment other than as directed or indicated at any dose 
(Note: this includes a situation where the investigational product is not used as directed at 
the dose prescribed by the protocol).

Overdose–Intentional or unintentional intake of a dose of maribavir exceeding a total daily 
dose of 400 mg BID, or a prespecified dose of the investigator-assigned anti-CMV 
treatment. The highest dose of maribavir studied in Phase 2 treatment studies (SHP620-202 
and SHP620-203) was 1200 mg BID. There was no significant difference in safety across 
all 3 doses (400 mg BID, 800 mg BID, and 1200 mg BID) studied.

Medication Error–An error made in prescribing, dispensing, administration, and/or use of 
the study treatment. For studies, medication errors are reportable to the sponsor only as 
defined below.
Cases of subjects missing doses of the study treatment are not considered reportable as 
medication errors. Medication errors should be reported for all products under investigation. The 
administration and/or use of an expired investigational product or an investigator-assigned 
anti-CMV treatment should be considered as a reportable medication error.
8.2
Serious Adverse Event Procedures
8.2.1
Reference Safety Information
The reference safety information to assess the expectedness of an AE for this study is as follows:

The maribavir investigator's brochure which the sponsor has provided under separate 
cover to all investigators

The respective summary of product characteristics (SmPC) for each 
investigator-assigned anti-CMV treatment (valganciclovir [Valcyte®, 
11 March 2015], ganciclovir [Cymevene®, 27 October 2016], and foscarnet 
[Foscavir®, 28 February 2014]) or country-specific product package insert for 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 105 
 
07 Dec 2018
For non-commercial use only


Shire
Page 106
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
cidofovir (eg, Tillomed Laboratories, Ltd; 12 September 2017 [UK], 
23 February 2017 [EU]) 
8.2.2
Reporting Procedures
-All initial and follow-up SAE reports must be reported by the investigator to the Shire Global 
Drug Safety  Department within 24 hours of the first awareness of the event. Note: The 24-hour 
reporting requirement for SAEs does not apply to reports of abuse, misuse, overdose, or 
medication errors (see Section 8.1.8) unless they result in an SAE.
The investigator must complete, sign, and date the Shire clinical study serious adverse event and 
nonserious AEs required by the protocol form and verify the accuracy of the information 
recorded on the form with the corresponding source documents (Note: Source documents are not 
to be sent unless requested) and fax or e-mail the form to the Shire Global Drug Safety  
Department. .
In the event of an SAE, the investigator must fax or e-mail the Shire clinical trial serious adverse 
event form within 24 hours to the Shire Global Drug Safety Department. Applicable fax numbers 
and an e-mail address can be found on the form (sent under separate cover) and are provided 
below:
Fax:
E-mail: 
8.2.3
Serious Adverse Event Definition 
A serious adverse event (SAE) is any untoward medical occurrence (whether considered to be 
related to investigational product or not) that at any dose:

Results in death.

Is life-threatening. Note: The term ‘life-threatening’ in the definition of “serious” 
refers to an event in which the subject was at risk of death at the time of the event. It 
does not refer to an event which hypothetically might have caused death if it was 
more severe.

Requires inpatient hospitalization or prolongation of existing hospitalization. Note: 
Hospitalizations, which are the result of elective or previously scheduled surgery for 
pre-existing conditions, which have not worsened after initiation of treatment, should 
not be classified as SAEs. For example, an admission for a previously scheduled 
ventral hernia repair would not be classified as an SAE; however, complication(s) 
resulting from a hospitalization for an elective or previously scheduled surgery that 
meet(s) serious criteria must be reported as SAE(s).

Results in persistent or significant disability/incapacity.

Is a congenital abnormality/birth defect.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 106 
 
07 Dec 2018
For non-commercial use only


Shire
Page 107
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018

Is an important medical event. Note: Important medical events that may not result in 
death, be life-threatening, or require hospitalization may be considered an SAE when, 
based upon appropriate medical judgment, they may jeopardize the subject and may 
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home; blood dyscrasias or 
convulsions that do not result in inpatient hospitalization; or the development of drug 
dependency or drug abuse.
For this protocol the following events will not be collected as SAE(s).

Pre-existing conditions that have not worsened during study participation:
o
Preplanned (planned prior to the initiation of the study) hospitalizations 
o
Preplanned treatments or surgeries

Hospitalization for the administration of foscarnet when it is the investigator's choice 
of therapy for the subjects randomized to 'control' treatment arm, or hospitalization 
for ganciclovir or cidofovir administration if this is a required practice at a local site.
8.2.4
Serious Adverse Event Collection Time Frame
All SAEs (regardless of relationship to study) are collected from the time the subject signs the 
informed consent until the end of defined follow-up period stated in Section 7.1.3, and must be 
reported to the Shire Global Drug SafetyDepartment   within 24 hours of the first awareness of 
the event. 
In addition, any SAE(s) considered “related” to the investigational product and discovered by the 
investigator at any interval after the study has completed must be reported to the Shire Global 
Drug Safety Department within 24 hours of the first awareness of the event.
8.2.5
Serious Adverse Event Onset and Resolution Dates
The onset date of the SAE is defined as the date the event meets serious criteria. The resolution 
date is the date the event no longer meets serious criteria, the date the symptoms resolve, or the 
event is considered chronic. In the case of hospitalizations, the hospital admission and discharge 
dates are considered the onset and resolution dates, respectively.
In addition, any signs or symptoms experienced by the subject after signing the informed consent 
form, or leading up to the onset date of the SAE, or following the resolution date of the SAE, 
must be recorded as an AE, if appropriate.
8.2.6
Fatal Outcome
Any SAE that results in the subject’s death (ie, the SAE was noted as the primary cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 107 
 
07 Dec 2018
For non-commercial use only


Shire
Page 108
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
For any SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another study treatment action was previously taken (eg, drug interrupted, reduced, withdrawn), 
the action taken with the study treatment should be recorded as “dose not changed” or “not 
applicable” (if the subject never received investigational product). The study treatment action of 
“withdrawn” should not be selected solely as a result of the subject’s death. 
8.2.7
Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting
The sponsor and/or the clinical CRO is responsible for notifying the relevant regulatory 
authorities US central IRBs/European Union (EU) central ECs of related, unexpected SAEs.
The study population is HSCT or SOT recipients with cytomegalovirus infections. The following 
SAEs are common in this study population and are anticipated to occur, hence these SAEs 
(including fatal outcomes) will not be considered unexpected and will not be individually 
reported to the regulatory agencies, IRBs, Ethics Committees, and investigators, provided 
there is no increased frequency of these events*:

Any CMV infection, including CMV reactivation/recurrence, CMV syndrome, and 
tissue invasive CMV disease

Any other bacterial, viral infection, or fungal infection

Acute and chronic graft versus host disease, graft rejection, and graft failure  

Reactivation of the malignancy under treatment in HSCT recipients
This includes fatal outcomes for the aforementioned SAEs.
*Maribavir Phase 2 (studies 1263-202 and 1263-203) data will be used as reference.
However, these are AESI and will be closely monitored and recorded on the CRF. Refer to 
Section 8.1.4 for more information on AESI.
In addition, if the event is serious (fulfilling seriousness criteria) it will be reported on SAE 
report form per Section 8.2.2. An independent DMC will be established per Section 9.4.
In addition sponsor or the sponsor's delegate is responsible for notifying active sites of all 
related, unexpected SAEs occurring during all interventional studies across the maribavir 
program.
The investigator is responsible for notifying the local IRB, local EC, or the relevant local 
regulatory authority of all SAEs that occur at his or her site as required.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 108 
 
07 Dec 2018
For non-commercial use only


Shire
Page 109
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
9.
DATA MANAGEMENT AND STATISTICAL METHODS
9.1
Data Collection
The investigators’ authorized site personnel must enter the information required by the protocol 
on the CRF. A study monitor will visit each site in accordance with the monitoring plan and 
review the CRF data against the source data for completeness and accuracy. Discrepancies 
between source data and data entered on the CRF will be addressed by qualified site personnel. 
When a data discrepancy warrants correction, the correction will be made by authorized site 
personnel. Data collection procedures will be discussed with the site at the site initiation visit 
and/or at the investigator’s meeting. Once a subject is randomized, it is expected that site 
personnel will complete the CRF entry within approximately 3 business days of the subject’s 
visit.
9.2
Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO’s data management plan. 
Quality control and data validation procedures are applied to ensure the validity and accuracy of 
the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.
9.3
Statistical Analysis Process 
The study will be analyzed by the sponsor or its agent. All statistical analyses will be performed
using SASVersion 9.1 2 or higher (SAS Institute, Cary, NC 27513). 
The statistical analysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficacy and safety data, as well as describe the approaches to be taken for 
summarizing other study information such as subject disposition, demographics, and baseline 
characteristics, investigational product exposure, and prior and concomitant medications. The 
SAP will also include a description of how missing, unused, and spurious data will be addressed 
and plan for subgroup analysis. In addition, the SAP will include statistical method to summarize 
the maribavir pharmacokinetics data and explore the relationship between maribavir Cmin
(predose concentration) and efficacy and safety measures of interest. To preserve the integrity of 
the statistical analysis and study conclusions, the SAP will be finalized prior to database lock. 
Maribavir PK concentrations will be analyzed by a population PK analysis approach. A separate 
SAP will be prepared for this analysis and a separate report will present the pharmacokinetic 
analysis results in addition to the primary clinical study report.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 109 
 
07 Dec 2018
For non-commercial use only


Shire
Page 110
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
9.4
Data Monitoring Committee
An independent data monitoring committee (DMC) will be established to act in an expert, 
advisory capacity for periodic assessment of the data to monitor participant safety and to ensure 
the validity and scientific merit of the trial.
Further details regarding the DMC can be found in the DMC charter, which will be available 
prior to the administration of study treatment.
9.5
Endpoint Adjudication Committee
An independent Endpoint Adjudication Committee has been established to confirm the diagnosis 
of CMV tissue invasive disease and CMV syndrome for symptomatic subjects at baseline and to 
confirm the change over time (no change, improvement, worsening, or resolution), or diagnosis 
of new tissue invasive CMV disease and CMV syndrome.
The roles, responsibilities, and rules governing operation of the Endpoint Adjudication 
Committee are discussed in full in the Endpoint Adjudication Committee charter, which will be 
available prior to the administration of investigational product.
9.6
Sample Size Calculation and Power Considerations 
In the Phase 2 Study SHP620-202, the proportion of subjects with undetectable plasma CMV 
DNA was 70%, 63%, and 68% for the 400 mg, 800 mg, and 1200 mg BID dose groups, 
respectively, within 6 weeks. The proportion of subjects with undetectable plasma CMV DNA 
was 70%, 65%, and 75% for the 400 mg, 800 mg, and 1200 mg BID dose groups, respectively, 
within 12 weeks. Therefore, it is assumed that at least 60% of maribavir treated subjects will 
have achieved undetectable plasma CMV DNA at Visit 9/Week 7 and Visit 10/Week 8 when 
calculating the sample size.
A proportion of approximately 40% is considered as a reasonable estimate of the proportion of 
subjects with confirmed undetectable plasma CMV DNA at Visit 9/Week 7 and Visit 10/Week 8 
in the investigator assigned treatment group when calculating the sample size. It is believed that 
the treatment difference of 20% higher in maribavir group compared to the control group is 
larger than a clinically meaningful difference.
For the proposed trial, to demonstrate statistical superiority in the reduction of CMV DNA, it is 
assumed that the proportion of subjects with confirmed unquantifiable plasma CMV DNA at
Visit 9/Week 7 and Visit 10/Week 8 in the maribavir and control groups is 60% and 40%, 
respectively, a total of 315 subjects is required in the ratio of 2:1 (210 subjects in maribavir 
group and 105 subjects in the control group) to provide 90% power in hypothesis testing at an 
alpha level of 0.05 (2-sided test). The sample size is estimated based on a 2-group continuity 
corrected Chi-square test of equal proportions by using nQuery Advisor 7.0. Considering 10% 
drop-outs, 351 subjects (234 subjects in maribavir group and 117 subjects in the control group) 
will be enrolled and randomized.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 110 
 
07 Dec 2018
For non-commercial use only


Shire
Page 111
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
9.7
Study Analysis Population

The enrolled set will consist of all subjects who have signed an informed consent and have 
begun some study procedures.

The randomized set will consist of all subjects in the enrolled set who have been 
randomized to the study. Subjects will be analyzed in the treatment group to which they are 
randomized.

The safety set will consist of all subjects who have taken any dose of study treatment. 
Subjects will be analyzed according to the treatment actually received.

The per-protocol (PP) set will consist of all subjects in the randomized set who do not have 
predefined major protocol deviations that may affect the primary efficacy assessment. 

The pharmacokinetic set will consist of all subjects in the safety set who had plasma 
samples drawn and tested for maribavir concentrations.
o
The adolescent pharmacokinetic set will consist of all subjects ≥12 to <18 years of 
age in the safety set who had plasma samples drawn and tested for maribavir 
concentrations. 
The randomized set and the PP set will be used for efficacy analyses, with the randomized set as 
the primary analysis set and the PP set as the supportive one. 
9.8
Efficacy Analyses
The following definitions will be used for study analyses: 
Confirmed viremia clearance: defined as plasma CMV DNA concentration below the lower 
limit of quantification (<LLOQ; ie, <137 IU/mL) when assessed by COBAS® 
AmpliPrep/COBAS® TaqMan® CMV Test at a central specialty laboratory, in 2 consecutive 
post-baseline samples, separated by at least 5 days.
Recurrence of CMV viremia: defined as plasma CMV DNA concentration ≥LLOQ when 
assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive plasma 
samples at least 5 days apart, after achieving confirmed viremia clearance.
Rebound of CMV viremia: defined as increase in viral DNA load for >1 log10 above nadir 
without prior clearance of viremia.
Recurrence of the Symptomatic CMV infection: defined as the presence of signs or symptoms 
of the tissue invasive CMV disease or CMV syndrome (same or new symptomatology) 
confirmed as per Ljungman et al., 2017, after the period of resolution of symptomatic infection 
in subjects symptomatic at baseline.
Subjects in the investigator-assigned treatment arm who are unable to continue taking 
investigator-assigned anti-CMV treatment due to the lack of anti-viral activity and/or intolerance 
to the assigned treatment (as evaluated starting at Visit 5/Week 3) may be evaluated for entry 
into a maribavir rescue arm. Subjects who take rescue medication will be considered as failures 
for primary efficacy analyses. The data collected post-maribavir rescue initiation will be 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 111 
 
07 Dec 2018
For non-commercial use only


Shire
Page 112
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
included in separate secondary analyses for efficacy and exploratory analysis for PK. Summary 
of all safety analyses will be provided separately for the maribavir rescue arm. The same is 
applicable for patients who might be discontinued from maribavir treatment due to intolerance. 
Subjects who discontinue due to intolerance and without viremia clearance at Study Week 8 will 
be considered failures in both treatment arms.
9.8.1
Primary Efficacy Endpoint
The primary efficacy endpoint (a binary response) for the study is confirmed clearance of plasma 
CMV DNA (CMV viremia clearance) at the end of Study Week 8.
For clearance of CMV viremia to be declared at the end of Study Week 8, the subject must have 
received exclusively study-assigned treatments.
Confirmed CMV viremia clearance at the end of Study Week 8 (Visit10) is defined as plasma 
CMV DNA concentrations <LLOQ (ie, <137 IU/mL), when assessed by COBAS®
AmpliPrep/COBAS® TaqMan® CMV Test at a central specialty laboratory, in 2 consecutive 
postbaseline samples separated by at least 5 days, regardless of whether either study-assigned 
treatment was discontinued before the end of the stipulated 8 weeks of therapy (see examples in 
Table 7 below).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 112 
 
07 Dec 2018
For non-commercial use only


Shire
Page 113
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Table 7:
Assessments of Virological Responders at Study Week 8
Scenario
CMV DNA Weeks on Study
Week 6
Week 7
Week 8
Week 9*
Response
Rationale
1
+ / -
-
-
+/-/NA
Yes
2 consecutive “-” at Week 7 and 
Week 8
2
+ / -
-
+
+/-/NA
No
Not 2 consecutive “-” at Week 7 
and Week 8
3
+ / -
+
-
+/-/NA
No
Not 2 consecutive “-” at Week 7 
and Week 8
4
+ / -
-
NA
-
Yes
2 consecutive “-” as shown by 
available data and both “-” at 
week 7 and week 9 for missing 
week 8, otherwise nonresponder
5
-
NA
-
+/-/NA
Yes
2 consecutive “-” as shown by 
available data and both ‘-‘ at 
week 6 and week 8 for missing 
Week 7, otherwise nonresponder
6
-
NA
NA
-
Yes
2 consecutive “-” as shown by 
available data at week 6 and week 
9 and both “-”, otherwise 
nonresponder
NA = not available for evaluation of study drug effect; reason could be not assessable by lab, or starting 
alternative anti-CMV treatment, withdrawal from study, etc.
*Week 9 data only to be used if Week 8 data are unavailable or missing.
Notes: Scenarios in the table above are provided as examples and may not be all-inclusive of all possibilities.
Only CMV DNA data evaluable for assessment of effect of study drug will be included (ie, prior to the 
start of alternative anti-CMV treatment if any).
“-” = CMV DNA concentration <LLOQ (<137 IU/mL) 
“-” = CMV DNA concentration ≥LLOQ (ie, quantifiable)
Confirmed clearance of plasma CMV DNA (CMV viremia clearance) = 2 consecutive postbaseline 
assessments of
CMV DNA target <LLOQ, separated by at least 5 days.
Statistical Methodology for Primary Efficacy Endpoint:
The difference in proportion of subjects with confirmed CMV viremia clearance, at the end of 
Study Week 8, between treatment groups (maribavir and investigator’s choice of anti-CMV 
treatment) will be obtained using Cochran-Mantel-Haenszel (CMH) weighted average across all 
strata, and analyzed using CMH test with transplant type and baseline plasma CMV DNA 
concentration as 2 stratification factors. The 95% confidence limits of the weighted average of 
difference across strata will be provided using the normal approximation. If the minimum 
number of subjects in a response category in a treatment group for the high viral load group is 
less than 5, the high and intermediate viral load groups will be collapsed into 1 stratum level. 
The baseline plasma CMV DNA levels will be the last central laboratory assessment before the 
first dose of study treatment. If the p-value from the CMH test is ≤0.0505 and the proportion of 
response from maribavir is higher, it will be concluded that maribavir is more efficacious 
compared to the control group.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 113 
 
07 Dec 2018
For non-commercial use only


Shire
Page 114
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Subjects who are unable to continue taking investigator’s assigned anti-CMV treatment due to 
the lack of anti-viral activity and/or intolerance to the assigned treatment (as evaluated starting at 
Visit 5/Week 3) may be evaluated for entry into a maribavir rescue arm. Subjects who take 
rescue medication will be considered as failures for primary efficacy analyses. The data collected 
postmaribavir rescue initiation, will be included in separate secondary analyses for efficacy and 
exploratory analysis for PK. Summary of all safety analyses will be provided separately for the 
maribavir rescue arm. Since intolerance to the assigned treatment alone will not qualify a subject 
for the rescue arm, such subjects will not be considered nonresponders for the purpose of the 
primary efficacy analysis. The same is applicable for subjects that might be discontinued from 
maribavir treatment due to intolerance. Subjects that do not achieve confirmed CMV viremia 
clearance will be considered failures in both treatment arms. Subjects who discontinue without 
confirmed CMV viremia clearance at Study Week 8 will be considered failures in both treatment 
arms.
Sensitivity and supportive analyses of the primary endpoint of CMV viremia clearance at 
Week 8 will be conducted to evaluate the robustness of the result from the primary method. This 
will be specified in the SAP. Two examples are given below:

Subjects who discontinue study treatment early without CMV DNA measurement 
available for evaluation of study drug effect at Week 8 (see Table 7). However, they meet 
the criteria of confirmed CMV viremia clearance defined as 2 consecutive post baseline 
assessments of CMV DNA target <LLOQ, separated by at least 5 days, at the time of 
study discontinuation will be included as responders.

Multivariate regression analysis to evaluate treatment difference after controlling for 
important demographic and baseline clinical characteristics. The list of demographic and 
baseline clinical characteristics to be considered will include but will not be limited to 
transplant type (HSCT versus SOT), CMV viral load resistant versus refractory, CMV 
serostatus, immune function status, presence of GVHD, high dose steroids use at 
baseline, prior use of CMV prophylaxis.
The analysis of primary efficacy endpoint and the key secondary efficacy endpoint will be 
conducted using both the randomized set and PP set.
9.8.2
Key Secondary Efficacy Endpoint
The key secondary endpoint of this study is a binary response (yes/no) with following criteria:

Achievement of CMV viremia clearance and resolution or improvement of tissue-
invasive CMV disease or CMV syndrome for subjects symptomatic at baseline or 
achievement of clearance of viremia and no symptoms of tissue invasive CMV disease or 
CMV syndrome for subjects asymptomatic at baseline at the end of Study Week 8, 
followed by maintenance of this treatment effect for an additional 8 weeks off treatment
(ie, Follow-up Week 16).
For treatment effect of clearance of CMV viremia and CMV infection symptom control 
(resolution or improvement of tissue invasive disease or CMV syndrome for symptomatic 
subjects at baseline, or no new symptoms for subjects asymptomatic at baseline) to be declared at 
the end of Study Week 8, regardless of whether either study-assigned treatment was discontinued 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 114 
 
07 Dec 2018
For non-commercial use only


Shire
Page 115
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
before the end of the stipulated 8 weeks of therapy, and maintenance of such effect through 
Week 16, the subject must have received exclusively a study-assigned treatment.
The investigator will perform the initial diagnosis of tissue-invasive CMV disease or CMV 
syndrome (absence or presence) for the symptomatic subjects at baseline and new occurrence of 
tissue invasive CMV disease or CMV syndrome for the asymptomatic subjects at baseline 
through the study, and will continue with the assessment of the infection status (ie, no change, 
improvement, worsening, or resolution) at subsequent visits through the study. All investigator-
assessed cases of tissue invasive CMV disease and CMV syndrome will be reviewed and 
adjudicated by an independent EAC both for the confirmation of the diagnosis of baseline and 
new symptomatic CMV infection and for the outcome (ie, no change, improvement, worsening, 
or resolution).
All investigator-assessed cases of tissue invasive CMV disease and CMV syndrome will be 
reviewed and adjudicated by an independent EAC both for the confirmation of the diagnosis at 
baseline and new tissue invasive CMV disease or CMV syndrome and for the outcome (ie, no 
change, improvement, worsening, or resolution). An adjudicated baseline disease diagnosis of 
“confirmed” or “probable” will be accepted (only “probable” for CMV syndrome). An 
adjudicated outcome of “improved” or “absent” will constitute improvement of tissue invasive 
CMV disease or CMV syndrome. New cases of tissue invasive CMV disease or CMV syndrome 
identified by the investigator will also be adjudicated. Endpoint Adjudication Committee
adjudicated cases will be used for the efficacy analyses.
Criteria for defining the key secondary efficacy endpoint are:

First being a responder at the end of Study Week 8, irrespective of study treatment duration, 
based on CMV viremia clearance and assessment of the tissue invasive CMV disease or 
CMV syndrome status (ie, resolution or improvement of tissue invasive CMV disease or 
CMV syndrome for subjects symptomatic at baseline or no symptoms of tissue invasive 
CMV disease or CMV syndrome for subjects asymptomatic at baseline).
AND 

Maintenance of this treatment effect (both CMV viremia clearance and tissue-invasive 
disease or CMV syndrome control) through Study Week 16 (criteria for the CMV viremia 
clearance are presented in Table 8).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 115 
 
07 Dec 2018
For non-commercial use only


Shire
Page 116
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Table 8:
Assessments of Responders for Key Secondary Endpoint
Response 
(both 
virological 
response and 
symptomatic 
CMV 
infection 
control) at 
Study Week 
8
CMV DNA Assessment Week
Key 
secondary 
endpoint 
responder*
Rationale
9
10
11
12
14
16
181
Yes
+/-
+/-
+/-
+/-
+/-
+/-
+/-/NA
No
Any 2 consecutive “+” in FU by 
week 16
Yes
+/-
+/-
+/-
+/-
+/-
-
+/-/NA
Yes
Week16 is “-” and no 2 
consecutive “+” during FU
Yes
+/-
+/-
+/-
+/-
+/-
+
+/-/NA
No
Week 16 is “+” and week 18 is 
“+” or NA, criteria of 2 
consecutive “+” is met
Yes
+/-
+/-
+/-
+/-
+/-
+
-
Yes
Week 16 is “+”, and 2 
consecutive “+” criteria is not met 
based on week 18 data
Yes
+/-
+/-
+
-
-
NA
-
Yes
Week 16 is missing, 2 
consecutive “+” criteria is not met 
based on week 14 and 18 data
Yes
+/-
+/-
+
-
-
NA
+/NA
No
Week 16 is missing, 2 
consecutive “+” criteria may be 
met based on available week 18 
data
Yes
+/-/NA +/-/NA +/-/NA +/-/NA NA
NA
+/-/NA
No
Lack of data to show maintaining 
effect through week 16 
No
No
1Week 18 data will be used only if Week 16 data are unavailable or missing.
*Must also meet the criterion of CMV infection symptom control to be a responder.
NA=not available for evaluation of study drug effect; reason could be starting alternative anti-CMV treatment, withdrawal from 
study, etc.
Notes: Scenarios in the table above are provided as examples and may not be all-inclusive of all possibilities.
Only CMV viremia data prior to receiving nonstudy CMV treatment or rescue treatment will be included in the 
assessment.
Statistical Methodology for Key Secondary Endpoint
The key secondary endpoint will be analyzed using the same approach as the primary endpoint.
The analysis of primary efficacy endpoint and the key secondary efficacy endpoint will be 
conducted using both the randomized set and PP set.
9.8.3
Multiplicity Adjustment 
The hypothesis-testing of the primary and key secondary endpoint will be adjusted for multiple 
comparisons using a fixed-sequence testing procedure to control the family-wise Type 1 error 
rate at 5% level. The statistical test will be performed sequentially in the order of primary 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 116 
 
07 Dec 2018
For non-commercial use only


Shire
Page 117
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
efficacy endpoint, and the key secondary endpoint. First, the primary endpoint analysis (CMV 
viremia clearance at Week 8) will be assessed at α=0.05. If and only after the primary efficacy 
endpoint is statistically significant, the key secondary endpoint will be assessed at α=0.05.
9.8.4
Subgroup Analyses
The primary and key secondary endpoints will be examined for the following subgroups 
(inclusive, but not limited to):

Subjects symptomatic at baseline

SOT/HSCT recipients 

CMV DNA viral load (high, intermediate, low)

Resistant (yes/no)

Adolescents ≥12 to <18 years of age (exploratory analysis: may be conducted if sample 
size is adequate)
The proportion of subjects achieving the primary efficacy endpoint and the key secondary 
efficacy endpoint, and the corresponding 95% CIs will be calculated for each group separately. 
In addition, the difference in each respective proportion between treatment group and the 
associated 95% CI will be presented.
9.8.5
Secondary Efficacy Endpoints
The secondary efficacy endpoints of this study are as follows:

The achievement of the confirmed CMV viremia clearance after 8 weeks of receiving 
study-assigned treatment.
o
The proportion of subjects achieving the confirmed CMV viremia clearance after 
receiving 8 weeks of study-assigned treatment, and the corresponding 95% CIs 
will be calculated for each treatment group separately. The difference in each 
respective proportion between treatment groups and the associated 95% CI will be 
calculated using the same approach as the primary efficacy endpoint, and will be 
assessed using CMH test with transplant type and baseline CMV DNA 
concentration as 2 stratification factors.

The achievement of the confirmed CMV viremia clearance and CMV infection symptom 
control after receiving 8 weeks of study-assigned treatment, followed by maintenance of 
this treatment effect through Study Weeks 12 (4 weeks post treatment period), 16 (8 
weeks post treatment/follow-up phase), and 20 (12 weeks post treatment).
o
The proportion of subjects who achieved confirmed CMV viremia clearance and
CMV infection symptom control after 8 weeks of receiving study-assigned 
treatment and maintaining the effect through Study Weeks 12, 16, and 20, and the 
corresponding 95% CIs will be calculated for each treatment group separately. 
The difference in each respective proportion between treatment groups and the 
associated 95% CI will be calculated using the same approach as the primary 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 117 
 
07 Dec 2018
For non-commercial use only


Shire
Page 118
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
efficacy endpoint, and will be assessed using CMH test with transplant type and 
baseline CMV DNA concentration as 2 stratification factors.

The maintenance of the CMV viremia clearance, and CMV infection symptom control, at 
the end of Study Week 8, through weeks 12 and 20, regardless of whether either study-
assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy.
o
The proportion of subjects who maintained confirmed CMV viremia clearance 
and CMV infection symptom control at end of Study Week 8 and maintained 
the effect through Study Week 12 and 20, and the corresponding 95% CIs will 
be calculated for each treatment group separately. The difference in each 
respective proportion between treatment groups and the associated 95% CI 
will be calculated using the same approach as the primary efficacy endpoint, 
and will be assessed using CMH test with transplant type and baseline CMV 
DNA concentration as 2 stratification factors.

The recurrence of CMV viremia during the first 8 weeks of the study, in the follow-up 
period of 12 weeks, and at any time during the 20 weeks of the study, regardless of 
whether either study-assigned treatment was discontinued before the end of the stipulated 
8 weeks of therapy.
o
The proportion of subjects with recurrence of CMV viremia during the first 8 
weeks of the study, and the corresponding 95% Cl will be calculated. 
o
The proportion of subjects with recurrence of CMV viremia, in the 12 weeks 
of the follow-up phase and the corresponding 95% Cl will be calculated.
o
The proportion of subjects with recurrence of CMV viremia any time on study 
and the corresponding 95% Cl will be calculated.
Additional subgroup analysis will be done for the subjects who completed 8 weeks of 
study-assigned treatment with the same type of endpoints:
o The proportion of subjects with recurrence of CMV viremia during the 8 weeks 
of study treatment, and the corresponding 95% Cl will be calculated.
o The proportion of subjects with recurrence of CMV viremia, in the 12 weeks of 
the follow-up phase and the corresponding 95% Cl will be calculated.
o The proportion of subjects with recurrence of CMV viremia at any time on the 
study and the corresponding 95% Cl will be calculated.

The recurrence of CMV viremia during study-assigned treatment and in the follow-up 
period after the subject is discontinued from study-assigned treatment.
o
The proportion of subjects with recurrence of CMV viremia while on study 
treatment, and the corresponding 95% Cl will be calculated.
o
The proportion of subjects with recurrence of CMV viremia, in the period 
from the termination of study treatment to the end of the study, and the 
corresponding 95% Cl will be calculated.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 118 
 
07 Dec 2018
For non-commercial use only


Shire
Page 119
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018

The maribavir CMV resistance profile
o
The proportion of maribavir subjects who developed maribavir CMV 
resistance on study and the corresponding 95% CI will be calculated.

All causes mortality by the end of the study (Visit 18/Week 20[Follow-up Week 12]) 
o
The proportion of subjects who died at the end of the study and the 
corresponding 95% CIs will be calculated for each group separately. In 
addition, the difference in each respective proportion between treatment group 
and the associated 95% CI will be presented.
The time to all causes mortality will also be summarized using the Kaplan-
Meier method.
The secondary efficacy endpoints assessed for the maribavir rescue arm are as follows:

The confirmed clearance of plasma CMV DNA at the end of 8 weeks after starting 
maribavir rescue treatment
o
The proportion of subjects receiving maribavir rescue treatment who achieved 
the CMV viremia clearance at the end of 8 weeks after starting maribavir 
rescue treatment and the corresponding 95% CI will be calculated.

Achievement of viremia clearance at the end of 8 weeks after starting maribavir rescue 
treatment and resolution or improvement of tissue invasive CMV disease or CMV 
syndrome for subjects who are symptomatic at the start of maribavir treatment or subjects 
who are asymptomatic at the start of maribavir treatment remain symptom free, followed 
by maintenance of the treatment effect for an additional 8 weeks when off maribavir 
rescue treatment (as evidenced by sustained clearance of viremia and improvement or 
resolution of symptomatic infection and no new tissue invasive CMV disease or CMV 
syndrome development between end of treatment and up to Week 16)
o
The proportion of subjects receiving maribavir rescue treatment who achieved 
the confirmed CMV viremia clearance and tissue invasive disease or CMV 
syndrome control at the end of 8 weeks after starting maribavir rescue 
treatment and maintain the effect through Week 16 and the corresponding 
95% CI will be calculated.
The analysis of the secondary efficacy endpoints will be conducted using the Randomized and 
PP set unless otherwise specified. Secondary efficacy endpoints will be summarized by treatment 
arm, and, if indicated, analyzed statistically at α=0.05 (2-sided), without adjustment for multiple 
comparisons.
9.8.6
Exploratory Efficacy Endpoints
The exploratory efficacy endpoints are as follows:
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 119 
 
07 Dec 2018
For non-commercial use only


Shire
Page 120
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
The randomized set will be used for the analysis of the exploratory efficacy endpoints. 
Descriptive statistics will be used to summarize the data. Summary statistics will include the 
number of subjects (N), mean, standard deviation, median, minimum and maximum (range) 
values for continuous variables, and incidences and percentages for categorical variables. The 
denominator for the percentages will be based on the number of patients with nonmissing 
information in the randomized set. Time-to-event endpoints will be summarized using Kaplan-
Meier estimation. Ninety-five percent (95%) confidence intervals for the estimated 25%, 50%, 
and 75% times will be presented.
9.9
Safety Analyses
The safety analyses will include evaluation and procedures to meet the secondary objective of 
assessing the safety and tolerability of maribavir.
Safety evaluation will be made during the periods as illustrated in Figure 1, ie, screening phase, 
treatment phase, and follow-up phase. 
Two observation periods are defined for the purpose of analyses:
1) The on-treatment observation period starts at the time of study treatment initiation through 
7 days after the last dose of study treatment or through 21 days if cidofovir is used. For 
subjects who transfer from the study treatment to either maribavir rescue or to a nonstudy 
CMV treatment, the on treatment observation period starts at the time of the study treatment 
initiation through 7 days after the last dose of study treatment (or through 21 days if cidofovir 
is used), or until the maribavir rescue treatment initiation or until the nonstudy CMV 
treatment initiation, whichever is earlier. This will serve as the primary analysis of safety.
2) The overall-study observation period minus the period on rescue arm starts at the time study 
treatment start through the end of the study. For subjects who receive maribavir rescue 
therapy, the overall-study observation period minus the period on rescue arm starts at the 
time study treatment start through the time before receiving maribavir rescue therapy.
Similar observation periods are defined for the safety analysis of the maribavir rescue arm.
The events that occur from the time of ICF signature to first dose will be collected but will not be 
evaluated in the safety analyses. They will be listed as pretreatment adverse events.
An AE (classified by preferred term) that has a start date on or after the first dose of study 
treatment or that has a start date before the date of first dose of study treatment, but increases in 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 120 
 
07 Dec 2018
For non-commercial use only


Shire
Page 121
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
severity after the first dose of study treatment will be considered a treatment-emergent AE 
(TEAE).
Safety endpoints will be summarized descriptively for the on treatment period, and overall-study 
period, as appropriate. Baseline assessments will be the last assessment before the first dose of 
study treatment. The safety set population will be used to analyze the safety data. Summary of all 
safety analyses will be provided separately for the maribavir rescue arm.
The safety endpoints include the following:

TEAEs and treatment-emergent SAEs, overall study AEs and overall study SAEs 

Clinical laboratory evaluations 
Safety assessment will also include vital sign measurements, physical examination, and ECG.
The number of events, incidence, and percentage of TEAEs and overall-study AEs will be 
displayed for each treatment group by system organ class (SOC) and by Preferred Terms using 
the Medical Dictionary for Regulatory Activities (MedDRA®). Summaries in terms of severity 
and relationship to study medication will also be provided. Treatment-emergent SAEs will be 
summarized separately in a similar fashion. Summaries of AEs causing discontinuation of study 
medication, withdrawals, AEs leading to death, SAEs and adverse of events special interest 
(AESI) will be provided.
Adverse events of special interest, eg, tissue invasive CMV disease, dysgeusia, GI events 
(nausea, vomiting and diarrhea), neutropenia, increased immunosuppressant drug concentration 
levels, graft rejection, opportunistic infections, and GVHD will be analyzed according to primary 
System Organ Classes (SOCs) and Preferred Terms (PTs). MedDRA queries (SMQs) may be 
used, as applicable. Additional grading of events of special interest will be applicable. Summary 
tables with SOCs and PTs will be generated presenting the number and percentage of subjects by 
AE, severity, seriousness, and relationship to study medication.
Usage of concomitant medications and procedures will be summarized descriptively for each of 
the treatment groups and the maribavir rescue treatment group for the on treatment period and 
overall-study period. Treatment of hemopoietic growth factors, blood and blood transfusion 
products will be summarized separately
Change from baseline in vital signs and clinical laboratory tests will be summarized for each 
treatment group with descriptive statistics at each assessment visit. Summary and shift tables will 
be produced for selected laboratory parameters based on National Cancer Institute (NCI) 
common terminology criteria for adverse events (CTCAE v4.0).
Abnormal physical examination findings will be listed.
Summary of ECG findings will be provided by treatment groups.
An independent data monitoring committee (DMC) will be established to assess the data for 
safety and to ensure the validity and scientific merit of the trial. Detailed plans for the DMC’s 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 121 
 
07 Dec 2018
For non-commercial use only


Shire
Page 122
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
purpose and responsibilities will be described in the DMC charter and the statistical analysis 
plan.
9.10
Other Analyses
9.10.3
Pharmacokinetic Analyses 
The Pharmacokinetic Set will be used to analyze the pharmacokinetic endpoints. The adolescent 
pharmacokinetic set will consist of all subjects ≥12 to <18 years of age in the safety set who 
had plasma samples drawn and tested for maribavir concentrations.
Pharmacokinetic endpoints for maribavir treatment either from treatment phase or rescue 
treatment are as follows:
Secondary endpoint
For all subjects who received maribavir treatment:

Maribavir Cmin (predose maribavir concentration)
For adolescent subjects who provided intensive PK samples at Visit 3/Week 1:

AUC(0-tau): area under the concentration time curve over the 12-hour dosing interval at steady 
state

Cmax: maximum concentration

Tmax: time when maximum concentration is observed

CL/F: apparent oral clearance

Vz/F: apparent volume of distribution 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 122 
 
07 Dec 2018
For non-commercial use only


Shire
Page 123
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Exploratory endpoints:
Blood samples at predose (Cmin) and 2-4 hour postdose administration will be assessed for 
plasma maribavir concentration levels. Maribavir PK will be analyzed for all subjects with 
maribavir plasma concentration results. Maribavir PK concentrations will be summarized by visit 
and planned sampling time. A scatter plot of all reportable maribavir concentration vs actual 
sampling time will be generated. A listing of subjects with maribavir concentration below the 
quantitation limit will be provided along with the Week 8 efficacy response. Analysis on the 
relationship between Cmin (predose maribavir concentration) and efficacy endpoints of interest 
will be conducted by graphical exploration and by statistical models.
In a separate analysis and report, maribavir concentrations will be analyzed by population PK 
analysis approach using nonlinear mixed effect model approach using NONMEM v7 or above. 
Post hoc maribavir PK parameters such as AUC, Cmax, and Cmin will be generated and 
summarized by identified covariates; relationship between post hoc maribavir PK parameter 
estimates (AUC, Cmax, and Cmin) and efficacy and safety measures of interest will be explored. 
This analysis maybe conducted by combining maribavir PK data from other Phase 2 and Phase 3 
studies.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 123 
 
07 Dec 2018
For non-commercial use only


Shire
Page 124
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
10.
SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES
This study is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates/revisions, and local ethical and legal requirements.
The name and address of each third party vendor (eg, CRO) used in this study will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1
Sponsor’s Responsibilities
10.1.1
Good Clinical Practice Compliance
The study sponsor and any third party to whom aspects of the study management or monitoring 
have been delegated will undertake their assigned roles for this study in compliance with all 
applicable industry regulations, ICH Good Clinical Practice (GCP) Guideline E6, EU Directive 
2001/20/EC, Integrated Addendum to ICH E6 (R1): Guideline for Good Clinical Practice E6 
(R2) Current Step 4 version dated 9 November 2016, and updates/revisions, as well as all 
applicable national and local laws and regulations.
Visits to sites are conducted by representatives of the study sponsor and/or the company 
organizing/managing the research on behalf of the sponsor to inspect study data, subjects’ 
medical records, and CRFs in accordance with current GCP and the respective local and 
(inter)national government regulations and guidelines. Records and data may additionally be 
reviewed by auditors or by regulatory authorities.
The sponsor ensures that local regulatory authority requirements are met before the start of the 
study. The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of any regulatory authority approvals required prior to release of 
investigational product for shipment to the site.
10.1.2
Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry Guidelines. If appropriate, a copy of the indemnity document is 
supplied to the investigator before study initiation, per local country guidelines.
The sponsor ensures that suitable clinical study insurance coverage is in place prior to the start of 
the study. An insurance certificate is supplied to the CRO/investigator as necessary.
10.1.3
Public Posting of Study Information
The sponsor is responsible for posting appropriate study information on applicable websites. 
Information included in clinical study registries may include participating investigators’ names 
and contact information.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 124 
 
07 Dec 2018
For non-commercial use only


Shire
Page 125
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
10.1.4
Submission of Summary of Clinical Study Report to Competent Authorities 
of Member States Concerned and Ethics Committees
The sponsor will provide a summary of the clinical study report to the competent authority of the 
member state(s) concerned as required by regulatory requirement(s) and to comply with the 
Community guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
the study completion date for pediatric studies and within 1 year for nonpediatric studies as per 
guidance. The sponsor will provide the ECs with a copy of the same summary.
10.1.5
Study Suspension, Termination, and Completion
The sponsor may suspend or terminate the study, or part of the study, at any time for any reason. 
If the study is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notified as appropriate. Additionally, the discontinuation of a 
registered clinical study which has been posted to a designated public website will be updated 
accordingly.
The sponsor will make an end of study declaration to the relevant competent authority as 
required by Article 10 (c) of Directive 2001/20/EC and its updates/revisions.
10.2
Investigator’s Responsibilities
10.2.1
Good Clinical Practice Compliance
The investigator must undertake to perform the study in accordance with ICH GCP Guideline 
E6, EU Directive 2001/20/EC, Integrated Addendum to ICH E6 (R1): Guideline for Good 
Clinical Practice E6 (R2) Current Step 4 version dated 9 November 2016, and updates/revisions, 
and applicable regulatory requirements and guidelines.
It is the investigator’s responsibility to ensure that adequate time and appropriately trained 
resources are available at the site prior to commitment to participate in this study. The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately qualified persons to whom the investigator 
has delegated significant study-related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any licenses and certifications necessary to demonstrate such 
qualification. Curriculum vitae for investigators and subinvestigators are provided to the study 
sponsor (or designee) before starting the study.
If a potential research subject has a primary care physician, the investigator will, with the 
subject’s consent, inform them of the subject’s participation in the study.
A coordinating principal investigator is appointed to review the final clinical study report for 
multicenter studies. Agreement with the final clinical study report is documented by the signed 
and dated signature of the principal investigator (single-site study) or coordinating principal 
investigator (multicenter study), in compliance with Directive 2001/83/EC and its 
updates/revisions as amended by Directive 2003/63/EC and ICH Guidance E3.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 125 
 
07 Dec 2018
For non-commercial use only


Shire
Page 126
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
The investigator is responsible for supervising any individual or party to whom the investigator 
delegates study tasks conducted at the trial site. If the investigator/institution retains the services 
of any party to perform study tasks they should ensure this party is qualified to perform those 
study tasks and should implement procedures to ensure the integrity of the study tasks performed 
and any data generated.
10.2.2
Protocol Adherence and Investigator Agreement
The investigator and any coinvestigators must adhere to the protocol as detailed in this 
document. The investigator is responsible for enrolling only those subjects who have met 
protocol eligibility criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply with the study protocol.
If the investigator suspends or terminates the study at their site, the investigator will promptly 
inform the sponsor and the IRB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational product, containers, and other study materials to 
the sponsor. Upon study completion, the investigator will provide the sponsor, IRB/EC, and 
regulatory agency with final reports and summaries as required by (inter)national regulations.
Communication with local IRBs/ECs, to ensure accurate and timely information is provided at 
all phases during the study, may be done by the sponsor, applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator according to national provisions and 
will be documented in the investigator agreement.
10.2.3
Documentation and Retention of Records
10.2.3.1
Case Report Forms
Case report forms are supplied by the sponsor/CRO and should be handled in accordance with 
instructions from the sponsor.
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded onto CRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed by the investigator or designee as stated in the site delegation log.
All data sent to the sponsor must be endorsed by the investigator.
The CRA/study monitor will verify the contents against the source data per the monitoring plan. 
If the data are unclear or contradictory, queries are sent for corrections or verification of data.
10.2.3.2
Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study will include, but are not limited to: 
subject’s medical file, subject diary, original clinical laboratory reports, and histology and 
pathology reports.
The investigator should maintain adequate and accurate source documents and trial records that 
include all pertinent observations on each of the site’s trial subjects. Source data should be 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 126 
 
07 Dec 2018
For non-commercial use only


Shire
Page 127
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
attributable, legible, contemporaneous, original, accurate, and complete. Changes to source data 
should be traceable, should not obscure the original entry and should be explained if necessary 
(eg, via an audit trail).
All key data must be recorded in the subject’s medical records.
The investigator must permit authorized representatives of the sponsor, the respective national, 
local, or foreign regulatory authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study, regardless of media.
The CRA/study monitor (and auditors, IRB/EC, or regulatory inspectors) may check the CRF 
entries against the source documents. The consent form includes a statement by which the 
subject agrees to the monitor/auditor from the sponsor or its representatives, national or local 
regulatory authorities, or the IRB/EC, having access to source data (eg, subject’s medical file, 
appointment books, original laboratory reports, X-rays, etc.). Nonstudy site personnel will not 
disclose any personal information or personal medical information (applicable in the UK).
These records must be made available within reasonable times for inspection and duplication, if 
required, by a properly authorized representative of any regulatory agency (eg, the US Food and 
Drug Administration (FDA), EMA, UK Medicines and Healthcare products Regulatory Agency) 
or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may not be 
destroyed without written permission from the sponsor.
10.2.3.3
Audit/Inspection
To ensure compliance with relevant regulations, data generated by this study must be available 
for inspection upon request by representatives of, for example, the US FDA (as well as other US 
national and local regulatory authorities), the EMA, the Medicines and Healthcare products 
Regulatory Agency, other regulatory authorities, the sponsor or its representatives, and the 
IRB/EC for each site.
10.2.3.4
Financial Disclosure
The investigator is required to disclose any financial arrangement during the study and for 1 year
after, whereby the outcome of the study could be influenced by the value of the compensation for 
conducting the study, or other payments the investigator received from the sponsor. The 
following information is collected: any significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; any proprietary interest in investigational product; any 
significant equity interest in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) (1998).
10.2.4
Compliance to all Local, State, and National Controlled-substance 
Biohazard and Infectious Disease Regulations and Legislation
When using controlled substances, biohazardous material, or substances for infectious diseases, 
the investigator must at all times comply with all local, state, and national laws pertaining to 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 127 
 
07 Dec 2018
For non-commercial use only


Shire
Page 128
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
registration and reporting with the appropriate regulatory body and control and handling of such 
substances.
10.3
Ethical Considerations
10.3.1
Informed Consent
It is the responsibility of the investigator to obtain written informed consent and assent, where 
applicable from all study subjects prior to any study-related procedures including screening 
assessments; parents will sign the assent form, as applicable. All consent and assent 
documentation must be in accordance with applicable regulations and GCP. Each subject or the 
subject’s legally-authorized representative, as applicable, is requested to sign and date the subject 
informed consent form or a certified translation if applicable, after the subject has received and 
read (or been read) the written subject information and received an explanation of what the study 
involves, including but not limited to: the objectives, potential benefits and risk, inconveniences, 
and the subject’s rights and responsibilities. A copy of the informed consent and assent 
documentation (ie, a complete set of subject information sheets and fully executed signature 
pages) must be given to the subject or the subject’s legally-authorized representative, as 
applicable. This document may require translation into the local language. Signed consent forms 
must remain in each subject’s study file and must be available for verification at any time.
Within the source documents, site personnel should document instruction of and understanding 
by a parent or both parents/legally-authorized representative/caregiver of the safe, responsible 
storage and administration of investigational product to the study subject.
10.3.2
Institutional Review Board or Ethics Committee
For sites outside the EU, it is the responsibility of the investigator to submit this protocol, the 
informed consent document (approved by the sponsor or their designee), relevant supporting 
information, and all types of subject recruitment information to the IRB/EC for review, and all 
must be approved prior to site initiation.
For sites within the EU, the applicant for an EC opinion can be the sponsor, the investigator, or 
for multicenter studies the coordinating principal investigator or sponsor, according to national 
provisions.
Responsibility for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study, the sponsor and the IRB/EC must approve any 
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safety issue.
Investigational product supplies will not be released until the sponsor/CRO has received written 
IRB/EC approval of and copies of revised documents.
For sites outside the EU, the investigator is responsible for keeping the IRB/EC apprised of the 
progress of the study and of any changes made to the protocol, but in any case at least once a 
year; for sites within the EU, this can be done by the sponsor, the investigator or for multicenter 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 128 
 
07 Dec 2018
For non-commercial use only


Shire
Page 129
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
studies the coordinating principal investigator, according to national provisions. The investigator 
must also keep the local IRB/EC informed of any serious and significant AEs.
10.4
Privacy and Confidentiality
All US-based sites and laboratories or entities providing support for this study, must, where 
applicable, comply with Health Insurance Portability and Accountability Act (HIPAA). A site 
that is not a covered entity as defined by HIPAA must provide documentation of this fact to the 
CRO/sponsor.
The confidentiality of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study, the sponsor and/or its representative 
reviews their medical records and data collected during the study. These records and data may, in 
addition, be reviewed by others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may develop, register, or 
market SHP620; national or local regulatory authorities; and the IRB(s)/EC(s) which gave 
approval for the study to proceed. The sponsor and/or its representatives accessing the records 
and data will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentiality of subjects’ identities.
Subjects are assigned a unique number for identification. The results of studies containing 
subjects’ unique identifying number and relevant medical records will be recorded. They may be 
transferred to, and used in, other countries which may not afford the same level of protection that 
applies within the countries where this study is conducted. The purpose of any such transfer 
would include: to support regulatory submissions, to conduct new data analyses to publish or 
present the study results, or to answer questions asked by regulatory or health authorities.
10.5
Study Results/Publication Policy
Shire will endeavor to publish the results of all qualifying, applicable, and covered studies 
according to external guidelines in a timely manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally, Shire adheres to external guidelines (eg, 
Good Publication Practices) when forming a publication steering committee, which is done for 
large, multicenter Phase 2-4 and certain other studies as determined by Shire. The purpose of the 
publication steering committee is to act as a noncommercial body that advises or decides on 
dissemination of scientific study data in accordance with the scope of this policy. A description 
of this clinical study may also be available on other externally facing public websites and 
registries. A summary of the study results may be potentially disclosed as per local and country 
specific requirements.
All publications relating to Shire products or projects must undergo appropriate technical and 
intellectual property review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary information existing either at the 
commencement of the study or generated during the study. To the extent permitted by the 
publisher and copyright law, the principal investigator will own (or share with other authors) the 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 129 
 
07 Dec 2018
For non-commercial use only


Shire
Page 130
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
copyright on his/her publications. To the extent that the principal investigator has such sole, joint 
or shared rights, the principal investigator grants the sponsor a perpetual, irrevocable, 
royalty-free license to make and distribute copies of such publications.
The term “publication” refers to any public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opinion pieces, book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study results, in printed, electronic, oral or 
other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study results, and any background information provided by the sponsor that is necessary to 
include in any publication of study results, or necessary for other scholars to verify such study 
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least 60 days prior to 
submission for publication. If requested in writing by Shire, the institution and principal 
investigator shall withhold submission of such publication for up to an additional 60 days to 
allow for filing of a patent application.
If the study is part of a multicenter study, the first publication of the study results shall be made 
by the sponsor in conjunction with the sponsor’s presentation of a joint, multicenter publication 
of the compiled and analyzed study results. If such a multicenter publication is not submitted to a 
journal for publication by the sponsor within an 18-month period after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study publication of the study results, an investigator may individually publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single-site data being presented.
Unless otherwise required by the journal in which the publication appears, or the forum in which 
it is made, authorship will comply with the International Committee of Medical Journal Editors 
(ICMJE) current standards. Participation as an investigator does not confer any rights to 
authorship of publications.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 130 
 
07 Dec 2018
For non-commercial use only


Shire
Page 131
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
11.
REFERENCES 
Asberg, A., Humar, A., Rollag, H., Jardine, A. G., Mouas, H., Pescovitz, M. D., Sgarabotto, D., 
Tuncer, M., Noronha, I. L.and Hartmann, A. 2007. Oral valganciclovir is noninferior to 
intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ 
transplant recipients. Am J Transplant, 7, 2106-13.
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., 
Donnelly, J. P., Edwards, J. E., Erjavec, Z., Fiere, D., Lortholary, O., Maertens, J., Meis, 
J. F., Patterson, T. F.and R 2002. Defining Opportunistic Invasive Fungal Infections in 
Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: 
An International Consensus. Clinical Infectious Diseases, 34, 7-14.
Avery, P. 2007. Management of late, recurrent, and resistant cytomegalovirus in transplant 
patients. Transplant Rev, 21, 65-76.
Avery, R. K., Marty, F. M., Strasfeld, L., Lee, I., Arrieta, A., Chou, S., Tatarowicz, W. and 
Villano, S. 2010. Oral maribavir for treatment of refractory or resistant cytomegalovirus 
infections in transplant recipients. Transpl Infect Dis, 12, 489-96.
Biron, K. K., Harvey, R. J., Chamberlain, S. C., Good, S. S., Smith, A. A., 3rd, Davis, M. G., 
Talarico, C. L., Miller, W. H., Ferris, R., Dornsife, R. E., Stanat, S. C., Drach, J. C., 
Townsend, L. B. and Koszalka, G. W. 2002. Potent and selective inhibition of human 
cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique 
mode of action. Antimicrob Agents Chemother, 46, 2365-72.
Boeckh, M., Nichols, W. G., Papanicolaou, G., Rubin, R., Wingard, J. R. and Zaia, J. 2003. 
Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known 
challenges, and future strategies. Biol Blood Marrow Transplant, 9, 543-58.
Boeckh, M., Zaia, J. A., Jung, D., Skettino, S., Chauncey, T. R.and Bowden, R. A. 1998. A study 
of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV 
prophylaxis in marrow transplantation. Biol Blood Marrow Transplant, 4, 13-9.
Busca, A., de Fabritiis, P., Ghisetti, V., Allice, T., Mirabile, M., Gentile, G., Locatelli, F.and 
Falda, M. 2007. Oral valganciclovir as preemptive therapy for cytomegalovirus infection 
post allogeneic stem cell transplantation. Transpl Infect Dis, 9, 102-7.
Chevillotte, M., Ersing, I., Mertens, T.and von Einem, J. 2010. Differentiation between 
polymorphisms and resistance-associated mutations in human cytomegalovirus DNA 
polymerase. Antimicrob Agents Chemother, 54, 5004-11.
Chou, S. 2011. Phenotypic diversity of cytomegalovirus DNA polymerase gene variants 
observed after antiviral therapy. J Clin Virol, 50, 287-91.
Chou, S., Marousek, G., Li, S. and Weinberg, A. 2008. Contrasting drug resistance phenotypes 
resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease 
locus. J Clin Virol, 43, 107-9.
Chulay, J., Biron, K., Wang, L., Underwood, M., Chamberlain, S., Frick, L., Good, S., Davis, 
M., Harvey, R., Townsend, L., Drach, J. and Koszalka, G. 1999. Development of novel 
benzimidazole riboside compounds for treatment of cytomegalovirus disease. Adv Exp 
Med Biol, 458, 129-34.
de la Hoz, R. E., Stephens, G. and Sherlock, C. 2002. Diagnosis and treatment approaches of 
CMV infections in adult patients. J Clin Virol, 25 Suppl 2, S1-12.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 131 
 
07 Dec 2018
For non-commercial use only


Shire
Page 132
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, 
P. G., Maertens, J., Lortholary, O., Kauffman, C. A., Denning, D. W. and Patterso 2008. 
Revised Definitions of Invasive Fungal Disease from the European Organization for 
Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the 
National Institute of Allergy and Infectious Diseases Mycoses Study Group 
(EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 46, 1813-1821.
Drew, W. L., Miner, R. C., Marousek, G. I. and Chou, S. 2006. Maribavir sensitivity of 
cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol, 37, 
124-7.
Dykewicz, C. A. 2001. Summary of the Guidelines for Preventing Opportunistic Infections 
among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis, 33, 139-44.
Emery, V. C., Sabin, C. A., Cope, A. V., Gor, D., Hassan-Walker, A. F.and Griffiths, P. D. 2000. 
Application of viral-load kinetics to identify patients who develop cytomegalovirus 
disease after transplantation. Lancet, 355, 2032-6.
Erice, A. 1999. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev, 12, 
286-97.
Farrugia, E. and Schwab, T. R. 1992. Management and prevention of cytomegalovirus infection 
after renal transplantation. Mayo Clin Proc, 67, 879-90.
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, II, 
Rolston, K. V., Young, J. A. and Wingard, J. R. 2011. Clinical practice guideline for the 
use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the 
infectious diseases society of america. Clin Infect Dis, 52, e56-93.
Harris, A. C., Young, R., Devine, S., Hogan, W. J., Ayuk, F., Bunworasate, U., 
Chanswangphuwana, C., Efebera, Y. A., Holler, E., Litzow, M., Ordemann, R., Qayed, 
M., Renteria, A. S., Reshef, R., Wolfl, M., Chen, Y. B., Goldstein, S., Jagasia, M., 
Locatelli, F., Mielke, S., Porter, D., Schechter, T., Shekhovtsova, Z., Ferrara, J. L.and 
Levine, J. E. 2016. International, Multicenter Standardization of Acute Graft-versus-Host 
Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD 
International Consortium. Biol Blood Marrow Transplant, 22, 4-10.
Hodson, E. M., Jones, C. A., Webster, A. C., Strippoli, G. F., Barclay, P. G., Kable, K., 
Vimalachandra, D. and Craig, J. C. 2005. Antiviral medications to prevent 
cytomegalovirus disease and early death in recipients of solid-organ transplants: a 
systematic review of randomised controlled trials. Lancet, 365, 2105-15.
Humar, A., Gregson, D., Caliendo, A. M., McGeer, A., Malkan, G., Krajden, M., Corey, P., 
Greig, P., Walmsley, S., Levy, G.and Mazzulli, T. 1999. Clinical utility of quantitative 
cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver 
transplant recipients. Transplantation, 68, 1305-11.
Jagasia, M. H., Greinix, H. T., Arora, M., Williams, K. M., Wolff, D., Cowen, E. W., Palmer, J., 
Weisdorf, D., Treister, N. S., Cheng, G. S., Kerr, H., Stratton, P., Duarte, R. F., 
McDonald, G. B., Inamoto, Y., Vigorito, A., Arai, S., Datiles, M. B., Jacobsohn, D., 
Heller, T., Kitko, C. L., Mitchell, S. A., Martin, P. J., Shulman, H., Wu, R. S., Cutler, C. 
S., Vogelsang, G. B., Lee, S. J., Pavletic, S. Z.and Flowers, M. E. 2015. National 
Institutes of Health Consensus Development Project on Criteria for Clinical Trials in 
Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group 
report. Biol Blood Marrow Transplant, 21, 389-401.e1.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 132 
 
07 Dec 2018
For non-commercial use only


Shire
Page 133
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Kanj, S., Sharara, A., Clavien, P.and Hamilton, J. 1996. Cytomegalovirus infection following 
liver transplantation: review of the literature. Clin Infect Dis, 22, 537-49.
Kern, E. R., Hartline, C. B., Rybak, R. J., Drach, J. C., Townsend, L. B., Biron, K. K.and 
Bidanset, D. J. 2004. Activities of benzimidazole D- and L-ribonucleosides in animal 
models of cytomegalovirus infections. Antimicrob Agents Chemother, 48, 1749-55.
Klumpp, T. R. 1993. Antibody-mediated neutropenia following bone marrow transplantation. Int 
J Clin Lab Res, 23, 4-7.
Komatsu, T. E., Pikis, A., Naeger, L. K.and Harrington, P. R. 2014. Resistance of human 
cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative 
resistance pathways. Antiviral Res, 101, 12-25.
Kotton, C. N., Kumar, D., Caliendo, A. M., Asberg, A., Chou, S., Danziger-Isakov, L.and 
Humar, A. 2013. Updated international consensus guidelines on the management of 
cytomegalovirus in solid-organ transplantation. Transplantation, 96, 333-60.
Krosky, P., Baek, M.and Coen, D. 2003. The human cytomegalovirus UL97 protein kinase, an 
antiviral drug target, is required at the stage of nuclear egress. J Virol, 77, 905-14.
Lansky, S. B., List, M. A., Lansky, L. L., Ritter-Sterr, C.and Miller, D. R. 1987. The 
measurement of performance in childhood cancer patients. Cancer, 60, 1651-6.
Legendre, C.and Pascual, M. 2008. Improving outcomes for solid-organ transplant recipients at 
risk from cytomegalovirus infection: late-onset disease and indirect consequences. Clin 
Infect Dis, 46, 732-40.
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. L., Hendriksen, S., Kusek, J. 
W.and Van Lente, F. 2006. Using standardized serum creatinine values in the 
modification of diet in renal disease study equation for estimating glomerular filtration 
rate. Ann Intern Med, 145, 247-54.
Limaye, A. P., Corey, L., Koelle, D. M., Davis, C. L.and Boeckh, M. 2000. Emergence of 
ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ 
transplants. Lancet, 356, 645-9.
Ljungman, P., Boeckh, M., Hirsch, H. H., Josephson, F., Lundgren, J., Nichols, G., Pikis, A., 
Razonable, R. R., Miller, V., Griffiths, P. D.and Disease Definitions Working Group of 
the Cytomegalovirus Drug Development, F. 2017. Definitions of Cytomegalovirus 
Infection and Disease in Transplant Patients for Use in Clinical Trials. Clin Infect Dis,
64, 87-91.
Ljungman, P., Deliliers, G. L., Platzbecker, U., Matthes-Martin, S., Bacigalupo, A., Einsele, H., 
Ullmann, J., Musso, M., Trenschel, R., Ribaud, P., Bornhauser, M., Cesaro, S., Crooks, 
B., Dekker, A., Gratecos, N., Klingebiel, T., Tagliaferri, E., Ullmann, A. J., Wacker, 
P.and Cordonnier, C. 2001. Cidofovir for cytomegalovirus infection and disease in 
allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the 
European Group for Blood and Marrow Transplantation. Blood, 97, 388-92.
Ljungman, P., Griffiths, P.and Paya, C. 2002. Definitions of cytomegalovirus infection and 
disease in transplant recipients. Clin Infect Dis, 34, 1094-7.
Ljungman, P., Perez-Bercoff, L., Johnsson, J., Avetisyan, G., Sparrelid, E., Aschan, J., Barkholt, 
L., Larsson, K., Winiarski, J., Yun, Z.and Ringden, O. 2006. Risk factors for the 
development of cytomegalovirus disease after allogeneic stem cell transplantation. 
Haematologica, 91, 78-83.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 133 
 
07 Dec 2018
For non-commercial use only


Shire
Page 134
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Loiseau, P., Busson, M., Balere, M. L., Dormoy, A., Bignon, J. D., Gagne, K., Gebuhrer, L., 
Dubois, V., Jollet, I., Bois, M., Perrier, P., Masson, D., Moine, A., Absi, L., Reviron, D., 
Lepage, V., Tamouza, R., Toubert, A., Marry, E., Chir, Z., Jouet, J. P., Blaise, D., 
Charron, D.and Raffoux, C. 2007. HLA Association with hematopoietic stem cell 
transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 
is strongly associated with overall survival. Biol Blood Marrow Transplant, 13, 965-74.
Lu, H.and Rosenbaum, S. 2014. Developmental pharmacokinetics in pediatric populations. 
Journal of Pediatric Pharmacology and Therapeutics, 19, 262-76.
Lurain, N. S.and Chou, S. 2010. Antiviral drug resistance of human cytomegalovirus. Clin 
Microbiol Rev, 23, 689-712.
Majhail, N. S., Rizzo, J. D., Lee, S. J., Aljurf, M., Atsuta, Y., Bonfim, C., Burns, L. J., Chaudhri, 
N., Davies, S., Okamoto, S., Seber, A., Socie, G., Szer, J., Lint, M. T., Wingard, J. R.and 
Tichelli, A. 2012. Recommended screening and preventive practices for long-term 
survivors after hematopoietic cell transplantation. Rev Bras Hematol Hemoter, 34, 109-
33.
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P.and Corey, L. 2002. Invasive aspergillosis in 
allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. 
Blood, 100, 4358-66.
Nishihori, T., Shaheen, M., El-Asmar, J., Aljurf, M.and Kharfan-Dabaja, M. 2015. Therapeutic 
strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation. 
Immunotherapy, 7, 1059-71.
Paya, C., Hermans, P., Wiesner, R., Ludwig, J., Smith, T., Rakela, J.and Krom, R. 1989. 
Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive 
orthotopic liver transplantations. J Infect Dis, 160, 752-8.
Peus, D., Newcomb, N.and Hofer, S. 2013. Appraisal of the Karnofsky Performance Status and 
proposal of a simple algorithmic system for its evaluation. BMC Med Inform Decis Mak,
13, 72.
Pouria, S., State, O. I., Wong, W.and Hendry, B. M. 1998. CMV infection is associated with 
transplant renal artery stenosis. Qjm, 91, 185-9.
Razonable, R. R.and Emery, V. C. 2004. Management of CMV infection and disease in 
transplant patients. 27-29 February 2004. Herpes, 11, 77-86.
Reusser, P., Einsele, H., Lee, J., Volin, L., Rovira, M., Engelhard, D., Finke, J., Cordonnier, C., 
Link, H., Ljungman, P.and Infectious Diseases Working Party of the European Group for 
Blood and Marrow Transplantation 2002. Randomized multicenter trial of foscarnet 
versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic 
stem cell transplantation. Blood, 99, 1159-64.
Richardson, W. P., Colvin, R. B., Cheeseman, S. H., Tolkoff-Rubin, N. E., Herrin, J. T., Cosimi, 
A. B., Collins, A. B., Hirsch, M. S., McCluskey, R. T., Russell, P. S.and Rubin, R. H. 
1981. Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N 
Engl J Med, 305, 57-63.
Rubin, R. H. 1989. The indirect effects of cytomegalovirus infection on the outcome of organ 
transplantation. Jama, 261, 3607-9.
Salzberger, B., Bowden, R. A., Hackman, R. C., Davis, C.and Boeckh, M. 1997. Neutropenia in 
allogeneic marrow transplant recipients receiving ganciclovir for prevention of 
cytomegalovirus disease: risk factors and outcome. Blood, 90, 2502-8.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 134 
 
07 Dec 2018
For non-commercial use only


Shire
Page 135
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Schag, C. C., Heinrich, R. L.and Ganz, P. A. 1984. Karnofsky performance status revisited: 
reliability, validity, and guidelines. J Clin Oncol, 2, 187-93.
Schwartz, G. J., Feld, L. G.and Langford, D. J. 1984. A simple estimate of glomerular filtration 
rate in full-term infants during the first year of life. J Pediatr, 104, 849-54.
Schwartz, G. J., Haycock, G. B., Edelmann, C. M., Jr.and Spitzer, A. 1976. A simple estimate of 
glomerular filtration rate in children derived from body length and plasma creatinine. 
Pediatrics, 58, 259-63.
Shulman, H. M., Cardona, D. M., Greenson, J. K., Hingorani, S., Horn, T., Huber, E., Kreft, A., 
Longerich, T., Morton, T., Myerson, D., Prieto, V. G., Rosenberg, A., Treister, N., 
Washington, K., Ziemer, M., Pavletic, S. Z., Lee, S. J., Flowers, M. E., Schultz, K. R., 
Jagasia, M., Martin, P. J., Vogelsang, G. B.and Kleiner, D. E. 2015. NIH Consensus 
development project on criteria for clinical trials in chronic graft-versus-host disease: II. 
The 2014 Pathology Working Group Report. Biol Blood Marrow Transplant, 21, 589-
603.
Singh, N., Wannstedt, C., Keyes, L., Wagener, M. M., de Vera, M., Cacciarelli, T. V.and 
Gayowski, T. 2004. Impact of evolving trends in recipient and donor characteristics on 
cytomegalovirus infection in liver transplant recipients. Transplantation, 77, 106-10.
Strasfeld, L., Lee, I., Tatarowicz, W., Villano, S.and Chou, S. 2010. Virologic characterization of 
multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with 
maribavir. J Infect Dis, 202, 104-8.
Tomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J. R., 
Young, J., Boeckh, M., Center for International Blood and Marrow Research, National 
Marrow Donor Program, European Blood and Marrow Transplant Group, American 
Society of Blood and Marrow Transplantation, Canadian Blood and Marrow Transplant 
Group, Infectious Disease Society of America, Society for Healthcare Epidemiology of 
America, Association of Medical Microbiology and Infectious Disease Canadaand 
Centers for Disease Control and Prevention 2009. Guidelines for preventing infectious 
complications among hematopoietic cell transplantation recipients: a global perspective. 
Biol Blood Marrow Transplant, 15, 1143-238.
Valcyte Prescribing Information. South San Francisco, CA: Genentech Inc.
Williams, S. L., Hartline, C. B., Kushner, N. L., Harden, E. A., Bidanset, D. J., Drach, J. C., 
Townsend, L. B., Underwood, M. R., Biron, K. K.and Kern, E. R. 2003. In vitro activities 
of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents 
Chemother, 47, 2186-92.
Winston, D. J., Wirin, D., Shaked, A.and Busuttil, R. W. 1995. Randomised comparison of 
ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-
transplant recipients. Lancet, 346, 69-74.
Wolf, D., Courcelle, C., Prichard, M.and Mocarski, E. 2001. Distinct and separate roles for 
herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and 
encapsidation. Proc Natl Acad Sci U S A, 98, 1895-900.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 135 
 
07 Dec 2018
For non-commercial use only


Shire
Page 136
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
12.
APPENDICES
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 136 
 
07 Dec 2018
For non-commercial use only


Shire
Page 137
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Appendix 1
PROTOCOL HISTORY
Document
Date
Global/Country/Site Specific
Original Protocol
25 April 2016
Global
Amendment 1
08 July 2016
Global
Amendment 2
01 December 2016
Global 
Amendment 2.1a 
18 May 2017
Germany
Amendment 3
01 March 2017
Global (except Germany)
Amendment 3.1a 
10 October 2017 
Germany, Singapore
Amendment 4
26 March 2018
Global (except Germany and Singapore)
Amendment 5
11 July 2018
Global (except Germany and Singapore)
Amendment 5.1a,b 
20 August 2018
Germany, Singapore, Switzerland
Amendment 6
07 December 2018
Global (except Germany, Singapore, Switzerland)
Amendment 6.1
07 December 2018
Germany, Singapore, Switzerland
a Summary of changes for country-specific amendments are included in the respective documents.  
b Amendment 5.1 replaces Amendment 3.1 (no intervening protocol version).
Amendment 5 to protocol SHP620-303 incorporated the following changes:

Added a study visit at Study Day 4 (+/-1) for subjects taking a narrow therapeutic index 
immunosuppressive agent (ie, tacrolimus, cyclosporine, everolimus, sirolimus) at 
baseline to align the protocol with a recent recommendation from the data monitoring 
committee (DMC).

Added a visit for subjects not taking a narrow therapeutic index immunosuppressive 
agent at baseline who begin therapy during the course of the treatment period (4 days 
after starting the immunosuppressive agent), and subjects in the investigator-assigned
therapy arm who enter the maribavir rescue arm (4 days after starting maribavir) to align 
the protocol with a recent recommendation from the DMC.

Updated definition of symptomatic CMV infection to include both tissue invasive CMV 
disease and CMV syndrome throughout the protocol.
Noteworthy changes to the protocol are captured in the table below. Other minor editorial 
revisions (including changes for consistency and clarity) are not described in this table.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 137 
 
07 Dec 2018
For non-commercial use only


Shire
Page 138
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
5
Amendment Date
11 Jul 2018
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
Updated the definition for “Refractory”:
Documented failure to achieve >1 log10 (common logarithm to base 10) 
decrease in CMV DNA level in whole blood or plasma after a 14 day or 
longer treatment period with IV ganciclovir/oral valganciclovir, IV 
foscarnet, or IV cidofovir. This definition applies to the current CMV 
infection and the most recently administered anti-CMV agent.
Definitions, Synopsis, Section 3.1
Updated the definition for “Resistant”:
Documented failure to achieve >1 log10 (common logarithm to base 10) 
decrease in CMV DNA level in whole blood or plasma after a 14 day or 
longer treatment period with IV ganciclovir/oral valganciclovir, IV 
foscarnet, or IV cidofovir. This definition applies to the current CMV 
infection and the most recently administered anti-CMV agent.
AND
Documentation of 1 or more CMV genetic mutations associated with 
resistance to ganciclovir/valganciclovir, foscarnet, and/or cidofovir.
Definitions, Synopsis, Section 3.1
Updated inclusion criterion 4 to clarify that the subject must have a 
current CMV infection that is refractory to the most 
recently administered of the four anti-CMV treatment 
agents; that refractory is defined as documented failure 
to achieve >1 log10 (common logarithm to base 10) 
decrease in CMV DNA level in whole blood or plasma 
after a 14 day or longer treatment period with IV 
ganciclovir/oral valganciclovir, IV foscarnet, or IV 
cidofovir; and that subjects with documentation of 1 or 
more CMV genetic mutations associated with 
resistance to ganciclovir/valganciclovir, foscarnet, 
and/or cidofovir must also meet the definition of 
refractory CMV infection.
Synopsis, Section 4.1
Removed the statement that prospectively, the study may enroll an 
additional cohort of 150 subjects with tissue-invasive 
CMV disease, in a 2:1 ratio (maribavir: investigator-
assigned anti-CMV therapy) to subsequently confirm 
the clinical benefit of maribavir in improvement or 
resolution of tissue-invasive CMV disease in a total of 
210 subjects (inclusive of 60 subjects enrolled 
initially); and that feasibility of this approach will be 
confirmed during the study conduct.
Synopsis, Section 2.2, Section 3.1
Clarified EAC review procedure.
Synopsis, Section 3.1
Updated number of site visits to 19 times.
Synopsis, Section 3.1
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 138 
 
07 Dec 2018
For non-commercial use only


Shire
Page 139
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
5
Amendment Date
11 Jul 2018
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
Added Visit 2A/2A-R to the Study design Flow Chart.
Synopsis, Section 3.1
Clarified the screening CMV DNA concentration limits (in whole blood 
or plasma) used for stratification of eligible subjects 
and specified that the most recent qPCR results should 
be used.
Synopsis, Section 3.1, Section 6.2.2
Clarified that, for subjects randomized to investigator-assigned 
anti-CMV treatment, switching between valganciclovir 
and ganciclovir is allowed, while switching to another 
CMV agent is not.
Synopsis, Section 6.2.3
Clarified that, in the randomized set, subjects will be analyzed in the 
treatment group to which they are randomized.
Synopsis, Section 9.7
Clarified that the safety set will consist of all subjects who have taken 
any dose of study treatment and that subjects will be 
analyzed according to the treatment actually received. 
Synopsis, Section 9.7
Removed the following statement: “Since intolerance alone will not 
qualify the patient for the rescue, such patients will not 
be considered nonresponders for the purpose of the 
primary analysis.”
Synopsis, Section 9.8
Removed the following statement: “It is expected that 60 subjects with 
tissue invasive disease (symptomatic subjects) will be 
enrolled in this study.
Synopsis, Section 9.8.2
Clarified that the on treatment observation period will serve as the 
primary analysis of safety.
Synopsis, Section 9.9
Clarified the overall study observation period as follows: “The overall-
study observation period minus the period on rescue 
arm starts at the time of the start of the study treatment 
through the end of the study or through the time before 
receiving maribavir rescue therapy for subjects who 
receive maribavir rescue therapy.”
Synopsis, Section 9.9
Clarified that similar observation periods are defined for the safety 
analysis of the maribavir rescue arm.
Synopsis, Section 9.9
Updated the definition of treatment emergent adverse events.
Synopsis, Section 9.9
Clarified exploratory endpoint to be
 
Synopsis, Section 9.10.3
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 139 
 
07 Dec 2018
For non-commercial use only


Shire
Page 140
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
5
Amendment Date
11 Jul 2018
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
Added a column for additional visit 2A/2A-R to collect the following 
assessments: Hematology/Chemistry, 
Immunosuppressant drug concentration levels, Study 
diary; Concomitant medications, therapies, and 
procedures, as well as Adverse events.
Table 1, Section 7.1.2
Added Visit 2A/2AR (Day 4) ± 1 day and Study Visit 3/3R (Day 7) +2 
days to the definition of the permissible assessment 
window. 
Table 1, Footnotes, Section 7.1.2
Clarified that local laboratory will be used for Visit 2A/2AR (Day 4) 
potassium and magnesium levels, and Day 4 after 
starting tacrolimus, cyclosporine, everolimus, or 
sirolimus if the subject is not taking at V2/2R.
Table 1, Footnotes, Section 7.2.3.5
Clarified when a blood sample to measure immunosuppressant drug 
concentration level will be obtained for subject 
receiving immunosuppressant drugs and for subjects 
not receiving immunosuppressant drugs at Day 0, but 
who started any time after Day 0. 
Table 1, Footnotes, Section 7.2.3.5
Added new footnote to clarify that Visit 2A/2AR is only required for 
subjects taking tacrolimus, cyclosporine, everolimus, 
or sirolimus at Visit 2/2R.
Table 1, Footnotes 
Updated timeframe for collection of medical history data from 5 years to 
2 years.
Section 7.2.3.1
Updated for consistencies with changes in Table 1.
Section 7.2.5, Table 5
Updated the blood volume expected to be drawn from each subject 
regardless of age or sex.
Section 7.2.5
Clarified criteria for reporting CMV infection as an AE or as an SAE.
Section 8.1.5, Table 6
Amendment 4 to Protocol SHP620-303 incorporates the following major changes:

Modified adverse event collection period to indicate that collection of nonserious adverse 
events that are not related to study treatment will be restricted to 30 days after the last 
dose of study drug.

Amended exclusion criterion 6 regarding patients who have tissue invasive CMV disease 
with central nervous system involvement to indicate that such central nervous system 
involvement includes the retina (eg CMV retinitis).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 140 
 
07 Dec 2018
For non-commercial use only


Shire
Page 141
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018

Modified the reporting requirements for prior therapeutic or diagnostic interventions 
performed prior to study enrollment.

Clarified procedure requirements for subjects moving from investigator-assigned 
treatment to rescue arm to indicate that procedures do not need to be repeated when the 
end-of-treatment visit is performed on the same day as rescue arm entry.

Clarified that study treatment may be interrupted for up to 7 consecutive days, or up to 2 
study treatment interruptions for a total of up to 7 days.

Clarified language regarding sample size calculation, removing anticipated treatment 
discontinuation rate for foscarnet-treated subjects.

Clarified restrictions regarding re-screening of subjects who have previously screen-
failed.

Limited hepatitis testing requirements at screening to antibody testing.

Added GVHD assessment criteria forms from cited publications in the appendices.

Added letermovir to list of prohibited medications during study, and washout instructions 
for letermovir use prior to study entry
Noteworthy changes to the protocol are captured in the table below. Other minor editorial 
revisions (including changes for consistency and clarity) are not described in this table.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 141 
 
07 Dec 2018
For non-commercial use only


Shire
Page 142
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4
Amendment Date
26 Mar 2018
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
Updated signatory to 
, MD
Protocol Signature Page
Updated Emergency Contact Information to provide more extensive 
information on the reporting of serious adverse events 
(SAEs).
Emergency Contact Information
Replaced “Pharmacovigilance” with “Drug Safety” to reflect the 
department name change
Emergency Contact Information, 
Section 8.1.7, Section 8.2.2, Section 
8.2.4
Updated PDD medical monitor to 
, MD, PhD, MBA, 
, PPD, Drug Safety
Emergency Contact Information
Clarified the definition for “Refractory”: requires 2 weeks of continuous
treatment, and applies to the current infection and the 
most recently administered anti-CMV agent.
The definition for “Resistant” is inclusive of the definition for “Refractory” 
and has been amended accordingly.
Definitions, Synopsis, Section 3.1, 
Section 4.1
Updated number of sites to approximately 140 sites worldwide.
Synopsis, Section 3.3
Updated planned study period to 2016 –2019.
Synopsis
Clarified changes to the investigator treatment of choice after 
randomization to include note that changes between IV 
ganciclovir and oral valganciclovir are allowed and that 
combination therapy with cidofovir and foscarnet is 
prohibited due to risk of nephrotoxicity.
Synopsis, Section 3.1, Section 6, 
Section 6.2.3
Updated permitted duration of treatment interruption from originally 4 to 7 
consecutive days, or up to 2 study treatment interruptions 
for a total of up to 7 days.
Synopsis, Section 3.1, Section 6.2.3
Changed exclusion criterion 3 to include the recently-approved anti-CMV 
agent letermovir.
Synopsis, Section 4.2
Changed exclusion criterion 6 to exclude subjects with CMV retinitis 
present at baseline.
Synopsis, Section 4.2
Clarified language regarding sample size calculation, removing mention of 
anticipated treatment discontinuation rate for foscarnet-
treated subjects.
Synopsis, Section 9.6
Clarified that the end of the on-treatment period is 7 days after the last dose 
of study drug or 21 days if cidofovir is used.
Synopsis, Section 9.9
Removed paragraph on the reporting of disease under study from Synopsis 
to avoid redundancy with Section 8.1.5.
Synopsis
Clarified several footnotes in the Schedules of Assessment to provide 
Table 1, Footnotes
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 142 
 
07 Dec 2018
For non-commercial use only


Shire
Page 143
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4
Amendment Date
26 Mar 2018
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
additional details regarding the timing and requirements 
of several study assessments.
Clarified procedure requirements for subjects moving from IAT to Rescue 
Arm.
Study Schedules, Section 4.5
Clarified procedure for tissue invasive CMV disease assessment in 
symptomatic and asymptomatic subjects.
Study Schedules, Section 7.2.2.3
Added new in vitro data on the effects of maribavir on drug metabolism 
enzymes.
Section 1.2.1
Included letermovir in the list of prior medications to be recorded on the 
CRF.
Section 5.1
Updated medical history to be recorded from “any therapeutic or diagnostic 
intervention performed within 3 months prior to the first 
dose of study treatment on Visit 2/Week0/Day 0” to “any 
therapeutic or diagnostic intervention performed within 
30 days prior to the first dose of study treatment on Visit 
2/Week0/Day 0”
Section 5.1
Added additional precaution with concomitant medication.
Section 5.2.1
Added procedure to be followed for subjects developing new CMV retinitis 
while in the maribavir treatment arm.
Section 5.2.2
Added letermovir to the list of systemic anti-CMV therapies prohibited for 
concomitant use in subjects receiving maribavir (except 
unintentional administration for no longer than 1 day).
Section 5.2.2
Added letermovir to the list of concomitant medications prohibited while 
the subject is receiving investigator-assigned anti-CMV 
treatment.
Section 5.2.2
Clarified that in cases where IV anti-CMV agents cannot be ordered, 
prepared, and administered immediately after 
randomization, the first dose of drug must be given 
within 24 hours of randomization.
Section 6.2.3
Clarified restrictions regarding rescreening of subjects who have previously 
screen-failed.
Section 7.1.1
Clarified clinical laboratory assessments for hepatitis.
Section 7.2.3.5
Amended adverse event collection period to specify that following the 
30 day capture period for all adverse events, only those 
adverse events deemed related to investigational product 
or other protocol-mandated procedures and all SAEs 
(regardless of causality assessment) will be collected 
Section 7.2.3.6, Section 8.1
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 143 
07 Dec 2018
For non-commercial use only


Shire
Page 144
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4
Amendment Date
26 Mar 2018
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
through the end of the study (Visit 18/Week 20 [Follow-
up Week 12]). 
Updated e-mail contact address for the Shire Global Drug Safety 
Department
Section 8.2.2
Updated tabular presentation of assessments of responders for key 
secondary efficacy endpoint to provide clearer rationales.
Section 9.8.2
Added additional descriptive summary to the study secondary efficacy 
endpoint of all causes mortality by the end of the study.
Section 9.8.5
Clarified safety endpoints for analysis.
Section 9.9
Clarified the shift analysis of laboratory results.
Section 9.9
Reproduced GVHD assessment criteria forms (from cited publications).
Appendix 10, Appendix 11
Updated wording and added two additional references:
Ascioglu, S., Rex, J. H., De Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., 
Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., Fiere, 
D., Lortholary, O., Maertens, J., Meis, J. F., Patterson, T. F. & R 
2002. Defining Opportunistic Invasive Fungal Infections in 
Immunocompromised Patients with Cancer and Hematopoietic 
Stem Cell Transplants: An International Consensus. Clinical 
Infectious Diseases, 34, 7-14.
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., 
Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., 
Kauffman, C. A., Denning, D. W. & Patterso 2008. Revised 
Definitions of Invasive Fungal Disease from the European 
Organization for Research and Treatment of Cancer/Invasive 
Fungal Infections Cooperative Group and the National Institute of 
Allergy and Infectious Diseases Mycoses Study Group 
(EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 
46, 1813-1821. 
References, Appendix 13
Amendment 3 to Protocol SHP620-303 incorporated the following major changes:

Modified primary, key secondary, and secondary objectives and corresponding endpoints 
to include subjects who discontinue study treatment early and meet the criteria of 
confirmed CMV viremia clearance as responders in the primary efficacy analysis.

Added an intensive pharmacokinetic sampling schedule at Visit 3/Week 1 for adolescent 
subjects (≥12 to <18 years of age).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 144 
 
07 Dec 2018
For non-commercial use only


Shire
Page 145
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018

Modified Inclusion Criterion 5 to indicate that the investigator is willing to treat the 
subject with at least 1 of the available anti-CMV drugs. Note: Combination therapy with 
foscarnet and cidofovir is not permitted in the IAT arm due to the potential for serious 
nephrotoxicity.

Clarified Inclusion Criterion 9 to indicate that urine-based pregnancy tests may be 
performed per institutional requirements (in addition to protocol-required serum β-hCG 
testing); however they are not sufficient for eligibility determination.

Modified Inclusion Criterion 10 to allow subjects the option to receive tablets crushed 
and/or dispersed in water via a nasogastric or orogastric tube.

Clarified in Exclusion Criterion 13 that subjects who have received an unapproved agent 
or device within 30 days before initiation of study treatment will not be eligible.

Added recommendations related to male contraception in clinical trials, per the clinical 
trial facilitation group (CTFG). Male subjects will be required to use a condom in 
conjunction with highly effective method of birth control for their female partners of 
child-bearing age. Both male participants and their female partners must use this form of 
birth control from the time prior to the first dosing until 90 days after the last dose of 
study treatment.
Noteworthy changes to the protocol are captured in the table below. Other minor editorial 
revisions (including changes for consistency and clarity) are not described in this table.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 145 
 
07 Dec 2018
For non-commercial use only


Shire
Page 146
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3
Amendment Date
01 Mar 2017
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
Updated signatory to 
, MD, MSc.
Protocol Signature Page
Added investigator-assigned anti-CMV treatment (IAT) to the 
abbreviations list.
Abbreviations
Added clarifying text to indicate that initiation of study treatment (ie, first 
dose) will only occur after completion of all required 
Visit 2/Day 0 procedures, confirmation of eligibility, and 
completion of randomization.
Synopsis, Table 1(footnote “c”), 
Section 3.1
Modified Exclusion Criterion 8 to indicate that historical results for human 
immunodeficiency virus (HIV) will be accepted to assess 
eligibility and no additional study testing will be 
required. 
“Have known (previously documented) positive results for human 
immunodeficiency virus (HIV).” Subjects must have a confirmed negative 
result within 3 months of study entry or be willing to be tested at screening. 
Local laboratory results are acceptable.”
Synopsis, Table 1 (footnote “i”), 
Section 3.1, Section 
4.2, Section 7.1.1, 
Section 7.2.3.5
Added the rationale for the inclusion of adolescent subjects ≥12 to <18 
years of age in the study.
Synopsis, Section 2.1, Section 2.3
Modified primary objective and corresponding endpoint and analysis to 
clarify that subjects who discontinue study treatment 
early and meet the criteria of confirmed CMV viremia 
clearance at Study Week 8 will be considered as 
responders in the primary efficacy analysis.
Synopsis, Section 2.4.1, Section 
9.8.1.
Modified key secondary objective and corresponding endpoints and 
analyses to clarify that subjects who discontinue study 
treatment early and meet the criteria of confirmed CMV 
viremia clearance will be considered for responder 
evaluation in the efficacy analysis.
Synopsis, Section 2.4.2, Section 9.8.2
Modified secondary objectives and corresponding endpoints and analyses 
to include subjects who discontinue study treatment early 
and meet the criteria of confirmed CMV viremia 
clearance as responders in the efficacy analysis.
Added the former primary and key secondary objectives as secondary 
objectives:
• “To compare the efficacy of maribavir to anti-CMV therapy (IAT) on 
CMV viremia clearance after completion of 8 weeks of study treatment 
in transplant recipients who are refractory or resistant to prior anti-
CMV treatment.”
• “To compare the efficacy of the 2 study treatment arms on CMV 
viremia clearance and tissue invasive CMV disease improvement or 
resolution after completion of 8 weeks of treatment and maintenance of 
this treatment effect through Study Weeks 12 (4 weeks of post 
Synopsis, Section 2.4.3, Section 9.8.5
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 146 
 
07 Dec 2018
For non-commercial use only


Shire
Page 147
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3
Amendment Date
01 Mar 2017
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
treatment period),16 (8 weeks post treatment/follow-up phase), and 20 
(12 weeks of post treatment).” 
Added the following secondary objectives and corresponding endpoints:
• “To assess the 2 study treatment arms for maintenance of CMV 
viremia clearance and resolution or improvement of tissue invasive 
CMV disease, achieved at the end of Study Week 8, through Weeks 12 
and 20.
• “To evaluate the incidence of recurrence of CMV viremia in the 2 
study treatment arms, during 8 weeks of study, during the 12 weeks of 
the follow-up phase, and at any time during the study.” 
• “To evaluate the incidence of recurrence of CMV viremia in the 2 
study treatment arms, when on treatment and off treatment.”
Deleted the following secondary objective and the corresponding endpoint 
since it is redundant with the modified primary objective:
“To assess the 2 study treatment arms for maintenance of CMV viremia 
clearance achieved while on study treatment, irrespective of its duration, at 
8 weeks of study.”
Deleted the following exploratory objectives and corresponding endpoints 
that are redundant with the modified secondary objective.
Synopsis, Section 2.4.4, Section 9.8.6
Modified the following for clarity:
“The CMV infection must be refractory to 1 or more of the anti-CMV 
agents (ganciclovir, valganciclovir, foscarnet, or cidofovir) currently 
administered to the subject, and the subjects must meet the remaining 
specified eligibility criteria.”
Synopsis, Section 3.1
Modified Inclusion Criterion 5:
Per “The investigator is willing to treat the subject ’s judgment, be 
eligible for treatment with at least 1 of the available anti-CMV drugs 
(ganciclovir, valganciclovir, foscarnet, or cidofovir)”. The treatment 
for which a subject would be eligible, if randomized to investigator 
assigned treatment, must be documented prior to randomization. Note: 
Combination therapy with foscarnet and cidofovir is not permitted in 
the IAT arm due to the potential for serious nephrotoxicity.
Synopsis, Section 3.1, Section 4.1
Updated Inclusion Criterion 10 to allow subjects the option to receive 
tablets crushed and/or dispersed in water:
Synopsis, Section 4.1, Section 6.2.3
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 147 
 
07 Dec 2018
For non-commercial use only


Shire
Page 148
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3
Amendment Date
01 Mar 2017
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
Be able to swallow tablets, or receive tablets crushed and/or dispersed 
in water via a nasogastric or orogastric tube
Added to Inclusion Criterion 9 that additional urine pregnancy tests may be 
performed per institutional requirements. 
Synopsis, Section 4.1, Section 7.1.1 
Clarified in Exclusion Criterion 13 that subjects who have received an 
unapproved agent or device within 30 days before 
initiation of study treatment will not be eligible.
Synopsis, Section 4.2, Section 5.2.2
Clarified that the randomized set rather than the FAS will be used for 
efficacy analysis along with the per-protocol set and that 
the randomized set would be used for the primary 
analysis and the per-protocol set would be used as the 
supportive analysis.
Synopsis, Section 9.7
Added the definition of adolescent pharmacokinetic set.
Synopsis, Section 9.7
Updated Tables 7 and 8 to include additional scenarios for responder 
determination. 
Synopsis, Section 9.8.1, Section 9.8.2
Updated the primary, key secondary, secondary, and exploratory endpoints 
to align with updates made to the objectives.
Synopsis, Section 9.8.1, Section 
9.8.2, Section 9.8.5, Section 9.8.6
Added an additional subgroup analysis for adolescents:
Adolescents ≥12 to <18 years of age (exploratory analysis: may be 
conducted if sample size is adequate)
Synopsis, Section 9.8.4
Added PK parameters assessed as secondary endpoints for adolescent 
subjects who provided intensive PK sample at 
Visit 3/Week 1. The secondary PK endpoint for all 
subjects who received maribavir will be maribavir Cmin
(predose maribavir concentration).
Synopsis, Section 9.10.3
Clarified that urine test results are not sufficient for eligibility 
determination.
Table 1 (footnote “h”), Section 7.1.1
Table 1 (footnote “m”) , Section 
7.1.2, Section 7.2.2.4
Added an intensive PK sampling schedule (at Visit 3/Week 1) for 
adolescent subjects participating in the study.
Table 1 (footnote “o”), Section 7.1.2, 
Section 7.2.4.1
Clarified that female subjects 12 years of age and older, who are 
amenorrheic for reasons other than menopause (12 
consecutive months of spontaneous amenorrhea in 
patients with previous normal menstruation), including 
subjects who did not yet have the menarche, would be 
Section 4.4.1
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 148 
 
07 Dec 2018
For non-commercial use only


Shire
Page 149
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3
Amendment Date
01 Mar 2017
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
allowed to participate provided they agree to abstinence 
or an acceptable form of contraception defined in the 
protocol.
Added recommendations related to male contraception in clinical trials, per 
the clinical trial facilitation group (CTFG): Male subjects 
will be required to use a condom in conjunction with 
highly effective method of birth control for their female 
partners of child-bearing age. Both male participants and 
their female partners must use this form of birth control 
from the time prior to the first dosing until 90 days after 
the last dose of study treatment.
Section 4.4.2
Removed text requiring retinal images to be collected and provided to 
support diagnosis and mention of EAC analysis of 
individual histopathology slides:
“In cases of CMV retinitis, the retinal images taken by the ophthalmologist 
may be collected and provided used as the evidence supporting the 
diagnosis.”
“EAC might request the individual histopathology slides to be read by an 
independent pathologist.”
Section 7.2.2.3
Added the additional blood draw volume required for intensive PK 
sampling for adolescents:
“Subjects between the ages of 12 and 18 years will have an additional 24 
mL of blood drawn for intensive PK visits.”
Section 7.2.5, Table 5
Updated the reference safety information section to indicate that the 
country-specific product package inserts for cidofovir 
should be checked to assess the expectedness of an AE 
for this study.
The respective summary of product characteristics (SmPC) for a 
comparator anti-CMV treatment (valganciclovir, ganciclovir, and 
foscarnet) or US country-specific product package insert for cidofovir.
Section 8.2.1
Amended reference safety information to include fatal outcomes:
The study population is HSCT or SOT recipients with cytomegalovirus 
infections. The following SAEs are common in this study population and 
are anticipated to occur, hence these SAEs (including fatal outcomes) will 
not be considered unexpected and will not be individually reported to the 
regulatory agencies, IRBs, Ethics Committees, and investigators, provided 
there is no increased frequency of these events*:
Any CMV infection, including CMV reactivation/recurrence, CMV 
syndrome, and tissue invasive CMV disease
Any other bacterial, viral infection, or fungal infection
Acute and chronic graft versus host disease and graft rejection and loss 
Reactivation of the malignancy under treatment in HSCT recipients
Section 8.2.7
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 149 
 
07 Dec 2018
For non-commercial use only


Shire
Page 150
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3
Amendment Date
01 Mar 2017
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
This includes fatal outcomes for the aforementioned SAEs.
*Maribavir phase 2 (studies 1263-202 and 1263-203) data will be used 
as reference.
Added new text to clarify subject entry into the study rescue arm:
“Subjects in the investigator-assigned treatment arm who are unable to 
continue taking investigator-assigned anti-CMV 
treatment due to the lack of anti-viral activity and/or 
intolerance to the assigned treatment (as evaluated 
starting at Visit 5/Week 3) may be evaluated for entry 
into a maribavir rescue arm. Subjects who take rescue 
medication will be considered as failures for primary 
efficacy analyses. The data collected post-maribavir 
rescue initiation will be included in separate secondary 
analyses for efficacy and exploratory analysis for PK. 
Summary of all safety analyses will be provided 
separately for the maribavir rescue arm. Since intolerance 
alone will not qualify the patient for the rescue, such 
patients will not be considered nonresponders for the 
purpose of the primary analysis. The same is applicable 
for patients who might be discontinued from maribavir 
treatment due to intolerance. Subjects who discontinue 
due to intolerance and without viremia clearance at Study 
Week 8 will be considered failures in both treatment 
arms.”
Section 9.8
Added additional reference to an updated industry regulation: Integrated 
Addendum to ICH E6 (R1): Guideline for Good Clinical 
Practice E6 (R2) Current Step 4 version dated 9 
November 2016.
Section 10.1.1, Section 10.2.1
Updated the table in Appendix 4 with the following pUL97 substitutions: 
D456N, M460L, C480R, P521L, C592F, L595T, 
N597D/I, G598D/V, and C603Y and the following 
pUL54 substitutions: L862F, D879G, and A972V.
Section 12
Applied editorial changes throughout the document for clarity.
Synopsis and throughout document, 
as needed
Amendment 2 to Protocol SHP620-303 incorporated the following major changes:

An additional pregnancy test at Visit 6/Week 4 performed at monthly interval.

Addition of highly effective method of female and male contraception per the 
recommendations related to contraception and pregnancy testing in clinical trials by 
clinical trial facilitation group (CTFG).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 150 
 
07 Dec 2018
For non-commercial use only


Shire
Page 151
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018

Modification of Inclusion Criterion 10 to only allow enrollment of subjects who will be 
able to swallow tablets.

Inclusion of cut off levels for CMV DNA concentration in whole blood for evaluating 
eligibility at screening. 

Emphasis on potent inducers of Cytochrome P450 (CYP) 3A4 and/or P-glycoprotein 
(P-gp) and caution for concomitant use of potent inhibitors of CYP 3A4, in alignment 
with the guidance to the investigators provided in the maribavir investigator’s brochure.

Caution and recommendation for careful monitoring of concentration levels of 
concomitant medications that are substrates of CYP 2C19 and P-gp both after initiation 
of maribavir (when substrate levels may increase) and after discontinuation of maribavir
(when substrate levels may decrease), in alignment with the guidance to the investigators 
provided in the maribavir investigator’s brochure.

Specified that since intolerance to assigned treatment alone does not qualify a subject for 
the rescue arm, such subjects will not be considered nonresponders for the purpose of 
primary analysis. The same is applicable for subjects that might be discontinued from 
maribavir treatment due to intolerance.

Creation of a list of definitions relevant for analyses for easy access and convenience.
Noteworthy changes to the protocol are captured in the table below. Other minor editorial 
revisions (including changes for consistency and clarity) are not described in this table.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 151 
 
07 Dec 2018
For non-commercial use only


Shire
Page 152
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
2
Amendment Date
01 Dec 2016
Global/Country/Site Specific
Global
Description and Rationale for Change 
Section(s) Affected by Change
Created a list of definitions pertaining to evaluations/analyses for the study 
for easy access and convenience, and for consistency 
throughout the document.
The list of definitions follows the list 
of abbreviations in the “Table of 
Content”, also in Section 9.8
Added screening value for CMV DNA concentration in whole blood along 
with that in plasma to Inclusion Criterion 3: “To be 
eligible for the study, subjects must have a documented 
CMV infection in whole blood or plasma, with a 
screening value of ≥2730 IU/mL in whole blood or ≥
910 IU/mL in plasma in 2 consecutive assessments…”
Synopsis, Section 3.1, Section 4.1
Specified CMV DNA concentration in whole blood for stratification based 
on baseline plasma CMV DNA concentration: “high viral 
load with CMV DNA ≥273000 IU/mL in whole blood
or ≥91000 IU/mL in plasma, intermediate viral load ≥
27300 IU/mL in whole blood or ≥9100 IU/mL in 
plasma, and low viral load <27300 IU/mL in whole 
blood or <9100 IU/mL in plasma as determined by the 
local or central specialty laboratory qPCR results….”
Synopsis, Section 3.1, Section 6.2.2
Amended Inclusion Criterion 10 to only allow enrollment of subjects who 
will be able to swallow tablets. Subjects who have the 
condition at baseline that requires orogastric or 
nasogastric administration of study treatment will not be 
enrolled until the results of additional in vitro recovery 
study, with 200mg maribavir tablets are available. 
Emphasized in “dosing” section that if subjects develop 
the condition requiring nasogastric or orogastric tube 
administration while on study treatment, maribavir tablets 
may be administered via this method to avoid 
interruption or discontinuation of treatment.
Synopsis, Section 4.1, Section 6.2.3
Added that there is no clinical experience with investigator assigned 
treatments (ganciclovir, valganciclovir, or cidofovir) in 
pregnant subjects and based on the reproductive toxicity 
observed in animal studies these should be considered a 
potential teratogen and carcinogen in humans (Valcyte 
and Vistide Prescribing Information). The reproductive 
toxicity studies with foscarnet (Foscavir) in animals were 
conducted using exposures that are inadequate to define 
the potential of teratogenicity at levels to which women 
will be exposed (Foscavir Prescribing Information).
Section 4.4.1
Added recommendations related to contraception in clinical trials, per the 
clinical trial facilitation group (CTFG). Elaborated on 
highly effective method of contraception for sexually 
active females of child bearing potential participating in 
the study. Added that vasectomized male partner is a 
highly effective birth control method provided that 
Section 4.4.1
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 152 
 
07 Dec 2018
For non-commercial use only


Shire
Page 153
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
2
Amendment Date
01 Dec 2016
Global/Country/Site Specific
Global
Description and Rationale for Change 
Section(s) Affected by Change
partner is the sole sexual partner of the female trial 
participant who is of child bearing potential and that the 
vasectomized partner has received medical assessment of 
the surgical success.
Added caution and recommendation for careful monitoring of 
concentration levels of concomitant medications that are 
substrates of CYP 2C19 and P-gp both after initiation of 
maribavir (when substrate levels may increase) and after 
discontinuation of maribavir (when substrate levels may 
decrease), in alignment with the guidance to the 
investigators provided in the maribavir investigator’s 
brochure.
Section 5.2.1
Added caution for concomitant use of potent inhibitors of CYP 3A4 and 
emphasized prohibition of potent inducers of Cytochrome 
P450 (CYP) 3A4 and/or P-glycoprotein (P-gp), in 
alignment with the guidance to the investigators provided 
in the maribavir investigator’s brochure. 
Section 5.2.1, Section 5.2.2
Added an additional pregnancy test at Visit 6/ Week 4 so that these test are 
performed at monthly interval since the female subjects 
included in the study could potentially receive drugs with 
known teratogenic effect.
Schedule of Assessment 1, 
Section 7.1.2, Section 7.2.3.5
Specified that since intolerance to assigned treatment alone does not qualify 
a subject for the rescue arm, such subjects will not be 
considered non responders for the purpose of the primary 
efficacy analysis. Also added that this is applicable to 
subjects that might discontinue for maribavir treatment 
due to intolerance. Subjects who do not achieve 
confirmed viremia clearance will be considered failures 
in both treatment arms.
Section 9.8.1
Amendment 1 to Protocol SHP620-303 incorporated the following major changes:

Removal of the restriction to utilize only a single commercially available anti-CMV 
treatment for 8 weeks of the study for the subjects in the Investigator-assigned anti-CMV 
treatment arm. Subjects may also continue on prior therapy if this is the best treatment 
option selected by the investigator.

Addition of assessment of “invasive bacterial and fungal infection” to the list of safety 
endpoints since it is one of the adverse events of special interest in the study population. 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 153 
 
07 Dec 2018
For non-commercial use only


Shire
Page 154
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018

Update to the table for prior medications/procedures/diagnostic interventions.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 154 
 
07 Dec 2018
For non-commercial use only


Shire
Page 155
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1
Amendment Date
08 Jul 2016
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
In order to facilitate recruitment and optimal inclusion of broader patient 
population, hematopoietic stem cell transplant (HSCT) 
and solid organ transplant (SOT) recipients, whose CMV 
infections are refractory to available anti-CMV treatment 
(ie, ganciclovir, valganciclovir, foscarnet, or cidofovir), 
the restriction to utilize only a single commercially 
available anti-CMV treatment for 8 weeks of the study 
was removed for the subjects in the Investigator-assigned 
anti-CMV treatment arm. Subjects may also continue on 
prior therapy if this is the best treatment option selected 
by the investigator.
Added text in Section 2.2
Investigator assigned anti-CMV treatment with 1 or 2 of the 4 anti-CMV 
drugs (ganciclovir, valganciclovir, foscarnet, or cidofovir) 
with additional strategies when deemed necessary by 
investigator (eg, change in the dose of the anti-CMV 
drug, reduction of immunosuppressant, addition of IVIG 
or CMV Ig) is the active control group for this study. The 
subject on single or dual therapy with anti –CMV 
agents at the time of enrollment, may either change 
therapy at the time of randomization/treatment 
initiation or remain on the same therapy as the 
investigator assigned anti-CMV treatment, if 
randomized to this study arm. If the treatment was 
continued or started as 2 anti-CMV agents, 
withdrawal of 1 agent, while continuing the second 
one will be possible.
Added text in Section 3.1 
The subjects randomized to maribavir treatment arm will discontinue 
the therapy they were currently on at the time of enrollment. For 
subjects randomized to the investigator assigned treatment arm, the 
investigator will determine at the time of randomization/treatment 
initiation whether the subject will change the therapy they were 
currently on at the time of enrollment, or will remain on the same 
therapy (single or dual anti-CMV agent therapy) after randomization. 
If the treatment was continued or started as 2 anti-CMV agents, 
withdrawal of 1 agent, while continuing the second one will be possible. 
Addition of another anti-CMV agent will be declared as failure for the 
purpose of study analysis. After randomization, changes to the 
investigator treatment of choice could include, change in dosing, dosing 
regimen, but will not include an addition of another anti-CMV agent. 
Modified text in Synopsis and Section 3.1 
“Subjects Randomized to Investigator-Assigned Anti-CMV 
Investigator-assigned anti-CMV treatment strategies for the 8 weeks of 
Synopsis, Section 2.2, Section 3.1
(Study design-Study Treatment 
Phase), Section 5.2.2 (Prohibited 
treatment during study drug 
treatment), and Section 6 (Identity of 
study treatments) and 6.2.3 (Dosing)
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 155 
 
07 Dec 2018
For non-commercial use only


Shire
Page 156
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1
Amendment Date
08 Jul 2016
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
the study treatment phase must only utilize up to 2 available anti-CMV 
agents from the following: ganciclovir, valganciclovir, foscarnet, or 
cidofovir. 
If investigator’s decision is to change the pre-study anti-CMV agent(s), 
the investigator can select up to 2 new anti-CMV drugs as the study 
treatment. 
Investigator may also decide to keep the subject on the same anti-CMV 
drug(s), which was/were used for treatment of subject prior to 
randomization/ treatment initiation. 
If the treatment was continued or started as 2 anti-CMV agents, 
withdrawal of 1 agent, while continuing the second one will be possible. 
After randomization changes to the investigator treatment of choice 
could include, change in dosing, change in dosing regimen, but will not 
include an addition of another anti-CMV agent. 
Dose adjustment is allowed as deemed appropriate by the investigator. 
The rationale for dose adjustment will be 
documented; change to another anti-CMV agent 
during the study treatment period is not allowed.
Investigational anti-CMV agents are not permitted. 
Additional treatment strategies can complement the 
use of a single anti-CMV agent, for example, reducing 
or modifying the immunosuppressant drug use, use of 
IVIg or CMV Ig.”
Subjects will follow the investigator’s prescribed anti-CMV treatment. 
Subjects will remain on their investigator-assigned anti-CMV therapy for 
the 8 weeks of the study treatment phase. The subject may stop treatment 
due to intolerance based on investigator judgment, however if the 
interruption is longer than protocol specified and/or subject is not able 
to continue with 8 weeks of treatment it may result in classifying the 
subject as a failure for analysis purposes. Subjects may be assessed for 
entry into a rescue arm, starting at Visit 5/Week 3 (after a minimum 3 
weeks of treatment), for treatment with maribavir 400 mg BID for 8 weeks. 
Subjects must meet 1 of the following criteria to be eligible to enter the 
maribavir rescue arm:
Modified text in Section 6:
Study investigators will choose and prescribe an anti-CMV drug of their 
choice from the available products utilized for treatment of CMV 
infection/disease in clinical practice, as endorsed in published guidance 
documents, institutional guidelines, and other published literature (Kotton 
et al., 2013; Tomblyn et al., 2009). The investigator-assigned anti-CMV 
treatment arm may only utilize 1 or 2 (only if subject’s current dual 
therapy at enrollment is continued after randomization or started at 
randomization) of the following 4 noninvestigational anti-CMV agents: 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 156 
 
07 Dec 2018
For non-commercial use only


Shire
Page 157
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1
Amendment Date
08 Jul 2016
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
(change from ganciclovir to valganciclovir or vice versa will be allowed):
Modified text in Section 6.2.3
Investigator-assigned anti-CMV treatment strategies for the 8 weeks of the 
study treatment phase must only utilize a single 1 or 2 of the available 
anti-CMV agent from the following: ganciclovir, valganciclovir, foscarnet, 
or cidofovir. The subject receiving 1 or 2 anti –CMV agents at the time 
of enrollment, may either change therapy at the time of 
randomization/treatment initiation or remain on the same therapy as 
the investigator assigned anti-CMV agent, if randomized to this study 
treatment arm. After randomization, changes to the investigator 
treatment of choice could include, change in dosing, change in dosing 
regimen, but will not include an addition of another anti-CMV agent. If 
the treatment was continued or was started (post-randomization) as 2 
anti-CMV agents, withdrawal of one agent while continuing with the 
second one will be possible. 
Dose adjustment is allowed as deemed appropriate by the investigator. The 
rationale for dose adjustment will be documented; change of treatment to 
another anti-CMV agent or addition of another anti-CMV agent during the 
study treatment will be considered declared as treatment failureexcept for 
change of therapy from ganciclovir to valganciclovir and vice versa. 
Clarified that the investigator-assigned anti-CMV agents to which the CMV 
infection is refractory is currently administered to an 
eligible subject.
Synopsis, Section 3.1 (Study Design 
and Flow Chart)
Clarified the definition for “Refractory” that the documented failure to 
achieve >1 log10 decrease in CMV DNA level in whole 
blood or plasma could be after 2 or more weeks of 
treatment with IV ganciclovir, oral valganciclovir, IV 
foscarnet, or IV cidofovir or could be after treatment with 
any combination of this anti-CMV agents.
Synopsis, Section 3.1 (Study Design 
and Flow Chart)
Removed a redundant statement not necessary for the definition of and 
clarified that “Resistant” will be defined as: 
Documented failure to achieve >1 log10 (common logarithm to base 10) 
decrease in CMV DNA level in whole blood or plasma after of 2 or more 
weeks of treatment with IV ganciclovir, oral valganciclovir, IV foscarnet, 
or IV cidofovir (or any combination thereof). Results from the same 
laboratory and the same sample type (blood or plasma) are to be used to 
determine the refractoriness”
Synopsis, Section 3.1 (Study Design 
and Flow Chart)
Specified for clarity this study will also assess improvement or resolution of 
tissue-invasive CMV disease at the end of the 8-week 
study treatment phase and during the follow-up phase for 
subjects with disease present at baseline.
Synopsis, Section 3.1 (Study Design 
and Flow Chart)
To be consistent with other sections in the protocol, it was clarified that 
subject enrollment will be monitored to achieve an 
approximate target of 60% of subjects who have a CMV 
infection with documented resistance to any of the 
Synopsis, Section 3.1 (Study design)
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 157 
 
07 Dec 2018
For non-commercial use only


Shire
Page 158
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1
Amendment Date
08 Jul 2016
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
anti-CMV agents (ganciclovir, valganciclovir, foscarnet, 
or cidofovir) proven by according to the central 
specialty results from samples taken at baseline. 
To facilitate study conduct and to be consistent with other sections in the 
protocol, the following details were added in the synopsis 
for the Screening Phase: “Historical laboratory results 
(local laboratory) for tests specified in the Schedule of 
Assessment 1 may be used during screening for the 
assessment of the eligibility, including local CMV DNA 
quantification test results. If local laboratory results are 
not available, the central laboratory assessments may be 
conducted. All clinical laboratory results required for 
eligibility verification must be available prior to 
randomization”
It was added that the historical laboratory results from local laboratory for 
CMV DNA quantification test may be used for assessment of eligibility at 
screening.
Synopsis, Section 3.1 (Screening 
Phase) 
Added information that the blood sample taken for CMV DNA test at the 
first visit of the maribavir rescue treatment period will be 
used as the ‘baseline’ assessment for the purpose of the 
analyses of the response to maribavir rescue treatment 
(including resistance analyses). 
Synopsis, Section 3.1
The following statements were added for clarity: 
“CMV DNA quantification may be performed in the local or central 
specialty laboratory. Already available results from the local 
laboratory (historical results) will be acceptable for screening, if taken 
within the time frames indicated and if from the same laboratory.”
“All clinical laboratory results required for eligibility verification must 
be available prior to randomization.”
Section 3.1 (Screening Phase)
Since not all required tests at baseline will be performed at screening for 
assessing eligibility, the text was modified to state that 
samples for all hematology/chemistry tests, and for the 
CMV DNA quantification test specified at baseline will 
be collected even if these tests were performed within 7 
days prior to the first dose, and central laboratory results 
were available. 
Modified text in the Synopsis
“The screening and Visit 2/Week 0/Day 0 visits can occur on the same day 
in the case when historical local laboratory results are 
available for determination of eligibility. All Visit 
2/Day 0 procedures must be completed prior to study 
treatment administration. The whole blood/plasma 
samples for CMV DNA quantification, hematology, 
and chemistry testing must be taken for all subjects at 
Synopsis, Section 3.1 (Study 
design-Study Treatment Phase), 
Section 7.1.1 (Screening Period), 
Schedule of assessment (Table 1), 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 158 
 
07 Dec 2018
For non-commercial use only


Shire
Page 159
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1
Amendment Date
08 Jul 2016
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
Visit 2/Week 0/Day 0. The test results of these assays 
will not be available prior to the start of treatment.” 
Modified text in Section 3.1
“The screening and Visit 2/Week 0/Day 0 visits can occur on the same day 
if the historical laboratory results, including CMV DNA quantification 
results, needed for evaluation of eligibility are available, or results can 
be obtained the same day. All Visit 2/Day 0 procedures, including blood 
collection for CMV DNA quantification, hematology and chemistry 
analysis in the central laboratory, must be completed prior to study 
treatment administration. Central laboratory results of CMV DNA 
quantification and genotyping, hematology, and chemistry from 
samples taken at Visit 2/Day 0 will not be available to for the screening 
of subjects.”
Modified text in Section 7.1.1

At screening, either central or local laboratory results for CMV DNA 
quantification hematology/chemistry/pregnancy testing can be used 
for qualification. 
Schedule of Assessment 1 
Footnotes “c” and “g” were modified to reflect that all required tests at
baseline will performed prior to study treatment initiation and these central 
specialty laboratory results will not be available for screening purpose.
Footnote “c”:
“Screening and Visit 2/Day 0 visits can occur on the same day in the case 
when historical laboratory values are available for determination of the 
eligibility. All Visit 2/Day 0 procedures must be completed prior to 
initiation of study treatment. The test results for the samples taken at 
Visit 2, from central laboratory or central specialty laboratory, will not 
be available to be used for screening.”
Footnote “g”:
“Clinical laboratory test will be performed at a central laboratory for all 
specified time points during the study including baseline. Central or local 
laboratory results for hematology/chemistry/pregnancy testing can be used 
for eligibility and their results must be available prior to randomization. 
Local laboratory -human chorionic gonadotropin test results can be used 
for the assessment of pregnancy on Day 0/Week 0. Only Central lab results 
for hematology/chemistry/pregnancy testing obtained within 7 days prior to 
initiation of study treatment will be acceptable for randomization (test will 
not be repeated on Day 0). Local or central laboratory analysis performed 
on samples taken between Day -7 and Day -14 will be repeated on Day 0 
before randomization.”
The sentences within the Inclusion Criterion 4 were modified:

to remove “requiring the change of current therapy” to align with the 
Inclusion Criterion 4 in the Synopsis 
and Section 4.1
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 159 
 
07 Dec 2018
For non-commercial use only


Shire
Page 160
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1
Amendment Date
08 Jul 2016
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
fact that subjects on the anti-CMV agent ganciclovir, valganciclovir, 
foscarnet, or cidofovir immediately prior to randomization may 
continue on the same if randomized to the investigator-assigned 
treatment arm, and 

to indicate that the subject could be refractory or resistant after 2 or 
more weeks of treatment with IV ganciclovir, oral valganciclovir, IV 
foscarnet, or IV cidofovir or after treatment with any combination of 
these anti-CMV agents
Modified Inclusion Criterion 4 is as follows:
“Have a current CMV infection refractory or resistant to treatment and 
requiring the change of current therapy. Refractory is defined as 
documented failure to achieve >1 log10 decrease in CMV DNA level in 
whole blood or plasma after 2 or more weeks of treatment with IV 
ganciclovir, oral valganciclovir, IV foscarnet, or IV cidofovir (or any 
combination thereof). Resistant is defined as documented failure to 
achieve >1 log10 (common logarithm to base 10) decrease in CMV DNA 
level in whole blood or plasma after an interval of 2 or more weeks of 
treatment with IV ganciclovir, oral valganciclovir, IV foscarnet, or IV 
cidofovir (or any combination thereof) AND documentation of 1 or more 
CMV genetic mutations associated with resistance to ganciclovir, 
valganciclovir, foscarnet, or cidofovir.
A statement within Exclusion Criterion 2 was modified for clarity and to 
align with the study design:
“A subject who is not continuing with the same anti-viral drug(s)
(ganciclovir, valganciclovir, or foscarnet) for the study treatment (if 
randomized to the investigator assigned anti-CMV treatment arm), 
must discontinue their use before the first dose of study drug. If subject is 
currently being treated with cidofovir and is assigned another anti-
CMV agent by the investigator, the subject must discontinue its use at 
least 14 days prior to randomization at Visit 2/Day 0 and the first dose of 
study treatment.
Exclusion Criterion 2 in the Synopsis 
and Section 4.2
A statement within the Exclusion Criterion 3 was modified to: “Subjects 
receiving artesunate must discontinue the use at least 1 
day prior to randomization at Visit 2/Day 0 and the first 
dose of study treatment”
Exclusion Criterion 3 in the Synopsis 
and 4.2.
Added a note for subjects with biopsy in Exclusion Criterion #7:
“Serum aspartate aminotransferase (AST) >5 times upper limit of normal 
(ULN) at screening, or serum alanine aminotransferase (ALT) >5 times 
ULN at screening, or total bilirubin ≥3.0 x ULN at screening (except for 
documented Gilbert’s syndrome), by local or central lab. NOTE: 
Subjects with biopsy confirmed CMV hepatitis will not be excluded 
from study participation despite AST or ALT >5 times ULN at 
screening. 
Exclusion Criterion 7 in Synopsis and 
Section 4.2
It was clarified in Exclusion Criterion 10 that breast feeding females will be 
Exclusion Criterion 10 in the 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 160 
 
07 Dec 2018
For non-commercial use only


Shire
Page 161
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1
Amendment Date
08 Jul 2016
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
excluded from the study. 
Be female and pregnant or nursing breast feeding
Synopsis and Section 4.2
Replaced “reactivation” of the malignancy under treatment with “relapse or 
progression” of the malignancy under treatment and 
modified the rest of the text for clarity in Exclusion 
Criterion 13:
“Have active malignancy with the exception of nonmelanoma skin cancer. 
Subjects who have had a HSCT and who experience relapse or 
progression of the malignancy under treatment with HSCT, as per 
investigator’s opinion are not to be enrolled.”
Exclusion Criterion 13 in the 
Synopsis and Section 4.2
“Disease symptomatology” was replaced with “disease status”, wherever 
applicable.
Synopsis and other sections of the 
protocol.
Transplant status will not be collected at screening. 
Schedule of Assessment 1 (Table 1), 
Section 7.1.1 (Study 
Schedule-Screening Period)
Liver function assessment by Child-Pugh classification will be performed at 
baseline, ie, Visit 2/Week 0. It will not be performed at 
screening.
Schedule of Assessment 1 (Table 1), 
Section 7.1.1 (Study 
Schedule-Screening Period), Section 
7.1.2, and Section 7.2.3.1
It was added that the e-diary will only be utilized for study treatments that 
are given orally. The IV administration will be tracked in 
the source documents and CRF. 
Footnote “s” in Schedule of 
Assessment 1 (Table 1), Section 7.1.2
(Study Schedule-Study Drug 
Administration)
For subjects who may withdraw consent during the study treatment phase 
or the follow-up phase, it was clarified that during the 
period after the study treatment discontinuation, and until 
the end of the study, subjects might be administered an 
anti-CMV treatment for lack of efficacy, recurrence of 
CMV viremia, or for worsening or new onset of CMV 
disease as deemed necessary by the investigator.
Synopsis, Section 4.5 
(Discontinuation and/or withdrawal)
Added for clarification that subjects who enter the rescue arm will be 
classified as failure for the purpose of analysis of the 
primary endpoint.
Synopsis and Section 3.1, and 
Section 6
Specified that study treatment interruption of up to 4 consecutive days at 2 
separate occurrences during the 8 weeks of study 
treatment is allowed in both treatment arms (maribavir or 
Investigator-assigned commercially available anti-CMV 
treatment). 
Synopsis. Section 3.1, Section 6.2.3
Added “In addition, viral UL27 gene will be tested” to reemphasize that 
besides genotyping viral UL97 and UL54 CMV genes 
isolated from Visit 2/Day 0 plasma samples, viral UL27 
gene will be genotyped too to identify mutations 
conferring resistance to commercially available 
anti-CMV agents.
Synopsis and Section 7.2.2.2
Added new text to Section for Tissue Invasive Disease Assessment to 
Section 7.2.2.3
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 161 
 
07 Dec 2018
For non-commercial use only


Shire
Page 162
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1
Amendment Date
08 Jul 2016
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
provide more information about this assessment.

In cases of CMV retinitis, the retinal images taken by the 
ophthalmologist may be collected and provided as the evidence 
supporting the diagnosis. 

EAC might request the individual histopathology slides to be read 
by an independent pathologist.

Presence and presentation of CMV syndrome in SOT subjects at 
baseline or a new onset should be reported as the event of special 
interest per definition provided in the Appendix 3. 
Added assessment of “invasive bacterial and fungal infection” to the list 
of safety endpoints since it is one of the adverse events of 
special interest in the study population. 
Added AEs of GI events (nausea, vomiting, and diarrhea) to be consistent 
with other sections.
Added that additional grading of events of special interest will be 
applicable.
Added that incidence of invasive bacterial and fungal infections for each 
treatment group for on treatment period and overall-study period will be 
provided. 
Added new text to state that additional shift tables may be produced for 
selected laboratory parameters using severity grades based on National 
Cancer Institute (NCI) common terminology criteria for adverse events 
(CTCAE v4.0) or using normal/above normal/below normal range.
Synopsis, Schedule of Assessments, 
Section 7.1, and Section 9.9
Following prior medications/procedures/diagnostic interventions were 
added to Table 3.
Any therapeutic or diagnostic intervention performed within 3 months prior 
to the first dose of study treatment on Visit 2/Week 0/Day 0:

Dialysis

X-rays, CT scans, MRI, ultrasound imaging (along with significant 
findings)
Anti-Rejection Therapies, Adjuvant Therapies and Other Related 
Therapies

Anti-rejection medications (for example belatacept) including T-
cell depleting therapies

Photopheresis
Induction therapies

Pre-transplant irradiation

Chemotherapy agents
Section 5.1 (Table 3)
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 162 
 
07 Dec 2018
For non-commercial use only


Shire
Page 163
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1
Amendment Date
08 Jul 2016
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
It was clarified that CMV specific T-cell transfer is considered 
investigational
A footnote note was added to Table 3:
*Subjects for whom transplant was performed >3 months from the 
time of screening limited (no dose data) information for induction 
therapy will be collected. Similarly for anti-CMV treatment data older 
than >3 month prior to screening will be recorded in more limited 
manner (dose prescribed, major interruptions, overall treatment 
duration)
Added diagnostic assessment imaging, such as X-ray, CT scans
Section 5.2
Based on the summary of product characteristic (SmPC) for valganciclovir, 
it was added that In vivo drug interaction studies with 
Valcyte have not been performed. Since valganciclovir 
is extensively and rapidly metabolized to ganciclovir; 
drug interactions associated with ganciclovir should 
be expected for valganciclovir (Valcyte SmPC).
Section 5.2.2
It was added that regulatory T-cells (Tregs), which is an experimental 
treatment, is not allowed for the control of transplant 
tolerance.
Section 5.2.2
It was added that presence of CMV syndrome in SOT patients at baseline or 
a new onset should be reported as adverse event of 
special interest
Footnote “f” in Schedule of 
Assessment 2 (Table 2) Section 
7.2.2.3 (Tissue Invasive CMV 
Disease Assessments)
Added a separate subsection under “Study Evaluations and 
Procedures-Efficacy” (now Section 7.2.2.6) for graft-
versus-host-disease (GVHD) assessment for HSCT 
recipients only. Rearranged and relocated the text 
relevant to this assessment in Section 8.1.4 for emphasis 
and clarity. 
Section 7.2.2.6 (GVHD assessment)
Section 8.1.4 (Adverse events of 
special interest [AESI])
Added a new citation Loiseau et al. 2007 in the section for GVHD 
assessments
Loiseau P, Busson M, Balere ML et al. 2007. HLA association with 
hematopoietic stem cell transplantation outcome: the number of mismatches 
at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall 
survival. Biol Blood Marrow Transplant, 13(8), 965-74.
Section 7.2.2.6 and Section 11
(References)
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 163 
 
07 Dec 2018
For non-commercial use only


Shire
Page 164
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1
Amendment Date
08 Jul 2016
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
Added a new citation, Harris et al 2016 as the guidance for acute GVHD 
staging and grading and for the confidence levels of the 
diagnosis:
Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, 
Chanswangphuuwana C, Efebra Y, Holler E, Litzow M, Ordemann R, 
Qayed M, Renteria AS, Reshef R, Wolfi M, Chen Y-B, Goldstein S, Jagasia 
M Locatelli F, Mielke S, Porter D, Schechter T, Shekhovtsova Z, Ferrara 
JLM and Levine JE, 2016. International, multicenter Standardization of 
Acute Graft-versus-host Disease Clinical Data collection: A report from the 
Mount Sinai Acute GVHD international Consortium. Biol Blood Marrow 
Transplant, 22, 4-10
Added Table 1 and Table 2 in Appendix 9 from this citation.
Section 7.2.2.6, Section 8.1.4, 
Section 11, and Appendix 9 in 
Section 12
Elaborated the reason for comorbidity assessment by the following 
addition:
“Transplant patients often have multiple other comorbidities, resulting 
from their immunosuppressed status (co-infections, graft versus host 
disease, transplant malfunctioning due to rejection), toxicities from 
therapies for maintenance of the transplant or reactivation of the 
baseline disease for which they had been transplanted (malignancy for 
example), and other concomitant diseases resulting in a very diverse 
population that might be enrolled into the study. The comorbidity 
assessment will be conducted to allow for the comparison of the 
population enrolled into 2 treatment arms and to account for the 
subjects’ health status when assessing overall and individual subject 
response.” Comorbidities are a physiological burden of disease and its 
interaction with ongoing treatment could impact the response to therapy.”
Section 7.2.2.7 (Comorbidity Status)
To be consistent with the schedule of assessment 1 (Table 1), a correction 
was made in Section 7.2.3.4 that electrocardiogram 
(ECG) will be performed at baseline (Visit2/Day0) and 
not at screening.
Section 7.2.3.4 (Electrocardiogram)
Modified text for clarity and consistency with regards to local laboratory 
data and reference range.
“During screening, clinical laboratory tests will be performed by the 
central laboratory, however local laboratory results if available might be 
utilized for the assessment of the eligibility. If local laboratory results 
are used for assessment of the eligibility, the reference ranges must be 
provided. This also applies to CMV DNA quantification results. At 
baseline (Visit 2/Week 0) blood samples will be taken for CMV DNA 
quantification”
Section 7.2.3.5 (Clinical laboratory 
evaluation)
Added that the samples for chemistry are preferred to be taken under fasting 
conditions, although this is not mandatory. The 
information whether samples were taken under fasting 
conditions will be collected. 
Section 7.2.3.5 (Clinical laboratory 
evaluation)
Added a note that only the levels of immunosuppressant drugs that are 
routinely conducted at the site will be collected since sites 
Section 7.2.3.5 (Clinical laboratory 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 164 
 
07 Dec 2018
For non-commercial use only


Shire
Page 165
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1
Amendment Date
08 Jul 2016
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
differ in the immunosuppressant drug levels they 
routinely monitor.
evaluation)
International normalized ratio (INR) and prothrombin time will be 
performed at baseline only. It was stated in the original 
version that this assessment will performed only at 
screening visit only.
Section 7.2.3.5
Replaced an incorrect citation Boeckh et al 2003 with Boeckh et 1998:
Boeckh M, Zaia JA, Jung D, Skettino S, Chauncey TR and Bowden RA 
1998. A study of the pharmacokinetics, antiviral activity, and tolerability of 
oral ganciclovir for (MV prophylaxis in marrow transplantation. Biol Blood 
Marrow Transplant, 4:13-19. 
Footnote” o” in Schedule of 
Assessment 1 (Table 1), Section 
7.2.4.1, and Section 11 (References)
Volume of blood to be drawn from each subject per visit (Table 5) was 
updated to reflect reduction in number of samples 
collected for 
 
Section 7.2.5 (Volume of blood to be 
drawn from each subject per visit), 
Table 5
Removed the following text to align with the case report form for the study: 
“The CTCAE identifies 5 distinct severity grades, 
including Grade 5=death related to AE. In this study, 
investigators will be instructed to utilize only severity 
Grades 1–4 for each event. Should any death occur during 
the study, this will be recorded in the CRF as the outcome 
of an AE rather than as a severity grade. Other detailed 
instructions will be provided in the study manual.”
Section 8.1.1 (Severity 
Categorization)
Added that CMV syndrome (applicable only in SOT patients) and details of 
the presentation will be collected as an adverse event of 
special interest.
Section 8.1.4
For the events of diarrhea recorded, it was further clarified that additional 
information for each case of diarrhea will be collected, 
including the information whether additional condition 
such as GVHD, GI-CMV or enteric infection confirmed 
by culture/PCR or other method is present. 
Section 8.1.4
Modified the infections of interest to add more details for monitoring and 
reporting invasive fungal and bacterial infections.
New text:
“Invasive fungal (eg, aspergillus, candida, Pneumocystis jiroveci, etc.) or 
bacterial infections (eg, Staphylococcus aureus, Streptococcus pneumonia, 
enterococcus, pseudomonas); see Appendix 13. Baseline conditions will be 
captured as part of medical history, while new events will be captured as 
AEs. The additional information such as diagnostic method used for the 
pathogen and the source of the sample used for the diagnosis will be 
collected. Additionally the presence of viral infections frequently occurring 
in transplant population will also be collected.” 
Section 8.1.4
Added the following:
CMV syndrome (applicable in SOT patients only)
Section 8.1.4 and Section 8.1.5
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 165 
 
07 Dec 2018
For non-commercial use only


Shire
Page 166
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1
Amendment Date
08 Jul 2016
Global/Country/Site Specific
Global
Description and Rationale for Change
Section(s) Affected by Change
“New onset of CMV syndrome (applicable only in SOT patients) and 
details of the presentation will be reported as the event of special interest”. 
Modified make sentence concise and indicate the time point, ie, “baseline” 
“If, at the end of the study treatment phase or at the end of the follow-up 
phase, there are abnormal clinical laboratory, vital sign, or ECG values 
which were not present at the pretreatment value observed closest to the 
start of study treatment baseline, further investigations should be performed 
until the values return to within the reference range or until a plausible 
explanation (eg, concomitant disease) is found for the abnormal values.”
Section 8.1.6
Removed the collection of subjects’ initials and dates of birth in Section 
10.4 (Privacy and Confidentiality) since these information 
should not be used for identifying purposes. The unique 
number in itself is sufficient for that purpose.
Section 10.4 (Privacy and 
Confidentiality)
Added a page after the protocol signature page for the summary of changes 
for Amendment 1, per the sponsor’s approved protocol 
template.
Added an appendix (Appendix 1) for protocol history and a table for 
summary of changes for the current and future 
amendments, per the sponsor’s approved protocol 
template. With the addition of this new appendix, all 
other appendices were renumbered throughout the 
document.
Section 12 (Appendices)
Modified Appendix 3 (Definition of Tissue Invasive CMV Disease and 
CMV Syndrome) to remove probable and proven 
methods of tissue invasive CMV disease diagnosis. 
Added CMV syndrome definition and the details of the 
assay performed for diagnosis.
Section 12 (Appendices)
Removed illegible snapshots from renumbered Appendices 10 
(Recommendations For Chronic GVHD Diagnosis and 
Grading; previously 9a) and 11(Diagnostic Criteria for 
Chronic GVHD; previously 9b) and indicated source 
figures and tables within the articles cited in those 
appendices for reference.
Section 12 (Appendices)
Added a new Appendix 13 with details for invasive bacterial and fungal 
assessments. Following new journal articles cited in this 
new appendix were added to the list of references:
Klumpp 1993; Dykewicz 2001; Majhail et al. 2012; Salzberger et al. 1997; 
Marr et al. 2002; Freifeld et al. 2011
Section 11 (References) and 
Section 12 (Appendices)
Applied editorial changes throughout the document for clarity
Synopsis and Sections, as needed
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 166 
 
07 Dec 2018
For non-commercial use only


Shire
Page 167
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Appendix 2
CHILD-PUGH CLASSIFICATION OF CHRONIC LIVER DISEASE
Score
Bilirubin
(mg/dL)
Albumin
(mg/dL)
INR
Hepatic Encephalopathy
(grade)
Ascites
(grade)
1
<2
>3.5
<1.7
None
None
2
2-3
2.8-3.5
1.7-2.2
Mild
(controlled medically)
Mild
(controlled medically)
3
>3
<2.8
>2.2
Marked
(poor control)
Marked
(poor control)
Child-Pugh Class:
A
Score of 5-6
B
Score of 7-9
C
Score >9
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 167 
 
07 Dec 2018
For non-commercial use only


Shire
Page 168
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Appendix 3
DEFINITIONS OF TISSUE INVASIVE CMV DISEASE AND CMV 
SYNDROME
TISSUE INVASIVE DISEASE 
The following definitions of CMV disease are based on a commonly cited reference that was 
intended for application to transplant recipients (Ljungman et al., 2002; Ljungman et al., 2017). 
Definitions often require clinical judgment regarding compatible symptoms or other factors. The 
investigator should utilize his/her best clinical judgment for this categorization, and apply these 
definitions whenever possible for consistency. When reporting CMV disease, the presence of any 
co-pathogens that may be contributing to the organ disease must be reported as well.
Pneumonia: “CMV pneumonia” is defined by the presence of signs and/or symptoms of 
pulmonary disease combined with the detection of CMV in bronchoalveolar lavage fluid or lung 
tissue samples. Detection of CMV should be performed by virus isolation, histopathologic 
testing, immunohistochemical analysis, or in situ hybridization. Detection of CMV by PCR alone 
may be too sensitive for the diagnosis of CMV pneumonia and is therefore insufficient for this 
purpose. The presence of fungal copathogens, such as Aspergillus species, together with 
radiologic signs typical of Aspergillus pneumonia (eg, a halo sign or a crescent sign) indicates 
fungal pneumonia rather than CMV pneumonia. CMV documented by culture from BAL might 
be used as the evidence in the absence of other preferred assays.
Gastrointestinal disease: “CMV gastrointestinal disease” is defined by the identification of a 
combination of clinical symptoms from the upper or lower gastrointestinal tract, findings of 
macroscopic mucosal lesions on endoscopy, and demonstration of CMV infection (by culture, 
histopathologic testing, immunohistochemical analysis, or in situ hybridization) in a 
gastrointestinal tract biopsy specimen. Detection of CMV by PCR alone is insufficient for the 
diagnosis of CMV gastrointestinal disease. Patients with CMV disease that involves the 
intestinal tract usually have mucosal abnormalities that can be seen by the endoscopist, but the 
appearance of some of these lesions is subtle. The spectrum of endoscopic lesions is variable and 
ranges from patchy erythema, exudates, and microerosions to diffusely edematous mucosa, to 
multiple mucosal erosions, to deep ulcers and pseudotumors. The diagnostic yield for CMV is 
higher when mucosal abnormalities are targeted for study. If CMV is detected in normal mucosa 
near a lesion consistent with those typical of CMV infection, this can be accepted as CMV 
gastrointestinal disease.
Cytomegalovirus documented in blood by PCR or antigenemia or CMV documented by PCR 
from tissue biopsies might be used in the absence of other preferred methods of diagnosis.
Hepatitis: “CMV hepatitis” is defined by the findings of elevated bilirubin and/or enzyme levels 
during liver function testing, absence of any other documented cause of hepatitis, and detection 
of CMV infection (by culture, histopathologic testing, immunohistochemical analysis, or in situ 
hybridization) in a liver biopsy specimen. Detection of CMV by PCR alone is insufficient for the 
diagnosis of CMV hepatitis because it can imply the presence of transient viremia. 
Documentation of CMV (ie, by immunohistochemical analysis) within the liver tissue is needed. 
Other pathogens, such as hepatitis C virus, may be present without excluding the diagnosis of 
CMV hepatitis.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 168 
 
07 Dec 2018
For non-commercial use only


Shire
Page 169
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Central Nervous System (CNS) disease: Cytomegalovirus “CNS disease” is defined by the 
identification of CNS symptoms together with the detection of CMV in cerebrospinal fluid 
samples, by culture or PCR, or in brain biopsy specimens, by culture, histopathologic testing, 
immunohistochemical analysis, or in situ hybridization.
Retinitis: The diagnosis of disease requires typical ophthalmological signs judged by an 
ophthalmologist experienced with the diagnosis of CMV retinitis. If the presentation is atypical 
or an experienced ophthalmologist is not available, it is recommended that the diagnosis is 
supported by CMV documented in vitreous fluid by PCR. The images of retina taken during 
ophthalmological exam should be provided.
Nephritis: Cytomegalovirus nephritis can be defined by the detection of CMV infection (by 
culture, immunohistochemical analysis, or in situ hybridization) together with the identification 
of histologic features of CMV infection in a kidney biopsy specimen obtained from a patient 
with renal dysfunction.
Cystitis: Cystitis is defined by the detection of CMV infection (by culture, 
immunohistochemical analysis, or in situ hybridization) together with the identification of 
conventional histologic features of CMV infection in a bladder biopsy specimen obtained from a 
patient with cystitis.
Myocarditis: Myocarditis is defined by the detection of CMV infection (by culture, 
immunohistochemical analysis, or in situ hybridization) together with the identification of 
conventional histologic features of CMV infection in a heart biopsy specimen obtained from a 
patient with myocarditis.
Pancreatitis: The definition of CMV pancreatitis requires the detection of CMV infection (by 
culture, immunohistochemical analysis, or in situ hybridization) together with the identification 
of conventional histologic features of CMV infection in a pancreatic biopsy specimen obtained 
from a patient with pancreatitis.
Other CMV disease categories: Cytomegalovirus can also cause disease in other organs, and 
the definitions of these additional disease categories include the presence of compatible 
symptoms and signs, and documentation of CMV by biopsy (detection of CMV by PCR alone is 
insufficient), with other relevant causes excluded.
CMV SYNDROME (only diagnosed in SOT recipients): 
The definition requires detection of CMV in blood by viral culture, antigenemia or a DNA/RNA-
based assay together with at least 2 of the following:
a.
Fever ≥38°C for at least 2 days
b. New or increased malaise (toxicity grade ≥2) or new or increased fatigue 
(toxicity grade ≥3) (National Cancer Institute: Common Terminology 
Criteria for Adverse Events, version 4.0)
c.
Leukopenia or neutropenia on 2 separate measurements at least 24 hours apart 
defined as: a WBC count of <3,500 cells/μL, if the WBC count prior to the 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 169 
 
07 Dec 2018
For non-commercial use only


Shire
Page 170
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
development of clinical symptoms was ≥4,000 cells/μL or a WBC decrease 
of >20%, if the WBC count prior to the development of clinical symptoms was 
<4,000 cells/μL. The corresponding neutrophil counts are <1,500 cells/μL or a 
decrease of >20% if the neutrophil count before the onset of symptoms was 
<1,500 cells/μL. 
d.
≥5% atypical lymphocytes
e.
Thrombocytopenia defined as a platelet count of <100,000 cells/μL if the 
platelet count prior to the development of clinical symptoms was ≥
115,000 cells/mL or a decrease of >20% if the platelet count prior to the 
development of clinical symptoms was <115,000 cells/mL
f.
Elevation of hepatic transaminases (ALT or AST) to 2 × upper limit of 
normal (applicable to nonliver transplant recipients)
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 170 
 
07 Dec 2018
For non-commercial use only


Shire
Page 171
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Appendix 4
CMV GENETIC MUTATIONS ASSOCIATED WITH RESISTANCE TO 
ANTI-CMV DRUGS
Specific mutations in the UL97 and/or UL54 human cytomegalovirus (HCMV) genes are 
associated with resistance to certain anti-CMV drugs (ganciclovir/valganciclovir, foscarnet, or 
cidofovir). The UL97 gene encodes a viral protein kinase, while the UL54 gene encodes a viral 
DNA polymerase.
Ganciclovir (administered intravenously, orally, or through its oral prodrug valganciclovir) is a 
guanosine analog that acts as a chain terminator once incorporated into the elongating viral DNA 
chain. In order for the drug to be incorporated into the viral DNA chain, ganciclovir first needs to 
be monophosphorylated by the UL97 HCMV protein kinase. Cellular kinases then di- and 
tri-phosphorylate the drug into a form that can be incorporated into the viral DNA chain. 
Mutations in the UL97 gene that inactivate the UL97 kinase prevent the monophosphorylation 
step and result in resistance to ganciclovir/valganciclovir. Foscarnet is a pyrophosphate analog 
that blocks the release of pyrophosphate by the UL54 viral polymerase. Cidofovir is a cytosine 
monophosphate analog that is dependent on diphosphorylation by cellular kinases for its 
inhibition of viral DNA synthesis.
The tables below list the mutations in UL97 that are proven to confer resistance to 
ganciclovir/valganciclovir and the mutations in UL54 that confer resistance to one or multiple 
anti-CMV agents, mostly based on the phenotyping, except in the case of deletions, that do not 
need to be confirmed due to the location of the deleted residues.
Since foscarnet and cidofovir do not require phosphorylation by the viral UL97 kinase for their 
activity, they are unaffected by mutations in the UL97 gene. Mutations in the UL54 gene that 
inactivate the viral DNA polymerase prevent incorporation of ganciclovir/valganciclovir and/or 
cidofovir into the elongating viral DNA chain, leading to resistance to the drug(s). Similarly, 
mutations in the UL54 gene can lead to foscarnet resistance.
The tables below are the reference for the investigators while the full list of reportable mutations 
should they be found in the clinical study analyses will be provided in the resistance analysis 
plan.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 171 
 
07 Dec 2018
For non-commercial use only


Shire
Page 172
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Reference for the Investigators: UL97 Mutations Known to Confer Resistance to 
Ganciclovir/Valganciclovir
UL97 Mutation
Ganciclovir/Valganciclovir
L405P
R
D456N
R
M460I
R
M460L
R
M460T
R
M460V
R
V466G
R
C480R
R
C518Y
R
H520Q
R
P521L
R
del590 to 593
R
del590to 600
R
del590 to 603
R
del591 to 594
R
del591 to 607
R
C592F
R
C592G
R
del594 to 601
R
A594E
R
A594G
R
A594P
R
A594T
R
A594V
R
L595F
R
L595S
R
L595T
R
L595W
R
del595
R
del595 to 603
R
del597 to 599
R
del597 to 603
R
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 172 
 
07 Dec 2018
For non-commercial use only


Shire
Page 173
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Reference for the Investigators: UL97 Mutations Known to Confer Resistance to 
Ganciclovir/Valganciclovir
UL97 Mutation
Ganciclovir/Valganciclovir
E596G
R
E596Y
R
E596D
R
N597D
R
N597I
R
G598D
R
G598S
R
G598V
R
K599T
R
del600
R
del601
R
del600 to 601
R
del601 to 602
R
del601 to 603
R
C603R
R
C603S
R
C603W
R
C603Y
R
C607F
R
C607Y
R
I610T
R
A613V
R
Source: Lurain and Chou, 2010; Komatsu et al., 2014
R=resistant
Mutations in bold letters are the most common mutations.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 173 
 
07 Dec 2018
For non-commercial use only


Shire
Page 174
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Reference for the Investigators: UL54 Mutations Known to Confer Resistance to One or 
More of the Anti-CMV drugs
UL54 Mutation
Cidofovir
Foscarnet
Ganciclovir
D301N
R
S
R
E303D4
R
S
R
E303G4
R
S
R
N408D
R
S
R
N408K4
R
S
R
N408S
R
S
R
N410K
R
S
R
F412C
R
S
R
F412L
R
S
R
F412S
R
S
R
F412V
R
S
R
D413A
R
S
R
D413E
R
S
R
D413N
R
S
R
D413Y4
R
S
R
P488R
R
S
R
N495K
S
R
S
K500N
R
S
R
L501I
R
S
R
T503I
R
S
R
A505V3
R
S
R
K513N
R
S
R
K513E
R
S
R
K513R
R
S
R
D515E
S
S
R
D515Y
S
R
R
L516R
R
S
R
L516W
R
S
R
I521T
R
S
R
P522A
R
S
R
P522S
R
S
R
del524
R
S
R
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 174 
 
07 Dec 2018
For non-commercial use only


Shire
Page 175
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Reference for the Investigators: UL54 Mutations Known to Confer Resistance to One or 
More of the Anti-CMV drugs
UL54 Mutation
Cidofovir
Foscarnet
Ganciclovir
V526L
R
S
R
C539G
R
S
R
C539R
R
S
R
D542E4
R
S
S
L545S
R
S
R
L545W
R
S
R
T552N
S
R
S
Q578H
R
R
R
Q578L
S
R
S
S585A
S
R
S
D588E
S
R
S
D588N
S
R
R
F595I
S
R
S
T700A
S
R
S
V715M
S
R
S
V715A
S
R
S
I726T
S
S
R
I726V3
R
S
R
E756K
R or S3
R
R or S3
E756D
S
R
S
E756Q
S
R
S
L773V
R
R
R
L776M
S
R
R
V781I
S
R
R3
V787A
S
R
R
V787L
S
R
R
L802M
S
R
R or S3
K805Q
R
S
S
A809V
S
R
R
V812L4
R
R
R
T813S
R
R
R
T821I
S
R
R
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 175 
 
07 Dec 2018
For non-commercial use only


Shire
Page 176
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Reference for the Investigators: UL54 Mutations Known to Confer Resistance to One or 
More of the Anti-CMV drugs
UL54 Mutation
Cidofovir
Foscarnet
Ganciclovir
P829S
S
S
R
A834P
R
R
R
T838A
S
R
S
G841A
R
R
R
G841S
S
R
R
M844V
S
R
R
V946L
S
R
S
L862F
S
S
R
D879G
R
L957F
ND
ND
R
A972V
R
del981 to 982
R
R
R
A987G
R
S
R
Source: Chou, 2011; Chou et al., 2008; Chevillotte et al., 2010; Erice, 1999; Komatsu et al., 2014
1 Most UL54 mutations also have UL97 mutations.
2 R and S denote resistant and sensitive, respectively. ND indicates Not Determined
3 Low-grade or variable resistance.
4 Also confers resistance to CMX001
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 176 
 
07 Dec 2018
For non-commercial use only


Shire
Page 177
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Appendix 5
KARNOFSKY PERFORMANCE STATUS SCALE
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 177 
 
07 Dec 2018
For non-commercial use only


The Karnofsky Performance Scale Index allows patients to be classified as to their functional 
impairment. This can be used to compare effectiveness of different therapies and to assess the 
prognosis in individual patients. The lower the Karnofsky score, the worse the survival for most 
serious illnesses.  
KARNOFSKY PERFORMANCE STATUS SCALE DEFINITIONS RATING (%) 
CRITERIA 
  100  Normal no complaints; no evidence of disease.
90 
Able to carry on normal activity; minor signs 
or symptoms of disease. 
Able to carry on normal activity and to work; no 
special care needed. 
80 
Normal activity with effort; some signs or 
symptoms of disease.  
70 
Cares for self; unable to carry on normal 
activity or to do active work. 
60 
Requires occasional assistance, but is able to 
care for most of his personal needs. 
Unable to work; able to live at home and care for 
most personal needs; varying amount of assistance 
needed. 
50 
Requires considerable assistance and frequent 
medical care.  
40 
Disabled; requires special care and assistance. 
30 
Severely disabled; hospital admission is 
indicated although death not imminent. 
20 
Very sick; hospital admission necessary; active 
supportive treatment necessary. 
10 
Moribund; fatal processes progressing rapidly. 
Unable to care for self; requires equivalent of 
institutional or hospital care; disease may be 
progressing rapidly. 
0 
Dead 
References: 
Crooks, V, Waller S, et al. The use of the Karnofsky Performance Scale in determining outcomes 
and risk in geriatric outpatients. J Gerontol. 1991; 46: M139-M144. 
O'Toole DM, Golden AM. Evaluating cancer patients for rehabilitation potential. West J Med. 
1991; 155:384-387. 
Oxford Textbook of Palliative Medicine, Oxford University Press. 1993;109. 
Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: Reliability, validity, 
and guidelines. J Clin Oncology. 1984; 2:187-193. 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 178 
 
07 Dec 2018
For non-commercial use only


Shire
Page 178
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Appendix 6
LANSKY PERFORMANCE STATUS SCALE
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 179 
 
07 Dec 2018
For non-commercial use only


Lansky play-performance scale for pediatric patients 
This scale may be used with children age 1-16 who have any type of malignancy. 
It may be used for both inpatients & outpatients, and for patients undergoing active 
treatment as well as long-term follow-up. It is rated by parents based on their 
child's activity over the past week. Parents fill out the assessment based on the 
directions on the form, and the form is readministered over time to assess for 
changes in performance status.  
An excerpt of the relevant directions for parents is as follows:  
"Think about your child's play and activity over the past week. Think about both 
good days and bad days. Average out this period. Now read the descriptions and 
pick the one that best describes your child's play during the past week." 
Rating 
Description  
100  
fully active, normal  
90  
minor restrictions with strenuous physical activity  
80  
active, but gets tired more quickly  
70  
both greater restriction of, and less time spent in, active play  
60  
up and around, but minimal active play; keeps busy with quieter activities  
50  
lying around much of the day, but gets dressed; no active play; participates 
in all quiet play and activities  
40  
mostly in bed; participates in quiet activities  
30  
stuck in bed; needs help even for quiet play  
20  
often sleeping; play is entirely limited to very passive activities  
10  
does not play nor get out of bed  
0  
unresponsive  
 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 180 
 
07 Dec 2018
For non-commercial use only


Shire
Page 179
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Appendix 7
SCALES AND ASSESSMENTS
The following scales/assessments will be utilized in this study: 
A separate master file containing each scale/assessment listed above will be provided to the site. 
Updates to scales/assessments during the study (if applicable) will be documented in the tables 
above and a new master file containing the revised scale/assessment will be provided to the site.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 181 
 
07 Dec 2018
For non-commercial use only


Shire
Page 180
SHP620-303 Protocol Amendment 6
Maribavir 
07 Dec 2018
Appendix 8
ACUTE GRAFT-VERSUS-HOST DISEASE: CLINICAL STAGING AND 
GRADING 
The clinical staging and grading of acute GVHD is done through evaluation of the skin, liver, 
and gastrointestinal tract (upper and lower) (Harris et al., 2016).
GVHD Target Organ Staging
Stage
Skin (Active Erythema Only)
Liver
(Bilirubin)
Upper GI
Lower GI (stool 
output/day)
0
No active (erythematous) GVHD 
rash
<2 mg/dL
No or intermittent 
nausea, vomiting, or 
anorexia
Adult: <500 mL/day or <3 
episodes/day
Child: <10 mL/kg/day or 
<4 episodes/day
1
Maculopapular rash
<25% BSA
2-3 mg/dL
Persistent nausea, 
vomiting or 
anorexia
Adult: 500-999 mL/day or 
3-4 episodes/day
Child: 10-19.9 mL/kg/day 
or 4-6 episodes/day
2
Maculopapular rash
25-50% BSA
3.1-6 mg/dL
Adult: 1000-1500 mL/day 
or 5-7 episodes/day
Child: 20-30 mL/kg/day or 
7-10 episodes/day
3
Maculopapular rash
>50% BSA
6.1-15 mg/dL
Adult: >1500 mL/day or >7 
episodes/day
Child: >30 mL/kg/day or 
>10 episodes/day
4
Generalized erythroderma
(>50% BSA) plus bullous formation 
and desquamation >5% BSA
>15 mg/dL
Severe abdominal pain with 
or without ileus or
grossly bloody stool 
(regardless of stool volume
Source: Table 1, Harris et al., 2016
Overall clinical grade (based on most severe target organ involvement):
Grade 0: No stage 1-4 of any organ.
Grade I: Stage 1-2 skin without liver, upper GI, or lower GI involvement.
Grade II: Stage 3 rash and/or stage 1 liver and/or stage 1 upper GI and/or stage 1 lower GI.
Grade III: Stage 2-3 liver and/or stage 2-3 lower GI, with stage 0-3 skin and/or stage 0-1 upper GI. Grade IV: Stage 4 skin, liver, 
or lower GI involvement, with stage 0-1 upper GI.
The differences in GVHD diagnosis make it challenging to conduct multicenter trials because of 
the difﬁculty determining whether a patient truly experienced GVHD. To address these varying 
practices, Harris et al., 2016 developed a structure for collecting granular GVHD data and 
assigning conﬁdence levels for the attribution of symptoms to GVHD based on the treatment 
decisions made by the clinician.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 182 
 
07 Dec 2018
For non-commercial use only


Confidence Level Criteria
Confidence 
Level
Pathologic 
Evidence
Clinical 
Assessment
Treatment for 
Acute GVHD
Comments
Confirmed
Unequivocal 
pathologic
evidence of GVHD
GVHD is the 
etiology for 
symptoms
Not applicable
GVHD is clearly present even if 
other etiologies may coexist 
simultaneously.
Probable
Not required
GVHD most likely 
etiology for
symptoms (as 
evidenced by
treatment being 
provided)
Yes
GVHD is most likely present, but 
other etiologies may also explain 
the symptoms, and there is 
insufficient evidence to make a 
confirmed diagnosis.
Possible
Not required
GVHD in 
differential 
diagnosis
(but no treatment 
is being provided)
No
GVHD may be present, but other 
etiologies are favored to the 
degree that GVHD treatment is 
not initiated.
Negative
Unequivocal 
evidence of a 
diagnosis other than 
GVHD (eg, drug 
rash)
GVHD is not 
considered as an 
explanation for the 
symptoms
No and the 
symptoms 
resolve without 
GVHD treatment
A “negative” biopsy (eg, normal 
skin) is not unequivocal evidence 
of a diagnosis other than GVHD.
Source: Table 2, Harris et al., 2016
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 183 
 
07 Dec 2018
For non-commercial use only


Appendix 9
RECOMMENDATIONS FOR CHRONIC GVHD DIAGNOSIS AND 
GRADING 
A.
Organ Scoring of Chronic GVHD as published in NIH GVHD Consensus for GVHD 
Consensus for Clinical Trials: I. The 2014 Diagnosis and Staging Working Group Report, 
Jagasia et al., 2015 (Figure 1).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 184 
 
07 Dec 2018
For non-commercial use only


EYES 
Keratoconjunctivitis 
sicca (KCS) confirmed 
by ophthalmologist: 
0 Yes 
0 No 
0 Not examined 
SCORE O 
0 No symptoms 
SCORE l 
0 Mild dry eye 
symptoms not 
affecting ADL 
(requirement of 
lubricant eye 
drops :0 3 x per 
day) 
SCORE2 
0 Moderate dry eye 
symptoms partially 
affecting ADL 
(requiring lubricant 
eye drops > 3 x per 
day or puncta! 
plugs), 
WITHOUT new 
vision impairment 
due to KCS 
SCORE3 
0 Severe dry eye 
symptoms significantly 
affecting ADL (special 
eyeware to relieve pain) 
OR unable to work 
because of ocular 
symptoms OR loss of 
vision due to KCS 
0 Abnormality present but explained entirely by non-GVHD documented cause (specifY).,_· 
Gl Tract 
Check all that apply: 
0 Esophageal web/ 
proximal stricture 
or ring 
0 Dysphagia 
0 Anorexia 
ONausea 
O Vomiting 
0 Diarrhea 
0 Weight loss ::>:5%* 
0 Failure to thrive 
0 No symptoms 
OSymptoms 
without 
significant weight 
loss• (<5%) 
0 Symptoms 
associated with 
mild to moderate 
weight loss• 
(5-15%)0R 
moderate diarrhea 
without 
significant 
interference with 
daily living 
0 Symptoms associated 
with significant weight 
loss• > 15%, requires 
nutritional supplement for 
most calorie needs OR 
esophageal dilation OR 
severe diarrhea with 
significant interference 
with daily living 
0 Abnormality present but explained entirely by non-GVHD documented cause (specify): ____________ _ 
L IVER 
0 Normal total 
0 Normal total 
0 Elevated total 
bilirubin and 
bilirubin with ALT 
bilirubin but 
ALTorAP 
2:3 to 5 x ULN or 
:03 mg/dL or 
< 3 x ULN 
AP ::>:3 xULN 
ALT > 5 ULN 
0 Abnormality present but explained entirely by 11011-G VHD documented cause (specifY): 
LUNGS** 
Symotom score: 
Lung score: 
Pulmo11ary [u11ction tests 
0 Not performed 
0 No symptoms 
0 FEVI2:80% 
0 Mild symptoms 
0 Moderate 
(shortness of 
symptoms 
breath after 
(shortness of breath 
climbing one flight 
after walking on 
of steps) 
flat ground) 
0 FEV I 60-79% 
0 FEVI 40-59% 
0 Elevated total 
bilirubin > 3 mg/dL 
0 Severe symptoms 
(shortness of breath at 
rest; requiring o,) 
0 FEVI :039% 
0 Abnormality present but explained entirely by non-G VHD documented cause (specify): _____________ ' 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 185 
 
07 Dec 2018
For non-commercial use only


Organ scoring of chronic GVHD. ECOG indicates Eastern Cooperative Oncology Group; KPS, Karnofsky 
Performance Status; LPS, Lansky Performance Status; BSA, body surface area; ADL, activities of daily 
living; LFTs, liver function tests; AP, alkaline phosphatase; ALT, alanine aminotransferase; ULN, normal 
upper limit. *Weight loss within 3 months. †Skin scoring should use both percentage of BSA involved by 
disease signs and the cutaneous features scales. When a discrepancy exists between the percentage of total 
body surface (BSA) score and the skin feature score, OR if superficial sclerotic features are present (Score 
2), but there is impaired mobility or ulceration (Score 3), the higher level should be used for the final skin 
scoring. ‡To be completed by specialist or trained medical providers (see Supplemental Figure). **Lung 
scoring should be performed using both the symptoms and FEV1 scores whenever possible. FEV1 should 
be used in the final lung scoring where there is discrepancy between symptoms and FEV1 scores.
Source: Figure 1, Jagasia et al., 2015
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 186 
 
07 Dec 2018
For non-commercial use only


Supplemental Genital Tract Chronic GVHD Scoring and Supplemental skin GVHD 
scoring (supplemental material for Jagasia et al., 2015)
Source: Supplemental Figure 1, supplemental material for Jagasia et al., 2015
Supplement Figure -Genital T1·act Chronic Gratl.-versus-Host Assessment and Sc01ing Form 
Name· 
Date of birth· 
Assessment date· 
SCORE O 
SCORE I 
SCORE 2 
SCORE3 
GENITAL TRACT 
0 
Nosigns 
0 Mild signs and 
0 Moderate signs 
0 Severe signs with 
Check: 
females may have 
and may have 
or without 
symptoms* WITH 
symptoms* with 
symptoms "' 
0Male 0Female 
discomfort on exam 
discomfort on exam 
Currently 
active: 
0 Yes 0No 
Check nllsic.ns that Of!LJlr_: 
D Erosions 
0 
Lichen planus-like featw-es 
D Fissures 
0 
Lichen sclerosis-like features 
D Ulcers 
0 
Vaginal scarring (female) 
D Phimosis (male) 
0 
ClitoraVlabial agglutination (female) 
D Urethral meatus scarring/ stenosis (male) 
0 
Labial •·esorption (female) 
0 
Abnormality present but NOT thought to represent GVHD (specifY ca11se): 
0 
Abnormality thought to represent GVHD PLUS other causes(specifY ccn1.se): 
symptoms are not specific to cGVHD and can represent premat11re gonadal f mltve or gem tal tract mfoctJon. 
If a gynecologist is unavailable, external examination may be 
to 
"discomf01t on exam" as follows: 
a) Spread the labia majora to inspect the vulva for the above signs. Touch the vestibular gland openings (Skene's and 
Bartl10lin's), labia minora and majora gently with a qtip. Vulvar pain elicited by the gentle touch of a qtip is 
classified as discomfort on examination. Palpate the vaginal walls with a single digit to detect 
shortening, 
naJTowing or other signs of vaginal scarring. 
b) If the woman is sexually active, determine whether qtip palpation or gentle palpation of scarred •·idges elicits pain 
similar to that which the woman expe11ences dm1ng intercourse. 
Female genitali:1: Severity of signs: 
1) Mild (any of the following); erythema on vulvar mucosal surfaces, vulvar lichen-planus or vulvar lichen-sclerosis. 
2) Moderate (any of the following); erosive inflammatory changes of the vulvar mucosa, fissures in vulvar folds 
3) Severe (any of the following); labial fusion, clitoral hood agglutination, fibrinous vaginal adhesions, circumferential 
Jibrous vaginal banding, vaginal sho11ening, synechia, dense sclerotic changes, and complete vaginal stenosis. 
Male genitalia: Diagnostic features include lichen planus-like or lichen sclerosis-like features and phymosis or urethral 
scan·ing or stenosis. Severity of signs: 
1) Mild: lichen planus-like Jeature; 
2) Moderate: lichen sclerosus-like feature or moderate erytl1en1a; 
3) Severe: phimosis or uretlu·aVmeatal scarring. 
Biopsy obtained: D Y•s 
D No 
Site biopsied: ______ GVHD <onlirmed by histology: DYes 
D No 
Change from previou.'i n •aluation: 0 No prior or current GVHD 0 .lmprovtd 
0 Stable 
0 Worse 0 N/A (ba .. nnc) 
Completed by (print name): _________________ Oate form completed: _____ _ 
44 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 187 
 
07 Dec 2018
For non-commercial use only


B.
NIH Severity Grading of Chronic GVHD as published in NIH GVHD Consensus for 
GVHD Consensus for Clinical Trials: I. The 2014 Diagnosis and Staging Working Group 
Report (Jagasia et al., 2015)
NIH Global Severity of chronic GVHD
Mild chronic GVHD
s involved with no more than score 1 plus
Lung score 0
Moderate chronic GVHD
gans involved with no more than score 1
OR
At least 1 organ (not lung) with a score of 2
OR
Lung score 1
Severe chronic GVHD
gan with a score of 3
OR
Lung score of 2 or 3
Key points:
er of the 2 scores to be used for calculating global severity.
In lung: FEV1 is used instead of clinical score for calculating global severity.
If the entire abnormality in an organ is noted to be unequivocally explained by a non-GVHD 
documented cause, that organ is not included for calculation of the global severity.
If the abnormality in an organ is attributed to multifactorial causes (GVHD plus other 
causes) the scored organ will be used for calculation of the global severity regardless of the 
contributing causes (no downgrading of organ severity score).
Source: Table 2, Jagasia et al., 2015
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 188 
 
07 Dec 2018
For non-commercial use only


Appendix 10 DIAGNOSTIC CRITERIA FOR CHRONIC GVHD 
A. Signs and Symptoms of Chronic GVHD (Table 1 in Jagasia et al., 2015)
Signs and Symptoms of chronic GVHD
Organ or Site
Diagnostic 
(Sufficient to 
Establish the 
Diagnosis of 
chronic GVHD)
Distinctive∗(Seen in 
chronic GVHD, but 
Insufficient Alone to 
Establish a Diagnosis)
Other Features or 
Unclassified Entities†
Common‡ (Seen 
with Both Acute 
and chronic 
GVHD)
Skin
Poikiloderma
Lichen planus–
like features
Sclerotic features 
Morphea-like 
features
Lichen sclerosus–
like features
Depigmentation
Papulosquamous lesions
Sweat impairment
Ichthyosis
Keratosis pilaris
Hypopigmentation
Hyperpigmentation
Erythema
Maculopapular 
rash
Pruritus
Nails
Dystrophy
Longitudinal ridging, 
splitting or brittle features
Onycholysis
Pterygium unguis
Nail loss (usually symmetric, 
affects most nails)
Scalp and body hair
New onset of scarring or 
nonscarring scalp alopecia 
(after recovery from 
chemoradiotherapy)
Loss of body hair
Scaling
Thinning scalp hair, 
typically patchy, coarse 
or dull (not explained by 
endocrine or other 
causes)
Premature gray hair
Mouth
Lichen planus–
like changes
Xerostomia
Mucoceles
Mucosal atrophy
Ulcers
Pseudomembranes
Gingivitis
Mucositis
Erythema
Pain
Eyes
New onset dry, gritty, or 
painful eyes
Cicatricial conjunctivitis
KCS
Confluent areas of punctate 
keratopathy
Photophobia
Periorbital 
hyperpigmentation
Blepharitis (erythema of 
the eyelids with edema)
Genitalia
Lichen planus–
like features
Lichen sclerosus–
like features
Erosions
Fissures
Ulcers
Females
Vaginal scarring 
or clitoral/labial 
agglutination
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 189 
 
07 Dec 2018
For non-commercial use only


Signs and Symptoms of chronic GVHD
Organ or Site
Diagnostic 
(Sufficient to 
Establish the 
Diagnosis of 
chronic GVHD)
Distinctive∗(Seen in 
chronic GVHD, but 
Insufficient Alone to 
Establish a Diagnosis)
Other Features or 
Unclassified Entities†
Common‡ (Seen 
with Both Acute 
and chronic 
GVHD)
Males
Phimosis or 
urethral/meatus 
scarring or 
stenosis
GI Tract
Esophageal web
Strictures or 
stenosis in the 
upper to mid third 
of the esophagus
Exocrine pancreatic 
insufficiency
Anorexia
Nausea
Vomiting
Diarrhea
Weight loss
Failure to thrive 
(infants and 
children
Liver
Total bilirubin, 
alkaline 
phosphatase > 2 × 
upper limit of 
normal
ALT > 2 × upper 
limit of normal
Lung
Bronchiolitis 
obliterans 
diagnosed with 
lung biopsy
BOS§
Air trapping and 
bronchiectasis on chest CT
Cryptogenic organizing 
pneumonia
Restrictive lung diseaseǁ
Muscles, fascia, 
joints
Fasciitis
Joint stiffness or 
contractures 
secondary to 
fasciitis or 
sclerosis
Myositis or polymyositis¶
Edema
Muscle cramps
Arthralgia or arthritis
Hematopoietic and 
Immune
Thrombocytopenia
Eosinophilia
Lymphopenia
Hypo- or hyper-
gammaglobulinemia
Autoantibodies (AIHA, 
ITP)
Raynaud's phenomenon
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 190 
 
07 Dec 2018
For non-commercial use only


Signs and Symptoms of chronic GVHD
Organ or Site
Diagnostic 
(Sufficient to 
Establish the 
Diagnosis of 
chronic GVHD)
Distinctive∗(Seen in 
chronic GVHD, but 
Insufficient Alone to 
Establish a Diagnosis)
Other Features or 
Unclassified Entities†
Common‡ (Seen 
with Both Acute 
and chronic 
GVHD)
Other
Pericardial or pleural 
effusions
Ascites
Peripheral neuropathy
Nephrotic syndrome
Myasthenia gravis
Cardiac conduction 
abnormality or 
cardiomyopathy
ALT indicates alanine aminotransferase; AIHA, autoimmune hemolytic anemia; ITP, idiopathic thrombocytopenic purpura.
∗In all cases, infection, drug effect, malignancy, or other causes must be excluded.
†Can be acknowledged as part of the chronic GVHD manifestations if diagnosis is confirmed.
‡Common refers to shared features by both acute and chronic GVHD.
§BOS can be diagnostic for lung chronic GVHD only if distinctive sign or symptom present in another organ (see text).
‖Pulmonary entities under investigation or unclassified.
¶Diagnosis of chronic GVHD requires biopsy.
Source: Table 1, Jagasia et al., 2015
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 191 
 
07 Dec 2018
For non-commercial use only


B. Histological Criteria for GVHD by Organ system according to NIH Consensus 
Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host 
Disease: II. The 2014 Pathology Working Group Report (Table 1 in Shulman et al., 
2015). Chronic GVHD is supported by histologic evidence of GVHD from any affected 
site. Investigators are expected to consider recommendations for chronic GVHD 
diagnosis including not only clinical but histological evidence.
Histological Criteria for GVHD by Organ System
Organ or System
Minimal Criteria for 
Acute/Active GVHD∗
Specific Criteria for Chronic GVHD†
Liver
Global assessment of 
dysmorphic or 
destroyed small bile 
ducts ± cholestasis, 
lobular and portal 
inflammation
Ductopenia, portal fibrosis, chronic cholestasis reflect 
chronicity but are not specific for chronic GVHD
GI
Variable apoptotic 
criteria (≥1/piece) in 
crypts
Destruction of glands, ulceration or submucosal fibrosis may 
reflect severe or long-standing disease but are not specific for 
chronic GVHD
Skin, in general
Apoptosis in epidermal 
basal layer or lower 
Malphigian layer or 
infundibulum/outer root 
sheath/hair bulge of hair 
follicle or 
acrosyringium/sweat 
ducts ± lichenoid 
inflammation ± vacuolar 
change ± lymphocytic 
satellitosis
Skin, lichen 
planus–like
Combination of epidermal orthohyperkeratosis, 
hypergranulosis and acanthosis resembling lichen 
planus ± lichenoid inflammation and/or vacuolar changes of 
eccrine units
Skin morpheic 
(localized or 
diffuse)
Thickening and homogenization of collagen bundles 
throughout reticular dermis or pandermal sclerosis with 
overlying interface changes ± thickening and 
homogenization of subcutaneous septa
Skin, lichen 
sclerosus–like
Homogenization ± sclerosis of papillary dermal collagen 
with overlying interface changes including melanophages in 
the papillary dermis and sparse lymphocytic infiltrate
Skin, fasciitis
Thickening of fascial septa with adjacent 
inflammation ± sclerosis of subcutis
Oral/oropharyngeal 
mucosa and 
conjunctiva
Lichenoid interface 
lymphocytes with 
infiltration of mucosa 
(exocytosis) and 
variable apoptosis‡
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 192 
 
07 Dec 2018
For non-commercial use only


Histological Criteria for GVHD by Organ System
Organ or System
Minimal Criteria for 
Acute/Active GVHD∗
Specific Criteria for Chronic GVHD†
Minor salivary or 
lacrimal gland
Periductal lymphocytic infiltrate with infiltration and 
damaged intralobular ducts, fibroplasia in periductal stroma, 
mixed lymphocytic and plasmacytic inflammation with 
destruction of acinar tissue§
Lung
CBO: dense eosinophilic scarring beneath the respiratory 
epithelium, resulting in luminal narrowing or complete 
fibrous obliteration. May be preceded by lymphocytic 
bronchiolitis without intraluminal fibrosisǁ
Kidney
Membranous nephropathy, minimal change disease
Lesions of Uncertain Pathogenesis
Lung
COP
Skeletal Muscle
Myositis
∗Conditions that result in lesser degrees of change include immunosuppressive treatment, biopsy very soon after onset 
of signs, suboptimal or small tissue sample, insufficient serial sectioning, confounding infection, drug reaction, or 
inflammatory conditions.
† After the diagnosis of chronic GVHD has been established or following immunosuppressive treatment, the 
histological manifestations of active disease may meet only minimal diagnostic criteria for activity. Different 
manifestations of cutaneous chronic GVHD may all be present together in 1 biopsy or in separate but concurrent 
biopsies.
‡ Inflammation of the oral mucosa and within the minor salivary glands may persist from prior chemo-irradiation or 
prior inflammation. The distinction between acute and chronic GVHD requires the addition of distinctive oral 
manifestations.
§ The distinction of past acinar destruction and fibrosis from ongoing chronic GVHD activity can be difficult and relies 
on assessing lobules that are not completely fibrotic. Acinar and periductal inflammation with features of damage to 
ducts, such as vacuolar change, lymphocytic exocytosis nuclear dropout, dyspolarity or apoptosis, and resultant 
fibroplasia indicate chronic GVHD activity.
‖ Constrictive bronchiolitis obliterans (CBO) should be distinguished from cryptogenic organizing pneumonia, which 
is also associated with GVHD but has a different clinicopathologic presentation and a more favorable outcome.
Source: Table 1, Shulman et al., 2015
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 193 
 
07 Dec 2018
For non-commercial use only


C. Recommendations for Final Diagnosis Categories of GVHD (Shulman et al., 2015)
Recommendation for Final Diagnosis Categories
Category
Definition
Examples
Comments
Not 
GVHD
No evidence for GVHD
Possible 
GVHD
Evidence of GVHD but 
other possible 
explanations

Obvious CMV enteritis with inclusions 
near the apoptotic changes

Focal colonic ulcers with marked 
apoptotic cryptitis and destruction of 
crypts associated with use of MMF

Coinfection with known active viral 
hepatitis

Clinical features which suggest or 
favor a drug reaction
Indicate possible alternate 
diagnoses and reasons for 
suspicion
Likely 
GVHD
Clear evidence of GVHD 
without a competing cause 
of injury
OR
Clear evidence of GVHD 
with mitigating factors
OR
GVHD most likely 
diagnosis but relevant 
clinical information is 
limited
OR
GVHD is validated by 
sequential biopsy or by 
absence of competing 
diagnosis

Abundant epithelial apoptosis without 
clinical or histological evidence of 
drug injury or infection

Evidence of CMV yet abundant 
apoptotic epithelial changes that are 
not associated with CMV infected 
cells by immunostaining

Single or rare apoptotic epithelial 
changes without other features of 
active GVHD and no alternative 
explanations

Limited sample or minimal or focal 
findings

Proximity to recent chemotherapy or 
radiotherapy
Included old categories of 
“consistent with” and 
“unequivocal” GVHD
Source: Table 2, Shulman et al., 2015
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 194 
 
07 Dec 2018
For non-commercial use only


Appendix 11 MODIFICATION OF DIET IN RENAL DISEASE (MDRD) AND 
SCHWARTZ FORMULAE
Subjects eligible for Study SHP620-303 must have estimated glomerular filtration rate (eGFR) 
>30 mL/min/1.73m2 as assessed by Modification of Diet in Renal Disease (MDRD) formula 
(Levey et al., 2006) for subjects ≥18 years of age or Schwartz formula (Schwartz et al., 1976; 
Schwartz et al., 1984) for subjects <18 years of age.
MDRD formula 
For creatinine in µmol/L:
Creatinine levels in µmol/L can be converted to mg/dL by dividing those by 88.4.
For creatinine in mg/dL:
For standardized (IDMS-calibrated) serum creatinine assays:
eGFR (mL/min/1.73 m2) = 175 × (Scr)-1.154 × (Age)-0.203 × (0.742 if Female) × (1.212 if Black) 
(conventional units)
For non-standardized (non-IDMS-calibrated) serum creatinine assays:
Schwartz formula 
GFR (ml/min/1.73m2)=[length or height (cm) × k] / Scr (mg/dl)
k=0.55 mg creatinine/100 min × cm × 1.73m2 for children 1-13 years old
k=0.55 for adolescent females 13-18 years old
k=0.7 for adolescent males 13-18 years old
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 195 
 
07 Dec 2018
For non-commercial use only


Appendix 12 BACTERIAL AND FUNGAL INFECTIONS ASSESSMENT
In HSCT population post-transplant infection remains a significant cause of morbidity and 
mortality, particularly after allogeneic transplantation. While the expected period of profound 
neutropenia after HSCT usually occurs during the pre-engraftment stage, normal neutrophil 
recovery is not always possible as neutrophil count is adversely affected by other risk factors and 
co-morbidities, such as graft failure or rejection, GVHD, relapse of the underlying neoplasm, 
drug-induced myelosuppression and concomitant infections (Klumpp, 1993).
Due to the gradual immune system reconstitution HSCT recipients are vulnerable to various 
opportunistic viral, bacterial or fungal pathogens at different stages after the transplant (Tomblyn 
et al., 2009). Opportunistic infection is defined as any infection that occurs with increased 
frequency or severity in HSCT population (Dykewicz, 2001).
Phases of opportunistic infections among allogeneic HSCT recipients Phase I: <15-45 days post transplant; Phase II: 30-100 days 
post transplant; Phase III: >100 days after HSCT. Abbreviations: EBV, Epstein-Barr virus; HHV, human herpes virus; PTLD, 
post-transplant lympho-proliferative disease (Figure 1, Tomblyn et al., 2009). 
Infectious complications are most frequent in the pre-engraftment period due to cytopenias and 
immune ablation and immune suppression but may continue for months or years in HSCT 
recipients with delayed immune reconstitution (Majhail et al., 2012). During the early post-
transplant period HSCT recipients are susceptible to bacteremia and fungal infections with 
Candida and Aspergillus species, along with herpes simplex virus (HSV) reactivation. Candida 
often causes superficial skin infection (thrush), with rare occasions of invasive disease 
manifested as esophagitis, endocarditis or hepatosplenic disease. During the early 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 196 
 
07 Dec 2018
For non-commercial use only


post-engraftment phase infections relate primarily to impaired cell-mediated immunity, which is 
influenced by a history of GVHD and the requirement for ongoing immunosuppression. The 
predominant organisms in this phase are herpesviruses, along with Pneumocystis jiroveci and 
Aspergillus species. In the late post-engraftment period common pathogens include CMV, VZV 
and infections with encapsulated bacteria, such as Streptococcus pneumonia, Haemophilus 
influenzae (Tomblyn et al., 2009; Majhail et al., 2012).
Prolonged neutropenia in the pre-engraftment phase results is a substantial risk for bacterial and 
fungal infections, and has been the most important risk factor for invasive aspergillosis 
(Schwartz et al., 1984; Salzberger et al., 1997; Marr et al., 2002).
The most common bacterial infections in neutropenia are provided in the table below.
Common Bacterial Pathogens in Neutropenic Patients
Common gram-positive pathogens
Coagulase-negative staphylococci
Staphylococcus aureus, including methicillin-resistant strains
Enterococcus species, including vancomycin-resistant stains
Viridans group streptococci
Streptococcus pneumoniae
Common gram negative pathogens
Escherichia coli
Klebsiella species
Enterobacter species
Pseudomonas aeruginosa
Citrobacter species
Acinetobacter species
Stenotrophomonas maltophilia
Source: Table 1; Freifeld et al., 2011
Fever during neutropenia in immunocompromised patients may be the only indication of a 
severe underlying infection, because signs and symptoms of inflammation typically are 
attenuated; pulmonary infection may have no signs on infiltrates on radiographs, CSF 
pleocytosis might be low or absent in the setting of meningitis. The guidance document for 
management of neutropenic patients with fever (Freifeld et al., 2011) also provides the details of 
the evidence to be used for the confirmation of the relevant bacterial or viral infection.
In this study, a history of infections, including ongoing infections at baseline, will be 
documented as part of the subject’s medical history. Any new infections that occur during the 
course of the study will be recorded as adverse events. It is recommended that invasive fungal 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 197 
 
07 Dec 2018
For non-commercial use only


infections be diagnosed and reported as possible, probable or proven per the criteria described by 
Ascioglu et al., 2002 and later revised in De Pauw et al., 2008.
FUNGAL INFECTIONS
A. Aspergillus spp. or other mold infection:

Proven: Clinical signs and symptoms plus a tissue biopsy revealing growth of an 
organism or positive histopathology.

Probable: Clinical signs and symptoms with bronchoalveolar lavage (BAL) yielding 
positive growth or positive histopathology.

Possible: at least 3 clinical signs or symptoms and growth of an organism from nonsterile 
fluid (ie, sputum).
B. Candida spp. or other yeast (e.g. T. glabrata):

Proven fungemia: Any single positive blood culture that is culture positive for Candida 
spp. or T. glabrata. [Note: Removal of indwelling catheters is strongly encouraged.]

Tissue documented: Clinical signs and symptoms compatible with invasive yeast 
infection and a positive culture from a normally sterile site with histologic evidence of 
tissue invasion (definite) or positive culture from sterile site without histologic evidence 
of invasion (probable).
BACTERIAL INFECTIONS 
C. Bacteremia: 

Any single positive blood culture that is culture positive for bacterial pathogens 
consistent with a serious bloodstream infection.
o
Urinary tract infections will not be captured as opportunistic infections of 
interest
D. Invasive Bacterial Tissue Infection:

Clinical signs and symptoms compatible with disease (sinusitis, pneumonia, intra-
abdominal abscess)
and 

Radiographic evidence of disease and pure or predominant culture or pathogen 
detection from a sterile site biopsy.
o
Pathogen detection in respiratory secretion or sinus aspirates or CSF 
specimens will be considered if they are predominant and compatible with the 
clinical picture.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 198 
 
07 Dec 2018
For non-commercial use only

SAP_001.pdf: 
STATISTICAL ANALYSIS PLAN 
 
 
NCT Number:   
NCT02931539 
 
Study Title:  
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to 
Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-
assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) 
Infections that are Refractory or Resistant to Treatment with Ganciclovir, 
Valganciclovir, Foscarnet, or Cidofovir 
 
 
Study Number:  
SHP620-303 
 
 
SAP Version and Date:   
Version 4.0 (Amendment 3):  
28 Sep 2020 


STATISTICAL ANALYSIS PLAN
Protocol No.:
SHP620-303
Protocol Title:
A Phase 3, Multicenter, Randomized, Open-label, 
Active-controlled Study to Assess the Efficacy and Safety 
of Maribavir Treatment Compared to Investigator-
assigned Treatment in Transplant Recipients with 
Cytomegalovirus (CMV) Infections that are Refractory or 
Resistant to Treatment with Ganciclovir, Valganciclovir, 
Foscarnet, or Cidofovir.
Drug:
SHP620
Sponsor: 
Shire ViroPharma, Incorporated
300 Shire Way, Lexington, MA 02421 USA
Version No. and Date
Final Version 4.0, 28 Sep 2020
Version No:
Document History
Description of Update
Author(s)
Effective Date
1.0
Final Version
30 May 2018
2.0
Amendment 1, update for protocol amendment 
5  
18 July 2018
3.0
Amendment 2, update for protocol amendment 
6, clarifications, additional analyses preparing 
for report  
02 June 2020
4.0
Amendment 3, update to include analysis
clarifications, additions, and COVID-19 
related sensitivity analysis
28 Sep 2020
For non-commercial use only


Shire
CONFIDENTIAL
Page 2
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
TABLE OF CONTENTS
LIST OF TABLES...........................................................................................................................6
LIST OF FIGURES .........................................................................................................................6
ABBREVIATIONS .........................................................................................................................7
1.
INTRODUCTION....................................................................................................................9
2.
STUDY DESIGN ...................................................................................................................10
2.1
General Study Design...............................................................................................10
2.2
Randomization .........................................................................................................13
2.3
Blinding....................................................................................................................13
2.4
Schedule of Assessments .........................................................................................14
2.5
Determination of Sample Size..................................................................................22
2.6
Multiplicity Adjustments for Type I Error Control..................................................22
3.
OBJECTIVES.........................................................................................................................23
3.1
Primary Objective ....................................................................................................23
3.2
Key Secondary Objective.........................................................................................23
3.3
Secondary Objectives...............................................................................................23
3.4
Exploratory Objectives.............................................................................................24
4.
SUBJECT POPULATION SETS...........................................................................................25
4.1
Enrolled Set..............................................................................................................25
4.2
Randomized Set........................................................................................................25
4.3
Modified Randomized Set........................................................................................25
4.4
Safety Set..................................................................................................................25
4.5
Per-protocol Set........................................................................................................25
4.6
Pharmacokinetic Set.................................................................................................26
4.7
Rescue Set ................................................................................................................26
5.
SUBJECT DISPOSITION......................................................................................................27
6.
PROTOCOL DEVIATIONS..................................................................................................28
7.
DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS .................................29
8.
EXTENT OF EXPOSURE AND TREATMENT COMPLIANCE .......................................31
8.1
Exposure to Study Assigned Treatment...................................................................31
8.2
Measurement of Treatment Compliance..................................................................33
9.
PRIOR AND CONCOMITANT MEDICATION AND PROCEDURE................................34
9.1
Prior and Concomitant Medication ..........................................................................34
9.2
Prior and Concomitant Procedure ............................................................................35
10. EFFICACY ANALYSES.......................................................................................................36
10.1
Primary Efficacy Endpoint and Analysis.................................................................37
10.1.1
Primary Efficacy Endpoint..................................................................................37
For non-commercial use only


Shire
CONFIDENTIAL
Page 3
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
10.1.2
Analysis of Primary Efficacy Endpoint...............................................................40
10.1.3
Sensitivity and Supplementary Analyses of the Primary Efficacy Endpoint......41
10.1.4
Subgroup Analyses of the Primary Efficacy Endpoint........................................45
10.2
Key Secondary Efficacy Endpoint and Analysis .....................................................46
10.2.1
Key Secondary Efficacy Endpoint ......................................................................46
10.2.2
Analysis of the Key Secondary Efficacy Endpoint .............................................49
10.2.3
Sensitivity and Supplementary Analyses of the Key Secondary Efficacy 
Endpoint ..............................................................................................................49
10.2.4
Subgroup Analyses..............................................................................................51
10.3
Other Secondary Efficacy Endpoints and Analysis .................................................52
10.3.1
The Achievement of the Confirmed CMV Viremia Clearance After 
8 Weeks of Receiving Study-Assigned Treatment..............................................52
10.3.2
The Achievement of the Confirmed CMV Viremia Clearance and CMV 
Infection Symptom Control After Receiving 8 Weeks of Study-Assigned 
Treatment and Maintaining the Effect Over Time ..............................................52
10.3.3
The Maintenance of the CMV Viremia Clearance and CMV Infection 
Symptom Control Achieved at the End of Study Week 8 Through 
Weeks 12 And 20 ................................................................................................53
10.3.4
The Recurrence of CMV Viremia .......................................................................53
10.3.5
The Recurrence of CMV Viremia During and Off-Study-Assigned 
Treatment.............................................................................................................54
10.3.6
The Maribavir CMV Resistance Profile..............................................................54
10.3.7
All-Cause Mortality.............................................................................................54
10.3.8
Assessment of Efficacy for Maribavir Rescue Arm............................................55
10.3.8.1
The Confirmed Clearance of Plasma CMV DNA at the End of 
8 Weeks of Maribavir Rescue Treatment Phase ....................................55
10.3.8.2
The Achievement of Viremia Clearance and Disease Control for 
Maribavir Rescue Treatment..................................................................55
10.4
Exploratory Efficacy Endpoint(s) and Analyses......................................................55
For non-commercial use only


Shire
CONFIDENTIAL
Page 4
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
11. SAFETY ANALYSES ...........................................................................................................60
11.1
Adverse Events.........................................................................................................61
11.1.1
Treatment-emergent Adverse Event....................................................................61
11.1.2
Adverse Events of Special Interest (AESIs)........................................................62
11.1.2.1
Time to Resolution for Dysgeusia and Similar Terms While on 
Treatment and When Off Treatment ......................................................63
11.1.2.2
Renal Disorder TEAEs...........................................................................64
11.1.3
Subgroup Analysis of TEAE and AESIs.............................................................64
11.2
Clinical Laboratory Variables ..................................................................................65
11.3
Vital Signs................................................................................................................67
11.4
Electrocardiogram (ECG).........................................................................................68
11.5
Treatment with Hemopoietic Growth Factors, Blood, and Blood Products 
Transfusions .............................................................................................................68
12. CLINICAL PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSES............69
12.1
Pharmacokinetics Population...................................................................................69
12.2
Pharmacokinetic Methods........................................................................................69
12.2.1
Concentration Data..............................................................................................69
12.2.2
Handling BLQ Values .........................................................................................69
12.2.3
Pharmacokinetic Parameters ...............................................................................70
12.3
Statistical Analysis of Pharmacokinetic Data ..........................................................70
12.4
Analyses of Pharmacokinetic/Pharmacodynamic Relationships .............................71
12.5
PK and PK/PD Analysis to Be Performed Separately from Clinical Study 
Report.......................................................................................................................72
13. OTHER ANALYSES .............................................................................................................73
14. INTERIM ANALYSIS...........................................................................................................74
15. DATA MONITORING/REVIEW COMMITTEE.................................................................75
16. COMPUTER METHODS ......................................................................................................76
17. CHANGES TO ANALYSES SPECIFIED IN PROTOCOL.................................................77
18. DATA HANDLING CONVENTIONS..................................................................................79
18.1
General Data Reporting Conventions ......................................................................79
18.2
Derived Efficacy Endpoints .....................................................................................79
18.3
Baseline for Efficacy and Safety Endpoints.............................................................79
18.4
Repeated or Unscheduled Assessments of Safety Parameters.................................79
18.5
Missing Date of Study Assigned Treatment ............................................................80
18.6
Missing Date Information for Prior or Concomitant Medications...........................80
18.6.1
Incomplete Start Date..........................................................................................80
18.6.2
Incomplete Stop Date ..........................................................................................81
18.7
Missing Date Information for Adverse Events ........................................................81
For non-commercial use only


Shire
CONFIDENTIAL
Page 5
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
18.7.1
Incomplete Start Date..........................................................................................82
18.7.2
Incomplete Stop Date ..........................................................................................82
18.8
Missing Severity Assessment for Adverse Events...................................................82
18.9
Missing Relationship to Investigation Product for Adverse Events ........................82
18.10
Character Values of Clinical Laboratory Variables .................................................82
19. REFERENCES .......................................................................................................................83
For non-commercial use only


Shire
CONFIDENTIAL
Page 6
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
LIST OF TABLES
Table 1
Schedule of Assessment 1: Screening Phase and Study Treatment 
Phase..............................................................................................................14
Table 2
Schedule of Assessment 2: Follow-up Phase ................................................19
Table 3
Assessments of Virological Responders at Study Week 8............................38
Table 4
Summary of Response Categorization for Primary Endpoint .......................39
Table 5
Estimand for Primary Efficacy Endpoint ......................................................39
Table 6
Response Categorization in Sensitivity Analysis for Primary Endpoint.......41
Table 7
Response Categorization in COVID-19 Impact Sensitivity Analysis for 
Primary Endpoint Using Multiple Imputation...............................................43
Table 8
Response Categorization in COVID-19 Impact Sensitivity Analysis 
Using Worst Case for Primary Endpoint.......................................................44
Table 9
Assessments of Responders for Key Secondary Endpoint............................47
Table 10
Summary of Response Categorization for Key Secondary Endpoint ...........48
Table 11
Estimand for Key Secondary Efficacy Endpoint...........................................48
Table 12
Response Categorization in Sensitivity Analysis for Key Secondary 
Endpoint ........................................................................................................50
Table 13
Response Categorization in COVID-19 Impact Sensitivity Analysis for 
Key Secondary Endpoint Using Multiple Imputation...................................51
Table 14
Criteria for Potentially Clinically Significant Vital Signs.............................67
Table 15
Criteria for Potentially Clinically Significant ECG Values ..........................68
Table 16
Noteworthy Changes since SAP Amendment 2............................................78
Table 17
Examples for Coding of Special Character Values for Clinical 
Laboratory Variables.....................................................................................82
LIST OF FIGURES
Figure 1
Study Design Flow Chart ..............................................................................12
For non-commercial use only


Shire
CONFIDENTIAL
Page 7
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
ABBREVIATIONS
AE
adverse event
AESI
Adverse event of special interest
ATC
anatomical therapeutic chemical
ALP
alkaline phosphatase
ALT
alanine aminotransferase
ANC
absolute neutrophil count
AST
aspartate aminotransferase
ATP
adenosine triphosphate
AUC
area under the plasma concentration versus time curve
-HCG
beta-human chorionic gonadotropin
BID
twice daily
Cmax
maximum observed plasma concentration 
Cmin
minimum observed plasma concentration
CMH
Cochran-Mantel-Haenszel
CMV
Cytomegalovirus 
CRA
clinical research associate
CTCAE
Common Terminology Criteria for Adverse Events 
DMC
data monitoring committee
EAC
Endpoint Adjudication Committee
eCRF
electronic case report form
eDiary
electronic Diary
ECG
Electrocardiogram
FAS
Full Analysis Set
FDA
Food and Drug Administration
GGT
gamma-glutamyltransferase
GI
Gastrointestinal
GVHD
graft-versus-host disease
HLA
human leukocyte antigen
HSCT
Hematopoietic stem cell transplant
ITT
Intention-to-treat
IAT
investigator-assigned anti-CMV treatment
IRT
interactive response technology
For non-commercial use only


Shire
CONFIDENTIAL
Page 8
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
IV
Intravenous
LLOQ
lower limit of quantification
MedDRA
Medical Dictionary for Regulatory Activities
OC
observed cases
PCS
potentially clinically significant
PD
pharmacodynamic
PK
pharmacokinetic(s)
PP
Per-protocol
QoL
quality of life
qPCR
quantitative polymerase chain reaction
QTc
corrected QT interval
QTcF
QT Interval Corrected for Heart Rate using Fridericia’s Formula
RAP
Resistance Analysis Plan
SAE
serious adverse event
SAP
statistical analysis plan
SOC
system organ class
SOT
solid organ transplant
TEAE
treatment-emergent adverse event
WHO
World Health Organization
For non-commercial use only


Shire
CONFIDENTIAL
Page 9
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
1.
INTRODUCTION
This statistical analysis plan (SAP) provides a technical and detailed elaboration of the statistical 
analyses of efficacy, safety, 
 and pharmacokinetic 
(PK)/pharmacodynamic (PD) data as described in the most recent protocol amendment 6 dated 
7 December 2018. 
 will be prepared separately. Population 
PK analysis plan and Resistance Analysis plan will also be prepared separately. Specifications 
for tables, figures, and listings will be provided in a separate document.
For non-commercial use only


Shire
CONFIDENTIAL
Page 10
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
2.
STUDY DESIGN
2.1
General Study Design
This is a multicenter, randomized, open-label, active-controlled study to assess the efficacy and 
safety of maribavir treatment compared to investigator-assigned anti-cytomegalovirus (CMV) 
treatment in hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) 
recipients with CMV infections that are refractory to treatment with ganciclovir, valganciclovir, 
foscarnet, or cidofovir, including CMV infections with confirmed resistance to 1 or more 
anti-CMV agents. The study will assess the efficacy of maribavir by measuring the plasma CMV 
DNA clearance.
To be eligible for the study, subjects must have a documented CMV infection in whole blood or 
plasma, with a screening value of ≥2730 IU/mL in whole blood or ≥910 IU/mL in plasma in 
2 consecutive assessments, separated by at least 1 day, as determined by local or central specialty 
laboratory quantitative polymerase chain reaction (qPCR) or comparable quantitative CMV 
DNA test. Results should be available before the subject is randomized to verify subject 
eligibility for the study. Both samples should be taken within 14 days prior to randomization 
with the second sample obtained within 5 days before randomization and will be used for the 
stratification level for the randomization. The same laboratory must be used for these 
assessments. The CMV infection must be refractory to 1 or more of the anti-CMV agents 
(ganciclovir, valganciclovir, foscarnet, or cidofovir) and the subjects must meet the remaining 
specified eligibility criteria.
“Refractory” will be defined as:
Documented failure to achieve >1 log10 (common logarithm to base 10) decrease in CMV DNA 
level in whole blood or plasma after 14 days or longer treatment period with IV ganciclovir, oral 
valganciclovir, IV foscarnet, or IV cidofovir. This definition applies to the current CMV 
infection and the most recently administered anti-CMV agent.
“Resistant” will be defined as:
Documented failure to achieve >1 log10 (common logarithm to base 10) decrease in CMV DNA 
level in whole blood or plasma after of 14 days or longer treatment period with IV ganciclovir, 
oral valganciclovir, IV foscarnet, or IV cidofovir. This definition applies to the current CMV 
infection and the most recently administered anti-CMV agent.
AND
Documentation of 1 or more CMV genetic mutations associated with resistance to ganciclovir, 
valganciclovir, foscarnet, and/or cidofovir.
Results from the same laboratory and the same sample type (whole blood or plasma) are to be 
used to determine the refractoriness. Note: Failure to respond to these agent(s) due to intolerance 
will not be considered ‘refractoriness.’
For non-commercial use only


Shire
CONFIDENTIAL
Page 11
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
The documentation of resistance during screening will be based on the local specialty laboratory 
genotyping assay results. Plasma samples obtained at baseline for CMV DNA genotyping will be 
used for the final determination of mutations in the UL97, UL27, and UL54 genes known to 
confer resistance to anti-CMV agents; this assessment will be based on the results from the 
central specialty laboratory and utilized for analysis.
The subjects randomized to the maribavir treatment arm will discontinue the anti-CMV therapy 
they were currently on at the time of enrollment. For subjects randomized to the investigator 
assigned treatment arm, the investigator will determine at the time of randomization/treatment 
initiation whether the subject will change the therapy they were currently on at the time of 
enrollment, or will remain on the same therapy (single or dual anti-CMV agent therapy) after 
randomization (per Inclusion Criterion 5). If the treatment was continued or started as 
2 anti-CMV agents, withdrawal of 1 agent, while continuing the second one will be possible. 
After randomization, changes to the investigator treatment of choice could include a change in 
dose and/or dosing regimen, but will not include an addition of or switch to another anti-CMV 
agent. Addition of or switch to another anti-CMV agent will be declared as a failure for the 
purpose of study analysis. Note that changes between intravenous (IV) ganciclovir and oral 
valganciclovir are allowed. Combination therapy with cidofovir and foscarnet is prohibited.
All eligible subjects will be stratified by transplant type (HSCT or SOT) and screening whole 
blood or plasma CMV DNA concentration (high viral load with CMV DNA ≥273000 IU/mL in 
whole blood or ≥91000 IU/mL in plasma, intermediate viral load ≥27300 and <273000 IU/mL in 
whole blood or ≥9100 and <91000 IU/mL in plasma, and low viral load <27300 and 
≥2730 IU/mL in whole blood or CMV DNA <9100 and ≥910 IU/mL in plasma as determined by 
the most recent local or central specialty laboratory qPCR results, available at the time of 
randomization) as 2 stratification factors and then randomized in a 2:1 allocation ratio to receive 
maribavir 400 mg twice daily (BID) or investigator-assigned anti-CMV treatment for 8 weeks.
A cohort of subjects will have tissue-invasive CMV disease or CMV syndrome at baseline, as 
determined by the investigator (also referred as “symptomatic subjects”). Therefore, this study 
will also assess improvement or resolution of tissue-invasive CMV disease or CMV syndrome at 
the end of the 8-week study treatment phase and during the follow-up phase for subjects with the 
symptomatic infection present at baseline.
“Asymptomatic subjects” will be defined as: Eligible enrolled subjects who do not have 
tissue-invasive CMV disease or CMV syndrome at baseline, as diagnosed by the investigator.
The investigator will perform the initial diagnosis of tissue invasive CMV disease or CMV 
syndrome for the symptomatic subjects at baseline and new occurrence of tissue invasive CMV 
disease or CMV syndrome for the asymptomatic subjects at baseline through the study, and will 
continue with the assessment of the status (ie, no change, improvement, worsening, or 
resolution) at subsequent visits through the study. All investigator-assessed cases of tissue 
invasive CMV disease and CMV syndrome will be reviewed and adjudicated by an independent 
Endpoint Adjudication Committee (EAC) both for the confirmation of the diagnosis of baseline 
and new symptomatic CMV infection and for the outcome (ie, no change, improvement, 
worsening, or resolution).
For non-commercial use only


Shire
CONFIDENTIAL
Page 12
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
An independent data monitoring committee (DMC) will be established to act in an expert, 
advisory capacity for periodic assessment of the data to monitor participant safety and to ensure 
the validity and scientific merit of the trial.
As shown in the study schematic in the Study Design Flow Chart (Figure 1), the study will have 
3 phases: (1) Up to a 2-week screening phase; (2) 8-week study treatment phase; and (3) 
12-week follow-up phase. Subjects will be required to visit the site up to 19 times for up to a 
22-week period. Subjects entering the maribavir rescue arm may participate in the study for a 
longer duration, depending on the time of the transition from the investigator-assigned study 
treatment to maribavir, with a maximal time of 29 weeks.
Approximately 140 sites in North America, Europe, and Asia Pacific will participate.
Additional details can be found in Section 3 of the Protocol.
Figure 1
Study Design Flow Chart
BID=twice daily; BL=baseline; R=rescue; Rand=randomized; wks=weeks
*Visit 2A/AR is only required for subjects taking tacrolimus, cyclosporine, everolimus, or sirolimus at Visit 2/2R.
Note: Eligibility to enter maribavir rescue arm will be assessed starting at Visit 5/Week 3 up to Visit 9/Week 7
For non-commercial use only


Shire
CONFIDENTIAL
Page 13
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
2.2
Randomization
All eligible subjects will be stratified by 2 stratification factors:

Transplant type (HSCT or SOT)
and

CMV DNA concentration levels, based on whole blood or plasma CMV DNA 
concentration as determined by the most recent local or central specialty laboratory 
qPCR results, available at the time of randomization:
o
high viral load with CMV DNA ≥273000 IU/mL in whole blood or 
≥91000 IU/mL in plasma,
o
intermediate viral load ≥27300 and <273000 IU/mL in whole blood or ≥9100 and 
<91000 IU/mL in plasma,
o
and low viral load <27300 and ≥2730 IU/mL in whole blood or CMV DNA 
<9100 and ≥910 IU/mL in plasma).
Following stratification, subjects will be randomized in a 2:1 allocation ratio to receive 
open-label maribavir 400 mg BID or investigator-assigned anti-CMV treatment for 8 weeks. The 
actual treatment given to individual subjects is determined by a randomization schedule 
automatically centrally assigned by the interactive response technology (IRT). The 
randomization number represents a unique number corresponding to study treatment allocated to 
the subject, once eligibility has been determined. Once a randomization number/unique identifier 
has been assigned, that number must not be used again if, for example, a subject is withdrawn 
from the study. If a randomization number/unique identifier is allocated incorrectly, the clinical 
research associate (CRA)/study monitor must be notified as soon as the error is discovered.
Randomization and drug-dispensing irregularities occur whenever:
1. A randomization is not in accordance with the protocol-defined randomization method, 
such as a) an ineligible subject is randomized, b) a subject is randomized based on an 
incorrect stratum, c) a subject is randomized twice.
OR
2. A subject is given a study drug not allocated by the protocol-defined randomization, such 
as a) a subject randomized to investigator-assigned anti-CMV treatment (IAT) received 
maribavir or vice versa, or b) a nonrandomized subject is treated with study drug reserved 
for randomized subjects.
Randomization and drug-dispensing irregularities will be monitored throughout the study and 
reviewed on an ongoing basis.
All randomization and drug-dispensing irregularities will be documented in the clinical study 
report.
2.3
Blinding
This is an open-label study. The investigator(s) and the subjects are unblinded to the treatment 
assignment.
For non-commercial use only


Shire
CONFIDENTIAL
Page 14
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
2.4
Schedule of Assessments
Table 1
Schedule of Assessment 1: Screening Phase and Study Treatment Phase
Phase
Screening 
Phase
Study Treatment Phaseu
Study Visit / Rescue Arm Visit
1/NA
2/2R
2A/2ARw
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
9/9R
10/10R
(End of 
Treatment)
Study Weeka/Rescue Arm Week
-2 to 0
0/0R
0.5/ 0.5R
1/1R
2/2R
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
Study Day /Rescue Arm Day
-14 to 0
0c/0R
4/4R
7/7R
14/14R
21/21R
28/28R
35/35R
42/42R
49/49R
56/56R
Informed consentb
X
Inclusion/exclusion criteriac
X
X
Randomization
X
Physical examination (including 
weight)d
X
X
X
Height
X
Weight
X
X
X
Vital signs
X
X
X
X
X
X
Medical history
X
Xe
Prior medications, therapies, and 
procedures
X
Xv
12-lead ECGf
X
X
Hematology/Chemistryg
X
X
X
X
X
X
X
Urinalysisg
X
X
X
X
X
Pregnancy testg,h
X
X
X
X
HIV statusi
X
HBV and HCV testsj
Xj,v
CMV DNA testk
X
X
X
X
X
X
X
X
X
X
Symptomatic CMV infection 
assessmentl
X
X
X
X
X
X
X
X
X
 
X
X
For non-commercial use only


Shire
CONFIDENTIAL
Page 15
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
Table 1
Schedule of Assessment 1: Screening Phase and Study Treatment Phase
Phase
Screening 
Phase
Study Treatment Phaseu
Study Visit / Rescue Arm Visit
1/NA
2/2R
2A/2ARw
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
9/9R
10/10R
(End of 
Treatment)
Study Weeka/Rescue Arm Week
-2 to 0
0/0R
0.5/ 0.5R
1/1R
2/2R
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
Study Day /Rescue Arm Day
-14 to 0
0c/0R
4/4R
7/7R
14/14R
21/21R
28/28R
35/35R
42/42R
49/49R
56/56R
Immunosuppressant drug 
concentration levels
Xn
Xn
Xn
X
PK sampleso
Xo
Xo
X
Rescue Arm Eligibilityp
Xp
X
X
X
X
Interactive Response Technologyq
X
X
X
X
X
X
X
X
X
X
Study treatment dispensedr
X
X
X
X
X
X
X
X
Study diarys
X
X
X
X
X
X
X
X
X
X
Invasive bacterial, viral and 
fungal infection/transplant 
relevant infections assessment
X
X
X
X
X
X
X
X
X
Transplant status
X
X
X
X
X
X
X
X
X
GVHD assessment (for HSCT 
subjects only)
X
X
X
X
X
X
X
X
X
Liver function assessment by 
Child-Pugh classification
Xv
Comorbidity status evaluation
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
For non-commercial use only


Shire
CONFIDENTIAL
Page 16
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
Table 1
Schedule of Assessment 1: Screening Phase and Study Treatment Phase
Phase
Screening 
Phase
Study Treatment Phaseu
Study Visit / Rescue Arm Visit
1/NA
2/2R
2A/2ARw
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
9/9R
10/10R
(End of 
Treatment)
Study Weeka/Rescue Arm Week
-2 to 0
0/0R
0.5/ 0.5R
1/1R
2/2R
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
Study Day /Rescue Arm Day
-14 to 0
0c/0R
4/4R
7/7R
14/14R
21/21R
28/28R
35/35R
42/42R
49/49R
56/56R
Concomitant medications, 
therapies, and procedurest
X
X
X
X
X
X
X
X
X
X
AE/SAE monitoring
X
X
X
X
X
X
X
X
X
X
AE=adverse event; CMV=cytomegalovirus; ECG=electrocardiogram; 
 GVHD=graft-versus-host disease; HBV=hepatitis B 
virus; HCV=hepatitis C virus; HIV=human immunodeficiency virus; HSCT=hematopoietic stem cell transplant; hx=history; IRT=interactive response technology; 
PK=pharmacokinetic; R=rescue; SAE=serious adverse event; 
Note: Subjects in the investigator-assigned anti-CMV treatment arm who discontinue study treatment phase to enter the maribavir rescue arm will follow the study procedures in
the Schedule of Assessment 1 for the study treatment phase, beginning with Study Week 0 (visits denoted as “R”), and will exit after 8 weeks of maribavir 400 mg BID treatment 
to enter the follow-up phase. For subjects entering the maribavir rescue arm on the day of their end-of-treatment visit, duplicate procedures do not need to be repeated.
a Permissible assessment windows: Study Visit 2A/2AR (Day 4) ±1 day; Study Visit 3/3R (Day 7) +2 days; Study Weeks 2-4 ±2 days; Study Weeks 5-8 ±3 days.
b Informed consent must be obtained before any study-specific procedures are performed. All screening procedures will be completed within 14 days prior to initiation of study 
treatment, with the exception of: 1) screening clinical laboratory tests (hematology, chemistry, pregnancy), which must be performed within 7 days prior to initiation of study 
treatment; either central or local laboratory results for hematology/chemistry/pregnancy testing can be used for qualification, and 2) documentation of CMV infection in whole 
blood or plasma, with a screening value of ≥2730 IU/mL in whole blood or ≥910 IU/mL in plasma 2 assessments, separated by at least 1 day, as determined by local or central 
specialty laboratory quantitative polymerase chain reaction (qPCR) or comparable quantitative CMV DNA results. Results should be available before the subject is randomized to 
verify subject eligibility for the study. Both samples should be taken within 14 days of randomization with second sample obtained within 5 days before randomization. Same 
laboratory should be used for these assessments.
c Screening and Visit 2/Day 0 visits can occur on the same day in the case when historical laboratory values are available for determination of the eligibility. All Visit 2/Day 0 
procedures and screening laboratory results needed to confirm eligibility must be completed and documented prior to randomization and initiation of study treatment 
administration. The test results for the samples taken at Visit 2, from central laboratory or central specialty laboratory, will not be available to be used for the screening. Initiation 
of study treatment (ie, first dose) will only occur after completion of all required Visit 2/Day 0 procedures, confirmation of eligibility, and completion of randomization. This will 
be done under the supervision of investigator site personnel. For subjects randomized to receive maribavir or investigator-assigned therapy, therapy must be initiated within 
24 hours of randomization.
d Symptom-oriented physical examinations other than protocol-specified examinations will be performed when clinically indicated.
e Updated medical history on Visit 2/Day 0.
f Electrocardiograms other than protocol-specified ECGs will be performed when clinically indicated.
g Clinical laboratory test will be performed at a central laboratory for all specified time points during the study including baseline. Central or local laboratory results for 
hematology/chemistry/serum pregnancy testing can be used for eligibility and their results must be available prior to randomization. Local laboratory -human chorionic 
For non-commercial use only


Shire
CONFIDENTIAL
Page 17
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
Table 1
Schedule of Assessment 1: Screening Phase and Study Treatment Phase
Phase
Screening 
Phase
Study Treatment Phaseu
Study Visit / Rescue Arm Visit
1/NA
2/2R
2A/2ARw
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
9/9R
10/10R
(End of 
Treatment)
Study Weeka/Rescue Arm Week
-2 to 0
0/0R
0.5/ 0.5R
1/1R
2/2R
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
Study Day /Rescue Arm Day
-14 to 0
0c/0R
4/4R
7/7R
14/14R
21/21R
28/28R
35/35R
42/42R
49/49R
56/56R
gonadotropin test results can be used for the assessment of pregnancy on Day 0/Week 0. Local laboratory will be used for Visit 2A/2AR (Day 4) potassium and magnesium levels, 
and Day 4 after starting tacrolimus, cyclosporine, everolimus, or sirolimus if the subject is not taking at V2/2R.
h Female subjects of child-bearing potential will have serum pregnancy testing performed at a central or local laboratory. Urine test results are not sufficient for eligibility 
determination.
i
HIV status will be used for the evaluation of this criterion. Subjects must have a confirmed negative result within 3 months of study entry or have testing done locally during the 
screening period. The test result must be available prior to randomization.
j
Hepatitis B and HCV historical results available within 3 months prior to study treatment initiation will be accepted. If historical values are not available then the test will be 
repeated at Visit 2/Day 0. The results of test do not have to be available prior to start of dosing.
k Blood samples taken at all study visits (processed to obtain plasma), for all CMV DNA tests (quantitation, genotyping), will be tested in the central specialty laboratory. Only 
during screening period, local specialty laboratory results for CMV DNA quantitation could be used for eligibility assessment; in this case CMV DNA results from central 
laboratory are not required. At all other visits, CMV DNA test will be conducted at a central specialty laboratory. The screening results, regardless whether from the local or 
central specialty laboratory, will be utilized for stratification for randomization.
l
Subjects with tissue invasive CMV disease or CMV syndrome (SOT subjects only) present at Visit 2/Day 0 (baseline) will have serial assessments at all subsequent visits for 
infection status (no change, improvement, worsening, or resolution of disease/syndrome and associated symptoms) until resolution. All subjects will be assessed at each visit for 
new tissue invasive disease or CMV syndrome, and any new tissue invasive disease or CMV syndrome will have serial assessments at all subsequent visits for infection status (no 
change, improvement, worsening, or resolution of disease/syndrome and associated symptoms) until resolution.
 
n If the subject is receiving immunosuppressant drugs (cyclosporine, tacrolimus, sirolimus, or everolimus), as mentioned in Study Protocol Section 7.2.3.5, on Study Day 0, then a 
blood sample to measure immunosuppressant drug concentration level will be obtained on Visit 2/2R (Day 0) prior to study treatment, Visit 2A/2AR [Day 4 (±1 day)], Visit 3/3R 
[Day 7 (+2 day)], and on Visit 10/10R (Week 8) If the subject is not receiving immunosuppressant drugs at Day 0, but starts any time after Day 0 while still receiving study 
treatment, then a blood sample to measure immunosuppressant drug concentration will be obtained 4 days after the first dose of immunosuppressant drug and at the next scheduled 
study visit. Additional monitoring of immunosuppressant drug levels may be performed at the discretion of the investigator. Tests will be performed at a local laboratory. For more 
details refer to Section 7.2.3.5 of the Study Protocol.
o Pharmacokinetic samples should be obtained and analyzed for only those subjects who are randomized to maribavir treatment arm. For subjects ≥18 years of age randomized to 
maribavir, a pre-morning dose PK sample should be obtained at all 3 PK visits and a 2-4 hour post-morning dose sample will be collected only at Visit 3/Week 1 and 
Visit 10/Week 8. There will be no post dose PK sample collected for Visit 6/Week 4. Pharmacokinetic sample collection for adolescent subjects ≥12 to <18 years of age, 
For non-commercial use only


Shire
CONFIDENTIAL
Page 18
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
Table 1
Schedule of Assessment 1: Screening Phase and Study Treatment Phase
Phase
Screening 
Phase
Study Treatment Phaseu
Study Visit / Rescue Arm Visit
1/NA
2/2R
2A/2ARw
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
9/9R
10/10R
(End of 
Treatment)
Study Weeka/Rescue Arm Week
-2 to 0
0/0R
0.5/ 0.5R
1/1R
2/2R
3/3R
4/4R
5/5R
6/6R
7/7R
8/8R
Study Day /Rescue Arm Day
-14 to 0
0c/0R
4/4R
7/7R
14/14R
21/21R
28/28R
35/35R
42/42R
49/49R
56/56R
randomized to maribavir, will be as follows: intensive PK sampling at Visit 3/Week 1 (pre-morning dose and 1, 2, 3, 4, 6, 8 [all ±5 min], and 12 hours [±15 min] post-morning 
dose); at Visit 6/Week 4 (one pre-morning dose PK sample); at Visit 10/Week 8 (one pre-morning dose and one between 2-4 hour post morning dose PK samples). Additional PK 
samples will be collected from any subjects with biopsy proven graft-versus-host disease (GVHD) of gastrointestinal (GI) with diarrhea (>300 ml/day) or biopsy proven GVHD of 
GI with nausea and vomiting or documented acute GVHD of liver (Stage II), total bilirubin >3 mg/dL or biopsy-proven) with diarrhea (>500 ml/day) or biopsy proven acute 
GVHD of the skin with diarrhea (>500 mL/day) per Boeckh et al., 1998. Refer to Study Protocol Section 7.2.4.1 for more details.
p The eligibility of subjects who must discontinue the investigator assigned anti-CMV treatment for lack of anti-viral activity and/or intolerance, will be assessed at Visit 
5/Week 3 up to Visit 9/Week 7 for entry into an rescue arm of treatment with maribavir 400 mg BID for up to 8 weeks.
q Except at screening, baseline, and end of treatment, IRT will be used for maribavir dispensing. Subjects who are eligible for the rescue arm will be assigned maribavir by the 
IRT system. The IRT system will be used for stratification and randomization of eligible subjects at baseline. The IRT will be used to manage maribavir.
r All dispensed study assigned treatment will be documented on the CRFs and/or other study assigned treatment record. Investigator assigned anti-CMV medication (ganciclovir, 
valganciclovir, foscarnet, or cidofovir) will also be documented on the CRFs and/or other study treatment accountability records, and may include additional information as 
required per applicable regulations. The disposition of unused supply of dispensed study assigned treatment and investigator assigned anti-CMV medication that has been 
prescribed to the subject will be documented in the accountability log.
s The study diary will be dispensed at baseline and will be collected at the last follow-up visit. The diary will be used for tracking treatment compliance with medication 
administered orally during the study treatment phase and it will be used for tracking completion of the
 
during the study treatment phase and through the 
follow-up phase (see Schedule of Assessment 2, Table 2). Note that the diary will only be utilized for study treatments that are given orally. The IV administration will be tracked 
in the source documents and CRF.
t
Includes recording of medications and transfusions (packed red blood cells, platelets, fresh frozen plasma). Changes in immunosuppression regimens will also be recorded.
u Subjects who prematurely discontinue study treatment will complete the end of treatment procedures described for Visit 10/Study Week 8; these subjects will continue a 
modified schedule of assessments through the remaining weekly visits scheduled for the study treatment phase and the regular schedule of assessments through the 12-week 
follow-up phase or if meeting criteria to enter maribavir rescue arm will start 8-week maribavir 400 mg BID treatment. The end of treatment (Visit 10/Study Week 8) sample for 
immunosuppressant drug concentration level will be collected at the next visit scheduled 1 week after the treatment discontinuation. For subjects entering the Rescue Arm, 
 
 the Visit 2R/Week 0R does not need to be 
collected. Subjects who discontinue study treatment early will not be asked to complete the following procedures after the end of treatment visit for subsequent visits in the 
treatment phase: the use of the diary for study treatment compliance, dispense or use of any study treatment, and PK sample collection. After completing the 8-week study 
treatment phase, subjects will enter the 12-week follow-up phase.
v Not required at V2R.
w V2A/A-R is only required for subjects taking tacrolimus, cyclosporine, everolimus, or sirolimus at Visit 2/2R.
For non-commercial use only


Shire
CONFIDENTIAL
Page 19
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
Table 2
Schedule of Assessment 2: Follow-up Phase
Phase
Follow-up Phasek,l
Visit
11/11R
12/12R
13/13R
14/14R
15/15R
16/16R
17/17R
18/18R 
(End of 
Study)
Study Week 
(Follow-up Week)a
9(1)/9R
(1R)
10(2)/10R
(2R)
11(3)/11R
(3R)
12(4)/12R
(4R)
14(6)/15R
(6R)
16(8)/16R
(8R)
18(10)/18R 
(10R)
20(12)/20R
(12R)
Study Day 
(Follow-up Day)
63(7)/63R
(7R)
70(14)/70R
(14R)
77(21)/77R
(21R)
84(28)/84R
(28R)
98(42)/98R
(42R)
112(56)/112R
(56R)
126(70)/126R
(70R)
140(84)/140R
(84R)
Physical examination 
(including weight)
X
Vital signs
X
12-Lead ECGb
X
Hematology/Chemistryc
X
X
X
X
Urinalysisc
X
Immunosuppressant 
drug concentration 
leveld
X
Invasive bacterial, viral 
and fungal Infection(s) 
assessment 
X
X
X
X
X
X
X
X
CMV DNA test
X
X
X
X
X
X
X
X
Symptomatic CMV 
infection assessmentf
X
X
X
X
X
X
X
X
Transplant status
X
X
X
X
X
X
X
X
GVHD assessment (for 
HSCT subjects only)
X
X
X
X
X
X
X
X
Comorbidity status 
evaluation 
X
X
X
Study diaryg
X
X
X
X
X
X
For non-commercial use only


Shire
CONFIDENTIAL
Page 20
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
Table 2
Schedule of Assessment 2: Follow-up Phase
Phase
Follow-up Phasek,l
Visit
11/11R
12/12R
13/13R
14/14R
15/15R
16/16R
17/17R
18/18R 
(End of 
Study)
Study Week 
(Follow-up Week)a
9(1)/9R
(1R)
10(2)/10R
(2R)
11(3)/11R
(3R)
12(4)/12R
(4R)
14(6)/15R
(6R)
16(8)/16R
(8R)
18(10)/18R 
(10R)
20(12)/20R
(12R)
Study Day 
(Follow-up Day)
63(7)/63R
(7R)
70(14)/70R
(14R)
77(21)/77R
(21R)
84(28)/84R
(28R)
98(42)/98R
(42R)
112(56)/112R
(56R)
126(70)/126R
(70R)
140(84)/140R
(84R)
X
X
X
 
X
X
X
X
X
X
X
X
X
AE monitoringi 
X
X
X
X
X
X
X
X
SAE monitoringi
X
X
X
X
X
X
X
X
Concomitant 
medications, therapies, 
and proceduresj
X
X
X
X
X
X
X
X
AE=adverse event; CMV=cytomegalovirus; ECG=electrocardiogram; GVHD=graft-versus-host disease; HBV=hepatitis B virus; HCV=hepatitis C virus; HIV=human 
immunodeficiency virus; HSCT=hematopoietic stem cell transplant; IRT=interactive response system; R=rescue; SAE=serious adverse event; SF-36=Short Form-36
Note: Subjects in the investigator-assigned anti-CMV treatment arm who discontinue the study treatment phase to enter the maribavir rescue arm will exit after 8 weeks of 
maribavir 400 mg BID treatment to enter the follow-up phase (visits denoted as “R”).
a Permissible assessment windows: Study Weeks 9-12 (Follow-up Weeks 1-4) ±2 days; Study Weeks 14-20 (Follow-up Weeks 6-12) ±3 days.
b Electrocardiograms other than protocol-specified ECGs will be performed when clinically indicated.
c Clinical laboratory testing performed at a central laboratory for all specified time points during the follow-up phase.
d Refer to Study Protocol Section 7.2.3.5 for more details.
e Blood samples taken at all study visits (processed to obtain plasma), for all CMV DNA tests (quantitation, genotyping) during the follow-up phase will be tested in the central 
specialty laboratory.
f Subjects with tissue invasive CMV disease or CMV syndrome (SOT subjects only) present at Visit 2/Day 0 (baseline) will have serial assessments at all subsequent visits for 
infection status (no change, improvement, worsening, or resolution of disease/syndrome and associated symptoms) until resolution. All subjects will be assessed at each visit for 
new tissue invasive disease or CMV syndrome, and any new tissue invasive disease or CMV syndrome will have serial assessments at all subsequent visits for infection status (no 
change, improvement, worsening, or resolution of disease/syndrome and associated symptoms) until resolution.
For non-commercial use only


Shire
CONFIDENTIAL
Page 21
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
Table 2
Schedule of Assessment 2: Follow-up Phase
Phase
Follow-up Phasek,l
Visit
11/11R
12/12R
13/13R
14/14R
15/15R
16/16R
17/17R
18/18R 
(End of 
Study)
Study Week 
(Follow-up Week)a
9(1)/9R
(1R)
10(2)/10R
(2R)
11(3)/11R
(3R)
12(4)/12R
(4R)
14(6)/15R
(6R)
16(8)/16R
(8R)
18(10)/18R 
(10R)
20(12)/20R
(12R)
Study Day 
(Follow-up Day)
63(7)/63R
(7R)
70(14)/70R
(14R)
77(21)/77R
(21R)
84(28)/84R
(28R)
98(42)/98R
(42R)
112(56)/112R
(56R)
126(70)/126R
(70R)
140(84)/140R
(84R)
g The study diary will be used for tracking completion of the 
 during the follow-up phase. The study diary will be collected at the last follow-up visit.
i Adverse events and SAEs will be monitored and recorded through Visit 18/Week 20/Follow-up Week 12 (end of study) according to Study Protocol Section 7.2.3.6.
j All medications, therapies, and procedures used to treat AEs will be recorded through Visit 18/Week 20 (Follow-up Week 12 (end of study).
k Subjects who withdraw from the study during the follow-up phase will perform the Visit 18/Week 20 (Follow-up Week 12) end of study procedures.
l If the subject is unable to or unwilling to travel to the site for the follow-up visits, these visits may be performed remotely (ie, at the subject’s home) by a qualified sponsor or site 
designee, and only if permitted according to local regulations. Blood sample for DNA quantitation and clinical laboratory assessments will be collected. Adverse events and SAE 
collection may be completed by telephone follow-up call on the day of the scheduled visit.
For non-commercial use only


Shire
CONFIDENTIAL
Page 22
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
2.5
Determination of Sample Size
In Phase 2 Study SHP620-202, the proportion of subjects with undetectable plasma CMV DNA 
within 6 weeks was 70%, 63%, and 68% for the 400 mg, 800 mg, and 1200 mg BID dose groups, 
respectively. The proportion of subjects with undetectable plasma CMV DNA within 12 weeks 
was 70%, 65%, and 75% for the 400 mg, 800 mg, and 1200 mg BID dose groups, respectively. 
Therefore, it is assumed that at least 60% of maribavir treated subjects will have achieved 
undetectable plasma CMV DNA at Visit 9/Week 7 and Visit 10/Week 8 when calculating the 
sample size for Study SHP620-303.
A proportion of approximately 40% is considered as a reasonable estimate of the proportion of 
subjects with confirmed undetectable plasma CMV DNA at Visit 9/Week 7 and Visit 10/Week 8 
in a control group when calculating the sample size. It is believed that the treatment difference of 
20% higher in maribavir group compared to control group is larger than a clinically meaningful 
difference.
In order to demonstrate statistical superiority in the reduction of CMV DNA, it is assumed that 
the proportion of subjects with confirmed unquantifiable plasma CMV DNA at Visit 9/Week 7 
and Visit 10/Week 8 in the maribavir and control groups is 60% and 40%, respectively. A total 
of 315 subjects is required in the ratio of 2:1 (210 subjects in maribavir group and 105 subjects in 
the control group) to provide 90% power in hypothesis testing at an alpha level of 0.05 (2-sided 
test). The sample size is estimated based on a 2-group continuity corrected Chi-square test of 
equal proportions by using nQuery Advisor 7.0. Considering 10% drop-outs, 351 subjects 
(234 subjects in maribavir group and 117 subjects in the control group) will be enrolled and 
randomized.
2.6
Multiplicity Adjustments for Type I Error Control
The hypothesis-testing of the primary and key secondary endpoint will be adjusted for multiple 
comparisons using a fixed-sequence testing procedure to control the family-wise Type 1 error 
rate at 2-sided 5% level. The statistical test will be performed sequentially in the order of 
primary efficacy endpoint, and the key secondary endpoint. First, the primary endpoint analysis 
will be assessed at α=0.05 (2-sided). If and only after the primary efficacy endpoint is 
statistically significant, the key secondary endpoint will be assessed at α=0.05 (2-sided).
For non-commercial use only


Shire
CONFIDENTIAL
Page 23
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
3.
OBJECTIVES
3.1
Primary Objective
The primary objective of this study is to compare the efficacy of maribavir to 
investigator-assigned anti-CMV therapy in CMV viremia clearance at the end of Study Week 8, 
in transplant recipients who are refractory or resistant to prior anti-CMV treatment.
3.2
Key Secondary Objective
The key secondary objective of this study is to compare the efficacy of the 2 study treatment 
arms on CMV viremia clearance and symptomatic CMV infection (tissue-invasive disease and 
CMV syndrome) improvement or resolution at the end of Study Week 8, and maintenance of this 
treatment effect through Study Week 16 (8 weeks of post-treatment/follow-up phase).
3.3
Secondary Objectives
The secondary objectives of this study are:

To compare the efficacy of maribavir to investigator-assigned anti-CMV therapy on CMV 
viremia clearance after completion of 8 weeks of study treatment in transplant recipients who 
are refractory or resistant to prior anti-CMV treatment.

To compare the efficacy of the 2 study treatment arms on CMV viremia clearance and 
tissue-invasive CMV disease and CMV syndrome improvement or resolution after 
completion of 8 weeks of study treatment and maintenance of this treatment effect through 
Study Weeks 12, 16, and 20.

To assess the maintenance of CMV viremia clearance, and resolution or improvement of 
tissue invasive CMV disease and CMV syndrome, achieved at the end of Study Week 8, 
through Weeks 12, and 20.

To evaluate the incidence of recurrence of CMV viremia in the 2 study treatment arms, 
during the first 8 weeks of the study, during the 12 weeks of the follow-up study phase, and 
at any time during the study.

To evaluate the incidence of recurrence of CMV viremia in the 2 study treatment arms, when 
subjects are on-treatment and off-treatment.

To assess the profile of mutations in the CMV genes conferring resistance to maribavir.

To evaluate the all-cause mortality.

To assess the safety and tolerability of maribavir.

To assess the efficacy, maintenance of the treatment effect, and the safety of maribavir 
administered as the rescue treatment.

To characterize the pharmacokinetics of maribavir.
For non-commercial use only


Shire
CONFIDENTIAL
Page 24
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
3.4
Exploratory Objectives
The exploratory objectives of this study are:
For non-commercial use only


Shire
CONFIDENTIAL
Page 25
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
4.
SUBJECT POPULATION SETS
4.1
Enrolled Set
Enrolled Set consists of all subjects who have signed informed consent and some study 
procedures have begun (e.g., dispensed study treatment, current drug has been withdrawn).
4.2
Randomized Set
Randomized Set consists of all subjects in the enrolled set who have been randomized to the 
study. Subjects will be analyzed in the treatment group to which they are randomized.
4.3
Modified Randomized Set
Modified Randomized Set consists of all subjects in the enrolled set who have been randomized 
to the study and have taken any dose of study-assigned treatment. Subjects will be analyzed in 
the treatment group to which they are randomized.
4.4
Safety Set
The Safety Set consists of all subjects who took any dose of study-assigned treatment. Subjects 
will be analyzed according to the treatment actually received.
4.5
Per-protocol Set
The Per-protocol (PP) Set consists of all subjects in the Randomized Set who do not have 
relevant major protocol deviations that may affect the primary efficacy assessment. Prior to 
database lock, the Sponsor medical lead will review the protocol deviations collected throughout 
the study and determine which of those are relevant major protocol deviations. 
The major protocol deviations that lead to exclusion from the Per Protocol Set include but are not 
limited to the following:
1. Violations of inclusion criteria 2, 3, and/or 4
2. Early discontinuation defined as discontinuation from study treatment within 72 hours 
of first dose of study assigned treatment.
3. Received prohibited concomitant medications other than assigned by the randomization 
while on-treatment  

Any of the following systemic anti-CMV therapies (except unintentional 
administration for no longer than 1 day, except cidofovir), if not already 
administered as investigator anti-CMV treatment of choice:

Ganciclovir

Valganciclovir

Foscarnet

Cidofovir

Leflunomide
For non-commercial use only


Shire
CONFIDENTIAL
Page 26
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020

Artesunate

Letermovir

Use of other investigational anti-CMV agent such as CMV specific T-cell 
transfer (considered investigational)
4. Taking wrong study treatment or receiving no study treatment
4.6
Pharmacokinetic Set
The Pharmacokinetic (PK) Set will consist of all subjects who took any dose of maribavir either 
as study assigned treatment or as rescue treatment, had plasma sample drawn and tested for 
maribavir concentrations.

The adolescent PK Set will consist of all subjects ≥12 to <18 years of age in the 
PK Set.
4.7
Rescue Set
The Rescue Set will consist of all subjects who entered rescue arm and received any dose of 
maribavir as rescue therapy.
The Randomized Set and PP Set will be used for efficacy analyses with the Randomized Set as 
the primary analysis set and the PP Set as the supportive one.
For non-commercial use only


Shire
CONFIDENTIAL
Page 27
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
5.
SUBJECT DISPOSITION
This section describes subject disposition for both the analysis sets and the study status.
The number of subjects in the following analysis sets will be summarized by treatment group and 
overall. Percentages will be provided (except the enrolled set) using the Randomized Set as the 
denominator.

Enrolled Set

Randomized Set

Modified Randomized Set

Safety Set

PP Set

PK Set

Adolescent PK Set (age ≥12 to <18 years)

Rescue Set
For subjects randomized to the IAT group, the number and percentage of subjects in each type of 
treatment will be provided.
For subject study status after receiving the study assigned treatment, the number and percentage 
of the subjects in the following categories will be presented by treatment group and overall using 
the Randomized Set.

Subjects who completed the 8 weeks of study treatment, or discontinued treatment 
early and by reason

Subjects who completed 8 visits for the 8-week treatment phase

Subjects who entered rescue treatment

Subjects who did not switch to rescue treatment, their study status at the end of 
study, the number and percentage of subjects who completed the study or 
prematurely discontinued from the study and by reason.
For subjects who entered rescue treatment phase, the number and percentage of the subjects in 
the following categories will be provided.

Subjects who completed rescue treatment or discontinued rescue treatment early 
and by reason

Subjects who completed 8 visits for the 8-week rescue treatment phase

Subjects study status at the end of study, the number and percentage of subjects 
who completed the study or discontinued early and by reason
A listing of all screen failures (ie, subjects who were screened and enrolled but not randomized) 
will be presented along with reasons for screen fail and details of any AEs.
In addition, the number of subjects enrolled and randomized will be summarized by region, 
country and site.
For non-commercial use only


Shire
CONFIDENTIAL
Page 28
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
6.
PROTOCOL DEVIATIONS
Protocol deviations are identified throughout study and categorized (major/significant or 
minor/nonsignificant) following the study specific Deviation Rules Document. Protocol 
deviations related to COVID-19 pandemic will be captured.
A summary of the number and percentage of subjects with any protocol deviations, major and 
minor, will be produced using the Randomized Set. A summary of the number and percentage of 
subjects with any COVID-19 related protocol deviations, major and minor, will also be produced 
using the Randomized Set. All protocol deviation data will be listed by subject using the 
Randomized Set. Additionally, all protocol deviations related to COVID-19 will be presented by 
region, country, site and subject.
For non-commercial use only


Shire
CONFIDENTIAL
Page 29
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
7.
DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS
All baseline safety and efficacy parameters (apart from those listed below) are presented along 
with the on-treatment summary statistics in the safety and efficacy sections (refer to Section 10
and Section 11).
Demographic and baseline characteristics will be determined using the screening visit or last 
observation on or prior to the first dose date of study assigned treatment.
Descriptive summaries of demographic and baseline characteristics will be presented by 
treatment group and overall for the Randomized Set and PP set. 
The following demographic characteristics will be summarized: age, age group (12-17, 18-44, 
45-64, and ≥65 years old), sex, ethnicity, race, weight, height, and BMI.
The following baseline characteristics including transplant history and CMV history will be 
summarized. Baseline characteristics treated as categorical variables include:

Current transplant type (SOT/HSCT)
o
If SOT, by organ type, and additional characteristics specific to each organ type
o
If HSCT, by

Underlying disease,

Recurrence of underlying disease (yes, no),

Type of HSCT transplant (autologous, allogenic),

If allogenic HLA match type,

If allogenic haploidentical (yes, no)

Stem cell source,

Current graft status at baseline,

Type of preparative conditioning regimen  

History of previous transplants (yes, no)
o
If yes, transplant type(s) prior to current transplant
o
  If HSCT, number of previous HSCT and reason for previous HSCT

CMV serostatus overall and by transplant type (SOT, HSCT)

CMV DNA category (high, medium, low) used in randomization from IRT

CMV DNA category (high, medium, low) based on baseline central laboratory results

Presence of CMV mutation resistant to ganciclovir/foscarnet/cidofovir per investigator 
(yes, no)

Presence of CMV mutation resistant to ganciclovir/foscarnet/cidofovir per central 
laboratory result (yes, no)

Is current CMV infection the first episode post-transplant (yes, no)

Have history of CMV tissue invasive disease (yes, no) and by type

Category of current CMV infection based on investigator’s assessment (CMV Syndrome 
for SOT subjects only, tissue invasive disease, asymptomatic)
For non-commercial use only


Shire
CONFIDENTIAL
Page 30
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
o
Symptoms present for CMV Syndrome 
o
Tissue invasive disease type

Symptomatic CMV infection (CMV tissue invasive disease or CMV syndrome) 
confirmed by EAC

Is net immunosuppression use changed prior to start of study treatment, specifically due 
to current CMV infection (yes, no)
o
If yes, strategies used

Prior anti-lymphocyte use (yes, no)

Acute GVHD status at baseline (presence, absence, and grade)

Chronic GVHD status at baseline (presence, absence, and grade)

Prior use of CMV prophylaxis (yes, no)

Hepatic impaired subjects (no impairment and by grade)

Renal impaired subjects (no, mild, moderate, severe)

Baseline total WBC from hematology panel (<2.7, ≤2.7 and <7, ≤7 10^9/L)

Baseline CD4+CD69+, and CD8+CD69+ T cells from immune function assay (<0.5%, 
≤0.5% and <2%, ≤2%)
Baseline characteristics treated as continuous variable:

Days from onset of current CMV infection to first dose of study assigned treatment

Baseline CMV DNA levels from central laboratory

The nucleated cell number transplanted, the number of CD34+ cells transplanted for the 
current HSCT 
The hepatic impairment is defined based on the baseline Total Bilirubin to be aligned with 
CTCAE V4.03 for toxicity grading:

≤upper limit of normal (ULN) – No impairment

>ULN to <1.5x ULN: Grade 1

≥1.5x ULN to <3x ULN: Grade 2

≥3x ULN: Grade 3 or 4
The renal impairment is defined based on the baseline creatinine clearance per Cockcroft-gault 
equation:

No [creatinine clearance >80 mL/minute]

Mild [creatinine clearance 50-80 mL/minute]

Moderate [creatinine clearance 30-<50 mL/minute]

Severe [creatinine clearance <30 mL/minute]
Medical history will be summarized by system organ class by treatment group and overall.
For non-commercial use only


Shire
CONFIDENTIAL
Page 31
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
8.
EXTENT OF EXPOSURE AND TREATMENT COMPLIANCE
The extent of exposure and treatment compliance will be summarized using the Safety Set.
8.1
Exposure to Study Assigned Treatment
Exposure data are recorded in both the patient eDiary and the eCRF for study drug administered 
orally, and CRF only for study drug administered intravenously (IV). The dose adjustment and 
dose interruption for study drugs are collected on the eCRF.
It is noted that there were reports of eDiary malfunction due to issues such as device or internet 
connection during the study resulting in some data loss. Exposure to maribavir treatment for the 
treatment phase will be measured in the following ways:

Exposure duration will be calculated as the number of days from the date of first dose to 
the date of the last dose of study treatment plus 1

Actual exposure days to maribavir will be calculated as the number of days on which at 
least 1 dose of study drug was taken from the available eDiary data.

Total number of maribavir doses taken will be calculated as the cumulative number of 
doses taken as recorded in the eDiary
The above exposure will also be summarized in the set of subjects without any eDiary issue to 
assess the impact by eDiary.
Exposure to maribavir received as the rescue therapy will also be calculated and summarized 
separately using the above definition.
For the investigator-assigned anti-CMV treatment group, it is up to the study investigators to
choose and prescribe an anti-CMV drug of their choice from the available products utilized for 
treatment of CMV infection/disease in clinical practice, as endorsed in published guidance 
documents, institutional guidelines, and other published literature (Kotton et al. 2013; Tomblyn 
et al. 2009). The IAT group may utilize 1 or 2 of the following 4 anti-CMV agents: (change from 
ganciclovir to valganciclovir or vice versa will be allowed):

Ganciclovir

Valganciclovir

Foscarnet

Cidofovir
For a subject receiving 1 or 2 anti–CMV agents at the time of enrollment, the investigator may 
either change therapy at the time of randomization/treatment initiation or the subject may remain 
on the same therapy as the investigator assigned anti-CMV agent, if randomized to this study 
treatment arm. After randomization, changes to the investigator treatment of choice could 
include: change in dosing or change in dosing regimen, but will not include an addition of or 
switch to another anti-CMV agent (switching between valganciclovir and ganciclovir is 
allowed). If the treatment was continued or was started (post-randomization) as 2 anti-CMV 
For non-commercial use only


Shire
CONFIDENTIAL
Page 32
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
agents, withdrawal of one agent while continuing with the second one will be possible.
Combination therapy of cidofovir with foscarnet is prohibited.
Dose and dose regimen of the investigator-assigned anti-CMV treatment will be at the discretion 
of the investigator following clinical practice. Adjustment of the dose (increase or decrease) 
could be done for either efficacy or safety, as deemed appropriate by the investigator. Reason for 
dose adjustment will be recorded in eCRF.
Given the varied dosing intervals for each agent and the possible combination, exposure for these 
anti-CMV treatments in the treatment phase will be defined as below.

Exposure duration for ganciclovir, valganciclovir, and foscarnet will be calculated as the 
number of days from the date of first dose to the date of the last dose of study treatment plus 
1; exposure duration for cidofovir as monotherapy will be calculated as the number of days 
from the date of first dose to the date of the last dose of cidofovir plus 14. If combination 
treatment is used, the exposure duration will be the longer of the two calculated treatment 
durations.

Actual exposure days to study drug will be calculated as the number of days on which any 
dose of study drug was taken or administered including days during an extended dosing 
interval (eg, Q48 hour for ganciclovir/valganciclovir, every other week for cidofovir). If 
combination treatment is used, the actual exposure days to study drug will be the longer of 
the two calculated treatment durations. The actual exposure days to valganciclovir will be 
calculated as the number of days on which at least 1 dose of study drug was taken per the 
eDiary.
Exposure will be summarized by treatment group and IAT type using the Safety Set. 
Additionally, exposure by study assigned treatment will be provided for the following subgroups.

Race (white, black or African American, Asian, Others)

Sex (male, female)

Age group,
o
≥16 to <18 years of age (adolescents)
o
≥18 to <45 years of age
o
≥45 to <65 years of age
o
≥65 years of age

Enrolling regions (North America, Europe and Asia)

Transplant type (SOT, SCT)

Presence of CMV mutation associated with resistance to ganciclovir/foscarnet/cidofovir 
per central laboratory result (yes, no)

Symptomatic infection (yes, no) as confirmed by EAC

Renal impaired subjects (no, mild, moderate/severe)

Hepatic impaired subjects (yes, no)  
Exposure to maribavir received as rescue therapy will be summarized separately using the 
Rescue Set.
For non-commercial use only


Shire
CONFIDENTIAL
Page 33
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
8.2
Measurement of Treatment Compliance
The dosing compliance for study-assigned treatment (maribavir or investigator-assigned 
anti-CMV treatment group) is defined as the number of actual exposure days divided by the 
exposure duration days multiplied by 100.
The number and percentage of subjects with dose change and type of change as recorded on 
eCRF will be provided.
The Safety Set will be used for all drug exposure and compliance information, dose change, and 
type of change will be presented chronologically in data listing, sorted by treatment type (ie, 
maribavir, ganciclovir, valganciclovir, foscarnet, cidofovir, and each combination type) and 
subject, and will include the route of administration, date and time of dose administration, and 
tablet/dose administered as applicable for each treatment type. Drug exposure and compliance 
information for maribavir as rescue therapy will be summarized and provided in a data listing 
using the Rescue Set.
For non-commercial use only


Shire
CONFIDENTIAL
Page 34
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
9.
PRIOR AND CONCOMITANT MEDICATION AND PROCEDURE 
9.1
Prior and Concomitant Medication
The version of World Health Organization (WHO) Drug Dictionary dated September 2013 or in 
effect at the time of analysis will be used to classify prior and concomitant medications by 
Anatomical Therapeutic Chemical (ATC) class and preferred term.
Prior medication is defined as any medication with the start date prior to the date of the first dose 
of study treatment.
Concomitant medication during the on-treatment period is defined as any medication with a start 
date prior to the date of the first dose of study treatment and continuing after the first dose of 
study treatment or with a start date on or after the study treatment initiation and before the end of 
the on-treatment period. The on-treatment observation period starts at the time of study treatment 
initiation through 7 days after the last dose of study treatment or through 21 days after the last 
dose of cidofovir. For subjects who transfer from the study treatment to either maribavir rescue 
or to a nonstudy anti-CMV treatment, the on-treatment observation period starts at the time of 
the study treatment initiation until the maribavir rescue treatment initiation or until the nonstudy 
anti-CMV treatment initiation, whichever is earlier.
Post-treatment medication is defined as any medication with a start date during the on-treatment 
period and continuing into the follow-up period through the end of study or with a start date after 
the end of the on-treatment period through the end-of-study observation period.
Concomitant medication during the on-rescue treatment period, and post-rescue treatment period
will be defined similarly.
Any technical details related to computation, dates, imputation for missing dates are described in 
Section 18.6.
Prior and concomitant medication usage will be summarized by the number and percentage of 
subjects receiving each medication by ATC Level III and preferred term by treatment group and 
overall using the Safety Set. Medications can be counted both as prior and concomitant 
medication. Multiple medication usage by a subject in the same category will be counted only 
once. Post-treatment anti-CMV medication usage will be summarized by treatment group and 
IAT type (valganciclovir/ganciclovir, foscarnet) using the Safety Set. 
Additionally, concomitant medications in the following specific categories will be summarized 
by treatment group and overall using the Safety Set.

Growth factor use

Blood product use
Similarly, the above summary of concomitant medications will be repeated for the on-rescue 
treatment and post-rescue treatment period using the Rescue Set.
For non-commercial use only


Shire
CONFIDENTIAL
Page 35
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
All prior, concomitant, post-treatment medication, concomitant medication to rescue treatment, 
and post rescue treatment medications will be provided in by-subject data listing.
9.2
Prior and Concomitant Procedure
A study concomitant procedure is any therapeutic and diagnostic intervention (eg, 
surgery/biopsy) or diagnostic assessment (bacterial cultures, imaging such as X-ray, CT scans) 
performed between the dates of the first dose of the study treatment and the end of the follow-up 
phase, inclusive.
Prior procedure is defined as any therapeutic and diagnostic intervention with the start date prior 
to the date of the first dose of study treatment.
Concomitant procedure during the on-treatment period, post-treatment procedure in the follow-
up period will be defined similarly as that of the concomitant medications or post-treatment 
medications respectively.  
Concomitant procedure during the on-rescue treatment period, and post-rescue treatment 
procedures will be defined similarly.
All prior, concomitant, post-treatment procedures, concomitant procedure to rescue treatment, 
and post rescue treatment procedure will be provided in by-subject data listings.
For non-commercial use only


Shire
CONFIDENTIAL
Page 36
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
10.
EFFICACY ANALYSES
Unless specifically noted otherwise, all statistical tests and confidence intervals will be two-sided 
at α=0.05. It is noted that the phrase "statistically significant" will be applied to only analyses of 
the primary and key secondary efficacy endpoints with adjustment for multiplicity (see 
Section 2.6).
Summary descriptive statistics will include the number of subjects (N), mean, standard deviation, 
median, minimum and maximum (range) values for continuous variables, and number and 
percentages for categorical variables. The denominator for the percentages will be based on the 
number of subjects in the analysis set unless otherwise specified. Time-to-event endpoints will 
be summarized using Kaplan-Meier estimation and ninety-five percent (95%) confidence 
intervals will be presented for the estimated 25%, 50%, and 75% times estimates.
All definitions and specifications described below will apply to all subsections.
Unless otherwise specified, all efficacy analyses will be based on results from central laboratory; 
for tissue invasive disease symptoms evaluation, the adjudicated results by EAC will be used for 
the efficacy analysis.
The baseline value for efficacy variables is defined as the last available value before or on the 
first dose date of study drug on Visit 2/Day 0 (refer Section 18.3). The strata level based on the 
central laboratory baseline plasma CMV DNA concentration for the efficacy analysis are defined 
as:

high viral load with CMV DNA ≥91000 IU/mL, 

intermediate viral load ≥9100 and <91000 IU/mL, 

low viral load CMV DNA <9100 IU/mL 
It is noted that low CMV DNA group includes subjects with baseline central laboratory (Day 0) 
CMV DNA <910 IU/mL. This is to account for all subjects enrolled on study after meeting 
eligibility criteria per the investigator and taking into consideration viral load fluctuation, 
differences in sampling time, specimen type, and testing methods. Baseline plasma CMV DNA 
concentration based the central laboratory may differ from the CMV DNA concentration used in 
eligibility and randomization, which required subjects to have a documented CMV infection in 
whole blood or plasma, with a screening value of ≥2730 IU/mL in whole blood or ≥910 IU/mL 
in plasma in 2 consecutive assessments, separated by at least 1 day, as determined by local or 
central specialty laboratory qPCR or comparable quantitative CMV DNA test within 14 days 
prior to randomization and the second sample within 5 days from the same laboratory and same 
sample type.  
For non-commercial use only


Shire
CONFIDENTIAL
Page 37
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
Confirmed CMV viremia clearance: defined as plasma CMV DNA concentration below the 
lower limit of quantification (<LLOQ; ie, <137 IU/mL) when assessed by COBAS®
AmpliPrep/COBAS® TaqMan® CMV Test at a central specialty laboratory, in 2 consecutive 
post-baseline samples, separated by at least 5 days.
Recurrence of CMV viremia: defined as plasma CMV DNA concentration ≥LLOQ when 
assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive plasma 
samples at least 5 days apart, after achieving confirmed viremia clearance.
Recurrence of the Symptomatic CMV infection: defined as the presence of signs or symptoms 
of the tissue invasive CMV disease or CMV syndrome (same or new symptomatology) 
confirmed as per Ljungman et al. (2017), after the period of resolution of the symptomatic 
infection in subjects symptomatic at baseline.
Subjects in the investigator-assigned treatment arm who are unable to continue taking 
investigator-assigned anti-CMV treatment due to the inadequate anti-viral activity and/or 
intolerance to the assigned treatment (as evaluated starting at Visit 5/Week 3) may be evaluated 
for entry into a maribavir rescue arm. The data collected post- maribavir rescue initiation, will be 
included in separate secondary analyses for efficacy and exploratory analysis for PK. Summary 
of all safety analyses will be provided separately for the maribavir rescue arm.
All efficacy measurements assessed after the initiation of rescue therapy or alternative anti-CMV 
treatment will be excluded from the primary study assigned treatment efficacy analysis unless 
otherwise specified. Efficacy after the initiation of rescue therapy will be summarized separately 
as specified. Efficacy measurements after the initiation of rescue therapy or alternative 
anti-CMV treatment will be indicated in listings.
Unless otherwise specified, for analysis purposes, the study week (Week 0 through Week 20) for 
all efficacy measurements on-treatment phase and follow-up phase will be determined based on 
the clinical visits. Efficacy measurements (Schedule of Assessment 1, Table 1, and Schedule of 
Assessment 2, Table 2, Section 7.2.2 of Protocol), assessed during the treatment phase and 
follow-up phase before receiving alternative anti-CMV treatment or rescue treatment, are 
included in the efficacy analysis to assess effect of the study-assigned treatment unless otherwise 
specified. If variation from the scheduled days of assessment, unscheduled visit, or early 
withdrawal from the treatment or study is found, a 4-day time window will be used for weekly 
assessment, and a 7-day time window will be used for biweekly assessment with the caveat that 
one measurement is counted only once for one week, and assessment done on or before the first 
dose of study treatment is considered for baseline determination. If two measurements are in the 
same week, the measurement closest to the scheduled visit from study start will be used for the 
summary.
10.1
Primary Efficacy Endpoint and Analysis 
10.1.1
Primary Efficacy Endpoint
The primary efficacy endpoint (a binary response) for the study is confirmed clearance of plasma 
CMV DNA (confirmed CMV viremia clearance) at the end of Study Week 8.
For non-commercial use only


Shire
CONFIDENTIAL
Page 38
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
For clearance of CMV viremia to be declared at the end of Study Week 8, the subject must have 
received exclusively study-assigned treatments.
Confirmed CMV viremia clearance at the end of Study Week 8 (Visit 10) is defined as plasma 
CMV DNA concentrations <LLOQ (ie, <137 IU/mL), when assessed by COBAS®
AmpliPrep/COBAS® TaqMan® CMV Test at a central specialty laboratory, in 2 consecutive 
postbaseline samples separated by at least 5 days, regardless of whether either study-assigned 
treatment was discontinued before the end of the stipulated 8 weeks of therapy (see Table 3).
Table 3
Assessments of Virological Responders at Study Week 8
Scenario
CMV DNA Weeks on Study
Week 6
Week 7
Week 8
Week 9*
Response
Rationale
1
+ / -
-
-
+/-/NA
Yes
2 consecutive ‘-‘ at Week 7 and Week 8
2
+ / -
-
+
+/-/NA
No
Not 2 consecutive ‘-‘ at Week 7 and 
Week 8
3
+ / -
+
-
+/-/NA
No
Not 2 consecutive ‘-‘ at Week 7 and 
Week 8
4
+ / -
-
NA
-
Yes
2 consecutive ‘-‘ as shown by available 
data and both ‘-‘ at Week 7 and Week 9 
for missing Week 8, otherwise 
nonresponder
5
-
NA
-
+/-/NA
Yes
2 consecutive ‘-‘ as shown by available 
data and both ‘-‘ at Week 6 and Week 8 
for missing Week 7, otherwise 
nonresponder
6
-
NA
NA
-
Yes
2 consecutive ‘-‘ as shown by available 
data at Week 6 and Week 9 and both ‘-‘, 
otherwise nonresponder
NA=not available for evaluation of study drug effect; reason could be not assessable by lab, or starting alternative anti-CMV 
treatment, withdrawal from study, etc.
*Week 9 data only to be used if Week 8 data are unavailable or missing.
Notes: Scenarios in the table above are provided as examples and may not be all-inclusive of all possibilities.
Only CMV DNA data evaluable for assessment of effect of study drug will be included (ie, on or prior to the start date of 
alternative anti-CMV treatment if any).
"-" = CMV DNA concentration <LLOQ (<137 IU/mL)
"+" = CMV DNA concentration ≥LLOQ (ie, quantifiable)
Confirmed clearance of plasma CMV DNA (confirmed CMV viremia clearance)=2 consecutive postbaseline assessments of 
CMV DNA target <LLOQ, separated by at least 5 days.
Plasma CMV DNA assessments after starting alternative anti-CMV treatment or rescue 
treatment are not evaluable for the assessment of study assigned treatment effect. The CMV 
DNA assessment on the same date as the alternative anti-CMV treatment will be included in the 
evaluation as the procedure is to be done prior to the start of alternative anti-CMV treatment. 
Subjects who discontinue study assigned treatment early are to complete the treatment phase 
For non-commercial use only


Shire
CONFIDENTIAL
Page 39
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
assessment as described in Section 4.5 of the Protocol. The response categorization based on the 
available data is summarized in Table 4.
Table 4
Summary of Response Categorization for Primary Endpoint
Data at Week 7 and Week 8
Responder
Available, or missing but can be imputed 
using adjacent week/s data  
Yes/no based on 2 consecutive samples separated by 
at least 5 days at Week 8 (See Table 3)
Not evaluable/missing due to rescue or 
alternative anti-CMV treatment
No
Missing but achieved confirmed viremia 
clearance at time of early discontinuation  
No
Missing without achieving confirmed 
viremia clearance at time of early 
discontinuation
No
Table 5
Estimand for Primary Efficacy Endpoint
Attributes
Planned
Population
Transplant recipients (HSCT or SOT) with a current CMV infection that is 
refractory or resistant to treatment with currently available anti-CMV therapies 
(ie, ganciclovir, valganciclovir, foscarnet, or cidofovir).
Variable (or 
endpoint)
Proportion of responders, defined as subjects with confirmed CMV viremia 
clearance at Study Week 8 regardless of whether either study-assigned treatment 
was discontinued before the end of the stipulated 8 weeks of therapy, and without 
alternative anti-CMV treatment
Strategy for 
addressing 
intercurrent 
events
Composite strategy is used. The following intercurrent events are considered:
1.
If a subject takes alternative anti-CMV treatment or maribavir as rescue 
treatment before Study Week 8, assume non-response
2.
If a subject had missing data due to early discontinuation to confirm viremia 
clearance at Study Week 8, assume non-response 
Population-
level 
summary
Difference in proportion of responders at Study Week 8 between maribavir and 
IAT treatment groups
For non-commercial use only


Shire
CONFIDENTIAL
Page 40
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
10.1.2
Analysis of Primary Efficacy Endpoint
The null hypothesis and alternative hypothesis for the primary endpoint (H1) to be tested are:
H10: P1T – P1C = 0
vs
H11: P1T – P1C ≠ 0
P1T: proportion of responder in maribavir treatment group who achieve confirmed viremia clearance at end of Study Week 8
P1C: proportion of responder in IAT group who achieve confirmed viremia clearance at end of Study Week 8
The proportion of responders (ie, subjects with confirmed CMV viremia clearance at the end of 
Study Week 8 regardless of whether either study-assigned treatment was discontinued before the 
end of the stipulated 8 weeks of therapy) will be calculated for each treatment group. The 
difference in proportion of responders between treatment groups will be obtained using 
Cochran-Mantel-Haenszel (CMH) weighted average across all strata (see Section 10 for strata 
definitions), and tested using CMH method, with transplant type and baseline plasma CMV 
DNA concentration as two stratification factors. The 95% confidence limits of the weighted 
average of difference across strata will be provided using the normal approximation. If the 
minimum number of subjects in a response category in a treatment group, for example, in the 
high viral load group, is less than 5, the high and intermediate viral load groups will be collapsed 
into 1 stratum level.
Homogeneity across strata will be tested using Breslow-Day test. If the test is significant at the 
alpha=0.05 level, stratum-specific differences in proportions will be reported and the adjusted 
difference and 95% CI in proportion of responders between treatment groups will be obtained 
and tested using minimum risk weight method of Mehrotra and Railkar (2000) instead of the 
CMH method, stratifying by transplant type and baseline plasma CMV DNA concentration. If 
the p-value from the test of adjusted difference in proportion of responders between treatment 
groups is ≤0.05 and the adjusted proportion of responders from maribavir is higher, it will be
concluded that maribavir is more efficacious compared to the control group. Unadjusted 
difference in proportion of responders between treatment groups and the 95% confidence limits 
using the normal approximation will be provided.
The analysis of the primary efficacy endpoint will be conducted using Randomized Set as the 
primary and PP Set as supportive according to the randomized treatment per intent-to-treat 
principle. The analysis will also be repeated using the Modified Randomized Set as supportive. If 
there are subjects who were randomized but did not receive any dose of study assigned 
treatment, the analysis will be conducted according to the randomized treatment.
The time to failure to achieve the primary endpoint of response at Study Week 8 due to missing 
CMV measurements, receipt of rescue medication, or receipt of alternative anti-CMV treatment 
will be presented using descriptive statistics. In addition, the number and percentage of subjects 
who failed the primary endpoint will be presented by reason (eg, received rescue or alternative 
anti-CMV treatment, early discontinuation and primary reason of study discontinuation).
For non-commercial use only


Shire
CONFIDENTIAL
Page 41
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
10.1.3
Sensitivity and Supplementary Analyses of the Primary Efficacy Endpoint
The following sensitivity and supplementary analysis for the primary efficacy endpoint will be 
conducted using the Randomized Set.
1. Subjects who discontinue study treatment early without CMV DNA measurement available 
for evaluation of effect at Week 8, but who meet the criteria of confirmed CMV viremia 
clearance at the time of discontinuation (defined as 2 consecutive post baseline assessments 
of CMV DNA target <LLOQ, separated by at least 5 days) will be included as responders 
(see Table 6). The analysis of this response will be conducted following the same method as 
described for the primary endpoint of response at Study Week 8.
Table 6
Response Categorization in Sensitivity Analysis for Primary Endpoint
Data at Week 7 and Week 8
Responder
Available, or missing but can be imputed 
using adjacent week/s data  
Yes/no based on 2 consecutive samples separated by 
at least 5 days at Week 8 (See Table 3)
Not evaluable/missing due to rescue or 
alternative anti-CMV treatment
No
Missing but achieved confirmed viremia 
clearance at time of early discontinuation 
Yes
Missing without achieving confirmed 
viremia clearance at time of early 
discontinuation
No
2. The primary endpoint of response will also be analyzed using multivariable logistic 
regression model to control for baseline stratification factors and other important baseline 
characteristics. The list of baseline characteristics to be considered will include but will not 
be limited to:

Transplant type (HSCT, SOT)

CMV DNA level (high, intermediate, low)

Presence of CMV mutation associated with resistance to ganciclovir/foscarnet/cidofovir 
per central laboratory result (yes, no)

CMV serostatus (D+R-, D+R+ or D-R+, D-R-)

Prior Anti-lymphocyte use (yes, no)

Immune function status as measured by baseline total WBC from hematology panel, 
CD4+CD69+, and CD8+CD69+ T cells from immune function assay if sample size is 
sufficient  

Enrolling Region (North America, Europe, Asia)

Prior use of CMV prophylaxis (yes, no).
For non-commercial use only


Shire
CONFIDENTIAL
Page 42
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
Below model selection approach will be followed:
a) Fit a logistic model including treatment, transplant type, CMV DNA level, and each 
baseline characteristic covariate, and interaction terms between baseline covariate and 
treatment, baseline covariate and transplant type, baseline covariate and CMV DNA 
level. Baseline covariates or covariates with interaction term significant at 0.25 level will 
be identified. Summary of such univariate analysis for each covariate will be provided.
b) Fit a multivariable logistic model including the baseline covariates and the identified 
interaction terms from step 1 using the backward selection to eliminate non-significant 
variables at level of 0.05. Check for change of coefficients (Δβ), if it is more than 20%, 
the deleted variables will be added back to the model one at a time for examination of 
biological meaning, and the model is iteratively reduced using the backward selection. 
The final model will include the variable/s statistically significant at level of 0.05 
(Categorical Data Analysis, Alan Agresti, 2013). The fit of the final model will be 
assessed including goodness of fit and regression diagnostics. If any baseline variable’s 
interaction term is significant, then this baseline variable is also included in the model, 
regardless of its p-value. Treatment, transplant type, and CMV DNA level will be fixed 
in the model selection.
c) Provide parameter estimates from the final model.
3. The analysis of the primary efficacy endpoint will be repeated using the CMV DNA level 
and transplant type used for randomization rather than CMV DNA level from the central 
laboratory results and transplant type as the stratification factors in the analysis. This is to 
evaluate the impact to the primary analysis of treatment effect due to the difference in strata 
data used in randomization and analysis.
4. The analysis of the primary efficacy endpoint will be repeated by excluding subjects who 
discontinue early from the analysis set. The following definitions of early discontinuation are 
defined to explore the impact of early discontinuation to the primary efficacy analysis: 
discontinue study early regardless of reason within 72 hours, and 7, 14, 21, and 28 days of 
starting the study-assigned treatment. This is to evaluate the impact of early discontinuation 
on the primary analysis of treatment effect.
5. Response within 8 weeks of study is defined as subjects who met the criteria of confirmed 
CMV viremia clearance defined as 2 consecutive postbaseline assessments of CMV DNA 
target <LLOQ, separated by at least 5 days any time in treatment phase. The analysis of this 
response within Study Week 8 will be conducted following the same method as described for 
the primary endpoint of response at Study Week 8. This is to evaluate the treatment effect 
based on the ability to achieve viremia clearance.
6. Response at Study Week 8 in the subset of subjects who received 8 weeks of study-assigned 
treatment will be conducted following the same method as described in the primary analysis. 
This is to evaluate the treatment effect as measured by response at Week 8 for those who 
were able to receive 8 weeks of treatment.
7. Response (defined as 2 consecutive postbaseline assessments of CMV DNA target <LLOQ, 
separated by at least 5 days) at end of Study Week 8 regardless of the use of alternative 
anti-CMV treatment for the IAT treatment group will be conducted following the same 
For non-commercial use only


Shire
CONFIDENTIAL
Page 43
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
method as described for the primary endpoint of response at Study Week 8. This is to assess 
the efficacy without the potential confounding of dose limiting toxicity for the IAT group.
8. To evaluate the impact of the difference in the CMV DNA used for enrollment (based on 
either central or local laboratory assay, plasma or whole blood sample in the screening 
period) and the baseline CMV DNA from the central laboratory prior to receiving the first 
dose of study assigned treatment, the following analyses will be conducted.
a.
Repeat the analysis of the primary efficacy endpoint in the set of subjects who had 
baseline CMV DNA from the central laboratory >LLOQ.
b. Repeat the analysis of the primary efficacy endpoint in the set of subjects who had 
baseline CMV DNA from the central laboratory ≥910 IU/mL.
9. To assess the impact of COVID-19 pandemic, the primary endpoint definition in Table 3 will 
be followed except for missing data due to the COVID-19 pandemic. Subjects who had 
missing CMV DNA level data to confirm response at Week 8 due to COVID-19 will be 
identified based on COVID-19 related missing assessment as recorded in the protocol 
deviations. The primary endpoint definition in Table 3 has considered missed visit (2 or less) 
scenarios around Week 8. With COVID-19 pandemic, 3 or more consecutive weeks of 
missed visits around Week 8 may occur. For such scenario, available CMV DNA level at 
Week 5 and/or 10 data will be included to assess the response at Week 8 following Table 3. 
Subjects with missing data post-baseline to confirm response at Week 8 due to COVID-19, 
will have the missing CMV DNA level imputed using the multiple imputation (MI) with the 
Markov chain Monte Carlo (MCMC) method. The imputation seed will be 1812 and the 
number of impute time will be 5. CMV DNA results reported as “Not detected or <LLOQ” 
will be imputed as half of the LLOQ value (ie, 137/2=68.5), and the log10 transformation 
will be applied to CMV DNA levels in the calculation.   
Once missing data are filled in, response at Study Week 8 will be assigned following Table 3. 
The imputed data sets will be analyzed using the CMH test for the adjusted difference in 
proportion of response controlling for two stratification factors, transplant type and baseline 
plasma CMV DNA level as in the primary analysis.  
This sensitivity analysis will be conducted only if there are ≥5% of subjects with missing 
data to confirm response at Week 8 due to COVID-19.
Table 7
Response Categorization in COVID-19 Impact Sensitivity Analysis for Primary 
Endpoint Using Multiple Imputation 
Data at Week 7 and Week 8
Responder
Available, or missing but can be 
imputed using adjacent week/s data  
Yes/no based on 2 consecutive samples separated by 
at least 5 days at Week 8 (See Table 3)
Not evaluable/missing due to rescue or 
alternative anti-CMV treatment
No
For non-commercial use only


Shire
CONFIDENTIAL
Page 44
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
Table 7
Response Categorization in COVID-19 Impact Sensitivity Analysis for Primary 
Endpoint Using Multiple Imputation 
Data at Week 7 and Week 8
Responder
Missing but can be assessed using 
available Week 10 or Week 5 data due 
to COVID-19 pandemic
Yes/no based on 2 consecutive samples separated by 
at least 5 days including data from Week 5 and 
Week 10 to account for missed visits due to 
COVID-19 pandemic
Missing without data to confirm 
response at Week 8 unrelated to 
COVID-19 pandemic 
No
Missing without data to confirm 
response at Week 8 related to 
COVID-19 
Yes/no based on CMV DNA levels from multiple 
imputation
10. To assess the impact of COVID-19 pandemic, additional sensitivity analysis for the primary 
endpoint using worst case scenario will be conducted. The primary endpoint definition in 
Table 3 will be followed except for missing data due to the COVID-19 pandemic. Subjects 
who had missing CMV DNA level data to confirm response at Week 8 due to COVID-19 
will be identified based on COVID-19 related missing assessment as recorded in the protocol 
deviations. The primary endpoint definition in Table 3 has considered missed visit (2 or less) 
scenarios around Week 8. With COVID-19 pandemic, 3 or more consecutive weeks of 
missed visits around Week 8 may occur. For such scenario, available CMV DNA level at 
Week 5 and/or 10 data will be included to assess the response at Week 8 following Table 3. 
Subjects with missing data to confirm response at Week 8 due to COVID-19, will have 
response assigned as non-responder if a subject was receiving maribavir and responder if a 
subject was receiving IAT as the study assigned treatment (see Table 8). The analysis of this 
response assignment will be conducted following the same method as described for the 
primary efficacy endpoint.
Table 8
Response Categorization in COVID-19 Impact Sensitivity Analysis Using Worst 
Case for Primary Endpoint
Data at Week 7 and Week 8
Responder
Available, or missing but can be 
imputed using adjacent week/s data  
Yes/no based on 2 consecutive samples separated by at 
least 5 days at Week 8 (See Table 3)
Not evaluable/missing due to rescue or 
alternative anti-CMV treatment
No
Missing but can be assessed using 
available Week 10 or Week 5 data due 
to COVID-19 pandemic
Yes/no based on 2 consecutive samples separated by at 
least 5 days including data from Week 5 and Week 10 
to account for missed visits due to COVID-19 
pandemic
For non-commercial use only


Shire
CONFIDENTIAL
Page 45
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
Table 8
Response Categorization in COVID-19 Impact Sensitivity Analysis Using Worst 
Case for Primary Endpoint
Data at Week 7 and Week 8
Responder
Missing without data to confirm 
response at Week 8 unrelated to 
COVID-19 pandemic 
No
Missing without data to confirm 
response at Week 8 related to 
COVID-19 pandemic
Yes for subjects in the IAT group, no for subjects in the 
maribavir group 
10.1.4
Subgroup Analyses of the Primary Efficacy Endpoint
The proportion of responders at Study Week 8 and the corresponding 95% CI will be 
summarized by treatment group for the following subgroups. Subgroups may be collapsed to 
have adequate sample size except for age group. The difference in proportion of responders 
between treatment groups and the 95% confidence limits will be calculated using methods 
similar to the primary efficacy analysis, stratifying for any factors used in the primary analysis 
that remain applicable. Subgroup analysis results will be summarized in a forest plot. The 
subgroup analyses for the primary efficacy endpoint will include the following:

Transplant type (SOT, HSCT, and kidney transplant) 

CMV DNA viral load (high, intermediate, low)

Symptom status (symptomatic or asymptomatic) at baseline as adjudicated by EAC

Presence of CMV mutation resistant to ganciclovir/foscarnet/cidofovir per central 
laboratory result (yes, no)

Age group
o
≥18 to <45 years of age
o
≥45 to <65 years of age
o
≥65 years of age

Enrolling regions (North America, Europe, Asia)

Gender (male, female)

Prior Anti-lymphocyte use (yes, no)

Maribavir versus individual IAT type if sample size is adequate
For non-commercial use only


Shire
CONFIDENTIAL
Page 46
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
10.2
Key Secondary Efficacy Endpoint and Analysis
10.2.1
Key Secondary Efficacy Endpoint
The key secondary endpoint of this study is a binary response (yes/no) with following criteria:

Achievement of CMV viremia clearance and resolution or improvement of 
tissue-invasive CMV disease or CMV syndrome for subjects symptomatic at baseline or 
achievement of clearance of viremia and no symptoms of tissue invasive CMV disease or 
CMV syndrome for subjects asymptomatic at baseline at the end of Study Week 8, 
followed by maintenance of this treatment effect for an additional 8 weeks off treatment 
(ie, Follow-up Week 16).
For treatment effect of clearance of CMV viremia and CMV infection symptom control to be 
declared at the end of Study Week 8, regardless of whether either study-assigned treatment was 
discontinued before the end of the stipulated 8 weeks of therapy, and maintenance of such effect 
through Week 16, the subject must have received exclusively a study-assigned treatment. CMV 
infection symptom control include:

Resolution or improvement of tissue invasive disease or CMV syndrome for symptomatic 
subjects at baseline, 

no new symptoms for subjects asymptomatic at baseline.
The investigator will perform the initial diagnosis of tissue-invasive CMV disease or CMV 
syndrome for the symptomatic subjects at baseline and new occurrence of tissue invasive CMV 
disease or CMV syndrome for the asymptomatic subjects at baseline through the study, and will 
continue with the assessment of the infection status (ie, no change, improvement, worsening, or 
resolution) at subsequent visits throughout the study. All investigator-assessed cases of tissue 
invasive CMV disease or CMV syndrome will be reviewed and adjudicated by an independent 
EAC both for the confirmation of the diagnosis at baseline and new symptomatic CMV infection 
and for the outcome (ie, no change, improvement, worsening, or resolution). EAC adjudicated 
cases will be used for the efficacy analyses.
Criteria for defining the key secondary efficacy endpoint are:

First being a responder at the end of Study Week 8, irrespective of study treatment duration, 
based on CMV viremia clearance and assessment of the tissue invasive CMV disease or 
CMV syndrome status (ie, resolution or improvement of tissue invasive CMV disease or 
CMV syndrome for subjects symptomatic at baseline or no symptoms of tissue invasive 
CMV disease or CMV syndrome for subjects asymptomatic at baseline).
AND

Maintenance of this treatment effect (both CMV viremia clearance and tissue-invasive 
disease or CMV syndrome control) through Study Week 16. Maintenance of CMV viremia 
clearance through Week 16 is determined by the absence of 2 consecutive “+” viral 
measurements (>LLOQ) through Week 16 (see Table 9).
For non-commercial use only


Shire
CONFIDENTIAL
Page 47
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
Table 9
Assessments of Responders for Key Secondary Endpoint
Response (both 
virological response 
and symptomatic 
CMV infection 
control) at Study 
Week 8
CMV DNA Assessment Week
Key 
secondary 
endpoint 
responder*
Rationale
9
10
11
12
14
16
181
Yes
+/-
+/-
+/-
+/-
+/-
+/-
+/-/NA
No
Any 2 consecutive “+” 
during FU by Week 16
Yes
+/-
+/-
+/-
+/-
+/-
-
+/-/NA
Yes
Week 16 is “- “and no 
2 consecutive 
“+”during FU
Yes
+/-
+/-
+/-
+/-
+/-
+
+/-/NA
No
Week 16 is ‘+’ and 
Week 18 is “+” or 
“NA”, criteria of 
2 consecutive “+” not 
met
Yes
+/-
+/-
+/-
+/-
+/-
+
-
Yes
Week 16 is ‘+’ and 
2 consecutive “+” 
criteria is not met 
based on Week 18 data
Yes
+/-
+/-
+
-
-
NA
-
Yes
Week 16 is missing, 
2 consecutive ‘+’ 
criteria not met based 
on Week 14 and 18 
data
Yes
+/-
+/-
+
-
-
NA
+/NA
No
Week 16 is missing, 
2 consecutive ‘+’ 
criteria may be met 
based on available 
Week 18 data
Yes
+/-/NA +/-/NA +/-/NA +/-/NA NA
NA +/-/NA
No
Lack of data to show 
maintaining effect 
through Week 16
No
No
1Week 18 data will be used toto confirm not having CMV viremia recurrence through Week 16 if Week 16 data is not available.
*Must also meet the criterion of CMV infection symptom control to be a responder.
NA=not available for evaluation of study drug effect; reason could be starting alternative anti-CMV treatment, withdrawal from 
study, etc.
"-" = CMV DNA concentration <LLOQ (<137 IU/mL)
"+" = CMV DNA concentration ≥LLOQ (ie, quantifiable)
Notes: Scenarios in the table above are provided as examples and may not be all-inclusive of all possibilities.
Only CMV viremia data on or prior to date of receiving nonstudy CMV treatment or rescue treatment will be included in the 
assessment.
A subject who fails to achieve response for the primary efficacy endpoint will be a 
non-responder for the key secondary efficacy endpoint. It is noted that plasma CMV DNA 
assessment done after the start of alternative anti-CMV treatment are not evaluable for the 
For non-commercial use only


Shire
CONFIDENTIAL
Page 48
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
responder assessment toward the study assigned treatment. Responder categorization for 
maintenance through Week 16 is also summarized in Table 10 below.
Table 10
Summary of Response Categorization for Key Secondary Endpoint
Data at Week 16
Key secondary endpoint responder*
Available, or missing but adjacent data are 
available
Yes/no based on no 2 consecutive “+”during 
FU (see Table 9)  
Not evaluable or missing due to rescue or 
alternative anti-CMV treatment
No
Missing with or without CMV viremia clearance 
maintained at time of discontinuation 
No
*Must first be a responder at the end of Study Week 8 with viremia clearance and symptom control, and also meet the criterion of 
CMV infection symptom control to be a responder.
Table 11
Estimand for Key Secondary Efficacy Endpoint
Attributes
Planned
Population
Transplant recipients (HSCT or SOT) with a current CMV infection that is 
refractory or resistant to treatment with currently available anti-CMV 
therapies (ie, ganciclovir, valganciclovir, foscarnet, or cidofovir)
Variable (or 
endpoint)
Proportion of responders, defined as subjects who achieved confirmed 
viremia clearance achieved and CMV infection symptom control at Study 
Week 8 regardless of whether study-assigned-treatment was discontinued 
before the stipulated 8-weeks of treatment and maintain through Study 
Week 16 and no alternative anti-CMV treatment
Strategy for 
addressing 
intercurrent 
events
Composite strategy is used. The following intercurrent events are 
considered:
1. If a subject takes alternative anti-CMV treatment or maribavir as rescue 
treatment before Study Week 16, assume non-response
2. If a subject discontinues study early before Study Week 16 without data 
to confirm the maintenance of viremia clearance and CMV infection 
symptom control at Study Week 16, assume non-response
Population-level 
summary
Difference in proportion of responders for the key secondary endpoint 
between SHP620 and IAT treatment groups
For non-commercial use only


Shire
CONFIDENTIAL
Page 49
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
10.2.2
Analysis of the Key Secondary Efficacy Endpoint
The null and alternative hypothesis for the key secondary endpoint (H2) to be tested:
H20: P2T – P2C = 0
vs
H21: P2T – P2C ≠ 0
P2T: proportion of responders, ie, subjects with confirmed viremia clearance and symptom control at end of Study Week 8 and 
maintain it through Week 16 in maribavir group
P2C: proportion of responders, ie, subjects with confirmed viremia clearance and symptom control at end of Study Week 8 and 
maintain it through Week 16 in IAT group
The proportion of responders for the key secondary endpoint will be calculated for each 
treatment group. The difference in proportion of responders between treatment groups will be 
obtained and tested using the same method as described for the primary efficacy endpoint. The 
EAC’s adjudicated tissue-invasive disease or CMV syndrome symptoms and outcome will be 
used for the analysis.
The hypothesis-testing of the primary and key secondary endpoint will be adjusted for multiple 
comparisons using a fixed-sequence testing procedure to control the family-wise Type 1 error 
rate at 5% level (see Section 2.6).
If the proportion of responders for the primary efficacy endpoint is higher in the maribavir group 
and the test of adjusted difference in proportion of responders between treatment groups is 
statistically significant, and the proportion of response for the key secondary efficacy endpoint is 
higher in maribavir group and the test is significant at 0.05 level, it will be concluded that the 
treatment effect is more durable for maribavir as compared to the control group.
The analysis of the key efficacy endpoint will be conducted using the Randomized Set as the 
primary and PP Set as supportive. The analysis will be repeated using the Modified Randomized 
Set as supportive if there are randomized subjects who did not receive any dose of study assigned 
treatment; subjects will be analyzed according to the randomized treatment.
10.2.3
Sensitivity and Supplementary Analyses of the Key Secondary Efficacy Endpoint
1. Subjects who discontinue study early without CMV DNA measurement available for 
evaluation of study drug effect at Week 16, however, they meet the criteria of confirmed 
CMV viremia clearance defined as 2 consecutive post baseline assessments of CMV DNA 
target <LLOQ, separated by at least 5 days, at the time of discontinuation, and meet the 
criterion of CMV symptom control will be included as responders for the key secondary 
endpoint (see Table 12). The analysis of this response will be conducted following the same 
method as described for the key secondary endpoint of response at Study Week 16.
For non-commercial use only


Shire
CONFIDENTIAL
Page 50
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
Table 12
Response Categorization in Sensitivity Analysis for Key Secondary Endpoint
CMV DNA Data at Week 16
Key secondary endpoint responder*
Available, or missing but adjacent are available
Yes/no based on no 2 consecutive “+”during 
FU (see Table 9)
Not evaluable or missing due to rescue or 
alternative anti-CMV treatment
No
Missing with CMV viremia clearance 
maintained at time of discontinuation 
Yes
Missing without CMV viremia clearance 
maintained at time of discontinuation 
No
*Must first be a responder at the end of Study Week 8 with viremia clearance and symptom control, and also meet the criterion of 
CMV infection symptom control to be a responder.
2. The analysis of the key secondary efficacy endpoint will be repeated by using the CMV 
DNA level and transplant type used for randomization rather than the CMV DNA level based 
on central laboratory values and transplant type as the stratification factors in the analysis.
3. The treatment effect between treatment groups for the key secondary efficacy endpoint will 
be estimated using multivariable logistic regression method after controlling for important 
baseline characteristics. The list of baseline characteristics to be considered and the model 
selection steps will follow the sensitivity analysis described above for the primary efficacy 
endpoint.
4. The analysis of the key secondary efficacy endpoint will be conducted in the subset of 
subjects who received 8 weeks of study assigned treatment following the same method as 
described above for the key secondary endpoint.
5. Alternative definition of response at Study Week 16 will include subjects who achieved 
confirmed CMV viremia clearance and CMV infection symptom control at Study Week 8 
and maintain such effect through Study Week 16, regardless the use of alternative anti-CMV 
treatment for the IAT treatment group. The proportion of alternative response at Study 
Week 16 will be analyzed following the same method as described above for the key 
secondary endpoint. This is to evaluate the treatment effect at Week 16 without the potential 
confounding of dose limiting toxicity for the IAT group.
6. To evaluate the impact of the difference in the CMV DNA used for enrollment (based on 
either central or local laboratory assay, plasma or whole blood sample in the screening 
period) and the baseline from the central laboratory prior to receiving the first dose of study 
assigned treatment, the following analyses will be conducted.
a.
Repeat the analysis of the key secondary efficacy endpoint in the set of subjects 
who had baseline CMV DNA from the central laboratory >LLOQ.
b. Repeat the analysis of the key secondary efficacy endpoint in the set of subjects 
who had baseline CMV DNA from the central laboratory ≥910 IU/mL.
7. To assess the impact of COVID-19 pandemic, the key secondary endpoint definition in 
Table 9 will be followed except for missing data due to the COVID-19 pandemic. If there are 
≥5% of subjects with missing data due to COVID-19 to confirm maintenance effect through 
For non-commercial use only


Shire
CONFIDENTIAL
Page 51
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
Week 16, the missing CMV DNA levels will be imputed using the MI method, and the CMV 
infection control adjudicated by EAC prior to study discontinuation will be assumed for 
Week 16 and the maintenance effect through Week 16 will be assigned as in Table 13. The 
analysis will follow the same method as the primary efficacy endpoint as described in 
Section 10.1.3.
Table 13
Response Categorization in COVID-19 Impact Sensitivity Analysis for Key 
Secondary Endpoint Using Multiple Imputation 
CMV DNA Data at Week 16
Key secondary endpoint responder*
Available, or missing but adjacent are available
Yes/no based on no 2 consecutive “+” during 
FU (see Table 9)
Not evaluable or missing due to rescue or 
alternative anti-CMV treatment
No
Had minimum two available CMV DNA data  
from Week 9 through Week 16 including 
Week 16 
Yes/No
Missing without data to confirm response at 
Week 16 unrelated to COVID-19 pandemic 
No
Missing without data to confirm response at 
Week 16 related to COVID-19 pandemic 
Yes/no based on CMV DNA levels from 
multiple imputation
*Must first be a responder at the end of Study Week 8 with viremia clearance and symptom control, and also meet 
the criterion of CMV infection symptom control to be a responder.
Summary of EAC’s assessment of symptomatic CMV infection (tissue-invasive disease or CMV 
syndrome symptoms) will be provided.
10.2.4
Subgroup Analyses
The proportion of responder and the corresponding 95% CI for the key secondary efficacy 
endpoint will be summarized by treatment group for the following subgroups. Subgroups may be 
collapsed to have adequate sample size. The difference in proportion of responders between 
treatment groups and the 95% confidence limits of the difference will be calculated using 
methods similar to the primary efficacy analysis, stratifying for any factors used in the primary 
analysis that remains applicable. Subgroup analysis results will be summarized in a forest plot.

Transplant type (SOT, HSCT, and kidney transplant)

CMV DNA viral load (high, intermediate, low)

Symptom status (symptomatic or asymptomatic) at baseline as adjudicated by EAC

Presence of CMV mutation resistant to ganciclovir/foscarnet/cidofovir per central 
laboratory result (yes, no)

Age group
For non-commercial use only


Shire
CONFIDENTIAL
Page 52
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
o
≥18 to <45 years of age
o
≥45 to <65 years of age
o
≥65 years of age

Enrolling regions (North America, Europe and Asia)

Gender (male, female)

Prior Anti-lymphocyte use (yes, no)

Maribavir versus individual IAT type if sample size is adequate
10.3
Other Secondary Efficacy Endpoints and Analysis
The analysis of the secondary efficacy endpoints will be conducted using the Randomized Set 
and PP Set unless otherwise specified. Secondary efficacy endpoints will be summarized by 
treatment arm, and, if indicated, analyzed statistically at α=0.05 (2-sided), without adjustment for 
multiple comparisons.
10.3.1
The Achievement of the Confirmed CMV Viremia Clearance After 8 Weeks of 
Receiving Study-Assigned Treatment
Subjects who achieved confirmed CMV viremia clearance after receiving 8 weeks 
study-assigned treatment at Week 8, 12, 16, 20 will be classified as responders (a binary 
response) for the respective timepoint.
A subject is counted as a responder (a binary response) at Week 8, 12, 16, 20 if meeting the 
following criteria, or non-responder if not meeting any of the following criteria:

The achievement of the confirmed CMV viremia clearance at Week 8, and 
maintained through Week 12, 16, 20

and received 8 weeks of study-assigned treatment
The analysis of response at Study Week 8, 12, 16, and 20 after receiving 8 weeks of 
study-assigned treatment will be conducted following the same method as described for the 
primary endpoint.
10.3.2
The Achievement of the Confirmed CMV Viremia Clearance and CMV Infection 
Symptom Control After Receiving 8 Weeks of Study-Assigned Treatment and 
Maintaining the Effect Over Time
The achievement of the confirmed CMV viremia clearance and CMV infection symptom control 
at Week 8, and maintained through Week 12, 16, and 20 after receiving 8 weeks of 
study-assigned treatment will be determined as below.
A subject is counted as a responder (a binary response) if meeting the following criteria, or 
non-responder if not meeting any of the following criteria:

The achievement of the confirmed CMV viremia clearance at Week 8
For non-commercial use only


Shire
CONFIDENTIAL
Page 53
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020

and CMV infection symptom control
o
resolution or improvement of tissue invasive CMV disease or CMV syndrome 
for subjects symptomatic at baseline,
o
or maintaining no symptoms of tissue invasive CMV disease or CMV 
syndrome for subjects asymptomatic at baseline

and received 8 weeks of study-assigned treatment
At Week 12, 16, and 20, a subject is counted as a responder if the effect of viremia clearance and 
CMV infection symptom control achieved after 8 weeks of study treatment is maintained.
The analysis of achievement of the confirmed CMV viremia clearance and CMV infection 
symptom control at Study Week 8, 12, 16, 20 after receiving 8 weeks of study-assigned 
treatment will be conducted following the same method as described for the primary endpoint.
10.3.3
The Maintenance of the CMV Viremia Clearance and CMV Infection Symptom 
Control Achieved at the End of Study Week 8 Through Weeks 12 And 20
The response based on the maintenance of the effect of CMV viremia clearance, and CMV 
infection symptom control achieved at the end of Study Week 8 regardless of whether either 
study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy, 
through Weeks 12 and 20 will be determined as below:

Identify subjects who achieved CMV viremia clearance, and CMV infection 
symptom control at Study Week 8 regardless of whether either study-assigned 
treatment was discontinued before the end of the stipulated 8 weeks of therapy; this is 
similar to the first step in identifying responder for the key secondary efficacy 
endpoint

Subjects who maintain the effect achieved at Study Week 8 through Week 12 (or 20) 
will be classified as responder for Week 12 (or 20). If the effect is not maintained, 
subject will be classified as a non-responder.
The analysis of achievement of the confirmed CMV viremia clearance and CMV infection 
symptom control at Study Week 8, and maintenance through Week 12, 20 will be conducted 
following the same method as described for the primary endpoint.
10.3.4
The Recurrence of CMV Viremia
The recurrence of CMV viremia is defined as plasma CMV DNA concentration ≥LLOQ when 
assessed by the central laboratory COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 
2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. 
All CMV DNA measurements after achieving confirmed viremia clearance regardless of rescue 
or alternative treatment will be included in the assessment.
The recurrence of CMV viremia during the first 8 weeks of the study, in the follow-up period of 
12 weeks, and at any time during the 20 weeks of the study, regardless of whether either 
study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy 
will be provided. Although the recurrence of CMV viremia prior to Week 8 may simply 
For non-commercial use only


Shire
CONFIDENTIAL
Page 54
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
represent fluctuations in the viral load during the course of treatment, it will be analyzed as well 
as the more clinically meaningful recurrence of CMV viremia after Week 8.

Of the number of subjects who achieved viremia clearance anytime on study after 
receiving study assigned treatment, the number and percentage who have recurrence in 
the following periods will be summarized
o
During the first 8 weeks of study, and in the 12 weeks of follow-up
o
Any time on study
Additionally, the above recurrence rates will be calculated in the subset of subjects who received 
8 weeks of study-assigned treatment.
10.3.5
The Recurrence of CMV Viremia During and Off-Study-Assigned Treatment
The recurrence of CMV viremia during study-assigned treatment and in the follow-up period 
after the subject is discontinued from study-assigned treatment will be calculated as follows.

Of the number of subjects who achieved the confirmed viremia clearance any time on 
study after receiving study-assigned treatment, the number and percentage of subjects 
who have recurrence in the following period will be summarized
o
While on study-assigned treatment
o
While off study-assigned treatment
10.3.6
The Maribavir CMV Resistance Profile
Analysis of maribavir CMV resistance will be included in the separate Resistance Analysis Plan. 
10.3.7
All-Cause Mortality
All-cause mortality by the end of study regardless of the use of rescue treatment or alternative 
anti-CMV treatment will be analyzed. The time to all-cause mortality by the end of the study 
participation in days will be calculated as stop date (event date of death due to any cause or 
censored date at the last contact) – randomization date +1. The time to all-cause mortality on 
study in days will be summarized descriptively (minimum, median, and maximum) for all-cause 
mortalities and using the Kaplan-Meier (KM) method, and compared using the log-rank test. 
Treatment difference (hazard ratio, and its 95% CI) between maribavir and IAT treatment groups 
will be estimated using the stratified Cox’s regression model with transplant type and baseline 
plasma CMV DNA level as two stratification factors.
Additionally, the analysis will be repeated for all-cause mortality on study after receiving study 
assigned treatments before rescue or alternative anti-CMV treatment. All-cause mortality on 
study after receiving study assigned treatments before rescue or alternative anti-CMV treatment 
in days will be calculated as stop date (date of death due to any cause before rescue or alternative 
anti-CMV treatment or censored date at the start of rescue treatment or alternative anti-CMV 
treatment or last contact, whichever is earlier) – randomization date +1.
The mortality status for all subjects will be provided in a data listing.
For non-commercial use only


Shire
CONFIDENTIAL
Page 55
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
10.3.8
Assessment of Efficacy for Maribavir Rescue Arm
The assessment of efficacy for maribavir rescue arm will be conducted using the rescue arm 
analysis set.
10.3.8.1
The Confirmed Clearance of Plasma CMV DNA at the End of 8 Weeks of 
Maribavir Rescue Treatment Phase
The number and percentage and the corresponding 95% CI of subjects who achieved the CMV 
viremia clearance (a binary response) at the end of 8 weeks of maribavir rescue treatment phase 
will be calculated, regardless of whether the rescue treatment was discontinued before the end of 
the stipulated 8 weeks of therapy.
10.3.8.2
The Achievement of Viremia Clearance and Disease Control for Maribavir 
Rescue Treatment
Subjects who achieved viremia clearance and CMV infection symptom control at Study Week 8 
after starting the maribavir rescue treatment and followed by maintenance of the treatment effect 
for an additional 8 weeks (as evidenced by sustained clearance of viremia and improvement or 
resolution of symptoms and no new symptom development between end of treatment and up to 
Week 16) is categorized as a responder. 
The number and percentage and the corresponding 95% CI of subjects who achieved viremia 
clearance and CMV infection symptom control at Week 8 and maintain the effect through 
Week 16 after maribavir rescue treatment will be summarized.
Additionally, the number and percentage and the corresponding 95% CI of subjects who 
achieved viremia clearance and infection symptom control at Study Week 8, and maintain the 
effect through Week 12, 20 after maribavir rescue treatment will be summarized.
10.4
Exploratory Efficacy Endpoint(s) and Analyses
For non-commercial use only


Shire
CONFIDENTIAL
Page 56
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
For non-commercial use only


Shire
CONFIDENTIAL
Page 57
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
For non-commercial use only


Shire
CONFIDENTIAL
Page 58
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
For non-commercial use only


Shire
CONFIDENTIAL
Page 59
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
For non-commercial use only


Shire
CONFIDENTIAL
Page 60
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
11.
SAFETY ANALYSES
The primary analysis of safety will be based on the “treatment-emergent” principle. This analysis 
will comprise the basis upon which conclusions will be drawn regarding the safety profile.
Safety evaluation will be made during the periods such as screening phase, treatment phase, and 
follow-up phase (See Figure 1 of the protocol). Baseline assessments will be the last assessment 
on or before the first dose date of study treatment. The adverse events (AEs) that occur from the 
time of ICF signature to first dose will be collected but will not be evaluated in the safety 
analyses. They will be listed as pretreatment adverse events. Two observation periods are 
defined for the purpose of safety analyses for the study assigned treatment using the Safety Set:
1) The on-treatment observation period starts at the date of study treatment initiation 
through 7 days after the last dose of study treatment, or through 21 days after the last 
dose of cidofovir (if cidofovir is the IAT). For subjects who transfer from the study 
treatment to either maribavir rescue or to a nonstudy anti-CMV treatment, the 
on-treatment observation period ends at the 7 days after the last dose of study treatment 
or through 21 days if cidofovir is used, or until initiation of maribavir rescue treatment or 
nonstudy anti-CMV treatment, whichever is earlier. The on-treatment observation period 
will serve as the primary period for analysis of safety.
2) The overall-study observation period starts at the date of study treatment initiation 
through the end of the follow-up phase of the study for subjects that do not receive 
maribavir rescue therapy, and the overall-study observation period starts at the date of 
study treatment initiation through the time before receiving maribavir rescue therapy for 
subjects who receive maribavir rescue therapy
The safety endpoints include the following:

Treatment-emergent AEs and treatment-emergent SAEs, overall study AEs and overall 
study SAEs

Clinical laboratory evaluations 
Safety assessment will also include vital sign measurements, physical examination and ECG.
Safety analyses for the maribavir rescue arm will be provided separately using the Rescue Set. 
Similarly, the following observation periods are defined for the safety analysis of rescue 
treatment.
1) The on-rescue treatment period starts at the rescue treatment initiation through 7 days 
after the last dose of rescue treatment or the start of alternative anti-CMV treatment, 
whichever is earlier.
2) The on-rescue overall observation period starts at the rescue treatment initiation through 
the end of study.
For non-commercial use only


Shire
CONFIDENTIAL
Page 61
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
Safety endpoints will be summarized descriptively for the on-treatment period and overall-study 
period, on-rescue treatment period and on-rescue treatment overall observation period, as 
appropriate.
11.1
Adverse Events
All AEs will be recorded from the time the informed consent is signed through 30 days after the 
last dose of study assigned treatment. This includes events occurring during the screening phase 
of the study, regardless of whether or not study treatment is administered. Following the 30-day 
capture period for all AEs, only those AEs deemed related to study assigned treatment or other 
protocol-mandated procedures and all SAEs (regardless of causality assessment) will be 
collected until the defined follow-up period.
All SAEs must be followed to closure (the subject’s health has returned to his/her baseline status 
or all variables have returned to normal), regardless of whether the subject is still participating in 
the study. Closure indicates that an outcome is reached, stabilization achieved (the investigator 
does not expect any further improvement or worsening of the event), or the event is otherwise 
explained.
Adverse events will be coded using MedDRA Version 23 (March 2020).
An AE (classified by preferred term) that has a start date on or after the first dose of study 
treatment or if it has a start date before the date of first dose of study treatment, but increases in 
severity after first dose of study treatment will be considered treatment emergent AE (TEAE) for 
the observation period.
If an AE onset date (occurrence, worsening, or becoming serious) is incomplete, an imputation 
algorithm will be used to classify the adverse event as pretreatment or treatment-emergent. The 
algorithm for imputing onset date will be conservative and will classify an adverse event as 
treatment emergent unless there is definitive information to determine it is pretreatment. 
Handling of missing AE start/end dates, missing severity and missing relationship are detailed in 
Section 18.7, Section 18.8, and Section 18.9.
If more than 1 AE occurs with the same preferred term for the same subject, then the subject will 
be counted only once for that preferred term using the most severe and most related occurrence 
for the summarization by severity and by relationship to study treatment.
11.1.1
Treatment-emergent Adverse Event
The following TEAE summaries will be produced for the on-treatment observation period, 
overall-study observation period for the study assigned treatment and IAT type, respectively 
using the Safety Set.

An overall summary of TEAEs, including the number and percentage of subjects with 
any AEs, any serious adverse events (SAEs), any severe AEs, AEs causing 
discontinuation of study medication, AEs leading to withdrawal from study, fatal AEs 
and AEs of special interest (AESI) as well as the total number of events for each category
For non-commercial use only


Shire
CONFIDENTIAL
Page 62
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020

Summary of TEAE by system organ class (SOC) and preferred term, including the 
number and percentage of subjects with a TEAE, as well as the total number of events in 
each treatment group

Summary of TEAE by preferred term in descending order of frequency for maribavir 
treatment group

Summary of TEAE by maximum severity, SOC, and preferred term

Summary of TEAEs related to study treatment by SOC and preferred term

Summary of treatment-emergent SAEs by SOC and preferred term

Summary of treatment-emergent SAEs by maximum severity, SOC and preferred term

Summary of treatment-emergent SAEs considered related to study drugs by SOC and 
preferred term

Summary of TEAE leading to study treatment discontinuation by SOC and preferred term

Summary of TEAE related to study treatment leading to study treatment discontinuation 
by SOC and preferred term

Summary of TEAE leading to withdrawal from study by SOC and preferred term

Summary of TEAE related to study treatment leading to withdrawal from study by SOC 
and preferred term

Summary of TEAE leading to death by SOC and preferred term

Summary of TEAE related to study treatment leading to death by SOC and preferred term

Summary of TEAEs related to study treatment by maximum severity, SOC, and preferred 
term
TEAEs of the rescue treatment will be analyzed in a similar fashion. Selected summaries of 
TEAE of the rescue treatment for the on-rescue treatment observation period and on-rescue 
treatment overall observation period using the Rescue Set will be provided. 
11.1.2
Adverse Events of Special Interest (AESIs)
The severity grading of AESIs are listed below (see Section 8.1.4 of study protocol for more 
details):

AESIs with severity grading based on CTCAE Version 4.03
o
Tissue invasive CMV
o
Taste disturbance (dysgeusia)
o
Nausea, Vomiting, Diarrhea
o
Neutropenia
o
CMV syndrome (applicable only in SOT subjects)

AESIs with grading based on standard severity categorization to mild, moderate, 
and severe
For non-commercial use only


Shire
CONFIDENTIAL
Page 63
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
o
Immunosuppressant drug concentration level increased:
o
Invasive fungal or bacterial infections
o
Graft-versus-host-disease (HSCT subjects):

Acute Graft-versus-host-disease

Chronic Graft-versus-host-disease
o
Graft rejection (acute, chronic, or failure)
AESI as reported by Investigator and reviewed using the list of MedDRA search terms defined 
by Sponsor medical lead will be analyzed according to the above class, and PTs for the 
on-treatment period and overall-study period. The following summaries will be provided for 
AESIs for the study assigned treatment and IAT type using the Safety Set for the on-treatment 
and overall-study periods:

Summary of frequently occurring TEAEs of special interest by AESI class, preferred 
term in descending order for maribavir treatment group

Summary of TEAEs of special interest by maximum severity, AESI class, and preferred 
term

Summary of TEAEs of special interest by AESI class and preferred term

• Summary of TEAEs of special interest related to study treatment by class and preferred 
term

Summary of TEAEs of special interest related to study treatment by AESI class, preferred 
term in descending order of frequency for maribavir treatment group

Summary of TEAEs of special interest related to study treatment by maximum severity, 
AESI class, and preferred term

Summary of serious TEAEs of special interest by AESI class, and preferred term

Summary of serious TEAEs of special interest related to study treatments by AESI class, 
and preferred term
11.1.2.1
Time to Resolution for Dysgeusia and Similar Terms While on Treatment and 
When Off Treatment 
For subjects who had reported AEs as dysgeusia and similar terms after receiving maribavir as 
study assigned treatment or as rescue treatment, the following durations will be calculated and 
summarized using Kaplan-Meier method and 95% confidence intervals for the estimated 25%, 
50%, and 75% times will be presented. 
Duration of AEs as dysgeusia and similar terms while on maribavir treatment will be calculated 
as event stop date – event start date + 1. The event start date is the start of the first reported event 
from the AEs as dysgeusia and similar terms while on maribavir treatment.
For subjects who had only one reported AE as dysgeusia and similar terms, the event stop date is 
the resolution date of the event or censored at the last dose of maribavir treatment, whichever is 
earlier.
For non-commercial use only


Shire
CONFIDENTIAL
Page 64
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
For subjects who had more than one reported AE as dysgeusia and similar terms, the event stop 
date is the resolution date of the last reported event or censored at the last dose date of maribavir 
treatment, whichever is earlier.  
Time to resolution of AE as dysgeusia and similar terms when off maribavir treatment will be 
calculated for all subjects with ongoing event at time of last dose of maribavir treatment as the 
event stop date – last dose date +1. For subjects who had one reported AE as dysgeusia and 
similar terms ongoing at time of last dose of maribavir treatment, the event stop date is the event 
resolution date in the off-treatment follow-up period or censored at the last study follow-up date, 
whichever is earlier.  For subjects who had more than one reported AE as dysgeusia and similar 
terms ongoing at time of last dose of maribavir treatment, the event stop date is the last event 
resolution date in the off-treatment follow-up period or censored at the last study follow-up date. 
11.1.2.2
Renal Disorder TEAEs
The following summaries of sponsor-defined renal disorder TEAEs will be provided for the 
study assigned treatment and IAT type using the Safety Set for the on-treatment period:

Summary of renal disorder TEAEs by preferred term and maximum severity

Summary of renal disorder TEAEs related to study treatment by preferred term and 
maximum severity

Summary of serious renal disorder TEAEs by preferred term and maximum severity

Summary of serious renal disorder TEAEs related to study treatment by preferred term 
and maximum severity
The above summaries of renal disorder TEAEs will be repeated for the following subgroups:

Renal impaired subjects (no, mild, moderate/severe)
11.1.3
Subgroup Analysis of TEAE and AESIs
Subgroup analysis of TEAE and AESI will be prepared for the following subgroups. 

Race (white, black or African American, Asian, Others)

Gender (male, female)

Age group,
o
≥16 to <18 years of age (adolescents)
o
≥18 to <45 years of age
o
≥45 to <65 years of age
o
≥65 years of age

Enrolling regions (North America, Europe and Asia)

Transplant type (SOT, HSCT)

Presence of CMV mutation resistant to ganciclovir/foscarnet/cidofovir per central 
laboratory result (yes, no)

Symptomatic infection (yes, no) as confirmed by EAC
For non-commercial use only


Shire
CONFIDENTIAL
Page 65
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020

Renal impaired subjects (no, mild, moderate/severe)

Hepatic impaired subjects (yes, no)
The following summaries of TEAEs and AESIs will be provided for the on-treatment period 
by treatment groups and IAT type for the subgroups.

Summary of TEAE by preferred term in descending order of frequency for maribavir 
treatment group for all the above subgroups.

Summary of treatment-emergent SAEs by SOC and preferred term for all above 
subgroups excluding Race, Symptomatic infection by EAC and Hepatic impaired 
subjects 

Summary of TEAEs of special interest by AESI class, preferred term in descending 
order of frequency for maribavir treatment group for all above subgroup excluding 
Race, Symptomatic infection by EAC and Hepatic impaired subjects
All AEs will be presented in a listing. Additional data listings will be presented for SAEs, AEs 
causing discontinuation of study treatment or withdrawal from the study, fatal AEs and AESIs.
11.2
Clinical Laboratory Variables
The clinical laboratory assessments are described in Section 7.2.3.5 of the study protocol at the 
time points specified in Table 1 and Table 2. Clinical laboratory tests will be performed at a 
central laboratory for all specified time points during the study including baseline. Local 
laboratory results can be used for eligibility and their results must be available prior to 
randomization. Analysis of clinical laboratory variables for hematology, chemistry and urinalysis 
will be based on results from central laboratories, unless otherwise specified. Local laboratory 
results will be provided in data listings.
The following outputs will be provided for the overall-study observation period for the study 
assigned treatment by visit; the last observation while on study treatment and the last observation 
on the overall-study observation period will be included unless otherwise specified. The analysis 
will be repeated for the rescue arm, as appropriate.

Summary of actual and change from baseline of hematology and chemistry laboratory 
values for continuous variables by treatment group and visit using descriptive statistics in 
tables and change from baseline will be presented using the box plots

Additionally, summary of actual and change from baseline for the following lab 
parameters by treatment group, IAT type (ganciclovir/valganciclovir, foscarnet), and 
visit using descriptive statistics, and the respective change from baseline for these 
laboratory parameters will also be presented using the box plots.  
To evaluate bone marrow effects: 

Hemoglobin

Leukocytes

Lymphocytes
For non-commercial use only


Shire
CONFIDENTIAL
Page 66
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020

Neutrophils

Platelets

Reticulocytes
To evaluate electrolyte abnormalities:

Calcium

Phosphate

Magnesium

Potassium
To evaluate renal toxicity:

Creatinine 

Urea nitrogen

Furthermore, the summary and box plots for creatinine and urea nitrogen will be 
repeated by renal impairment (no, mild, moderate/severe) at baseline

The summary and box plots for creatinine and urea nitrogen will also be presented for 
the subset of subjects who received kidney transplant

Summary of actual and change from baseline of immunosuppressant drug level for 
subjects who received immunosuppressant drug at baseline by treatment group and visit 
using descriptive statistics 

Summary of categorical urinalysis laboratory parameter results by treatment group and 
visit

Summary of clinically significant (yes/no) laboratory (hematology, chemistry, and 
urinalysis) results as determined by the study investigator by treatment group and visit
The following hematology and chemistry laboratory results will be graded according to the 
NCI-CTCAE version 4.03.

Hematology: ANC, Hgb, platelet, WBC, ALC

Chemistry: Serum sodium, potassium, glucose, creatinine, calcium, phosphorus, 
magnesium, uric acid, creatinine phosphokinase, total bilirubin, ALT, AST, 
gamma-glutamyltransferase (GGT), alkaline phosphatase (ALP), total cholesterol, 
triglycerides
Shift tables showing the shift in NCI CTC toxicity grades from baseline to maximum grade 
post-baseline for the on-treatment period and the overall-study period will be provided reflecting 
the toxicity trend in the course of treatment by treatment group.
Additionally, the number and percentage of subjects with shifts in laboratory results from lower 
grade to maximum grade of either 3 or 4 post-baseline for the on-treatment period and the 
overall-study period will be provided by treatment group. Specifically for ANC, the number and 
percentage of subjects with shifts in laboratory results from lower grade to a maximum grade of 
3 (ANC <1000/mm3 [0.5×109/L]), to a maximum grade of 4 (ANC <500/mm3 [1.0×109/L]) in 
For non-commercial use only


Shire
CONFIDENTIAL
Page 67
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
addition to a maximum grade of either 3 or 4 post-baseline for the on-treatment period and the 
overall-study period by treatment group will be provided.
Furthermore, the time to maximum grade for those subjects who have experienced shifts in 
laboratory results including ANC, Hgb, platelet, WBC, ALC and creatinine from lower grade to 
maximum grade of 3 or 4 post-baseline will be evaluated. The time to the first episode of shift 
from lower grade at baseline to either grade of 3 or 4 post-baseline for the on-treatment period 
and the overall-study period will be summarized using descriptive statistics by treatment group.
The number and percentage of subjects with shifts in laboratory results from lower grade to 
maximum grade of either 3 or 4 post-baseline for the on-treatment period and the overall-study 
period will be provided by treatment group and IAT type (valganciclovir/ganciclovir, foscarnet) 
for decreasing ANC, Hgb, platelet, WBC, ALC, and increasing creatinine.
11.3
Vital Signs
Vital sign values will be considered potentially clinically significant (PCS) if they meet the 
observed value criteria or the change from baseline criteria listed in Table 14. The number and 
percentage of subjects with PCS post-baseline values will be tabulated by treatment group and 
visit. The percentages will be calculated relative to the number of subjects with baseline and 
post-baseline assessment. The numerator is the total number of subjects with at least 1 PCS 
post-baseline vital sign value. A supportive listing of subjects with post-baseline PCS values will 
be provided including the subject number, site, baseline, and post-baseline PCS values. All vital 
signs data will be presented in a by-subject listing.
Table 14
Criteria for Potentially Clinically Significant Vital Signs
Vital Sign Parameter
Criteria
Observed Value
Change from Baseline
Systolic blood pressure
(mmHg)
<90
≥140
≥160
Diastolic blood pressure (mmHg)
<60
≥90
≥100
Pulse rate
(beats per minute)
≤50
≥100
≥120
Weight (kg)
-
Increase of 7%
-
Decrease of 7%
Temperature (°C)
<35.0
>39.0
For non-commercial use only


Shire
CONFIDENTIAL
Page 68
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
11.4
Electrocardiogram (ECG)
A 12-lead electrocardiogram (ECG) will be performed at Visit 2/Day 0, Visit 10/Week 8 (end of 
treatment visit), Visit 18/Week 20 (end of study visit), and at any additional time during the 
study, if clinically indicated. Each ECG will include heart rate, RR duration, PR duration, QT 
duration, and QRS duration. The corrected QT interval (QTc) will be calculated using the 
Fridericia’s formula. The investigator will be responsible for providing the interpretation for all 
ECGs in terms of clinical significance to the subject. A summary of investigator’s interpretation 
of ECG results will be provided.
In addition, ECG variable values will be considered PCS if they meet or exceed the upper limit 
values listed in Table 15. The number and percentage of subjects with post-baseline PCS values 
will be tabulated by treatment group and visit. The percentages will be calculated relative to the 
number of subjects with available non-PCS baseline and at least 1 post-baseline assessment. The 
numerator is the total number of subjects with at least 1 PCS post-baseline ECG value. A listing 
of all subjects with post-baseline PCS value will be provided including the subject number, site, 
baseline, and post-baseline PCS values.
Table 15
Criteria for Potentially Clinically Significant ECG Values
ECG Parameter
Criteria
Observed Value
Heart Rate
(bpm)
≤50
≥100
QRS Duration (msec)
≥120
QTcF (msec)
≥450 and <480
≥480 and <500
≥500
QTcF (msec) change from baseline
≥30 and <60
≥60
PR interval (msec)
>200 
bpm=beat per minute; msec=millisecond
All ECG data will be presented in a by-subject listing.
11.5
Treatment with Hemopoietic Growth Factors, Blood, and Blood Products 
Transfusions
The number and percentage of subjects receiving hemopoietic growth factors, blood, blood 
products transfusion at least once and by type during the on-treatment period and overall-study 
period for the study assigned treatment will be provided by treatment group.
All blood and blood products transfusions will be provided in a data listing. A data listing 
including the hemopoietic growth factors will be provided.
For non-commercial use only


Shire
CONFIDENTIAL
Page 69
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
12.
CLINICAL PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSES
12.1
Pharmacokinetics Population
The PK Set and adolescent PK Set are defined in Section 4.6.
12.2
Pharmacokinetic Methods
All summaries and analyses of the pharmacokinetic data will be based on the PK Set and 
adolescent PK Set as applicable.
12.2.1
Concentration Data
In adult subjects of at least 18 years old who will receive maribavir treatment or maribavir rescue 
treatment, sparse blood samples at predose (Cmin) and 2-4 hour postdose administration at 
Week 1, Week 4, and Week 8 will be collected. For subjects ≥12 to <18 years of age, an 
intensive PK sampling will be performed at Week 1 and sparse PK sampling similar to adults 
(≥18 years) will be performed at Week 4 and Week 8. PK samples will be analyzed for the 
determination of plasma maribavir concentrations.
It is noted that eDiary malfunctions occurred during the study resulting in some loss of dosing 
date and time data. Some of the plasma maribavir concentrations are impacted because the lack 
of actual time relative to dosing. It is noted that remediation by having the dosing date and time 
recorded at the site when drawing the PK samples has been implemented when the issue was 
confirmed. To evaluate the impact due to the eDiary malfunction, two sets of plasma maribavir 
concentrations will be constructed. The primary plasma maribavir concentrations dataset will 
include all plasma maribavir concentrations, and the impacted plasma maribavir concentrations 
will have the PK sampling time be imputed according to the sparse sampling or intensive 
sampling schedule (primary concentration dataset). The impacted maribavir concentrations will 
be evaluated individually to confirm the appropriateness of this method, and previous dosing 
pattern may be examined. A secondary plasma maribavir concentrations dataset will include the 
subset of plasma maribavir concentrations where actual time are confirmed with the available 
dosing data (secondary concentration dataset).
12.2.2
Handling BLQ Values
The following procedures will be used for plasma concentrations below the LLOQ:

Samples that are below LLOQ are treated as zero in the calculation of summary statistics 
(eg, mean, SD, etc) for the plasma concentrations at individual time points.

Mean concentrations are reported as zero if all values are below LLOQ, and no 
descriptive statistics are reported. If the calculated mean (±SD) concentration is less than 
the LLOQ, the value will be reported as calculated. The mean values derived using these 
conventions will be used to create the mean plasma concentration versus time plots.

For calculation of area under the plasma concentration curve (AUC), below LLOQ values 
are set equal to zero in the dataset loaded into WinNonlin for pharmacokinetic analysis. 
WinNonlin uses the zero values that occur before the first time point with a concentration 
For non-commercial use only


Shire
CONFIDENTIAL
Page 70
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
greater than LLOQ, but WinNonlin excludes the zero values from the AUC calculation 
for all later time points.

Missing values will not be imputed.
12.2.3
Pharmacokinetic Parameters
Pharmacokinetic endpoints for maribavir treatment either from treatment phase or rescue 
treatment are as follows:
For all subjects who received maribavir treatment:

Maribavir Cmin (predose maribavir concentration)
For adolescent subjects who provided intensive PK samples at Visit 3/Week 1:

AUC(0-tau): area under the concentration time curve over the 12-hour dosing interval at 
steady state

Cmax: maximum concentration

Tmax: time when maximum concentration is observed

CL/F: apparent oral clearance

Vz/F: apparent volume of distribution 
12.3
Statistical Analysis of Pharmacokinetic Data
Maribavir concentrations will be listed by subject, visit and planned sampling time for all 
subjects as well as adolescent subjects only. Maribavir concentrations will also be summarized 
by visit and nominal time using descriptive statistics (number of observations, mean, SD, 
coefficient of variation, median, maximum, minimum) for all subjects as well as adolescent 
subjects only.
A scatter plot of all reportable maribavir concentration vs actual sampling time will be generated 
using the primary concentration dataset with PK Set. This will be repeated using the secondary 
concentration dataset using the PK Set. A listing of subjects with maribavir concentration below 
LLOQ will be provided along with the Week 8 efficacy response.
Cmin calculated using the primary concentration dataset will be listed and summarized by visit 
using the PK Set. Cmin calculated using the secondary concentration dataset will be listed and 
summarized by visit using the PK Set. This will be repeated separately using the adolescent PK 
Set if it has at least 6 subjects. For adolescent, AUC(0-tau), Cmax, Tmax, CL/F, and Vz/F at Week 1
will be listed and summarized if the adolescent PK Set has at least 6 subjects to provide number 
of observations, mean, SD, coefficient of variation, median, maximum, minimum, geometric 
mean, and coefficient of variation of geometric mean.
For non-commercial use only


Shire
CONFIDENTIAL
Page 71
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
12.4
Analyses of Pharmacokinetic/Pharmacodynamic Relationships
Cmin values at Week 1, Week 4, and Week 8 will be averaged for use in the analysis model. Cmin
values that are below LLOQ will be assigned ½ LLOQ for these analyses.
PK/pharmacodynamic (PD) relationship analysis will be based on the PK Set using PK 
parameter (Cmin) derived from the primary concentration dataset. The analysis will be repeated 
for the PK Set using Cmin calculated from the secondary concentration dataset only if the 
difference between the Cmin calculated from the primary concentration data and the secondary 
concentration data are more than 10% as a sensitivity analysis. Furthermore, if there are more 
than 10% difference in the number of subjects between the PK Set and the supportive PK Set 
(defined as all subjects in PK Set who are also in the PP Set), then the PK/PD relationship 
analysis will be repeated using the supportive PK Set.
Analysis on the relationship between Cmin of maribavir and efficacy endpoints of interest will be 
conducted by logistic regression analysis and graphical exploration using the PK Set (primary), 
and supportive PK Set if needed. Efficacy endpoints of interest will include the primary efficacy 
endpoint, key secondary efficacy endpoint, other secondary and exploratory efficacy endpoints 
as listed below to the extent data allow:

Primary efficacy endpoint:
o
Confirmed CMV viremia clearance at Study Week 8 (response=yes/no)

Key secondary efficacy endpoint:
o
Achievement of the confirmed CMV viremia clearance and CMV infection 
control at Study Week 8 followed by maintenance through Study Week 16 
(response=yes/no)

Secondary efficacy endpoint:
o
CMV recurrence any time on study

Exploratory efficacy endpoint:
o
Time to first CMV viremia clearance
o
Time from the first CMV viremia clearance to CMV viremia recurrence
A logistic regression model will be fitted using response (primary and key secondary efficacy 
endpoints as listed above) as the dependent variable and Cmin of maribavir as the independent 
variable. Probability of confirmed CMV viremia clearance response at Week 8 versus maribavir 
Cmin will be plotted. Box plot of confirmed CMV viremia clearance response at Week 8 and of 
maribavir Cmin will be provided. Scatter plots of time from first CMV viremia clearance to CMV 
viremia recurrence versus maribavir Cmin and time to first CMV viremia clearance versus 
maribavir Cmin will be displayed. In addition, Kaplan-Meier estimates of time from first CMV 
viremia clearance to CMV viremia recurrence, time to first CMV viremia clearance using 
maribavir Cmin (above median and below median) will be graphically presented.
A list of subjects with average maribavir trough concentrations that are below LLOQ and 
viremia response, and recurrence will be provided. A categorical treatment summary table of 
Cmin (below LLOQ or >LLOQ) versus the response will be included.
For non-commercial use only


Shire
CONFIDENTIAL
Page 72
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
12.5
PK and PK/PD Analysis to Be Performed Separately from Clinical Study Report
In a separate analysis and report, maribavir concentrations will be analyzed by population PK 
analysis approach using nonlinear mixed effect model approach using NONMEM v7 or above. 
Impact of subject demographics (eg, age, gender, race, body weight) and other subject 
characteristics (eg, hepatic impairment, renal impairment, concurrent medications, subject 
population) in model parameters will be evaluated. Post hoc maribavir PK parameters such as 
AUC, Cmax, and Cmin will be generated and summarized by identified covariates; relationship 
between post hoc maribavir PK parameter estimates (AUC, Cmax, and Cmin) and efficacy and 
safety measures of interest will be explored. This analysis may be conducted by combining 
maribavir PK data from other Phase 2 and Phase 3 studies.
For non-commercial use only


Shire
CONFIDENTIAL
Page 73
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
13.
OTHER ANALYSES
Exploratory endpoints of 
 
are included under Section 10.
For non-commercial use only


Shire
CONFIDENTIAL
Page 74
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
14.
INTERIM ANALYSIS
An independent data monitoring committee (DMC) is established to act in an expert, advisory 
capacity for periodic assessment of the data to monitor participant safety and to ensure the 
validity and scientific merit of the trial. No formal interim analysis for efficacy will be 
performed. For further details of the DMC, see Section 15.
For non-commercial use only


Shire
CONFIDENTIAL
Page 75
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
15.
DATA MONITORING/REVIEW COMMITTEE
An independent DMC is established to assess the data for safety and to ensure the validity and 
scientific merit of the trial. It is anticipated that the DMC meetings will be conducted 
approximately every 6 months. Detailed plans for the DMC’s purpose and responsibilities are 
described in the DMC charter and its statistical analysis plan.
For non-commercial use only


Shire
CONFIDENTIAL
Page 76
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
16.
COMPUTER METHODS
Statistical analyses will be performed using Version 9.3 (or newer) of SASon a suitably 
qualified environment.
Pharmacokinetic analysis will use WinNonlin Phoenix version 6.3 or higher (Pharsight 
Corporation, Mountain View, California, USA).
For non-commercial use only


Shire
CONFIDENTIAL
Page 77
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
17.
CHANGES TO ANALYSES SPECIFIED IN PROTOCOL
Changes noted in SAP Amendment 1
No major change to the analyses specified in the DATA MANAGEMENT AND STATISTICAL 
METHODS section of the original protocol.
The following changes in STATISTICAL METHODS section were incorporated in protocol 
amendment 5 dated 11 July 2018.

Update definition of CMV infection symptoms to include CMV syndrome in addition to 
tissue invasive disease to be followed for symptom control (resolution or improvement of 
tissue invasive disease or CMV syndrome for those with symptoms at baseline or no new 
tissue invasive disease or CMV syndrome for those asymptomatic at baseline)

Update the overall-study observation period for safety analysis to stop at the start of the 
rescue treatment only so that all safety observation on study will be summarized either in 
the overall-study observation period minus the period on-rescue treatment or in the 
overall-rescue arm observation period
Changes noted in SAP Amendment 2
Analyses specified in the DATA MANAGEMENT AND STATISTICAL METHODS section of 
the study protocol amendment 6 dated 7 December 2018 are being followed. In addition to 
clarifications, specification of more sensitivity or supplementary analyses or subgroup analysis 
of key efficacy and safety parameters, the following change is included in this SAP amendment 
under Section 10.4.3 (Time from first CMV viremia clearance to CMV viremia recurrence).
The endpoint of CMV viremia recurrence requiring alternative treatment after Week 8 is added 
in this SAP amendment. The CMV viremia recurrence is defined as plasma CMV DNA 
concentration ≥LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 
2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. 
Recurrence by this laboratory definition may not be clinically meaningful due to usual viral load 
fluctuations. However, a viral load recurrence requiring alternative treatment as determined by 
the investigator is clinically meaningful. Therefore, the endpoint of CMV viremia recurrence 
requiring alternative treatment after Week 8 is added in Section 10.4.3 to evaluate the time from 
CMV viremia clearance at Week 8 to CMV viremia recurrence requiring alternative treatment 
after Week 8 for those who achieved confirmed CMV viremia clearance at Week 8 (ie, responder 
for the primary efficacy endpoint).
Changes noted in SAP Amendment 3
Noteworthy changes since SAP Amendment 2 are noted in the table below. Other minor editorial 
revisions (including changes for consistency and clarity) are not described in this table.
For non-commercial use only


Shire
CONFIDENTIAL
Page 78
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
Table 16
Noteworthy Changes since SAP Amendment 2
Section 
Number
Section Title
Description
4.5
Per protocol set
Clarify rule of prohibited concomitant medication is to be 
determined while on treatment, not while on treatment phase
6
Protocol deviation
Add listing to present all COVID-19 related protocol 
deviation
7
Baseline characteristic
Add definitions of renal impairment and hepatic impairment 
Add summary of baseline WBC, CD4, CD8 
8
Extent of exposure
Update the sensitivity analysis to focus on the set of subjects 
without impact due to eDiary issue as identified from 
protocol deviation log
9
Prior and Concomitant 
Medication and Procedure
Replace the summary of post-treatment medication with 
summary of post-treatment anti-CMV treatment
10
Efficacy Analysis
Explicitly state the viral load strata based on central 
laboratory result used in the analysis 
10.1.3
Sensitivity and 
Supplementary Analyses of 
the Primary Efficacy 
Endpoint
Update COVID-19 sensitivity analyses
10.1.4
Subgroup Analysis of the 
Primary Efficacy Endpoint
Add kidney transplant type to the subgroup analysis 
10.2.3
Sensitivity and 
Supplementary Analyses of 
the Key Secondary Efficacy 
Endpoint
Update COVID-19 sensitivity analysis
10.2.4
Subgroup Analysis of the 
Primary Efficacy Endpoint
Add kidney transplant type to the subgroup analysis 
10.4.3
Time from the First CMV 
Viremia Clearance to CMV 
Viremia Recurrence 
Clarify keeping viral load measurements after the start of 
rescue or alternative anti-CMV treatment in the recurrence 
assessment
11.1
Adverse Events
Add analyses of time to resolution for dysgeusia and similar 
events and clarify summaries for subgroup analysis
11.2
Clinical Laboratory Variables
Add summary of selected lab parameters by IAT type, and by 
renal impairment subgroup, and kidney transplant subgroup
17
Changes to Analyses 
Specified in Protocol
Added summary of changes since last SAP version
18
Data Handling Conventions 
Added a section for baseline for efficacy and safety endpoints
For non-commercial use only


Shire
CONFIDENTIAL
Page 79
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
18.
DATA HANDLING CONVENTIONS
18.1
General Data Reporting Conventions
Continuous variables will be summarized using the following descriptive statistics: n, mean, 
median, standard deviation, minimum, maximum. Categorical and count variables will be 
summarized by the number of subjects (n) and the percent of subjects in each category. 
Percentages will be presented as whole numbers.
The number of decimal places to present data and p-values will follow Shire standards.
18.2
Derived Efficacy Endpoints
Efficacy endpoints are defined under Section 10.
18.3
Baseline for Efficacy and Safety Endpoints
Baseline or treatment onset is defined as the last measurement on or prior to the first dose date of 
study-assigned treatment during the study (Visit 2/Day 0).   
In this study, the time information of oral administration of maribavir or valganciclovir are 
recorded using the patient eDiary. The administration of study-assigned treatment administered 
intravenously are recorded on the eCRF with date only information. There were subjects who 
received either maribavir or valganciclovir and had the study procedure time on Day 0 after the 
first dose administration time as recorded in the eDiary. For these subjects, study procedures 
(including laboratory assessments, vital signs, ECGs, 
) after the first 
dose time on Day 0 will be used as baseline. For adverse events, if AE start/stop date and time 
were recorded on eCRF and dose administration time were available as recorded on eDiary for 
maribavir and valganciclovir, the time information will be used in the determination of the onset 
period of an AE; if either time information was unavailable, only the date information will be 
used in the determination of the onset period of an AE.
18.4
Repeated or Unscheduled Assessments of Safety Parameters
It is possible that repeat or unscheduled assessments are made for some safety variables (eg, 
clinical laboratories, vital signs, and ECGs, etc).
If a subject has repeated assessments before the start of study assigned treatment, then the results 
from the most recent assessment prior to the start of study assigned treatment will be used as 
baseline. If end of study assessments are repeated or unscheduled, the last post-baseline 
assessment will be used as the end of study assessment for generating descriptive statistics. 
However, all post-baseline assessments will be used for PCS value determination and all 
assessments will be presented in the data listings.
For non-commercial use only


Shire
CONFIDENTIAL
Page 80
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
18.5
Missing Date of Study Assigned Treatment
When the date of the last dose of study assigned treatment is missing for a subject in the safety 
set, all efforts should be made to obtain the date from the investigator. If it is still missing after
all efforts, then the last visit date when study assigned treatment was returned will be used in the 
calculation of treatment duration.
18.6
Missing Date Information for Prior or Concomitant Medications
For prior or concomitant medications, or procedure, incomplete (ie, partially missing) start date 
and/or stop date will be imputed. When the start date and the stop date are both incomplete for a 
subject, impute the start date first.
18.6.1
Incomplete Start Date
The following rules will be applied to impute the missing numerical fields. If the stop date is 
complete and the imputed start date is after the stop date, then the start date will be imputed 
using the stop date.
Missing Day and Month

If the year of the incomplete start date is the same as the year of the date of the first dose of 
study assigned treatment, then the day and month of the date of the first dose of study 
assigned treatment will be assigned to the missing fields

If the year of the incomplete start date is before the year of the date of the first dose of 
study assigned treatment, then December 31 will be assigned to the missing fields

If the year of the incomplete start date is after the year of the date of the first dose of study 
assigned treatment, then 01 January will be assigned to the missing fields.
Missing Month Only

The day will be treated as missing and both month and day will be replaced according to 
the above procedure.
Missing Day Only

If the month and year of the incomplete start date are the same as the month and year of the 
date of the first dose of study assigned treatment, then the day of the date of the first dose 
of study assigned treatment will be assigned to the missing day.

If either the year is before the year of the date of the first dose of study assigned treatment
or if both years are the same but the month is before the month of the date of the first dose 
of study assigned treatment, then the last day of the month will be assigned to the missing 
day.

If either the year is after the year of the date of the first dose of study assigned treatment or 
if both years are the same but the month is after the month of the date of the first dose of 
For non-commercial use only


Shire
CONFIDENTIAL
Page 81
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
study assigned treatment, then the first day of the month will be assigned to the missing 
day.
18.6.2
Incomplete Stop Date
The following rules will be applied to impute the missing numerical fields. If the date of the last 
dose of study assigned treatment is missing, then replace it with the last visit date. If the imputed 
stop date is before the start date (imputed or non-imputed start date), then the imputed stop date 
will be equal to the start date.
Missing Day and Month

If the year of the incomplete stop date is the same as the year as of the date of the last dose 
of study assigned treatment, then the day and month of the date of the last dose of study 
assigned treatment will be assigned to the missing fields

If the year of the incomplete stop date is before the year of the date of the last dose of study 
assigned treatment, then 31 December will be assigned to the missing fields

If the year of the incomplete stop date is after the year of the date of the last dose of study 
assigned treatment, then 01 January will be assigned to the missing fields.
Missing Month Only

The day will be treated as missing and both month and day will be replaced according to 
the above procedure.
Missing Day Only

If the month and year of the incomplete stop date are the same as the month and year of the 
date of the last dose of study assigned treatment, then the day of the date of the last dose of 
study assigned treatment will be assigned to the missing day

If either the year is before the year of the date of the last dose of study assigned treatment
or if both years are the same but the month is before the month of the date of the last dose 
of study assigned treatment, then the last day of the month will be assigned to the missing 
day

If either the year is after the year of the last dose of study assigned treatment or if both 
years are the same but the month is after the month of the date of the last dose of study 
assigned treatment, then the first day of the month will be assigned to the missing day.
18.7
Missing Date Information for Adverse Events
For AEs, the default is to only impute incomplete (ie, partially missing) start dates. Incomplete 
stop dates may also be imputed when calculation of the duration of an AE is required per the 
protocol. If imputation of an incomplete stop date is required, and both the start date and the stop 
date are incomplete for a subject, impute the start date first.
For non-commercial use only


Shire
CONFIDENTIAL
Page 82
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
It is noted that AE eCRF page has fields for AE start/stop date and time as part of the standard 
AE capture, but the AE start/stop time were not mandated to be collected or be queried since 
CRF Completion Guide version 4. If the AE start/stop date and time were collected, the 
information will be used to compare with the dose administration time (if collected), if not, only 
date information will be used.
18.7.1
Incomplete Start Date
Follow same rules as in Section 18.6.1.
18.7.2
Incomplete Stop Date 
When required per the protocol, follow the same rules as in Section 18.6.2.
18.8
Missing Severity Assessment for Adverse Events
If severity is missing for an AE starting prior to the date of the first dose of study assigned 
treatment, then a severity of “Mild” will be assigned. If the severity is missing for an AE starting 
on or after the date of the first dose of study assigned treatment, then a severity of “Severe” will 
be assigned. The imputed values for severity assessment will be used for incidence summaries, 
while the actual values will be used in data listings.
18.9
Missing Relationship to Investigation Product for Adverse Events
If the relationship to study assigned treatment is missing for an AE starting on or after the date of 
the first dose of study assigned treatment, a causality of “Related” will be assigned. The imputed 
values for relationship to double-blind study assigned treatment will be used for incidence 
summaries, while the actual values will be presented in data listings.
18.10 Character Values of Clinical Laboratory Variables
If the reported value of a clinical laboratory variable cannot be used in a statistical analysis due 
to, for example, a character string being reported for a numerical variable, the appropriately 
determined coded value will be used in the statistical analysis (see Table 17). However, the 
actual values as reported in the database will be presented in data listings.
Table 17
Examples for Coding of Special Character Values for Clinical Laboratory 
Variables
Clinical Laboratory Test
Possible Results (in SI units)
Coded Value for Analysis
Chemistry: ALT
<5
0
Chemistry: AST
<5
0
Chemistry: Total Bilirubin
<2
0
Urinalysis: Glucose
55
Positive
0
Negative
Urinalysis: pH
8.0
8.0
For non-commercial use only


Shire
CONFIDENTIAL
Page 83
SHP620-303 Statistical Analysis Plan Amendment 3
Maribavir
28 Sep 2020
19.
REFERENCES
Agresti A., 2013. Categorical Data Analysis, 3rd Edition, Wiley
Boeckh, M., Zaia, J. A., Jung, D., Skettino, S., Chauncey, T. R. and Bowden, R.A. (1998). A 
study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV 
prophylaxis in marrow transplantation. Biol Blood Marrow Transplant, 4(1), 13-9.
Kotton, C. N. (2013). CMV: Prevention, Diagnosis and Therapy American Journal of 
Transplantation, 13:24–40.
Ljungman, P., Boeckh, M., Hirsch, H.H., Josephson, F., Lundgren, J., Nichols, G., Pikis, A., 
Razonable, R.R., Miller, V., Griffiths, P.D. (2017). Definitions of Cytomegalovirus Infection and 
Disease in Transplant Patients for Use in Clinical Trials. Clinical Infectious Disease, 64(1):87-
91.
Mehrotra D. and Railkar R. (2000). Minimum risk weights for comparing treatments in stratified 
binomial trials Statistics in Medicine, 19(6):811-825
 
 
Tomblyn et al. (2009). Guidelines for Preventing Infectious Complications among 
Hematopoietic Cell Transplantation Recipients: A Global Perspective. Biol Blood Marrow 
Transplant 15: 1143-238.
SF36 User Guide, 2016 by QualityMetric Incorporated.
 
 
For non-commercial use only